ࡱ> 2WXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~)` bjbj 4{{%NNNNNNNbffff,t9b% F\ F\ F\ ^\ 9] 9] 9] c! e! e! e! e! e! e! $& hD) ! ENn 9] 9] n n ! NNF\ ^\ $  n x4NF\ N^\ c! n c! N; NN F\  fh f x 0w $ 0%  x) ") `  ) N `9] 'c < cg dj 9] 9] 9] ! ! 9] 9] 9] % n n n n bbb1&8.bbb&8bbbNNNNNN  The ESMO posters / abstracts are here:  HYPERLINK "https://academic.oup.com/annonc/search-results?f_TocHeadingTitle=Posters" https://academic.oup.com/annonc/search-results?f_TocHeadingTitle=Posters Abstracts here:  HYPERLINK "https://academic.oup.com/annonc/issue/29/suppl_5" https://academic.oup.com/annonc/issue/29/suppl_5 P-032 Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure therapy in treatment of pancreatic cancer, A Ozet, Turkey P-137 Intraperitoneal chemotherapy for pancreatic cancer with peritoneal metastases: A single center retrospective analysis of 25 patients, Y Tsuji, Japan P-141 PanCO: An open-label, single-arm pilot study of Oncosil"! in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies, M Harris, Australia, UK P-147 Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma, M McNult, Australia P-155 Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results, V Sahai, USA P-163 Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre Zagreb, J Prejac, Croatia P-164 Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival, V Pacheco-Barcia, Canada P-183 A pilot trial of PEGPH20 (Pegvorhyaluronidase alfa) in combination with avelumab (anti-PD-L1 MSB0010718C) in chemotherapy resistant pancreatic cancer (PDAC), L Medina Rodriguez, Spain P-184 CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC), T Bekaii-Saab, USA Mayo Clinic P-185 PANOVA-3: A phase 3 study of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma, U Weinberg, Israel P-137: Intraperitoneal chemotherapy for pancreatic cancer with peritoneal metastases: A single center retrospective analysis of 25 patients  HYPERLINK "javascript:;" Y Tsuji  HYPERLINK "javascript:;" T Takayama  HYPERLINK "javascript:;" N Okamura  HYPERLINK "javascript:;" J Sugiyama  HYPERLINK "javascript:;" S Oiwa  HYPERLINK "javascript:;" M Yoshida  HYPERLINK "javascript:;" Y Okagawa  HYPERLINK "javascript:;" M Hirayama  HYPERLINK "javascript:;" D Sato  HYPERLINK "javascript:;" Y Suzuki Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.136,  HYPERLINK "https://doi.org/10.1093/annonc/mdy151.136" https://doi.org/10.1093/annonc/mdy151.136 Published: 20 June 2018 | Japan |  HYPERLINK "https://academic.oup.com/annonc/article/29/suppl_5/mdy151.136/5039178" https://academic.oup.com/annonc/article/29/suppl_5/mdy151.136/5039178  HYPERLINK "https://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.136/25056695/mdy151.136.pdf" PDF  Introduction: Unresectable pancreatic cancer is one of the unfavorable prognosis cancers with merely one year of median overall survival (OS). Furthermore, the prognosis becomes even worse with peritoneal metastases due to reduced delivery capacity of anti-cancer drugs and lots of associated complications. Recently, the efficacy and safety data of intraperitoneal paclitaxel (ip PTX) in combination with systemic chemotherapy for gastric cancer with peritoneal metastases has been published by Ishigami at the ASCO 2016. We have participated in this intraperitoneal chemotherapy study projects and here we applied this strategy to pancreatic cancer with peritoneal metastases. Methods: Data from 25 patients with pancreatic cancer with peritoneal metastases who underwent intraperitoneal chemotherapy from August 2013 to January 2018 at our hospital were retrospectively analyzed. Results: Of the 25 patients, 8 were chemotherapy-nave, and the remaining 17 had been adopted after prior non-intraperitoneal chemotherapy. 9 patients had undergone primary tumor resection before peritoneal recurrence. The intraperitoneal regimens were assigned mainly according to the prior treatment: ip PTX plus S-1/PTX was the most frequent (8 cases), followed by ip PTX plus FOLFIRINOX (7 cases), ip PTX plus gemcitabine (6 cases), and the rest. The median progression free survival (PFS) for all 25 patients was 6.1 months, and the median OS was 17.3 months. The median PFS and OS for the chemotherapy-nave group [n=8] were 8.6 and 17.3 months and for the prior-chemotherapy group [n=17] were 3.1 and 11.9 months, respectively. The median PFS and OS for 11 patients without non-excision factors [no other metastases?] other than peritoneal metastases were 11.5 and 18.4 months. A point of extreme interest is that 5 of 11 patients achieved conversion surgery after confirmed complete disappearance of peritoneal metastases. Adverse events of grade 3 or 4 were observed: leukopenia at 40%, neutropenia 64% and anemia 24%, which we attributed to the systemic treatments. 2 cases of localized infection of peritoneal port were observed specific to intraperitoneal therapy. All treatments were well tolerable and there were no treatment-related deaths. Conclusion: This suggests the combination of ip PTX with systemic chemotherapy for pancreatic cancer with peritoneal metastases provides survival benefit superior to conventional chemotherapy. We now only need to confirm these very promising results by a multicenter trial, and as soon as possible. Published by Oxford University Press on behalf of the European Society for Medical Oncology 2018. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( HYPERLINK "https://academic.oup.com/journals/pages/about_us/legal/notices" \t "_blank" https://academic.oup.com/journals/pages/about_us/legal/notices) Issue Section:  HYPERLINK "https://academic.oup.com/annonc/search-results?f_TocHeadingTitle=Posters" Posters P-184: CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) - Trial in progress  HYPERLINK "javascript:;" T Bekaii-Saab  HYPERLINK "javascript:;" T Okusaka  HYPERLINK "javascript:;" D Goldstein  HYPERLINK "javascript:;" B ONeill  HYPERLINK "javascript:;" J Tabernero  HYPERLINK "javascript:;" C Li  HYPERLINK "javascript:;" M Reni  HYPERLINK "javascript:;" B Jin  HYPERLINK "javascript:;" C Oh  HYPERLINK "javascript:;" L Borodyansky  HYPERLINK "https://academic.oup.com/annonc/article/29/suppl_5/mdy151.183/5039270" ... Show more USA 189 locations Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.183,  HYPERLINK "https://doi.org/10.1093/annonc/mdy151.183" https://doi.org/10.1093/annonc/mdy151.183 Published: 20 June 2018  HYPERLINK "https://academic.oup.com/annonc/article/29/suppl_5/mdy151.183/5039270" https://academic.oup.com/annonc/article/29/suppl_5/mdy151.183/5039270  HYPERLINK "https://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.183/25056887/mdy151.183.pdf" PDF  Introduction: NAPA is an oral investigational agent, which has been hypothesized to inhibit cancer stemness pathways, including STAT3 pathway implicated in cancer stem-cell viability. Preclinical studies suggest that NAPA may sensitize heterogeneous cancer cells to chemotherapeutic agents, including nPTX and Gem. Encouraging anticancer activity in mPDAC was observed in a phase 1b study (NCT02231723) of 59 patients (pts), reporting 92% (46/50) disease control rate (DCR) and 56% (28/50) overall response rate (ORR), with 2 complete and 26 partial responses in pts who had a RECIST evaluation. Maturing median progression-free survival (mPFS) and median overall survival (mOS) were 7.06 and 9.59 mo, respectively. On the basis of these data, a phase 3 trial is being conducted in North America, Europe, Australia and Asia. Methods: This randomized, open-label, multicenter study (NCT02993731) will assess the efficacy of NAPA + nPTX + Gem vs nPTX + Gem in pts with mPDAC (n = 1132). Pts must not have received systemic treatment for mPDAC. Pts will be randomized in a 1:1 ratio to receive NAPA 240mg PO twice daily continuously plus IV nPTX 125mg/m 2 + Gem 1000mg/m 2 weekly for 3 of every 4 weeks or nPTX + Gem weekly for 3 of every 4 weeks. Pts will be stratified by geography, Eastern Cooperative Oncology Group performance status, and presence of liver metastases. Treatment will continue until disease progression or another discontinuation criterion. The primary endpoint is OS in the general study population (HR 0.80 for OS improvement from 8.5 to 10.63 months); secondary endpoints include ORR, DCR, and PFS. In addition, OS, PFS, ORR, and DCR will be evaluated in the biomarker positive sub-population. Study enrollment is ongoing with >30% of patients enrolled to date. Issue Section:  HYPERLINK "https://academic.oup.com/annonc/search-results?f_TocHeadingTitle=Posters" Posters P-147: Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma  HYPERLINK "javascript:;" M McNulty  HYPERLINK "javascript:;" A Dean  HYPERLINK "javascript:;" A Das  HYPERLINK "javascript:;" M Gordon Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.146,  HYPERLINK "https://doi.org/10.1093/annonc/mdy151.146" https://doi.org/10.1093/annonc/mdy151.146 Published: 20 June 2018  HYPERLINK "https://academic.oup.com/annonc/article/29/suppl_5/mdy151.146/5039276" https://academic.oup.com/annonc/article/29/suppl_5/mdy151.146/5039276  HYPERLINK "https://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.146/25056904/mdy151.146.pdf" PDF  Introduction: First line treatment for advanced pancreatic adenocarcinoma is well documented and typically involves therapy with FOLFIRINOX or gemcitabine plus nab-paclitaxel. The CONKO-003 trial demonstrated efficacy of 2nd line treatment with the OFF regimen (oxaliplatin, 5-fluorouracil and folinic acid) and more recently the phase III trial, NAPOLI-1, established a tolerable and effective 2nd line treatment option, combining nal-irinotecan with 5-fluorouracil and leucovorin. Despite these advances, there remains minimal amount of data regarding the options for or the efficacy of 3rd line treatment in these patients. This retrospective analysis assessed the use of gemcitabine plus nab-paclitaxel as a 3rd line treatment option in a single hospital settling. Methods: Using an electronic database, we conducted a retrospective analysis of 20 patients with locally advanced or metastatic adenocarcinoma of the pancreas who received third line treatment with gemcitabine and nab-paclitaxel between 2013 and 2017. We selected patients who had received first line gemcitabine-based therapy, to assess the subsequent outcome of retreatment with gemcitabine and nab-paclitaxel (800 mg/m2 and 125 mg/m2 respectively, on days 1, 8 and 15 every four weeks). Overall survival (OS) was estimated by the Kaplan-Meier method. Results: Twenty patients were reviewed. Median age was 70 years (range, 44 81). 55% of the patients were females. Majority of the studied patients had locally advanced cancer at diagnosis (85%). The median OS was 6.0 months (95% CI, 4.0 26.0) from re-initiation of gemcitabine plus nab-paclitaxel. Conclusion: This retrospective study showed that retreatment of advanced pancreatic adenocarcinoma patients with gemcitabine plus nab-paclitaxel could be a suitable third-line treatment option. In order to evaluate the actual efficacy of this third-line chemotherapy regimen, phase III trials would need to be conducted to compare gemcitabine plus nab-paclitaxel with other chemotherapeutic agents. Issue Section:  HYPERLINK "https://academic.oup.com/annonc/search-results?f_TocHeadingTitle=Posters" Posters P-155: Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results  HYPERLINK "javascript:;" V Sahai  HYPERLINK "javascript:;" W Saif  HYPERLINK "javascript:;" A Kalyan  HYPERLINK "javascript:;" P Philip  HYPERLINK "javascript:;" C Rocha-Lima  HYPERLINK "javascript:;" A Ocean  HYPERLINK "javascript:;" M Ondovik  HYPERLINK "javascript:;" D Simeone  HYPERLINK "javascript:;" M Karnoub  HYPERLINK "javascript:;" C Louis  HYPERLINK "https://academic.oup.com/annonc/article/29/suppl_5/mdy151.154/5039355" ... Show more USA Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.154,  HYPERLINK "https://doi.org/10.1093/annonc/mdy151.154" https://doi.org/10.1093/annonc/mdy151.154 Published: 20 June 2018  HYPERLINK "https://academic.oup.com/annonc/article/29/suppl_5/mdy151.154/5039355" https://academic.oup.com/annonc/article/29/suppl_5/mdy151.154/5039355  HYPERLINK "https://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.154/25057087/mdy151.154.pdf" PDF  Introduction: Pancreatic cancer (PC) is a leading cause of cancer-related deaths globally, with a dismal all-stage 5-year survival rate of 8%. Systemic chemotherapy can prolong survival and palliate symptoms in patients with metastatic PC (MPC). The phase III MPACT trial demonstrated superiority of first-line nab -paclitaxel plus gemcitabine vs gemcitabine monotherapy across all endpoints, including the primary endpoint of overall survival (OS) in patients with MPC. Promising results have been observed with regimens containing nab -paclitaxel and 5-fluorouracil (5-FU); however, toxicity is a major concern with high-dose intermittent therapy. The goal of this study is to determine whether metronomic therapy (continuous, low-dose treatment) with FABLOx can reduce the associated toxicities without affecting efficacy. Methods: Patients (aged 18 - 65 years) with previously untreated, histologically or cytologically confirmed MPC and an ECOG performance status of 0 or 1 were eligible. Patients with preexisting peripheral neuropathy grade > 1 were excluded. Phase I of the study assessed potential dose-limiting toxicities (DLTs) to determine the recommended phase II dose (RP2D); phase II was designed to evaluate efficacy and further assess safety of the RP2D. During the dose-determining phase, a minimum of 6 patients were to be enrolled in each consecutive dosing cohort, and 5-FU, nab -paclitaxel, and oxaliplatin doses were to be de-escalated to the next lower dose if e" 2 of 6 patients experienced a DLT in cycle 1 (to a maximum of dose level "2). Patients received 5-FU 180 mg/m 2/day on days 1 to 14; nab -paclitaxel 75 mg/m 2 on days 1, 8, and 15; bevacizumab 5 mg/kg on days 1 and 15; leucovorin 20 mg/m 2 on days 1, 8, and 15; and oxaliplatin 40 mg/m 2 on days 1, 8, and 15 of each 28-day cycle in cohort I (the starting dose level). The primary endpoint of phase I was incidence of DLTs, and the secondary endpoint was safety. Patients were treated until disease progression, unacceptable toxicity, withdrawal of consent, physician decision, or death. Results: Two DLTs were observed in 1 patient (grade 3 anemia requiring a transfusion and grade 3 mucositis unresponsive to medical treatment within 4 days of onset); cohort I was expanded from 6 to 12 patients. The median age was 57.5 (range, 41 - 64) years; 3 women and 9 men were enrolled, and 3 patients continue to be followed up for survival analysis. Patients received a median of 7.0 treatment cycles of nab -paclitaxel, bevacizumab, leucovorin, and 5-FU and 5.5 cycles of oxaliplatin. The evaluation of grade e" 3 treatment-emergent adverse events is pending. The objective response rate was 42% (5 partial responses); the median PFS and OS were 5.6 and 11.5 months, respectively. Conclusion: Results from phase I of this study demonstrate that metronomic FABLOx treatment is feasible for patients with MPC. Preliminary data suggest promising antitumor activity with the regimen. NCT02620800. Issue Section:  HYPERLINK "https://academic.oup.com/annonc/search-results?f_TocHeadingTitle=Posters" Posters P-141: PanCO: An open-label, single-arm pilot study of Oncosil"! in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies  HYPERLINK "javascript:;" M Harris  HYPERLINK "javascript:;" D Croagh  HYPERLINK "javascript:;" M Aghmesheh  HYPERLINK "javascript:;" A Nagrial  HYPERLINK "javascript:;" N Nguyen  HYPERLINK "javascript:;" H Wasan  HYPERLINK "javascript:;" T Ajithkumar  HYPERLINK "javascript:;" A Kraszewski  HYPERLINK "javascript:;" T Maher  HYPERLINK "javascript:;" P Ross Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.140,  HYPERLINK "https://doi.org/10.1093/annonc/mdy151.140" https://doi.org/10.1093/annonc/mdy151.140 Published: 20 June 2018  HYPERLINK "https://academic.oup.com/annonc/article/29/suppl_5/mdy151.140/5039210" https://academic.oup.com/annonc/article/29/suppl_5/mdy151.140/5039210  HYPERLINK "https://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.140/25056760/mdy151.140.pdf" PDF  Introduction: Locally advanced pancreatic cancer (LAPC) is associated with a poor prognosis. Current standard treatment is limited to chemotherapy or chemo-radiotherapy. Novel treatment approaches are crucial in attempting to combat this unmet medical need. Phosphorus-32 (P-32) Microparticles is a brachytherapy device that implants a predetermined dose of the beta radiation emitting isotope (P-32) directly into pancreatic tumours via endoscopic ultrasound (EUS) guidance. The presented data are early results from an ongoing international, multi-institutional, single-arm pilot study. The study objective is to determine the safety and efficacy of P-32 Microparticles in a patient population undergoing standard chemotherapy for unresectable LAPC. Methods: Eligible patients were allocated to receive either gemcitabine+nab-paclitaxel or FOLFIRINOX by physician choice. P-32 implantation took place during the 4th or 5th week following the initiation of chemotherapy. P-32 was implanted directly into the pancreatic tumour via EUS guidance, using a fine needle aspiration (FNA) needle. Each patients dose was calculated from the tumour volume where the absorbed dose of P-32 to the tumour was calculated to equal 100 Gy. Diffusion pattern of the P-32 suspension following implantation was assessed by EUS and by bremsstrahlung SPECT/CT imaging. Chemotherapy was continued after the implantation. Safety data was collected weekly and toxicity was graded using the Common Terminology Criteria for Adverse Events (CTCAE). Centrally-read CT scans were conducted every 8 weeks to assess response defined as complete response [CR], partial response [PR], and stable disease [SD]) rate, according to RECIST 1.1 criteria. FDG-PET scans were performed at baseline and at week 12. Results: Data is reported on the first 15 implanted patients (10 males and 5 females, median age 65 years [range 54-73]) up to week 16 of follow up. At 16 weeks, the objective response rate was 20% - PR in 3/15 patients. The local disease control rate (CR, PR and SD) was 87% - either PR or SD in 13/15 patients. Median change in tumour volume from baseline to week 16 was -33% (range +36% to -72%). Total lesion glycolysis (TLG) as measured via FDG-PET scan showed a median reduction of 52% (range +45% to -100%) from baseline to week 12. The EUS-guided implantation was carried out successfully in all patients and without any complications. By week 16, 223 adverse events (AEs) were reported. Twenty-four Grade 3 AEs (11%) and 5 (2%) Grade 4 toxicities were reported. The most common AEs of Grade 3 and 4 severity were neutropenia (6), anaemia (2), constipation (2), vomiting (2) and fatigue (2). None of the G3 and G4 AEs were attributable to the device or the implantation procedure. Conclusion: Early data indicates that the use of EUS-guided implantation of P-32 is highly feasible, well tolerated and has an acceptable safety profile in combination with standard first-line chemotherapy for LAPC. Preliminary data shows evidence of tumour regression and local disease control. These results, however, warrant further evaluation. The clinical trial is ongoing and additional safety and efficacy data will be presented. ClinicalTrials.gov Identifier: NCT03003078. Acknowledgement: Nab-paclitaxel was supported by Specialised Therapeutics Australia Pty Ltd. Issue Section:  HYPERLINK "https://academic.oup.com/annonc/search-results?f_TocHeadingTitle=Posters" Posters P-163: Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre Zagreb (Croatia)  HYPERLINK "javascript:;" J Prejac  HYPERLINK "javascript:;" I Gorai  HYPERLINK "javascript:;" M Vidovi  HYPERLINK "javascript:;" H Golem  HYPERLINK "javascript:;" D Kekez  HYPERLINK "javascript:;" N Librenjak  HYPERLINK "javascript:;" S Pleatina Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.162,  HYPERLINK "https://doi.org/10.1093/annonc/mdy151.162" https://doi.org/10.1093/annonc/mdy151.162 Published: 20 June 2018  HYPERLINK "https://academic.oup.com/annonc/article/29/suppl_5/mdy151.162/5039448" https://academic.oup.com/annonc/article/29/suppl_5/mdy151.162/5039448  HYPERLINK "https://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.162/25057290/mdy151.162.pdf" PDF  Introduction: The goal of this non-randomized, retrospective, and observational study was to assess the efficacy of three different first-line chemotherapy regimens in the treatment of metastatic pancreatic cancer. Methods: Data were retrieved on 139 patients (pts) who were treated for metastatic pancreatic cancer in the University Hospital Centre Zagreb between January 1st, 2015 and March 1st, 2018. Pts were treated with nab-paclitaxel plus gemcitabine (Nab-Gem), gemcitabine plus cisplatin (Cis-Gem), or gemcitabine alone (Gem). Median age at the time of the beginning of therapy was 62 yrs in the Nab-Gem group (n = 45), 64.4 yrs in the Cis-Gem group (n = 19), and 70 yrs in the Gem group (n = 75). Results: The median duration of treatment for Nab-Gem, Cis-Gem, and Gem regimens was 23.1, 24.7, and 12.9 weeks (w), respectively. Multivariate analyses tested influence of prognostic factors on treatment duration. In accordance with previous studies, for the pts treated with Nab-Gem the duration of treatment was negatively correlated with age (p < 0.05). The same age-dependent relationship was not observed in the Cis-Gem and Gem groups. Pts treated with Nab-Gem showed significant difference in terms of time to failure of treatment when analyzed for the two age groups separately, <65 and >65 yrs of age. The <65 group received chemotherapy for the median duration of 57.1 w compared to the >65 group which was treated with Nab-Gem for median of 21.5 w. No significant sex-dependent difference was found in regard to duration of treatment in any of the three treatment regimen groups. Conclusion: With regards to the above limitations of the study, we conclude that, for pts younger than 65 y, Nab-Gem is an effective chemotherapy regimen with significant clinical effect. Furthermore, for selected patients, a combined use of Cis-Gem is superior to Gem alone in the first-line treatment for metastatic pancreatic cancer. Issue Section:  HYPERLINK "https://academic.oup.com/annonc/search-results?f_TocHeadingTitle=Posters" Posters P-164: Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival  HYPERLINK "javascript:;" V Pacheco-Barcia  HYPERLINK "javascript:;" T France  HYPERLINK "javascript:;" G Zogopoulos  HYPERLINK "javascript:;" N Bouganim  HYPERLINK "javascript:;" O Donnay  HYPERLINK "javascript:;" T Alcindor  HYPERLINK "javascript:;" R Mondjar Sols  HYPERLINK "javascript:;" K Guo  HYPERLINK "javascript:;" E Martin  HYPERLINK "javascript:;" R Colomer  HYPERLINK "https://academic.oup.com/annonc/article/29/suppl_5/mdy151.163/5039455" ... Show more Canada Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.163,  HYPERLINK "https://doi.org/10.1093/annonc/mdy151.163" https://doi.org/10.1093/annonc/mdy151.163 Published: 20 June 2018  HYPERLINK "https://academic.oup.com/annonc/issue/29/suppl_5" https://academic.oup.com/annonc/issue/29/suppl_5  HYPERLINK "https://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.163/25057304/mdy151.163.pdf" PDF  Introduction: Gemcitabine plus nab-paclitaxel and modified FOLFIRINOX have been established as first line chemotherapy in metastatic pancreatic cancer, but there is no conclusive data on their comparison. The aim of our study is to evaluate survival and toxicity profile of metastatic pancreatic cancer patients treated with these therapies. Methods: Retrospective review of 85 metastatic PC diagnosed between January 2014 and January 2018 at two tertiary hospitals. Differences in treatment-related toxicity were assessed by the Chi-square test, progression-free survival (PFS) and overall survival (OS) with the log-rank test. Results: 46 patients were included: 25 Gemcitabine plus Nab-Paclitaxel and 21 received modified FOLFIRINOX. Median age was 63 years. Demographic and baseline characteristics were similar as follows (gemcitabine plus nab-paclitaxel/mFOLFIRINOX): Gender (male): 72%/71%, comorbidities: 16%/14%, liver metastasis: 72%/63%, jaundice that required stent insertion: 32%/48% and thromboembolic events: 56%/62%. The population of elderly patients (> 70y) was similar between both cohorts (36% vs. 42%, p = 0.2) but, 48% of patients treated with gemcitabine plus nab-paclitaxel showed ECOG PS > 1 compared to 4% of patients treated with mFOLFIRINOX (p = 0.01). Similar toxicity profile between both treatments was observed (36% vs 28%, p = 0.67). Incidence of grade 4 neutropenia was similar in both cohorts (12% vs 10%, p = 0.7), probably due to an increased use of G-CSF in patients receiving mFOLFIRINOX. Also, peripheral neuropathy (5% vs 7%, p = 0.8) and diarrhea (3% vs 2.1%, p = 0.6) were similar between groups. No differences were observed in median PFS of mFOLFIRINOX compared to gemcitabine plus nab-paclitaxel (8 months vs 4 months, p = 0.26). However, median OS was significantly longer in patients treated with mFOLFIRINOX (14 months vs 7 months, p = 0.02). Conclusion: Metastatic pancreatic cancer patients treated with mFOLFIRINOX showed increased survival compared to gemcitabine plus nab-paclitaxel, with a similar toxicity profile. These results raise the issue of appropriately selecting patients with poor ECOG PS who can benefit from gemcitabine plus nab-paclitaxel for an adequate control of disease. Issue Section:  HYPERLINK "https://academic.oup.com/annonc/search-results?f_TocHeadingTitle=Posters" Posters P-185: PANOVA-3: A phase 3 study of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma - Trial in progress  HYPERLINK "javascript:;" U Weinberg  HYPERLINK "javascript:;" O Faber  HYPERLINK "javascript:;" M Giladi  HYPERLINK "javascript:;" Z Bomzon  HYPERLINK "javascript:;" G Lavy-Shahaf  HYPERLINK "javascript:;" E Kirson Israel Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.184,  HYPERLINK "https://doi.org/10.1093/annonc/mdy151.184" https://doi.org/10.1093/annonc/mdy151.184 Published: 20 June 2018  HYPERLINK "https://academic.oup.com/annonc/article/29/suppl_5/mdy151.184/5039292" https://academic.oup.com/annonc/article/29/suppl_5/mdy151.184/5039292  HYPERLINK "https://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.184/25056944/mdy151.184.pdf" PDF  Introduction: Tumor Treating Fields (TTFields) are a non-invasive, regional antimitotic treatment modality that predominantly acts by disrupting the formation of the mitotic spindle during metaphase. TTFields are delivered at specific frequencies (150 to 200 KHz) to the tumor region through transducer arrays placed on the skin surface. TTFields (200 KHz) are approved for the treatment of patients with recurrent and newly diagnosed glioblastoma. The effectiveness of TTFields has been demonstrated in multiple preclinical models of pancreatic cancer. TTFields in vitro showed a significant decrease in pancreatic adenocarcinoma cell count, an increase in cell volume and reduced clonogenicity. TTFields in vivo studied either alone or in combination with gemcitabine and paclitaxel in hamsters bearing syngeneic, orthotopic pancreatic tumors significantly reduced tumor volume. The Phase 2 PANOVA study [NCT01971281], the first trial of TTFields (150 KHz) in pancreatic cancer patients, demonstrated the safety of TTFields when combined with nab-paclitaxel and gemcitabine in both metastatic and locally advanced pancreatic cancer (LAPC). Dermatitis was seen below the arrays: Grades 1-2 and 3-4 in 15% and 10% of patients respectively. The median progression-free survival (PFS) with TTFields + gemcitabine + nab-paclitaxel was 12.7 months (95% CI 5.4, NA). The Phase 3 PANOVA-3 trial (NCT03377491) is designed to test the efficacy and safety of adding TTFields to nab-paclitaxel and gemcitabine combination in LAPC. Methods: Patients (N = 556) with unresectable, LAPC (per NCCN guidelines) will be enrolled in this prospective, randomized trial. Patients will have an ECOG score of 0-2 and no prior progression or treatment. Patients, stratified based on their performance status and geographical region will be randomized 1:1 to TTFields plus nab-paclitaxel and gemcitabine or to nab-paclitaxel and gemcitabine alone. Chemotherapy will be administered at standard dose of nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2 once weekly). TTFields at a frequency of 150 kHz will be delivered at least 18 hours/day until local disease progression per RECIST Criteria V1.1. Transducer arrays are placed on the back and front of the patient to deliver the highest field intensities to the abdominal region. Follow up to be performed q8w, will include a CT scans of the chest and abdomen. Following local disease progression, patients will be followed monthly for survival. Overall survival will be the primary endpoint. PFS, objective response rate, rate of resectability, quality of life and toxicity will all be secondary endpoints. Sample size was calculated using a log-rank test comparing time to event in patients treated with TTFields plus chemotherapy with control patients on chemotherapy alone. PANOVA-3 is designed to detect a hazard ratio 0.75 in overall survival. Type I error is set to 0.05 (two-sided) and power to 80%. Published by Oxford University Press on behalf of the European Society for Medical Oncology 2018. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( HYPERLINK "https://academic.oup.com/journals/pages/about_us/legal/notices" \t "" https://academic.oup.com/journals/pages/about_us/legal/notices) Issue Section:  HYPERLINK "https://academic.oup.com/annonc/search-results?f_TocHeadingTitle=Posters" Posters P-183: A pilot trial of PEGPH20 (Pegvorhyaluronidase alfa) in combination with avelumab (anti-PD-L1 MSB0010718C) in chemotherapy resistant pancreatic cancer (PDAC) - Trial in progress  HYPERLINK "javascript:;" L Medina Rodriguez  HYPERLINK "javascript:;" C Guilln-Ponce  HYPERLINK "javascript:;" J Feliu  HYPERLINK "javascript:;" M Hidalgo Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.182,  HYPERLINK "https://doi.org/10.1093/annonc/mdy151.182" https://doi.org/10.1093/annonc/mdy151.182 Published: 20 June 2018  HYPERLINK "https://academic.oup.com/annonc/article/29/suppl_5/mdy151.182/5039256" https://academic.oup.com/annonc/article/29/suppl_5/mdy151.182/5039256 Introduction: PDAC is characterized by excessive hyaluronan (HA) accumulation in the tumor microenvironment, elevating interstitial pressure, resulting in tumor vascular collapse, hypoxia, blocking chemotherapeutic agent perfusion and immune cells. Consequently, checkpoint inhibitors and immunotherapy strategies have failed in PDAC. PEGPH20 targets tumors that accumulate HA. Enzymatically depleting HA from the extracellular matrix (ECM), resulting in decompression of intratumoral blood vessels and increased penetration of antitumor agents. In preclinical models, depletion of HA in the tumor microenvironment has been shown to inhibit the growth of tumors characterized by accumulation of HA. PEGPH20 has been evaluated in a phase II trial in combination with gemcitabine and nabpaclitaxel (PAG) versus gemcitabine plus nabpaclitaxel (AG). For patients with high HA expression on baseline biopsies, the combination arm with PEGPH20 increased progression-free survival (PFS) by 4 months (9.2 vs. 5.2 months; HR 0.51; p = 0.048). Our study tests the hypothesis that elimination of HA in tumor microenvironment by PEGPH20 will result in stromal remodeling and may facilitate the activity of checkpoint inhibitors like avelumab, by at least two mechanisms including increase in drug delivery and increasing immune infiltrate. Methods: A pilot, open label, multicenter, pharmacodynamics, safety, and efficacy study of PEGPH20 in combination with avelumab in chemotherapy resistant advanced or locally advanced PDAC. PEGPH20 3 microg/Kg dose will be administered on days 1, 4, 8, 11, 15, 18 during the first cycle (28 days) and days 1 and 15 thereafter. Avelumab at dose of 10 mg/Kg will start on day 15 after 4 doses of PEGPH20 and continued to be administered every 2 weeks during the study. Enoxaparin will be administered to all subjects to minimize the risk of thromboembolic events (TE) associated to PEGPH20 administration. Pharmacokinetics (Pk) samples for PEGPH20 will be collected. Other assessments: serum CA 19-9 and tissue biomarkers (including collagen content, cancer associated fibroblasts [CAF], and immune infiltrate). Objectives: Primary: To determine the objective response rate (ORR) as per RECIST v1.1 criteria. Secondary: To determine the overall survival (OS), progression free survival (PFS) and CA19-9 tumor marker response. Exploratory: To determine the effect of PEGPH20 in HA content in plasma and paired tumor biopsies. Key inclusion criteria: progression to first line treatment for locally advanced or advanced disease, life expectancy e" 3 months and no clinical evidence of prior TE within 12 months or other known TE during the screening. Issue Section:  HYPERLINK "https://academic.oup.com/annonc/search-results?f_TocHeadingTitle=Posters" Posters Intraperitoneal Chemotherapy (IP Chemo) Karen Arnold-Korzeniowski, BSN, RN | Last Modified: December 8, 2017 |  HYPERLINK "https://www.oncolink.org/cancer-treatment/chemotherapy/overview/intraperitoneal-chemotherapy-ip-chemo" https://www.oncolink.org/cancer-treatment/chemotherapy/overview/intraperitoneal-chemotherapy-ip-chemo Some cancers of the abdominal or gastrointestinal region can be treated using a type of chemotherapy infusion called intraperitoneal. There are two types of intraperitoneal chemotherapy. The first is used at the bedside in the hospital or in an outpatient facility. The second type is done in the operating room, after surgery to debulk (partial or total removal) a tumor. In this article both types will be discussed. What is intraperitoneal (IP) chemotherapy? Intraperitoneal is described as the space within the peritoneum. The peritoneum is the membrane (thin tissue) that lines the abdominal cavity and surrounds your abdominal organs. Chemotherapy can be administered directly into this space to treat cancers of the abdominal region such as gastric (stomach), appendiceal (appendix) and ovarian. There are two types of IP chemotherapy. The first type is infused through a port in the abdomen and is administered in either the hospital or an outpatient (clinic) setting. The second type, referred to as Hyperthermic Intraperitoneal Chemotherapy (HIPEC), is administered in the operating room after a surgery to debulk tumor tissue. The chemotherapy is warmed and infused directly into the intraperitoneal cavity. Why is intraperitoneal chemotherapy prescribed? Higher doses of chemotherapy can be administered intraperitoneally as compared to through an IV (intravenously). By administering chemotherapy through this route you minimize the systemic (entire body) effects that can be caused by IV chemotherapy. IP chemotherapy is exposed only to your peritoneal cavity, minimizing side effects in the rest of the body. However, for IP chemotherapy to be effective, the surgeon must be able to remove (or debulk) the tumor(s) to a size of less than 1cm being left behind. The IP chemotherapy is unable to penetrate a tumor larger than 1 cm in diameter. During surgery to debulk a tumor, cancer cells may break off and still be in your body. Hyperthermic IP chemotherapy is administered to directly kill these cells after surgery. The chemotherapy is warmed because it is thought that heat helps break down and eliminate cancer cells more effectively. Also, the physician will manually disperse (move around) the chemotherapy in the peritoneal cavity with his or her hands or by repositioning the patient's body, which will allow it to get into the many crevices in the abdomen, where residual cancer cells could be hiding. Standard Intraperitoneal Chemotherapy Prior to IP chemotherapy being administered, a port must be placed to allow the medicine to be infused into the abdominal cavity. The port is placed in the abdomen during a surgical procedure, either in the operating room during surgery to debulk a tumor, or by an interventional radiology team if no surgery is being done or there are complications during surgery. The port is placed underneath the skin and then sutured to the ribs. You can feel the port under the skin. There is a tube that extends from the port, into the peritoneal cavity. Typically a port can be used just 24 hours after it is placed, as long as there are no complications and the port is functioning properly. Prior to your treatment, your nurse may place an IV or access your central line. You will have your labs checked. You may receive intravenous fluids and pre-medications, including anti-nausea medications and steroids. You will be prompted to use the bathroom or you may even have a foley catheter (catheter inserted into the bladder through the urethra to collect urine) placed. It is important to empty your bladder prior to your treatment as you will not be able to get up during the infusion, or the infusion would need to be interrupted. Lastly, your nurse will access your abdominal port by placing a needle directly into the port securing the needle. The nurse may or may not use a numbing medication prior to inserting the needle. Once your port is accessed your nurse will start your infusion. Infusions can last anywhere from 30 minutes to 3 hours. The fluid infused may be only chemotherapy or a combination of chemotherapy and an IV fluid, depending upon the ordered medications. It is important that you remain still during the infusion to keep the needle from becoming dislodged from your port. You may be required to lay flat or keep your head and back only slightly elevated. Because you are lying flat and are having fluid introduced into a cavity within your belly the pressure of the fluid may press against your diaphragm and lungs and cause you to feel short of breath. You may also feel some discomfort, like a fullness after eating a large meal. It is important to notify your nurse if you become short of breath or the pressure is becoming intolerable. After your infusion is complete, the needle will be removed from your port. You will then be instructed to change your position every 15 minutes for 1-2 hours. This is important so that the chemotherapy is evenly distributed within your peritoneal cavity. The chemotherapy will be absorbed into your peritoneal cavity. Depending on the treatment plan, you may undergo IP chemotherapy 1-2 times during each cycle of chemotherapy. Hyperthermic Intraperitoneal Chemotherapy During surgery to debulk a tumor, cancer cells may be left behind in the abdomen. HIPEC is administered to directly kill these cells after surgery. The chemotherapy is warmed because it is thought that heat helps break down and eliminate cancer cells more effectively. After your surgeon has removed as much of the tumor as they can, warmed chemotherapy will be infused into the peritoneal cavity. The chemotherapy runs through a machine to warm it and fills the peritoneal cavity. The chemotherapy is then manually dispersed (moved around) by a physician using his or her hands, or by manipulating the patient's position. The goal is for the entire abdominal cavity to be uniformly exposed to the heated chemotherapy. If there are any complications, such as bleeding or the patient becomes unstable, the chemotherapy is suctioned out of the peritoneal cavity and the patient is treated for the complication. The chemotherapy is manipulated for about 90 minutes. Then the chemotherapy remains in the peritoneal cavity and the surgical wound is closed. The chemotherapy is slowly absorbed into the peritoneal cavity (abdominal cavity), with about 90% being absorbed within 4 hours. Benefits of Intraperitoneal Chemotherapy Chemotherapy is administered in a way that allows it to directly affect the cancer cells, which studies have shown can improve survival in certain types and stages of cancer. Potentially fewer side effects in other areas of the body. A higher dose of chemotherapy can be safely administered than can be prescribed for intravenous use. Treatment using HIPEC may require only one round of chemotherapy, which is completed in the operating room. Risks of IP Chemotherapy Side effects can include: nausea, vomiting, electrolyte imbalance, abdominal pain and kidney injury. Some patients will experience low blood counts (called myelosuppression), which may be caused by the IP chemotherapy or IV chemotherapy given in conjunction with IP. Other side effects are possible based on the type of chemotherapy you are receiving. Your doctor or nurse will discuss the potential side effects related to the medications you will be receiving. The need to lie flat for a prolonged period of time may be difficult for some. Issues with your port including infection, pain and inability to infuse the chemotherapy due to kinking of the catheter. Penetration of chemotherapy directly into tumor is limited, so tumor must be debulked to less than 1cm in size. Metastasis beyond the peritoneal cavity may not be affected by IP chemotherapy due to minimal absorption into the blood stream. Please ask you provider specific questions regarding treatment with IP chemotherapy. Always report any side effects during and after your treatment to your provider or nurse. Intraperitoneal chemotherapy is not an appropriate treatment for everyone so please consult with your provider. ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER  HYPERLINK "https://www.postersessiononline.eu/pr/congreso.asp?cod=519481837" https://www.postersessiononline.eu/pr/congreso.asp?cod=519481837 ESMO 20th World Congress on Gastrointestinal Cancer 20-23 June, 2018 Barcelona N. PosterPoster titleApplicant nameStatus 1-LB Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)Mia Chen Received Received 2-PD A phase I/II trial of hafnium oxide nanoparticles activated by radiotherapy in hepatocellular carcinoma and liver metastasisAngelo Cho Received Received 3-PD Comparison of prognosis after hepatic resection of hepatocellular carcinoma between intermediate stage tumor and early stage tumorJunichi Arita Received Received 3-P Targeted-sequencing and comprehensive molecular profiling of gastric signet ring cell carcinomaJia Wei Received Received 4-P MicroRNAs and CDH1 regulation in intestinal-type gastric cancerchiara molinari Received Received 5-O A multicentre, prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancerYoshinori Kagawa Received Received 5-P Retrospective analysis of the frequency of the ALK translocation obtained by immunohistochemistry in gastric adenocarcinomas in a single Costa Rican hospitalLuis Corrales-Rodriguez Received Received 5-PD Post-Operative Venous Thromboembolism and Mortality in Patients with Pancreatic Cancer SurgeryKaushal Majmudar Received Received 6-PD Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patientsMaud Marques Received Received 6-P Personalization of treatment for patients with stomach cancer using molecular genetic markersIgor Bykov Received Received 7-O Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cetiri: Final results and translational analyses of the CRICKET study by GONODaniele Rossini Received Received 8-P Treatment decisions in adolescents and young adults with gastric cancer in North Estonia Medical Centre from 2007-2016Mari Lhmus Received Received 8-PD Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA countingMirella Giordano Received Received 9-PD Emergence of KRAS mutation may play a major role in the secondary resistance to EGFR blockadeTakeshi Yamada Received Received 9-P Epidemiology and overall survival of gastric carcinoma patients (about 210 cases) experience of medical oncology department of CHU Hassan II Fezhayat erraichi Received Received 10-P Berberine inhibits the migration and invasion via AMPK/HNF4a pathway in gastric cancerQian Hu Received Received 10-PD REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysisKohei Shitara Received Received 11-PD SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety resultsTomoko Miura Received Received 11-P Estrone is a marker of the pre-metastatic niche in patients with stomach cancerOleg Kit Received Received 11-O Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)Philippe Merle Received Received 12-PD Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studiesKatarina Gluic Received Received 12-O Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from the prospective, observational CORRELATE studyKatarina Gluic Received Received 13-PD Usefulness of colonic tattooing using ICG in patients with colorectal tumorsJae Ho Park Received Received 13-P Redox forms of glutathione mark the aggressiveness of stomach cancerIrina Goroshinskaya Received Received 13-O Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT studySarah Novack Received Received 14-P Diagnostic and therapeutic efficacy of endoscopic enucleation for subepithelial tumors originating from muscularis propria layerbyoung wook bang Received Received 14-O Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) An ACCRU Network studyTanios Bekaii-Saab Received Received 15-P Patient derived xenografts from American minority gastric cancer patientsSam Wang Received Received 16-PD Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumabVilma Pacheco-Barcia Received Received 16-O First-line FOLFOX plus panitumumab (pan) followed by 5-FU/LV plus pan or single-agent pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO studyFilippo Pietrantonio Received Received 17-O FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONOFederica Marmorino Received Received 17-PD Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC)Elena Ongaro Received Received 17-P Overall survival of patients with HCC treated with sorafenib versus patients treated with supportive therapy in evidence in Oncology Cabinet of Municipal Hospital of Pascani in session 2013-2018Elena-Carmen Bosteanu Received Received 18-PD Comparing survival in left-sided and right-sided colorectal carcinoma: A Belgian population-based studyKatleen Janssens Received Received 19-P Clinic-pathological pattern of hepatocellular carcinoma (HCC) in EgyptAhmed Gaballah Received Received 19-PD RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles U.S.FDA BB-IND 10091Angelica Nazarian Received Received 20-P Immunohistochemical study of KRAS, NRAS, BRAF and MSI phenotype in small bowel adenocarcinomaVasiliki Michalaki Received Received 21-P Molecular profiling of gastrointestinal cancerPANAGIOTIS PARSONIDIS Received Received 23-P Gastrointestinal stromal tumours: Retrospective review of an institutionHelena Magalhaes Received Received 24-P Varying distribution of tissue plasminogen activators in gastrointestinal adenocarcinomaOleg Kit Received Received 26-P Tumor-associated universal inhibitors and free plasmin in adenocarcinoma of stomach and pancreatic headElena Frantsiyants Received Received 27-P Polymer hydrogels as innovative carriers for anticancer therapyMagdalena K&281;dzierska Received Received 28-P Lipoxin A4 inhibits the paracrine of Nodal in CAFs by suppressing FPRL1/ROS/NF-?B signaling to attenuate invasion and metastasis of gallbladder carcinomaYu Shi Received Received 28-O Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaborationShintaro Takeuchi Received Received 30-P Epidemiological profile and factors associated with mortality among patients with gastrointestinal cancers in a Haitian cancer programJoseph Jr Bernard Received Received 31-P Morbidity trends for ed gastrointestinal cancers in Poland and the costs of treatmentMiroslaw Jarosz Received Received 33-P Longitudinal assessment of neutrophil-to-lymphocyte ratio (NLR) from diagnosis until death reveals a biphasic trend in metastatic pancreatic adenocarcinoma patientsCristina Morelli Received Received 35-P Hepatic stellate cells (HSCs) activating HSF1-mediated COMP secretion promote liver metastasis of pancreatic cancer through CD36/AKT/FOXM1 signalingLiankang Sun Received Received 36-P High proliferation is independently associated with disease progression in metastatic pancreatic adenocarcinomaSally Temraz Received Received 40-P Biochemical and radiological inflammatory markers in oesophageal squamous cell carcinoma treated with radical chemoradiationKhin Ni Sann Received Received 41-P Prognostic impact of C-reactive protein / albumin ratio in locally advanced esophageal cancerJoana Simes Received Received 42-P Definitive chemoradiation in esophageal squamous-cell carcinoma: Carboplatin/paclitaxel versus cisplatin/5-FUNuno Tavares Received Received 43-P Oncologic outcomes of elderly patients with localized esophageal cancer who underwent curative surgery compared with younger patientsHyun Ho Choi Received Received 44-P Long term survival in advanced esophageal cancer, treated with a French modality of hypofractionated radiotherapy chemotherapy with or without surgery, the experience at the Instituto Nacional de Cancerologa, MxicoJesus Zamora Moreno Received Received 45-P Analysis of global factors associated with survival in esophageal squamous cell carcinoma: Our experience at Ramon y Cajal HospitalArantzazu Barqun Garca Received Received 48-P Neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of esophagus: Clinical profile and outcomes from tertiary care cancer centreNaveen kumar Received Received 52-P A phase 3 study of chemotherapy pembrolizumab versus chemotherapy placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590Ken Kato Received Received 53-P Pre-treatment peripheral neutrophil-lymphocyte ratio as a prognostic factor in gastric cancerAhmed Gaballah Received Received 54-P Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogramIRENE PECORA Received Received 55-P Prolonged overall survival of metastatic gastric cancer patients with BRCA germline mutationsNaama Halpern Received Received 56-P Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are independent prognostic factors for overall survival in Hispanic patients with gastric adenocarcinomaAllan Ramos-Esquivel Received Received 57-P Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomicsFabiola Cecchi Received Received 58-P The prognostic value of systemic inflammatory factors in patients with HER2-positive metastatic gastric cancerNieves Martinez Lago Received Received 60-P Comparison of efficacy and safety between redo-endoscopic treatment and surgery for recurrent gastric neoplasms at the scar of prior endoscopic submucosal dissectionDo Hoon Kim Received Received 63-P The clinical outcomes and the pathogenetic background of gastric MALT lymphoma in KoreaSANG MIN LEE Received Received 64-P Early outcomes of a pilot study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at dose of 130mg/m2 (nacG-SOX130) in stage III gastric cancerSayuri Konishi Received Received 65-P Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide auditNazim Abbas Received Received 67-P Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: A retrospective studyTakatsugu Ogata Received Received 69-P Associated factors with overlooked multiple synchronous gastric epithelial neoplasiaCheol Woong Choi Received Received 72-P Is the prognostic effect of etiologies in patients with gastric cardia cancer during a recent decade of Korea?Suyun Oh Received Received 73-P Prognostic factors for gastric cancer after curative gastrectomySarra Karrit Received Received 74-P Outcome and prognostic factors of gastric cancer in TunisiaSarra Karrit Received Received 78-P Management, outcome and prognostic factors of metastatic gastric cancerSarra Karrit Received Received 79-P Efficacy and safety of nivolumab monotherapy for metastatic gastric cancerKohei Akiyoshi Received Received 80-P Gastric cancer in young patients under the age of 45 years old: A comparative study with older patientsSarra Karrit Received Received 81-P Early experience on the histopathological response to perioperative docetaxel, oxaliplatin and 5-FU/Sodium levofolinate (FLOT) for patients with resectable gastric adenocarcinoma when compared to cisplatin/5-fluorouracil (CF)Ana Rolo Received Received 82-P Neoadjuvant chemotherapy in gastric cancerAdda Bounedjar Received Received 85-P The impact of the difference in total diameter of metastatic tumor as a prognostic factor for advanced gastric cancer treated with systemic chemotherapyYusuke Sasaki Received Received 86-P Treatment and testing patterns among patients with HER2 advanced/metastatic gastric, esophageal or gastroesophageal junction (GEJ) adenocarcinoma in the United StatesLisa Hess Received Received 88-P Genetic polymorphisms and PG1/PG2 and G17 levels can predict gastric carcinoids in autoimmune atrophic chronic gastritis patientsRenato Cannizzaro Received Received 89-P Gastric cancer in Lynch Syndrome: Are precancerous conditions co- risk factors?Renato Cannizzaro Received Received 90-P Ethnic and racial disparities among young patients with noncardia gastric cancerMatthew Porembka Received Received 95-P A randomized clinical trial of apatinib on an intermittent versus continuous dosing schedule in combination with docetaxel for advanced gastric cancer in second-line settingXianmeng Wu Received Received 96-P A phase 3 study of chemotherapy pembrolizumab vs chemotherapy placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585Yung-Jue Bang Received Received 97-P SIRT therapy with Yttrium-90 resin microspheres in patients with liver cirrhosis Child Pugh B7-9 and unresectable nonmetastatic hepatocellular cancerJan Eick Received Received 98-P Treatment patterns and costs of care for patients diagnosed with hepatocellular carcinoma (HCC) in the United States (U.S.)LISA HESS Received Received 101-P HEPANOVA: A phase 2 trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinomaHugo Siedlecki Received Received 102-P A retrospective review of neutrophil-lymphocyte ratio as a predictive prognostic marker in upper gastrointestinal cancers in three UK hospitals over a nine year periodNicholas Wreglesworth Received Received 103-P The prospective multicenter study of relation between 5-HIAA / substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapyTetsuhito Muranaka Received Received 105-P Clinical outcomes and toxicity of chemoradiation with IMRT for anal cancerJoo Fonseca Received Received 109-P Detection and management of hyperglycaemia in oncology patients receiving systemic anti-cancer therapyLaura Morrison Received Received 110-P Squamous cell carcinoma of the anal canal and the results of radical treatment with intensity-modulated radiotherapyIrena Oblak Received Received 114-P The prognostic values of tumor characteristics and clinical factors of neuroendocrine tumors: Two centers experienceBanu Ozturk Received Received 116-P A long-term analysis of imatinib palliative treatment in gastrointestinal stromal tumorsIsabel Domingues Received Received 117-P 30-day mortality associated with systemic anti-cancer therapy (SACT) in gastrointestinal malignancies: The Christie experienceFrancisca Elena Marti Marti Received Received 118-P Chemoradiation for anal canal carcinoma in a comprehensive cancer center: Retrospective cohort studyJoo Dias Received Received 119-P The feasibility study of short hydration with oral rehydration therapy in chemotherapy with cisplatin plus gemcitabine for biliary tract cancer (KHBO-1302)Tatsuya Ioka Received Received 121-P Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapyNobumichi Takeuchi Received Received 123-P Quality of life by Karnofsky index in patients with gastrointestinal cancer subject to parenteral nutritional therapyTICIANA MARIA RANGEL DE PAULA PESSOA Received Received 124-P De novo malignancies in patients after liver transplantation: A single centre experienceKlara Chmelova Received Received 125-P Laparoscopic liver resection for tumors in proximity to major vasculature and the impact of neo-adjuvant systemic therapyMathieu DHondt Received Received 126-P Impact of revision surgery timing on overall survival in incidentally detected gall bladder cancer: An experience from tertiary care centre of Northern IndiaAshutosh Mishra Received Received 127-P Impact of lymph node positivity on overall survival in operable gall bladder cancer: An experience from tertiary cancer care centre from Northern IndiaAshutosh Mishra Received Received 128-P Surgical resection of primary tumor site is prolonged survival in metastatic pancreatic neuroendocrine carcinomaTingting Feng Received Received 129-P Comparing efficacy of 1-L Peg-Asc with prucalopride versus 2-L Peg-Asc for bowel preparationSe Hyun Jang Received Received 130-P A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignanciesJia Wei Received Received 131-P Endoscopic detachable auxiliary manipulator in endoscopic submucosal dissection: Animal model studYHan Jo Jeon Received Received 132-P Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabineplacebo versus gemcitabineevofosfamide and identifies candidate targetsValeriy Domenyuk Received Received 133-P The use of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and CA 19-9 as prognostic markers for locally advanced pancreatic cancerMeabh McNulty Received Received 136-P Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimenAlessandro Parisi Received Received 137-P Intraperitoneal chemotherapy for pancreatic cancer with peritoneal metastases: A single center retrospective analysis of 25 patientsYasushi Tsuji Received Received 138-P Predictive factors for early relapse and survival in resected pancreatic cancer: A single institution experienceCristina Saavedra Received Received 139-P HGCSG 1403: Phase I trial of oxaliplatin / irinotecan / S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancerSatoshi Yuki Received Received 141-P PanCO: An open-label, single-arm pilot study of Oncosil in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabinenab-paclitaxel chemotherapiesThomas Maher Received Received 142-P Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancerMaria Drizou Received Received 143-P Safety of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients presenting with hyperbilirubinemia secondary to bile duct obstructionMitsuhito Sasaki Received Received 147-P Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinomaMeabh McNulty Received Received 149-P Risk factors and epidemiological features of pancreatic cancer in IranAkram Pourshams Received Received 154-P Real life triplet FIr/FOx chemotherapy in first line metastatic pancreatic ductal adenocarcinoma: Recommended schedule for expected activity and safety and phase II studyGemma Bruera Received Received 156-P Effectiveness and costs of FOLFIRINOX in the treatment of advanced pancreatic cancer in a Portuguese oncology centerHelena Magalhaes Received Received 157-P Gemcitabine/nabpaclitaxel efficacy in elderly patients with metastatic or locally advanced pancreatic adenocarcinomaVasiliki Michalaki Received Received 158-P Correlation of neutrophil lymphocyte ratio, platelet lymphocyte ratio and rate of change of CA 19-9 in predicting outcome for metastatic pancreatic cancerAdarsh Das Received Received 159-P Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine nab-paclitaxelVivaldi Caterina Received Received 160-P Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practiceGerarrd Carot-Sans Received Received 161-P Folfirinox versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort studyIN RAE CHO Received Received 162-P Second line in pancreatic cancer: Resuming our experience and looking for prognostic factorsBeatriz Antn Received Received 163-P Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre ZagrebJuraj Prejac Received Received 164-P Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survivalVilma Pacheco-Barcia Received Received 165-P Clinical outcomes for modified FOLFIRINOX chemotherapy for pancreatic cancerDANIEL HOLYOAKE Received Received 168-P Multiple dose pharmacokinetics of erlotinib when combined with gastric acid reducing agents: A comparison with a physiologically based pharmacokinetic modelAzra Sahmanovic Hrgovcic Received Received 170-P Management of patients with unresectable HCC: A simulation-based assessment of medical oncologists practice choicesEmily Meier Received Received 171-P Analysis of echoendoscopic punctures of a solid pancreatic lesions in a private institution in BrazilTICIANA MARIA RANGEL DE PAULA PESSOA Received Received 172-P Treatment modalities and prognostic factors of pancreatic cancer: A retrospective studyImtinane Belaid Received Received 175-P Clinical implication of inflammation markers for identifying radiotherapy candidates in inoperable locally advanced pancreas cancerwon kyung cho Received Received 176-P Analysis of various clinical and pathological factors affecting survival in patients diagnosed with pancreatic adenocarcinoma: Single institute studyAhmed Nagy Received Received 177-P Epidemiology of pancreatic cancerImtinane Belaid Received Received 180-P Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma: An updated analysisSally Temraz Received Received 181-P Pancreatic head resections: Impact factors, perioperative morbidity, mortality and long-term survivalBojan ILIJEVEC Received Received 184-P CanStem 111P Trial: A Phase 3 Study of Napabucasin (NAPA) Plus Nab-Paclitaxel (nPTX) With Gemcitabine (Gem) in Adult Patients With Metastatic Pancreatic Adenocarcinoma (mPDAC)Natalie Johnson Received Received 185-P PANOVA-3: A phase 3 study of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinomaHugo Siedlecki Received Received 187-P Erythrocyte membrane fatty acids as the potential biomarkers for detection of early-stage and progression of colorectal cancerMargarita Kruchinina Received Received 189-P Retinoic acid-induced 2 (RAI2) is a potential tumor suppressor and RAI2 promoter methylation is a poor prognostic marker in colorectal cancerWenji Yan Received Received 191-P Combined analysis of KRAS, NRAS, BRAF mutations and mismatch repair deficiency testing in Indian patients with metastatic colorectal carcinoma: A single centre experienceTANVI SOOD Received Received 193-P RAS status in Algerian metastatic colorectal cancerAssia Bensalem Received Received 194-P Transcribed ultraconserved regions Uc160 and Uc346 in colon cancer progressionFoteinos- Ioannis Dimitrakopoulos Received Received 195-P Cost of illness for colorectal cancer at low middle income countries Egypt caseAbdalla Abotaleb Received Received 197-P Repurposing ponatinib for the treatment of colorectal cancerRodney Luwor Received Received 199-P Colorectal cancer screening in Flanders: Advances in personalised screeningWessel van de Veerdonk Received Received 201-P Evaluation of the prognostic value of lymph-node ratio in patients with colon cancer in the oxaliplatin eraDarragh Connell Received Received 203-P Survival and prognostic factors of non metastatic rectal adenocarcinoma: Analytic multifactor review of 91 casesKhadija Darif Received Received 204-P Prognostic value of neo-adjuvant treatment in localized rectal cancer about 78 casesKhadija khadija Received Received 205-P Preoperative short course of radiotherapy in ed high risk patientsMonica Caro Gallarin Received Received 206-P Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkersGemma Bruera Received Received 208-P Autophagy (A) related proteins evaluation represents an independent survival factor of colorectal cancer (CRC) patients (pts)Michalis Karamouzis Received Received 209-P P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximabMarco Puzzoni Received Received 210-P Unexpected discordance in 5-year OS rates between Nx colon cancer patients and those in stages II plus IIIIvan Tonev Received Received 211-P Serum angiogenesis associated proteins and clinical outcome in metastatic colorectal cancer patients receiving bevacizumabAlessandro Passardi Received Received 212-P CDX2 immunohistochemistry as a prognostic biomarker for colorectal cancerAbiola Fatimilehin Received Received 213-P An evaluation of the clinical utility of a panel of variants in DPYD and ENOSF1 for predicting common capecitabine related toxicitiesFotheringham Susan Received Received 214-P Bevacizumab combined with 1st line chemotherapy in elderly patients with metastatic colorectal cancer: Are there good prognostic indicators?Katarina Gluic Received Received 216-P Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective methodMichle Boisdron-Celle Received Received 217-P ABCG2 and TOP-1 as predictive biomarkers and targets for therapy in colon cancerNils Brnner Received Received 221-P Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer: The optimization of pharmacological costsJacopo Giuliani Received Received 223-P NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeonsSatoshi Yuki Received Received 224-P Analysis of clinical outcomes of two antiEGFR antibodies, cetuximab and panitumumab, in the 1st line chemotherapy of RAS wild metastatic colorectal cancer, by neutrophil-to-lymphocyte ratio (NLR) kineticsDai Manaka Received Received 225-P The role of maintenance therapy in the first line treatment of metastatic colorectal cancerDanila Gridnev Received Received 226-P HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatmentMichio Nakamura Received Received 227-P Analysis of the benefit of the adjuvant chemotherapy in stage II colon cancer according to the presence of classic poor risk factors: Our experience in Ramon y Cajal HospitalCristina Saavedra Received Received 228-P VOLTAGE: Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy (CRT) with capecitabine in patients with locally advanced rectal cancer (LARC)Hideaki Bando Received Received 230-P Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factorsRenata Biernacka Received Received 231-P Clinical significance of microsatellite instability in gender-dependent patients with right-sided colorectal cancerJi Hun Choi Received Received 232-P Efficacy of adjuvant chemotherapy for elderly patients with colon cancerMaria Villamayor Received Received 233-P Trifluridine/ tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective studyHironaga Satake Received Received 235-P Adjuvant chemotherapy for colorectal cancer using oxaliplatin induced irreversible sinusoidal obstruction syndromeKeisuke Hara Received Received 236-P Clinical and pathological features in colorectal cancer associated to Lynch syndromeOLIVER HIGUERA Received Received 237-P Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trialMarco Stellato Received Received 238-P Analysis of classical high risk factors in stage III colon cancer: Experience at University Hospital Ramon y Cajal (UHRyC)Juan Jos Serrano Domingo Received Received 239-P Impact of adding oxaliplatin to fluoropyrimidines in the adjuvant therapy in stage II in colon cancer: Experience in Ramon y Cajal Universitary HospitalRoberto Martn Huertas Received Received 240-P Benefit of the addition of oxaliplatin to 5-FU/leucovorin or capecitabine in adjuvant therapy for stage II/III colorectal cancer in elderly patients: Experience in Ramon y Cajal University Hospital.Elena Corral de la Fuente Received Received 242-P International prospective multi-center clinical trial with adherence to surgical and pathological quality measures: Influence of body mass index (BMI) on outcome in colon cancerMladjan Protic Received Received 243-P Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapyAKIHITO TSUJI Received Received 244-P Dose finding phase Ib study of triplet plus cetuximab for patients with wild-type RAS gene metastatic colorectal cancer (TRICETSU study)Hironaga Satake Received Received 246-P Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patientsMercedes Martinez Villacampa Received Received 250-P Capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer: Experience of the oncology department of the university hospital of Oran, Algeriazoubida Behourah Received Received 251-P The prognostic ad predictive value of primary tumor sidedness in the mCRC ptsBanu Ozturk Received Received 252-P The evaluation of liver resection for colorectal cancer liver metastasesMasaichi Ogawa Received Received 253-P A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON studyMasaru Iwata Received Received 256-P Treatment efficacy and survival analysis of extremely elderly (80 years of age or older) patients with metastatic colorectal cancer: Single institute retrospective studyYi-Hsin Liang Received Received 257-P Improvement of metastatic colorectal cancer patient survival: a Single institution experienceElisabetta Fenocchio Received Received 258-P HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenibSatoshi Yuki Received Received 259-P Variability of current global practice patterns in the management of metastatic colorectal cancerKrista Marcello Received Received 260-P Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI: Interim results of the non-interventional AIO study QoLiTrapLiliana Borsellino Received Received 261-P HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR indexSatoshi Yuki Received Received 262-P Trial-level analysis of early tumor shrinkage and disease control rate as intermediate end points of first-line medical treatment in randomized studies of metastatic colorectal cancerGiuseppe Colloca Received Received 264-P HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunctionSatoshi Yuki Received Received 265-P Treatment choices in metastatic colorectal cancer according to sidedness and RAS/BRAF status: A national survey by the Brazilian Group of Gastrointestinal Tumors (GTG)Renata Peixoto Received Received 266-P Retrospective analysis from efficacy with trifluridine-tipiracil (TAS-102) in patients with metastatic colorectal cancer and possible clinical factors associated with a greater benefit: experience at seven hospitalsJess Miranda Received Received 267-P The prognostic impact of sidedness in RAS wild-type colorectal cancerNuno Tavares Received Received 269-P Dynamics of the monoclonal antibodies (MABs) treatment rate and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia from 2013 to 2016Mikhail Fedyanin Received Received 270-P Association between duration of oxaliplatin-free interval and effect of reintroduction of oxaliplatin-containing chemotherapy in patients with metastatic colorectal cancer (mCRC)Mikhail Fedyanin Received Received 271-P Prognostic impact of K-RAS mutational status and primary tumour location in patients undergoing resection for colorectal cancer liver metastases: A METHEPAR analysis (multicentre study in Argentina)Juan Manuel OConnor Received Received 272-P Understanding of metastatic colorectal cancer (mCRC) in the real world: Initial results from a European survey on the unmet needs of patients living with metastatic colorectal cancerZorana Maravic Received Received 273-P Recruitment for a survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC): Lessons from a European studyZorana Maravic Received Received 274-P The clinical effectiveness and safety of re-induction oxaliplatin, irinotecan and fluorouracil (FOLFOXIRI regimen) for the treatment of metastatic colorectal cancer after two lines of chemotherapy (oxaliplatin- and irinotecan-based regimens)Anastasia Mochalova Received Received 275-P Selective internal radiation therapy (SIRT) with yttrium-90 microspheres and peri-procedural FOLFIRI/Irinotecan in pre-treated colorectal liver metastases patients: An analysis of outcomes from a UK Cancer Centre between 2009 and 2017Gregory Wilson Received Received 276-P Raltitrexed as salvage therapy for metastatic colorectal cancer: A multicenter retrospective studyIsmael Ghanem Received Received 277-P Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study)Carles PERICAY Received Received 279-P Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer centerCarolina Sales Received Received 281-P The impact of primary tumor location in patients with resected colorectal liver metastasisVilma Pacheco-Barcia Received Received 282-P RAS status in metastatic colorectal cancer: What is the relationship to epidemiological and anatomo-clinical factors?mariam haffadi Received Received 283-P Skin disorders and primary tumor location as a prognostic factor of cetuximab plus chemotherapy in the treatment of advanced colorectal cancerTakada Shinya Received Received 284-P Characteristics of colorectal cancer in the elderly patients about 60 casesHanane Fatima Zahra Aliane Received Received 285-P Optimizing the use of EGFR antibodies across the continuum of care in mCRC: Effect of online education on clinician knowledge, competence and confidenceEmily Meier Received Received 286-P Integrating a paradigm shift in the treatment of metastatic colorectal cancer: Effect of online CME on oncologists knowledge and competenceEmily Meier Received Received 287-P Treatment based on tumor sidedness in mCRC: Effect of online education on clinician knowledge, competence and confidenceEmily Meier Received Received 288-P Causes of death in a cohort of early stage colorectal cancer patients at a regional centre in AustraliaLisi Elizabeth Lim Received Received 289-P Prognostic factors for early recurrences following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastasesNaveeshini Nair Chandran Received Received 291-P The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE statusPina Ziranu Received Received 292-P A phase II study of dose-escalation of regorafenib for patients with previously treated metastatic colorectal cancer DEREGULATE studyKiyotaka Kawaguchi Received Received 293-P Comorbidities (CM) and potential impact in outcomes of advanced colorectal cancer patients (ACC) in Argentina: EVIREPRO real life programAndres Jorge Schmilovich Received Received 294-P Multicenter phase Ib/ II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study)Takeshi Kato Received Received 295-P A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancerOwen Murray Received Received 297-P CanStem 303C Trial: A Phase 3 Study of Napabucasin (NAPA) in CombinationWith 5-Fluorouracil (5-FU), Leucovorin, and Irinotecan (FOLFIRI) in AdultPatients With Previously Treated Metastatic Colorectal Cancer (mCRC)Natalie Johnson Received Received 299-P Predictive factors of complete pathological response in operated patients with locally advanced rectal cancer after chemoradiotherapy neoadjuvant treatment in PeruRodrigo Motta Received Received 300-P Predictive value of circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CT-RT): preliminary resultsPaola Simona Ravenda Received Received 301-P CRP / albumin ratio can be a predictor of response to neoadjuvant chemoradiotherapy (CRT) in rectal cancerTarkan Yetisyigit Received Received 302-P Pathological complete response after chemoradiotherapy in locally advanced rectal cancer: Capecitabine or 5-fluorouracil? Which is better?Xavier Hernndez-Yague Received Received 303-P Food intake and nutritional status of colorectal cancer patients undergoing radio-chemotherapy in Sardjito hospitalMARTALENA PURBA Received Received 304-P Preoperative chemoradiation in locally advanced rectal cancer: A single center experienceLiliana Oliveira Received Received 305-P The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer patients who received preoperative chemoradiation and total mesorectal excisionSooYoon Sung Received Received 307-P Preoperative predictors for pathologic response and prognosis of rectal cancer after neoadjuvant chemoradiationGyu Sang Yoo Received Received 309-P Quality improvement in the management of rectal cancer in a large healthcare system in the United StatesWilliam Sause Received Received 311-P Comparison between the toxicity profile of fluorouracil versus capecitabine concomitant with radiotherapy in patients with non-metastatic rectal cancerAhmed Nagy Received Received 313-P Nonstandard hypofraction radiotherapy in neoadjuvant chemo-radiation therapy of locally advanced rectal cancerAbror Abdujapparov Received Received 314-P Prone vs supine position in patients with rectal cancer treated with volumetric arc therapy and concurrent chemotherapyLaura Daz Received Received 315-P The role of palliative re-irradiation in management of rectal cancermohan hingorani Received Received 316-P Is there any association of dose received by pelvic bone marrow in preoperative radiotherapy in rectal cancer with hematological toxicity of subsequent oxaliplatin-based chemotherapy?Mateusz Spalek Received Received 317-P A single centre experience of in-field recurrence following pre-operative radio(chemo)therapy in patients with rectal cancerRajarshi Roy Received Received 319-P Long term efficacy results from the phase II CRAB trial: Neoadjuvant bevacizumab, capecitabine and radiotherapy in locally advanced rectal cancerVaneja Velenik Received Received 320-P Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancerSusan Higgins Received Received 321-P Profile of neurotoxicity of oxaliplatin in young versus elderly patients treated for colorectal carcinomaHanane Fatima Zahra Aliane Received Received 322-P First study in North Africa: Screening colorectal cancermazouzi chahira Received Received Annals of Oncology Volume 29 Issue suppl_5 June 2018  HYPERLINK "https://academic.oup.com/annonc/issue/29/suppl_5" https://academic.oup.com/annonc/issue/29/suppl_5 Orals  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtf4-63syewy1/" \t "_blank" O-001 Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtf5-63syewy2/" \t "_blank" F Meric-Bernstam;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtf6-63syewy3/" \t "_blank" H Arkenau;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtf7-63syewy4/" \t "_blank" B Tran;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtf8-63syewy5/" \t "_blank" R Bahleda ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtf9-63syewy6/" \t "_blank" R Kelley ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfa-63syewy6/" \t "_blank" O-002 Geographic variation in systemic treatment of metastatic pancreatic adenocarcinoma (mPAC) patients in real world across Europe  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfb-63syewy7/" \t "_blank" J Taieb ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfc-63syewy8/" \t "_blank" A Carrato;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfd-63syewy9/" \t "_blank" Mellbring;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfe-63syewy0/" \t "_blank" G Prager;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtff-63syewy1/" \t "_blank" D Melisi ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfg-63syewy2/" \t "_blank" O-003 Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A quality of life randomized cross-over study (QOLINPAC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfh-63syewy3/" \t "_blank" G Chiritescu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfi-63syewy4/" \t "_blank" K Dumon ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfj-63syewy5/" \t "_blank" C Verslype;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfk-63syewy6/" \t "_blank" H Prenen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfl-63syewy7/" \t "_blank" G Houbiers ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfm-63syewy8/" \t "_blank" O-004 Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfn-63syewy9/" \t "_blank" T Macarulla Mercad;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfo-63syewy0/" \t "_blank" K Lee;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfp-63syewy1/" \t "_blank" G Lakatos;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfq-63syewy2/" \t "_blank" A Wang-Gillam ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfr-63syewy3/" \t "_blank" L Chen ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfs-63syewy4/" \t "_blank" O-005 A multicentre, prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtft-63syewy5/" \t "_blank" Y Kagawa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfu-63syewy6/" \t "_blank" T Kato;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfv-63syewy7/" \t "_blank" H Bando;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfw-63syewy8/" \t "_blank" K Akagi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfx-63syewy9/" \t "_blank" T Denda ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfy-63syewy0/" \t "_blank" O-006 Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtfz-63syewy1/" \t "_blank" J Vidal ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtg0-63syewy8/" \t "_blank" A Dalmeses;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtg1-63syewy9/" \t "_blank" C Santos Vivas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtg2-63syewy0/" \t "_blank" R Garcia-Carbonero;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtg3-63syewy1/" \t "_blank" P Garca-Alfonso ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtg4-63syewy2/" \t "_blank" O-007 Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtg5-63syewy3/" \t "_blank" D Rossini;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtg6-63syewy4/" \t "_blank" C Cremolini ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtg7-63syewy5/" \t "_blank" E Conca;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtg8-63syewy6/" \t "_blank" M Del Re;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtg9-63syewy7/" \t "_blank" A Busico ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtga-63syewy7/" \t "_blank" O-008 The prognostic role of microsatellite status, tumor mutational burden and protein expression in CRC  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgb-63syewy8/" \t "_blank" J Lam;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgc-63syewy9/" \t "_blank" Y Kim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgd-63syewy0/" \t "_blank" F Cecchi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtge-63syewy1/" \t "_blank" S Woo ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgf-63syewy2/" \t "_blank" A Chambers ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgg-63syewy3/" \t "_blank" O-009 A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgh-63syewy4/" \t "_blank" R Kim ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgi-63syewy5/" \t "_blank" D Kim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgj-63syewy6/" \t "_blank" O Alese;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgk-63syewy7/" \t "_blank" D Li;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgl-63syewy8/" \t "_blank" B El-Rayes ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgm-63syewy9/" \t "_blank" O-010 Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgn-63syewy0/" \t "_blank" M Moehler;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgo-63syewy1/" \t "_blank" A Maderer ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgp-63syewy2/" \t "_blank" P Thuss-Patience;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgq-63syewy3/" \t "_blank" B Brenner;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgr-63syewy4/" \t "_blank" J Hecker ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgs-63syewy5/" \t "_blank" O-011 Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgt-63syewy6/" \t "_blank" P Merle;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgu-63syewy7/" \t "_blank" L Rimassa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgv-63syewy8/" \t "_blank" B Ryoo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgw-63syewy9/" \t "_blank" I Cicin ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgx-63syewy0/" \t "_blank" W Harris ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgy-63syewy1/" \t "_blank" O-012 Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from the prospective, observational CORRELATE study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtgz-63syewy2/" \t "_blank" M Ducreux;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wth0-63syewy9/" \t "_blank" L Petersen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wth1-63syewy0/" \t "_blank" L hler;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wth2-63syewy1/" \t "_blank" F Bergamo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wth3-63syewy2/" \t "_blank" J Metges ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wth4-63syewy3/" \t "_blank" O-013 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wth5-63syewy4/" \t "_blank" A Falcone ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wth6-63syewy5/" \t "_blank" T Andr;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wth7-63syewy6/" \t "_blank" J Edeline;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wth8-63syewy7/" \t "_blank" E Franois;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wth9-63syewy8/" \t "_blank" J Taieb ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtha-63syewy8/" \t "_blank" O-014 Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) An ACCRU Network study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthb-63syewy9/" \t "_blank" T Bekaii-Saab;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthc-63syewy0/" \t "_blank" F Ou ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthd-63syewy1/" \t "_blank" D Anderson;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthe-63syewy2/" \t "_blank" D Ahn;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthf-63syewy3/" \t "_blank" P Boland ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthg-63syewy4/" \t "_blank" O-015 A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthh-63syewy5/" \t "_blank" G Chiritescu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthi-63syewy6/" \t "_blank" K Dumon;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthj-63syewy7/" \t "_blank" T Macarulla Mercad;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthk-63syewy8/" \t "_blank" I Lang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthl-63syewy9/" \t "_blank" C Santos Vivas ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthm-63syewy0/" \t "_blank" O-016 First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthn-63syewy1/" \t "_blank" F Pietrantonio;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtho-63syewy2/" \t "_blank" F Morano;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthp-63syewy3/" \t "_blank" S Corallo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthq-63syewy4/" \t "_blank" A Raimondi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthr-63syewy5/" \t "_blank" F Loupakis ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wths-63syewy6/" \t "_blank" O-017 FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtht-63syewy7/" \t "_blank" F Marmorino ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthu-63syewy8/" \t "_blank" C Cremolini;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthv-63syewy9/" \t "_blank" F Bergamo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthw-63syewy0/" \t "_blank" N Pella;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthx-63syewy1/" \t "_blank" C Antoniotti ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthy-63syewy2/" \t "_blank" O-018 Plasma miRNAs signature validation for early detection of colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wthz-63syewy3/" \t "_blank" M Herreros-Villanueva;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wti0-63syewy0/" \t "_blank" S Durn-Sanchn;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wti1-63syewy1/" \t "_blank" A Martn ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wti2-63syewy2/" \t "_blank" R Prez-Palacios;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wti3-63syewy3/" \t "_blank" E Vila-Navarro ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wti4-63syewy4/" \t "_blank" O-019 PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabine +/- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wti5-63syewy5/" \t "_blank" H Schmoll;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wti6-63syewy6/" \t "_blank" K Haustermans;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wti7-63syewy7/" \t "_blank" T Price;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wti8-63syewy8/" \t "_blank" B Nordlinger;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wti9-63syewy9/" \t "_blank" R Hofheinz ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtia-63syewy9/" \t "_blank" O-020 Activity of larotrectinib in patients with TRK fusion GI malignancies  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtib-63syewy0/" \t "_blank" M Nathenson;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtic-63syewy1/" \t "_blank" G Demetri ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtid-63syewy2/" \t "_blank" U Lassen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtie-63syewy3/" \t "_blank" D Hong;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtif-63syewy4/" \t "_blank" V Boni ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtig-63syewy5/" \t "_blank" O-021 Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instabilityhigh (MSI-H) colorectal cancer: KEYNOTE-164  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtih-63syewy6/" \t "_blank" D Le;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtii-63syewy7/" \t "_blank" P Kavan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtij-63syewy8/" \t "_blank" T Kim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtik-63syewy9/" \t "_blank" M Burge ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtil-63syewy0/" \t "_blank" E Van Cutsem ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtim-63syewy1/" \t "_blank" O-022 Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtin-63syewy2/" \t "_blank" K Lesniewski-Kmak;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtio-63syewy3/" \t "_blank" V Moiseenko;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtip-63syewy4/" \t "_blank" M Saunders;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtiq-63syewy5/" \t "_blank" H Wasan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtir-63syewy6/" \t "_blank" G Argiles ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtis-63syewy7/" \t "_blank" O-023 FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtit-63syewy8/" \t "_blank" H Schmoll;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtiu-63syewy9/" \t "_blank" B Garlipp ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtiv-63syewy0/" \t "_blank" C Junghan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtiw-63syewy1/" \t "_blank" A Vogel;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtix-63syewy2/" \t "_blank" U Kaiser ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtiy-63syewy3/" \t "_blank" O-024 mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtiz-63syewy4/" \t "_blank" M Geissler;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtj0-63syewy1/" \t "_blank" T Klingler;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtj1-63syewy2/" \t "_blank" J Riera-Knorrenschield;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtj2-63syewy3/" \t "_blank" A Tannapfel;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtj3-63syewy4/" \t "_blank" T Seufferlein ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtj4-63syewy5/" \t "_blank" O-025 Association between tumor mutation burden (TMB) and MLH1, PMS2, MSH2, and MSH6 alterations in 395 microsatellite instability-high (MSI-High) gastrointestinal (GI) tumors  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtj5-63syewy6/" \t "_blank" M Salem;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtj6-63syewy7/" \t "_blank" A Grothey;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtj7-63syewy8/" \t "_blank" R Goldberg;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtj8-63syewy9/" \t "_blank" J Xiu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtj9-63syewy0/" \t "_blank" W Korn ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtja-63syewy0/" \t "_blank" O-026 Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjb-63syewy1/" \t "_blank" J Hamfjord ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjc-63syewy2/" \t "_blank" T Guren;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjd-63syewy3/" \t "_blank" O Dajani;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtje-63syewy4/" \t "_blank" B Glimelius;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjf-63syewy5/" \t "_blank" H Sorbye ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjg-63syewy6/" \t "_blank" O-027 BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + antiepidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjh-63syewy7/" \t "_blank" E Van Cutsem;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtji-63syewy8/" \t "_blank" P Cuyle ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjj-63syewy9/" \t "_blank" S Huijberts;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjk-63syewy0/" \t "_blank" J Schellens;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjl-63syewy1/" \t "_blank" E Elez ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjm-63syewy2/" \t "_blank" O-028 Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjn-63syewy3/" \t "_blank" S Takeuchi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjo-63syewy4/" \t "_blank" T Yoshino;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjp-63syewy5/" \t "_blank" T Yamanaka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjq-63syewy6/" \t "_blank" M Kotaka ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjr-63syewy7/" \t "_blank" D Manaka ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjs-63syewy8/" \t "_blank" O-029 The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The SORAMIC trial palliative cohort  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjt-63syewy9/" \t "_blank" J Ricke;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtju-63syewy0/" \t "_blank" B Sangro;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjv-63syewy1/" \t "_blank" H Amthauer;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjw-63syewy2/" \t "_blank" I Bargellini;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjx-63syewy3/" \t "_blank" P Bartenstein ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjy-63syewy4/" \t "_blank" O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtjz-63syewy5/" \t "_blank" H Hochster ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtk0-63syewy2/" \t "_blank" Paul J Catalano;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtk1-63syewy3/" \t "_blank" Peter J O'Dwyer;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtk2-63syewy4/" \t "_blank" Edith P Mitchell;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtk3-63syewy5/" \t "_blank" Deirdre Jill Cohen ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   Poster Discussions  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtk4-63syewy6/" \t "_blank" PD-001 Endoscopic prediction of tumor invasion depth in early gastric signet ring cell carcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtk5-63syewy7/" \t "_blank" H Moon;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtk6-63syewy8/" \t "_blank" S Kang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtk7-63syewy9/" \t "_blank" J Sung;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtk8-63syewy0/" \t "_blank" H Jeong  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtk9-63syewy1/" \t "_blank" PD-002 A phase I/II trial of hafnium oxide nanoparticles activated by radiotherapy in hepatocellular carcinoma and liver metastasis  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtka-63syewy1/" \t "_blank" E Chajon;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkb-63syewy2/" \t "_blank" M Pracht ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkc-63syewy3/" \t "_blank" T De Baere;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkd-63syewy4/" \t "_blank" F Nguyen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtke-63syewy5/" \t "_blank" J Bronowicki ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkf-63syewy6/" \t "_blank" PD-003 Comparison of prognosis after hepatic resection of hepatocellular carcinoma between intermediate stage tumor and early stage tumor  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkg-63syewy7/" \t "_blank" J Arita;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkh-63syewy8/" \t "_blank" T Kokudo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtki-63syewy9/" \t "_blank" N Akamatsu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkj-63syewy0/" \t "_blank" J Kaneko ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkk-63syewy1/" \t "_blank" T Ishizawa ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkl-63syewy2/" \t "_blank" PD-004 Baseline characteristics and second-line treatment for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line FOLFIRINOX, gemcitabine+nab-paclitaxel or gemcitabine-monotherapy in routine clinical practice across Europe  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkm-63syewy3/" \t "_blank" G Prager;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkn-63syewy4/" \t "_blank" T Macarulla Mercad;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtko-63syewy5/" \t "_blank" Mellbring;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkp-63syewy6/" \t "_blank" J Taieb;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkq-63syewy7/" \t "_blank" A Carrato ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkr-63syewy8/" \t "_blank" PD-005 Post-operative venous thromboembolism increased mortality in patients with either adenocarcinoma or non-adenocarcinoma pancreatic cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtks-63syewy9/" \t "_blank" K Majmudar ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkt-63syewy0/" \t "_blank" L Diaz Quintero;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtku-63syewy1/" \t "_blank" H Fuentes;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkv-63syewy2/" \t "_blank" S Stocker;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkw-63syewy3/" \t "_blank" A Tafur ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkx-63syewy4/" \t "_blank" PD-006 Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtky-63syewy5/" \t "_blank" M Marques;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtkz-63syewy6/" \t "_blank" K Gambaro ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtl0-63syewy3/" \t "_blank" M Couetoux du Tertre;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtl1-63syewy4/" \t "_blank" M Witcher;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtl2-63syewy5/" \t "_blank" B Samson ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtl3-63syewy6/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtl4-63syewy7/" \t "_blank" PD-008 Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtl5-63syewy8/" \t "_blank" M Giordano ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtl6-63syewy9/" \t "_blank" R Moretto;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtl7-63syewy0/" \t "_blank" R Giannini;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtl8-63syewy1/" \t "_blank" G Zucchelli;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtl9-63syewy2/" \t "_blank" F Pietrantonio ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtla-63syewy2/" \t "_blank" PD-009 Emergence of KRAS mutation may play a major role in the secondary resistance to EGFR blockade  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlb-63syewy3/" \t "_blank" T Yamada;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlc-63syewy4/" \t "_blank" G Takahashi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtld-63syewy5/" \t "_blank" T Iwai ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtle-63syewy6/" \t "_blank" K Takeda;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlf-63syewy7/" \t "_blank" H Furuki ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlg-63syewy8/" \t "_blank" PD-010 REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlh-63syewy9/" \t "_blank" T Yoshino;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtli-63syewy0/" \t "_blank" T Yamanaka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlj-63syewy1/" \t "_blank" T Denda;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlk-63syewy2/" \t "_blank" Y Tsuji ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtll-63syewy3/" \t "_blank" K Shinozaki ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlm-63syewy4/" \t "_blank" PD-011 SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtln-63syewy5/" \t "_blank" M Takahashi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlo-63syewy6/" \t "_blank" Y Munemoto;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlp-63syewy7/" \t "_blank" M Nakamura;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlq-63syewy8/" \t "_blank" M Kotaka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlr-63syewy9/" \t "_blank" H Kuroda ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtls-63syewy0/" \t "_blank" PD-012 Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlt-63syewy1/" \t "_blank" J Taieb ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlu-63syewy2/" \t "_blank" M Geissler;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlv-63syewy3/" \t "_blank" F Rivera;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlw-63syewy4/" \t "_blank" M Karthaus;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlx-63syewy5/" \t "_blank" R Wilson ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtly-63syewy6/" \t "_blank" PD-013 Usefulness of colonic tattooing using ICG in patients with colorectal tumors  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtlz-63syewy7/" \t "_blank" J Park;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtm0-63syewy4/" \t "_blank" H Moon;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtm1-63syewy5/" \t "_blank" I Kwon ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtm2-63syewy6/" \t "_blank" J Kim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtm3-63syewy7/" \t "_blank" S Kang ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtm4-63syewy8/" \t "_blank" PD-014 Survival following curative indented treatment of brain metastases from colorectal cancer: A Danish population-based cohort study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtm5-63syewy9/" \t "_blank" A Boysen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtm6-63syewy0/" \t "_blank" A Ording;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtm7-63syewy1/" \t "_blank" A Astradsson;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtm8-63syewy2/" \t "_blank" M Hyer;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtm9-63syewy3/" \t "_blank" K Spindler  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtma-63syewy3/" \t "_blank" PD-015 Optimizing the use of first-line chemotherapy in metastatic colorectal cancer patients with mucinous histology. A multicenter, retrospective, combined analysis on 897 patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmb-63syewy4/" \t "_blank" V Catalano ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmc-63syewy5/" \t "_blank" F Bergamo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmd-63syewy6/" \t "_blank" C Cremolini;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtme-63syewy7/" \t "_blank" B Vincenzi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmf-63syewy8/" \t "_blank" F Negri ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmg-63syewy9/" \t "_blank" PD-016 Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmh-63syewy0/" \t "_blank" V Pacheco-Barcia;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmi-63syewy1/" \t "_blank" R Mondjar Sols ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmj-63syewy2/" \t "_blank" O Martnez Saez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmk-63syewy3/" \t "_blank" F Longo Muoz;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtml-63syewy4/" \t "_blank" E Bermejo ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmm-63syewy5/" \t "_blank" PD-017 Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmn-63syewy6/" \t "_blank" E Ongaro;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmo-63syewy7/" \t "_blank" D Rossini;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmp-63syewy8/" \t "_blank" F Pietrantonio;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmq-63syewy9/" \t "_blank" F Morano ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmr-63syewy0/" \t "_blank" F de Braud ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtms-63syewy1/" \t "_blank" PD-018 Comparing survival in left-sided and right-sided colorectal carcinoma: A Belgian population-based study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmt-63syewy2/" \t "_blank" K Janssens ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmu-63syewy3/" \t "_blank" N Boeckx;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmv-63syewy4/" \t "_blank" G Van Camp;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmw-63syewy5/" \t "_blank" K Op De Beeck;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmx-63syewy6/" \t "_blank" E Fransen ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmy-63syewy7/" \t "_blank" PD-019 RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtmz-63syewy8/" \t "_blank" A Nazarian;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtn0-63syewy5/" \t "_blank" Z Andrada ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtn1-63syewy6/" \t "_blank" J Thomas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtn2-63syewy7/" \t "_blank" S Sureshbabu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtn3-63syewy8/" \t "_blank" N Berman ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtn4-63syewy9/" \t "_blank" PD-020 Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtn5-63syewy0/" \t "_blank" D Modest;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtn6-63syewy1/" \t "_blank" L Fischer von Weikersthal;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtn7-63syewy2/" \t "_blank" T Decker;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtn8-63syewy3/" \t "_blank" U Vehling-Kaiser;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtn9-63syewy4/" \t "_blank" J Uhlig ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   Posters  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtna-63syewy4/" \t "_blank" P-001 Factors influencing late presentation for health care among men with cancer esophagus attending Hospice Africa Uganda (HAU)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnb-63syewy5/" \t "_blank" N Bandese  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnc-63syewy6/" \t "_blank" P-002 A novel patient derived orthotopic xenograft model of gastro-esophageal junction cancer: Key platform for translational discoveries  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnd-63syewy7/" \t "_blank" O Veeranki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtne-63syewy8/" \t "_blank" Z Tong ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnf-63syewy9/" \t "_blank" A Mejia;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtng-63syewy0/" \t "_blank" R Katkhuda;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnh-63syewy1/" \t "_blank" B Mino ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtni-63syewy2/" \t "_blank" P-003 Targeted-sequencing and comprehensive molecular profiling of gastric signet ring cell carcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnj-63syewy3/" \t "_blank" J Wei;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnk-63syewy4/" \t "_blank" N Wu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnl-63syewy5/" \t "_blank" Y Wang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnm-63syewy6/" \t "_blank" B Xu ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnn-63syewy7/" \t "_blank" Y Yang ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtno-63syewy8/" \t "_blank" P-004 MicroRNAs and CDH1 regulation in intestinal-type gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnp-63syewy9/" \t "_blank" C Molinari ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnq-63syewy0/" \t "_blank" T Rossi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnr-63syewy1/" \t "_blank" R Abou Khouzam;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtns-63syewy2/" \t "_blank" G Ranzani;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnt-63syewy3/" \t "_blank" G Tedaldi ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnu-63syewy4/" \t "_blank" P-005 Retrospective analysis of the frequency of the ALK translocation obtained by immunohistochemistry in gastric adenocarcinomas in a single Costa Rican hospital  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnv-63syewy5/" \t "_blank" L Corrales-Rodriguez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnw-63syewy6/" \t "_blank" J Porras ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnx-63syewy7/" \t "_blank" M Araya;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtny-63syewy8/" \t "_blank" A van der Laat;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtnz-63syewy9/" \t "_blank" P Khanna ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wto0-63syewy6/" \t "_blank" P-006 Personalization of treatment for patients with stomach cancer using molecular genetic markers  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wto1-63syewy7/" \t "_blank" I Bykov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wto2-63syewy8/" \t "_blank" M Mikerova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wto3-63syewy9/" \t "_blank" M Nemtsova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wto4-63syewy0/" \t "_blank" T Kchorobryh  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wto5-63syewy1/" \t "_blank" P-007 Neoadjuvant FLOT: Real world toxicity from a specialist UK centre  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wto6-63syewy2/" \t "_blank" Z Kordatou;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wto7-63syewy3/" \t "_blank" G Papaxoinis;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wto8-63syewy4/" \t "_blank" T Waddell ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wto9-63syewy5/" \t "_blank" V Owen-Holt;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtoa-63syewy5/" \t "_blank" J Weaver ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtob-63syewy6/" \t "_blank" P-008 Treatment decisions in adolescents and young adults with gastric cancer in North Estonia Medical Centre from 2007-2016  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtoc-63syewy7/" \t "_blank" M Lhmus;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtod-63syewy8/" \t "_blank" K Lepik;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtoe-63syewy9/" \t "_blank" T Ktt;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtof-63syewy0/" \t "_blank" T Seufferlein;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtog-63syewy1/" \t "_blank" K Oselin  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtoh-63syewy2/" \t "_blank" P-009 Epidemiology and overall survival of gastric carcinoma patients (about 210 cases) experience of medical oncology department of CHU Hassan II Fez  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtoi-63syewy3/" \t "_blank" H Erraichi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtoj-63syewy4/" \t "_blank" Z Benbrahim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtok-63syewy5/" \t "_blank" S Berrad;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtol-63syewy6/" \t "_blank" K Darif;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtom-63syewy7/" \t "_blank" L Nouikh ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wton-63syewy8/" \t "_blank" P-010 Berberine inhibits the migration and invasion depending on HNF4via Wnt/beta-catenin pathway in gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtoo-63syewy9/" \t "_blank" Q Hu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtop-63syewy0/" \t "_blank" P Yi  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtoq-63syewy1/" \t "_blank" P-011 Estrone and prolactin can be markers of risk of metastasis and pre-metastatic niche in patients with stomach cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtor-63syewy2/" \t "_blank" O Kit;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtos-63syewy3/" \t "_blank" E Frantsiyants;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtot-63syewy4/" \t "_blank" V Bandovkina ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtou-63syewy5/" \t "_blank" Y Pogorelova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtov-63syewy6/" \t "_blank" Y Gevorkyan ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtow-63syewy7/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtox-63syewy8/" \t "_blank" P-013 Redox forms of glutathione mark the aggressiveness of stomach cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtoy-63syewy9/" \t "_blank" I Goroshinskaya;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtoz-63syewy0/" \t "_blank" E Surikova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtp0-63syewy7/" \t "_blank" E Frantsiyants ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtp1-63syewy8/" \t "_blank" I Neskubina;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtp2-63syewy9/" \t "_blank" Y Pogorelova ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtp3-63syewy0/" \t "_blank" P-014 Diagnostic and therapeutic efficacy of endoscopic enucleation for subepithelial tumors originating from muscularis propria layer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtp4-63syewy1/" \t "_blank" B Bang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtp5-63syewy2/" \t "_blank" E Ko;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtp6-63syewy3/" \t "_blank" K Kwon;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtp7-63syewy4/" \t "_blank" Y Shin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtp8-63syewy5/" \t "_blank" H Kim  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtp9-63syewy6/" \t "_blank" P-015 Patient derived xenografts from American minority gastric cancer patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpa-63syewy6/" \t "_blank" S Wang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpb-63syewy7/" \t "_blank" M Zhu ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpc-63syewy8/" \t "_blank" S Hammer;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpd-63syewy9/" \t "_blank" J Shen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpe-63syewy0/" \t "_blank" I Nassour ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpf-63syewy1/" \t "_blank" P-016 Impact of HIF-1alpha and PKM1 expression on acquisition of paclitaxel resistance in gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpg-63syewy2/" \t "_blank" S Fushida;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtph-63syewy3/" \t "_blank" M Okazaki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpi-63syewy4/" \t "_blank" J Kinoshita;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpj-63syewy5/" \t "_blank" T Yamaguchi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpk-63syewy6/" \t "_blank" T Ohta  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpl-63syewy7/" \t "_blank" P-017 Overall survival of patients with HCC treated with sorafenib versus patients treated with supportive therapy in evidence in Oncology Cabinet of Municipal Hospital of Pascani in session 2013-2018  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpm-63syewy8/" \t "_blank" E Bosteanu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpn-63syewy9/" \t "_blank" V Hincu  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpo-63syewy0/" \t "_blank" P-018 The role of endothelial filtration for locoregional targeting of hepatic tumours with endothelium-specific antibodies and nanoparticles  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpp-63syewy1/" \t "_blank" N Winkler;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpq-63syewy2/" \t "_blank" F Strbing;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpr-63syewy3/" \t "_blank" D Kyuno;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtps-63syewy4/" \t "_blank" B Qian;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpt-63syewy5/" \t "_blank" Z Wang ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpu-63syewy6/" \t "_blank" P-019 Clinic-pathological pattern of hepatocellular carcinoma (HCC) in Egypt  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpv-63syewy7/" \t "_blank" H Elghazaly;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpw-63syewy8/" \t "_blank" A Gaballah ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpx-63syewy9/" \t "_blank" N Bahie Eldin  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpy-63syewy0/" \t "_blank" P-020 Immunohistochemical study of KRAS, NRAS, BRAF and MSI phenotype in small bowel adenocarcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtpz-63syewy1/" \t "_blank" V Michalaki ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtq0-63syewy8/" \t "_blank" G Frangulidis;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtq1-63syewy9/" \t "_blank" A Poydorou;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtq2-63syewy0/" \t "_blank" T Theodosopoulos;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtq3-63syewy1/" \t "_blank" A Vezakis ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtq4-63syewy2/" \t "_blank" P-021 Molecular profiling of gastrointestinal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtq5-63syewy3/" \t "_blank" P Apostolou;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtq6-63syewy4/" \t "_blank" M Papadimitriou;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtq7-63syewy5/" \t "_blank" P Parsonidis;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtq8-63syewy6/" \t "_blank" A Iliopoulos;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtq9-63syewy7/" \t "_blank" I Papasotiriou  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqa-63syewy7/" \t "_blank" P-022 Clinico epidemiological and therapeutic profile of GIST: Oran center's experience  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqb-63syewy8/" \t "_blank" F Boudinar ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqc-63syewy9/" \t "_blank" Z Sara;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqd-63syewy0/" \t "_blank" B Larbaoui  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqe-63syewy1/" \t "_blank" P-023 Gastrointestinal stromal tumours: Retrospective review of an institution  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqf-63syewy2/" \t "_blank" A Silva;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqg-63syewy3/" \t "_blank" H Magalhes;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqh-63syewy4/" \t "_blank" C Vieira;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqi-63syewy5/" \t "_blank" A Ferreira;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqj-63syewy6/" \t "_blank" J Dinis ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqk-63syewy7/" \t "_blank" P-024 Varying distribution of tissue plasminogen activators in gastrointestinal adenocarcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtql-63syewy8/" \t "_blank" O Kit;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqm-63syewy9/" \t "_blank" E Frantsiyants ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqn-63syewy0/" \t "_blank" L Kozlova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqo-63syewy1/" \t "_blank" A Maslov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqp-63syewy2/" \t "_blank" E Kolesnikov ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqq-63syewy3/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqr-63syewy4/" \t "_blank" P-026 Tumor-associated universal inhibitors and free plasmin in adenocarcinoma of stomach and pancreatic head  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqs-63syewy5/" \t "_blank" E Frantsiyants ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqt-63syewy6/" \t "_blank" O Kit;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqu-63syewy7/" \t "_blank" L Kozlova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqv-63syewy8/" \t "_blank" A Maslov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqw-63syewy9/" \t "_blank" E Kolesnikov ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqx-63syewy0/" \t "_blank" P-027 Polymer hydrogels as innovative carriers for anticancer therapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqy-63syewy1/" \t "_blank" M Kdzierska;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtqz-63syewy2/" \t "_blank" A Drabczyk;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtr0-63syewy9/" \t "_blank" S KudBacik Kramarczyk ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtr1-63syewy0/" \t "_blank" P Potemski;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtr2-63syewy1/" \t "_blank" B Tyliszczak  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtr3-63syewy2/" \t "_blank" P-028 Lipoxin A4 inhibits the paracrine of Nodal in CAFs by suppressing FPRL1/ROS/NF-B signaling to attenuate invasion and metastasis of gallbladder carcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtr4-63syewy3/" \t "_blank" Y Shi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtr5-63syewy4/" \t "_blank" Y Fan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtr6-63syewy5/" \t "_blank" Y Hu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtr7-63syewy6/" \t "_blank" J Jing;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtr8-63syewy7/" \t "_blank" E Li  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtr9-63syewy8/" \t "_blank" P-029 The therapeutic effect of newly developed endoscopic irreversible electroporation ablative device in gastrointestinal tract: Application to live porcine esophagus, stomach and rectum  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtra-63syewy8/" \t "_blank" J Lee;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrb-63syewy9/" \t "_blank" S Choi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrc-63syewy0/" \t "_blank" S Kim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrd-63syewy1/" \t "_blank" J Lee;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtre-63syewy2/" \t "_blank" H Choi ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrf-63syewy3/" \t "_blank" P-030 Epidemiological profile and factors associated with mortality among patients with gastrointestinal cancers in a Haitian cancer program  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrg-63syewy4/" \t "_blank" J Bernard;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrh-63syewy5/" \t "_blank" V DeGennaro  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtri-63syewy6/" \t "_blank" P-031 Morbidity trends for selected gastrointestinal cancers in Poland and the costs of treatment  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrj-63syewy7/" \t "_blank" M Jarosz;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrk-63syewy8/" \t "_blank" E Rychlik  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrl-63syewy9/" \t "_blank" P-032 FOLFIRINOX versus gemcitabine-cisplatin combination as first line therapy in treatment of pancreatic cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrm-63syewy0/" \t "_blank" A Ozet;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrn-63syewy1/" \t "_blank" N Kayahan Sat1_;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtro-63syewy2/" \t "_blank" H Sat1_  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrp-63syewy3/" \t "_blank" P-033 Longitudinal assessment of neutrophil-to-lymphocyte ratio (NLR) from diagnosis until death reveals a biphasic trend in metastatic pancreatic adenocarcinoma patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrq-63syewy4/" \t "_blank" C Morelli;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrr-63syewy5/" \t "_blank" V Formica ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrs-63syewy6/" \t "_blank" S Pellicori;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrt-63syewy7/" \t "_blank" A Nardecchia;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtru-63syewy8/" \t "_blank" M Roselli  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrv-63syewy9/" \t "_blank" P-034 Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrw-63syewy0/" \t "_blank" W Eisterer;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrx-63syewy1/" \t "_blank" A Gerger;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtry-63syewy2/" \t "_blank" L hler;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtrz-63syewy3/" \t "_blank" B Mlineritsch ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wts0-63syewy0/" \t "_blank" T Sliwa ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wts1-63syewy1/" \t "_blank" P-035 Hepatic stellate cells (HSCs) activating HSF1-mediated COMP secretion promote liver metastasis of pancreatic cancer through CD36/AKT/FOXM1 signaling  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wts2-63syewy2/" \t "_blank" L Sun;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wts3-63syewy3/" \t "_blank" Y Wang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wts4-63syewy4/" \t "_blank" Q Li;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wts5-63syewy5/" \t "_blank" L Wang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wts6-63syewy6/" \t "_blank" C Wang ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wts7-63syewy7/" \t "_blank" P-036 High proliferation is independently associated with disease progression in metastatic pancreatic adenocarcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wts8-63syewy8/" \t "_blank" S Temraz ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wts9-63syewy9/" \t "_blank" M Salim Hammoud;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsa-63syewy9/" \t "_blank" I Makki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsb-63syewy0/" \t "_blank" S Nassif;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsc-63syewy1/" \t "_blank" M Charafeddine ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsd-63syewy2/" \t "_blank" P-037 Pancreatic cancer in Morocco: A retrospective review  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtse-63syewy3/" \t "_blank" A Haimer;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsf-63syewy4/" \t "_blank" F Habib;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsg-63syewy5/" \t "_blank" A Soulaymani;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsh-63syewy6/" \t "_blank" A Mokhtari;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsi-63syewy7/" \t "_blank" H Hami  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsj-63syewy8/" \t "_blank" P-038 Stereotactic body radiation therapy (SBRT) for locally advanced pancreatic cancer (LAPC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsk-63syewy9/" \t "_blank" M Vera Merino ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsl-63syewy0/" \t "_blank" C Nio de Guzmn;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsm-63syewy1/" \t "_blank" D Angel Schutte;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsn-63syewy2/" \t "_blank" D Venencia;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtso-63syewy3/" \t "_blank" L Suarez Villasmil ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsp-63syewy4/" \t "_blank" P-039 Vascular endothelial growth factor (VEGF) splice isoforms may hold the key to targeting tumour angiogenesis in oesophageal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsq-63syewy5/" \t "_blank" F Mehedi  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsr-63syewy6/" \t "_blank" P-040 Biochemical and radiological inflammatory markers in oesophageal squamous cell carcinoma treated with radical chemoradiation  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtss-63syewy7/" \t "_blank" N Khin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtst-63syewy8/" \t "_blank" W Peh;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsu-63syewy9/" \t "_blank" W Tham ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsv-63syewy0/" \t "_blank" W Lam;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsw-63syewy1/" \t "_blank" M Wang ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsx-63syewy2/" \t "_blank" P-041 Prognostic impact of C-reactive protein/albumin ratio in locally advanced esophageal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsy-63syewy3/" \t "_blank" J Simes;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtsz-63syewy4/" \t "_blank" N Tavares;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtt0-63syewy1/" \t "_blank" M Ribeiro;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtt1-63syewy2/" \t "_blank" C Borges;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtt2-63syewy3/" \t "_blank" D Almeida ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtt3-63syewy4/" \t "_blank" P-042 Definitive chemoradiation in esophageal squamous-cell carcinoma: Carboplatin/paclitaxel versus cisplatin/5-FU  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtt4-63syewy5/" \t "_blank" N Tavares ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtt5-63syewy6/" \t "_blank" M Ribeiro;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtt6-63syewy7/" \t "_blank" S Meireles;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtt7-63syewy8/" \t "_blank" D Almeida;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtt8-63syewy9/" \t "_blank" L guas ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtt9-63syewy0/" \t "_blank" P-043 Oncologic outcomes of elderly patients with localized esophageal cancer who underwent curative surgery compared with younger patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtta-63syewy0/" \t "_blank" H Choi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttb-63syewy1/" \t "_blank" S Sung  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttc-63syewy2/" \t "_blank" P-044 Long term survival in advanced esophageal cancer, treated with a French modality of hypofractionated radiotherapy + chemotherapy with or without surgery, the experience at the Instituto Nacional de Cancerologa, Mxico  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttd-63syewy3/" \t "_blank" J Zamora Moreno;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtte-63syewy4/" \t "_blank" V Aiello-Crocifoglio ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttf-63syewy5/" \t "_blank" B Garca Pantoja;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttg-63syewy6/" \t "_blank" E Ruiz-Garcia;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtth-63syewy7/" \t "_blank" G Estrada ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtti-63syewy8/" \t "_blank" P-045 Analysis of global factors associated with survival in esophageal squamous cell carcinoma: Our experience at Ramon y Cajal Hospital  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttj-63syewy9/" \t "_blank" A Barqun Garca;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttk-63syewy0/" \t "_blank" J Serrano Domingo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttl-63syewy1/" \t "_blank" C Saavedra Serrano;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttm-63syewy2/" \t "_blank" V Albarrn Artahona ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttn-63syewy3/" \t "_blank" M Villamayor Delgado ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtto-63syewy4/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttp-63syewy5/" \t "_blank" P-047 Feasibility of docetaxel, cisplatin and S-1 chemotherapy in elderly patients: Comparison with younger  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttq-63syewy6/" \t "_blank" Y Nakamura;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttr-63syewy7/" \t "_blank" T Nishimaki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtts-63syewy8/" \t "_blank" H Shimoji ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttt-63syewy9/" \t "_blank" H Karimata  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttu-63syewy0/" \t "_blank" P-048 Neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of esophagus: Clinical profile and outcomes from tertiary care cancer centre  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttv-63syewy1/" \t "_blank" N Kumar;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttw-63syewy2/" \t "_blank" S Deo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttx-63syewy3/" \t "_blank" N Shukla;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtty-63syewy4/" \t "_blank" S Bhoriwal;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wttz-63syewy5/" \t "_blank" A Sharma ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtu0-63syewy2/" \t "_blank" P-049 Liver metastases from esophageal carcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtu1-63syewy3/" \t "_blank" D Kostov  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtu2-63syewy4/" \t "_blank" P-050 Outcomes of minimal invasive three stage esophagectomy from a cancer centre in Pakistan  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtu3-63syewy5/" \t "_blank" H Ali;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtu4-63syewy6/" \t "_blank" IUI Nasir;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtu5-63syewy7/" \t "_blank" A W Anwer  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtu6-63syewy8/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtu7-63syewy9/" \t "_blank" P-052 A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtu8-63syewy0/" \t "_blank" K Kato;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtu9-63syewy1/" \t "_blank" M Shah;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtua-63syewy1/" \t "_blank" P Enzinger;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtub-63syewy2/" \t "_blank" J Bennouna;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuc-63syewy3/" \t "_blank" L Shen ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtud-63syewy4/" \t "_blank" P-053 Pre-treatment peripheral neutrophil-lymphocyte ratio as a prognostic factor in gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtue-63syewy5/" \t "_blank" A Gaballah;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuf-63syewy6/" \t "_blank" T Hussein ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtug-63syewy7/" \t "_blank" A Ezzat;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuh-63syewy8/" \t "_blank" M Magdy  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtui-63syewy9/" \t "_blank" P-054 Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuj-63syewy0/" \t "_blank" L Fornaro;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuk-63syewy1/" \t "_blank" A Parnofiello;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtul-63syewy2/" \t "_blank" C Ugolini;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtum-63syewy3/" \t "_blank" N Cardarelli;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtun-63syewy4/" \t "_blank" G De Maglio ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuo-63syewy5/" \t "_blank" P-055 Prolonged overall survival of metastatic gastric cancer patients with BRCA germline mutations  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtup-63syewy6/" \t "_blank" N Halpern;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuq-63syewy7/" \t "_blank" A Grinshpun;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtur-63syewy8/" \t "_blank" B Boursi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtus-63syewy9/" \t "_blank" T Golan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtut-63syewy0/" \t "_blank" O Margalit ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuu-63syewy1/" \t "_blank" P-056 Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are independent prognostic factors for overall survival in Hispanic patients with gastric adenocarcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuv-63syewy2/" \t "_blank" A Ramos-Esquivel;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuw-63syewy3/" \t "_blank" D Brenes;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtux-63syewy4/" \t "_blank" E Cordero;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuy-63syewy5/" \t "_blank" W Alpizar-Alpizar  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtuz-63syewy6/" \t "_blank" P-057 Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtv0-63syewy3/" \t "_blank" E An ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtv1-63syewy4/" \t "_blank" M Ryu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtv2-63syewy5/" \t "_blank" D Yan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtv3-63syewy6/" \t "_blank" Y Park;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtv4-63syewy7/" \t "_blank" H Na ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtv5-63syewy8/" \t "_blank" P-058 The prognostic value of systemic inflammatory factors in patients with HER2-positive metastatic gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtv6-63syewy9/" \t "_blank" N Martnez-Lago;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtv7-63syewy0/" \t "_blank" R Lesta-Mellid;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtv8-63syewy1/" \t "_blank" C Reboredo Rendo ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtv9-63syewy2/" \t "_blank" M Reboredo-Lopez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtva-63syewy2/" \t "_blank" L Antn Aparicio  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvb-63syewy3/" \t "_blank" P-059 The overview of H. pylori prevalence in patients with dyspepsia and its association with gastric adenocarcinoma at different locations.  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvc-63syewy4/" \t "_blank" S Aghayeva  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvd-63syewy5/" \t "_blank" P-060 Comparison of efficacy and safety between redo-endoscopic treatment and surgery for recurrent gastric neoplasms at the scar of prior endoscopic submucosal dissection  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtve-63syewy6/" \t "_blank" D Kim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvf-63syewy7/" \t "_blank" H Na;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvg-63syewy8/" \t "_blank" J Ahn;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvh-63syewy9/" \t "_blank" J Lee;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvi-63syewy0/" \t "_blank" K Jung ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvj-63syewy1/" \t "_blank" P-061 Immunocytochemical method for diagnosis of metastases of signet ring cell carcinoma of the stomach  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvk-63syewy2/" \t "_blank" S Lukmonov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvl-63syewy3/" \t "_blank" O Usmanov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvm-63syewy4/" \t "_blank" M Ismailov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvn-63syewy5/" \t "_blank" K Madatov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvo-63syewy6/" \t "_blank" U Kurbankulov ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvp-63syewy7/" \t "_blank" P-062 Radiation therapy in locally distributed inoperable cancer of the stomach without the symptoms of obstruction  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvq-63syewy8/" \t "_blank" S Lukmonov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvr-63syewy9/" \t "_blank" O Usmanov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvs-63syewy0/" \t "_blank" K Madatov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvt-63syewy1/" \t "_blank" M Ismailov ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvu-63syewy2/" \t "_blank" U Kurbankulov ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvv-63syewy3/" \t "_blank" P-063 The clinical outcomes and the pathogenetic background of gastric MALT lymphoma in Korea  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvw-63syewy4/" \t "_blank" S Lee ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvx-63syewy5/" \t "_blank" D Cheung  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvy-63syewy6/" \t "_blank" P-064 Early outcomes of a pilot study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at dose of 130mg/m2 (nacG-SOX130) in stage III gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtvz-63syewy7/" \t "_blank" S Konishi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtw0-63syewy4/" \t "_blank" D Manaka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtw1-63syewy5/" \t "_blank" H An;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtw2-63syewy6/" \t "_blank" Y Nishikawa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtw3-63syewy7/" \t "_blank" T Ota ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtw4-63syewy8/" \t "_blank" P-065 Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide audit  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtw5-63syewy9/" \t "_blank" N Abbas ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtw6-63syewy0/" \t "_blank" M Barnes;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtw7-63syewy1/" \t "_blank" T Price;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtw8-63syewy2/" \t "_blank" C Karapetis;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtw9-63syewy3/" \t "_blank" T Bright ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwa-63syewy3/" \t "_blank" P-066 Feasibility study of intraperitoneal docetaxel combined with intravenous cisplatin and oral S-1 for gastric cancer patients with peritoneal carcinomatosis  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwb-63syewy4/" \t "_blank" K Lam;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwc-63syewy5/" \t "_blank" B Law ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwd-63syewy6/" \t "_blank" W Chan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwe-63syewy7/" \t "_blank" Y Wong;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwf-63syewy8/" \t "_blank" K Chiu ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwg-63syewy9/" \t "_blank" P-067 Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: A retrospective study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwh-63syewy0/" \t "_blank" T Ogata;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwi-63syewy1/" \t "_blank" H Satake;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwj-63syewy2/" \t "_blank" M Ogata;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwk-63syewy3/" \t "_blank" Y Hatachi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwl-63syewy4/" \t "_blank" H Yasui  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwm-63syewy5/" \t "_blank" P-068 Clinical outcomes of endoscopic submucosal dissection for lesions on the proximal location of the stomach  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwn-63syewy6/" \t "_blank" S Kim ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwo-63syewy7/" \t "_blank" C Choi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwp-63syewy8/" \t "_blank" D Kang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwq-63syewy9/" \t "_blank" H Kim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwr-63syewy0/" \t "_blank" S Park ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtws-63syewy1/" \t "_blank" P-069 Associated factors with overlooked multiple synchronous gastric epithelial neoplasia  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwt-63syewy2/" \t "_blank" D Kang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwu-63syewy3/" \t "_blank" C Choi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwv-63syewy4/" \t "_blank" H Kim ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtww-63syewy5/" \t "_blank" S Park;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwx-63syewy6/" \t "_blank" S Kim ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwy-63syewy7/" \t "_blank" P-070 A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604): Interim analysis in the first stage  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtwz-63syewy8/" \t "_blank" A Kawazoe;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtx0-63syewy5/" \t "_blank" D Takahari;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtx1-63syewy6/" \t "_blank" Y Nakamura;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtx2-63syewy7/" \t "_blank" M Suzuki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtx3-63syewy8/" \t "_blank" H Tamura ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtx4-63syewy9/" \t "_blank" P-071 Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: A network meta-analysis for the literature of past 20 years  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtx5-63syewy0/" \t "_blank" Z Cai ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtx6-63syewy1/" \t "_blank" Y Yin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtx7-63syewy2/" \t "_blank" C Shen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtx8-63syewy3/" \t "_blank" B Zhang  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtx9-63syewy4/" \t "_blank" P-072 Is there a prognostic effect of etiologies in patients with gastric cardia cancer during a recent decade of Korea?  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxa-63syewy4/" \t "_blank" W Chung;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxb-63syewy5/" \t "_blank" Y Kim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxc-63syewy6/" \t "_blank" S Oh  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxd-63syewy7/" \t "_blank" P-073 Prognostic factors for gastric cancer after curative gastrectomy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxe-63syewy8/" \t "_blank" S Karrit;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxf-63syewy9/" \t "_blank" I Belaid;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxg-63syewy0/" \t "_blank" F Ezzairi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxh-63syewy1/" \t "_blank" A El Ghali;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxi-63syewy2/" \t "_blank" A Bedioui ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxj-63syewy3/" \t "_blank" P-074 Outcome and prognostic factors of gastric cancer in Tunisia  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxk-63syewy4/" \t "_blank" S Karrit ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxl-63syewy5/" \t "_blank" I Belaid;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxm-63syewy6/" \t "_blank" F Ezzairi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxn-63syewy7/" \t "_blank" A El Ghali;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxo-63syewy8/" \t "_blank" A Bedioui ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxp-63syewy9/" \t "_blank" P-075 Dendritic cell vaccine-based immunotherapy in combination with salvage chemotherapy for patients with advanced or relapsed gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxq-63syewy0/" \t "_blank" M Ogasawara  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxr-63syewy1/" \t "_blank" P-076 The correlation between RhoA, CDH1 expression and clinicopathological characteristics in Chinese gastric cancer patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxs-63syewy2/" \t "_blank" Q Wei;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxt-63syewy3/" \t "_blank" Q He;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxu-63syewy4/" \t "_blank" Q Xu ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxv-63syewy5/" \t "_blank" J Li;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxw-63syewy6/" \t "_blank" L Chen ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxx-63syewy7/" \t "_blank" P-077 Benefit of neoadjuvant chemotherapy for resectable gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxy-63syewy8/" \t "_blank" N Chorna;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtxz-63syewy9/" \t "_blank" A Lukashenko;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wty0-63syewy6/" \t "_blank" Y Ostapenko;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wty1-63syewy7/" \t "_blank" O Kolesnik;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wty2-63syewy8/" \t "_blank" A Boiko  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wty3-63syewy9/" \t "_blank" P-078 Management, outcome and prognostic factors of metastatic gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wty4-63syewy0/" \t "_blank" S Karrit;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wty5-63syewy1/" \t "_blank" I Belaid ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wty6-63syewy2/" \t "_blank" F Ezzairi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wty7-63syewy3/" \t "_blank" A El Ghali;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wty8-63syewy4/" \t "_blank" A Bedioui ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wty9-63syewy5/" \t "_blank" P-079 Efficacy and safety of nivolumab monotherapy for metastatic gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtya-63syewy5/" \t "_blank" K Akiyoshi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyb-63syewy6/" \t "_blank" Y Tsuboguchi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyc-63syewy7/" \t "_blank" S Ueda;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyd-63syewy8/" \t "_blank" S Okazaki ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtye-63syewy9/" \t "_blank" A Tsuya ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyf-63syewy0/" \t "_blank" P-080 Gastric cancer in young patients under the age of 45 years old: A comparative study with older patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyg-63syewy1/" \t "_blank" S Karrit ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyh-63syewy2/" \t "_blank" I Belaid;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyi-63syewy3/" \t "_blank" F Ezzairi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyj-63syewy4/" \t "_blank" A Bedioui;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyk-63syewy5/" \t "_blank" A El Ghali ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyl-63syewy6/" \t "_blank" P-081 Early experience on the histopathological response to perioperative docetaxel, oxaliplatin and 5-FU/Sodium levofolinate (FLOT) for patients with resectable gastric adenocarcinoma when compared to cisplatin/5-fluorouracil (CF)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtym-63syewy7/" \t "_blank" A Rolo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyn-63syewy8/" \t "_blank" S Campelos ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyo-63syewy9/" \t "_blank" P Carvalho;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyp-63syewy0/" \t "_blank" L Oliveira;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyq-63syewy1/" \t "_blank" B Lima ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyr-63syewy2/" \t "_blank" P-082 Neoadjuvant chemotherapy in gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtys-63syewy3/" \t "_blank" A Bounedjar;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyt-63syewy4/" \t "_blank" R Yaici;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyu-63syewy5/" \t "_blank" M A Melzi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyv-63syewy6/" \t "_blank" N Kechad ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyw-63syewy7/" \t "_blank" M Abada  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyx-63syewy8/" \t "_blank" P-083 Impact of the length of the resection margin on local recurrence after curative endoscopic submucosal dissection for early gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyy-63syewy9/" \t "_blank" H Chung;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtyz-63syewy0/" \t "_blank" J Park;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtz0-63syewy7/" \t "_blank" S Shin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtz1-63syewy8/" \t "_blank" S Lee;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtz2-63syewy9/" \t "_blank" Y Lee  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtz3-63syewy0/" \t "_blank" P-084 First line mFOLFOX6 for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtz4-63syewy1/" \t "_blank" H Osumi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtz5-63syewy2/" \t "_blank" D Takahari;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtz6-63syewy3/" \t "_blank" K Chin ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtz7-63syewy4/" \t "_blank" M Ogura;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtz8-63syewy5/" \t "_blank" T Ichimura ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtz9-63syewy6/" \t "_blank" P-085 The impact of the difference in total diameter of metastatic tumor as a prognostic factor for advanced gastric cancer treated with systemic chemotherapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtza-63syewy6/" \t "_blank" Y Sasaki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzb-63syewy7/" \t "_blank" J Hirota;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzc-63syewy8/" \t "_blank" J Konno  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzd-63syewy9/" \t "_blank" P-086 Treatment and testing patterns among patients with HER2+ advanced/metastatic gastric, esophageal or gastroesophageal junction (GEJ) adenocarcinoma in the United States  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtze-63syewy0/" \t "_blank" Y Janjigian;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzf-63syewy1/" \t "_blank" L Hess;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzg-63syewy2/" \t "_blank" Y Zhu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzh-63syewy3/" \t "_blank" Y Fang ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzi-63syewy4/" \t "_blank" A Liepa ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzj-63syewy5/" \t "_blank" P-087 Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and disseminated gastric cancer: Results of a single-centre study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzk-63syewy6/" \t "_blank" R Yarema;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzl-63syewy7/" \t "_blank" M Ohorchak;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzm-63syewy8/" \t "_blank" Y Oliynyk;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzn-63syewy9/" \t "_blank" M Matusak;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzo-63syewy0/" \t "_blank" M Zubarev ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzp-63syewy1/" \t "_blank" P-088 Genetic polymorphisms and PG1/PG2 and G17 levels can predict gastric carcinoids in autoimmune atrophic chronic gastritis patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzq-63syewy2/" \t "_blank" R Cannizzaro ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzr-63syewy3/" \t "_blank" R Magris;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzs-63syewy4/" \t "_blank" S Maiero;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzt-63syewy5/" \t "_blank" M Fornasarig;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzu-63syewy6/" \t "_blank" M De Zorzi ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzv-63syewy7/" \t "_blank" P-089 Gastric cancer in Lynch Syndrome: Are precancerous conditions co- risk factors?  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzw-63syewy8/" \t "_blank" M Fornasarig;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzx-63syewy9/" \t "_blank" R Magris;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzy-63syewy0/" \t "_blank" S Maiero ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wtzz-63syewy1/" \t "_blank" A Viel;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu00-63syewy4/" \t "_blank" E Canton ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu01-63syewy5/" \t "_blank" P-090 Ethnic and racial disparities among young patients with noncardia gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu02-63syewy6/" \t "_blank" C Hester;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu03-63syewy7/" \t "_blank" A Yopp;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu04-63syewy8/" \t "_blank" P Polanco;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu05-63syewy9/" \t "_blank" J Mansour;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu06-63syewy0/" \t "_blank" S Wang ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu07-63syewy1/" \t "_blank" P-091 Influence of the visceral vessels structure variations on peculiarity of radical surgical treatment of stomach cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu08-63syewy2/" \t "_blank" S Khoshimov ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu09-63syewy3/" \t "_blank" S Lukmonov  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0a-63syewy3/" \t "_blank" P-092 Multivisceral resections for locally advanced gastric cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0b-63syewy4/" \t "_blank" Y Ostapenko ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0c-63syewy5/" \t "_blank" A Lukashenko;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0d-63syewy6/" \t "_blank" O Kolesnik;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0e-63syewy7/" \t "_blank" N Chorna;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0f-63syewy8/" \t "_blank" A Boiko  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0g-63syewy9/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0h-63syewy0/" \t "_blank" P-094 A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0i-63syewy1/" \t "_blank" F Ciardiello;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0j-63syewy2/" \t "_blank" Y Bang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0k-63syewy3/" \t "_blank" J Bendell;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0l-63syewy4/" \t "_blank" A Cervantes;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0m-63syewy5/" \t "_blank" R Brachmann ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0n-63syewy6/" \t "_blank" P-095 A randomized clinical trial of apatinib on an intermittent versus continuous dosing schedule in combination with docetaxel for advanced gastric cancer in second-line setting - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0o-63syewy7/" \t "_blank" Y He ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0p-63syewy8/" \t "_blank" Y Yan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0q-63syewy9/" \t "_blank" L Ke;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0r-63syewy0/" \t "_blank" X Hu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0s-63syewy1/" \t "_blank" S Wu ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0t-63syewy2/" \t "_blank" P-096 A phase 3 study of chemotherapy + pembrolizumab vs chemotherapy + placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585 - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0u-63syewy3/" \t "_blank" Y Bang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0v-63syewy4/" \t "_blank" E Van Cutsem ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0w-63syewy5/" \t "_blank" C Fuchs;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0x-63syewy6/" \t "_blank" A Ohtsu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0y-63syewy7/" \t "_blank" J Tabernero ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu0z-63syewy8/" \t "_blank" P-097 SIRT therapy with Yttrium-90 resin microspheres in patients with liver cirrhosis Child Pugh B7-9 and unresectable nonmetastatic hepatocellular cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu10-63syewy5/" \t "_blank" J Eick;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu11-63syewy6/" \t "_blank" M Burbelko;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu12-63syewy7/" \t "_blank" M Plotkin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu13-63syewy8/" \t "_blank" J Steinberg ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu14-63syewy9/" \t "_blank" W Ring ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu15-63syewy0/" \t "_blank" P-098 Treatment patterns and costs of care for patients diagnosed with hepatocellular carcinoma (HCC) in the United States (U.S.)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu16-63syewy1/" \t "_blank" L Hess ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu17-63syewy2/" \t "_blank" Z Cui;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu18-63syewy3/" \t "_blank" X Li;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu19-63syewy4/" \t "_blank" Y Wu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1a-63syewy4/" \t "_blank" A Girvan ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1b-63syewy5/" \t "_blank" P-099 Predictive factor for early recurrence of resected hepatocellular carcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1c-63syewy6/" \t "_blank" T Kato;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1d-63syewy7/" \t "_blank" H Noda;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1e-63syewy8/" \t "_blank" A Yoshizawa ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1f-63syewy9/" \t "_blank" N Kasahara;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1g-63syewy0/" \t "_blank" F Watanabe ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1h-63syewy1/" \t "_blank" P-100 Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1i-63syewy2/" \t "_blank" A Cheng;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1j-63syewy3/" \t "_blank" G Abou-Alfa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1k-63syewy4/" \t "_blank" Z Ren;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1l-63syewy5/" \t "_blank" E Assenat ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1m-63syewy6/" \t "_blank" A Cubillo ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1n-63syewy7/" \t "_blank" P-101 HEPANOVA: A phase 2 trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1o-63syewy8/" \t "_blank" A Grosu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1p-63syewy9/" \t "_blank" J Strouthos;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1q-63syewy0/" \t "_blank" T Brunner;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1r-63syewy1/" \t "_blank" U Weinberg  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1s-63syewy2/" \t "_blank" P-102 A retrospective review of neutrophil-lymphocyte ratio as a predictive prognostic marker in upper gastrointestinal cancers in three UK hospitals over a nine year period  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1t-63syewy3/" \t "_blank" N Wreglesworth;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1u-63syewy4/" \t "_blank" C Roberts;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1v-63syewy5/" \t "_blank" P Innominato  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1w-63syewy6/" \t "_blank" P-103 The prospective multicenter study of relation between 5-HIAA/substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1x-63syewy7/" \t "_blank" T Muranaka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1y-63syewy8/" \t "_blank" Y Komatsu ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu1z-63syewy9/" \t "_blank" S Ohnishi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu20-63syewy6/" \t "_blank" M Yagisawa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu21-63syewy7/" \t "_blank" K Sawada ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu22-63syewy8/" \t "_blank" P-104 Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu23-63syewy9/" \t "_blank" H Osumi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu24-63syewy0/" \t "_blank" E Shinozaki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu25-63syewy1/" \t "_blank" K Chin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu26-63syewy2/" \t "_blank" D Takahari ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu27-63syewy3/" \t "_blank" M Ogura ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu28-63syewy4/" \t "_blank" P-105 Clinical outcomes and toxicity of chemoradiation with IMRT for anal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu29-63syewy5/" \t "_blank" J Fonseca ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2a-63syewy5/" \t "_blank" N Ferreira;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2b-63syewy6/" \t "_blank" C Viveiros;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2c-63syewy7/" \t "_blank" G Fernandez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2d-63syewy8/" \t "_blank" C Travancinha ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2e-63syewy9/" \t "_blank" P-106 Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin chemotherapy: retrospective analysis of 142 patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2f-63syewy0/" \t "_blank" H Engin  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2g-63syewy1/" \t "_blank" P-107 Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A single center experience  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2h-63syewy2/" \t "_blank" H Engin  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2i-63syewy3/" \t "_blank" P-108 Effectiveness of radical radiochemotherapy (RCT) in patients with anal cancer managed at the Bank of Cyprus Oncology Centre: 15 years experience  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2j-63syewy4/" \t "_blank" V Vassiliou;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2k-63syewy5/" \t "_blank" M Pittaka ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2l-63syewy6/" \t "_blank" A Gudenian;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2m-63syewy7/" \t "_blank" K Michailidou;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2n-63syewy8/" \t "_blank" L Michael ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2o-63syewy9/" \t "_blank" P-109 Detection and management of hyperglycaemia in oncology patients receiving systemic anti-cancer therapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2p-63syewy0/" \t "_blank" L Morrison;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2q-63syewy1/" \t "_blank" R Gillmore;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2r-63syewy2/" \t "_blank" R Pierce  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2s-63syewy3/" \t "_blank" P-110 Squamous cell carcinoma of the anal canal and the results of radical treatment with intensity-modulated radiotherapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2t-63syewy4/" \t "_blank" I Oblak;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2u-63syewy5/" \t "_blank" V Velenik;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2v-63syewy6/" \t "_blank" F Anderluh ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2w-63syewy7/" \t "_blank" E Brecelj;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2x-63syewy8/" \t "_blank" J But-Hadzic ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2y-63syewy9/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu2z-63syewy0/" \t "_blank" P-112 Prevalence and genotyping of HPV in anal squamous cell carcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu30-63syewy7/" \t "_blank" S Iseas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu31-63syewy8/" \t "_blank" M Coraglio;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu32-63syewy9/" \t "_blank" J Gonzalez ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu33-63syewy0/" \t "_blank" E Slutsky;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu34-63syewy1/" \t "_blank" D Carvajal ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu35-63syewy2/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu36-63syewy3/" \t "_blank" P-114 The prognostic values of tumor characteristics and clinical factors of neuroendocrine tumors: Two centers experience  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu37-63syewy4/" \t "_blank" E Sezer;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu38-63syewy5/" \t "_blank" K Eser ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu39-63syewy6/" \t "_blank" V Ercolak;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3a-63syewy6/" \t "_blank" Y Ac1kgoz;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3b-63syewy7/" \t "_blank" B Ozturk  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3c-63syewy8/" \t "_blank" P-115 Starting a tumor board meeting at a public sector hospital problems faced and its impact on patient care: A lower middle income country experience  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3d-63syewy9/" \t "_blank" A Malik;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3e-63syewy0/" \t "_blank" M Afzal  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3f-63syewy1/" \t "_blank" P-116 A long-term analysis of imatinib palliative treatment in gastrointestinal stromal tumors  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3g-63syewy2/" \t "_blank" I Domingues;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3h-63syewy3/" \t "_blank" J Carvalho;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3i-63syewy4/" \t "_blank" E Pratas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3j-63syewy5/" \t "_blank" S Pinheiro ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3k-63syewy6/" \t "_blank" S Amaral ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3l-63syewy7/" \t "_blank" P-117 30-day mortality associated with systemic anti-cancer therapy (SACT) in gastrointestinal malignancies: The Christie experience  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3m-63syewy8/" \t "_blank" F Marti Marti;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3n-63syewy9/" \t "_blank" A McGurk;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3o-63syewy0/" \t "_blank" N Alam;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3p-63syewy1/" \t "_blank" L Bhatt;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3q-63syewy2/" \t "_blank" M Braun ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3r-63syewy3/" \t "_blank" P-118 Chemoradiation for anal canal carcinoma in a comprehensive cancer center: Retrospective cohort study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3s-63syewy4/" \t "_blank" J Dias;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3t-63syewy5/" \t "_blank" F Pereira;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3u-63syewy6/" \t "_blank" N Sousa ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3v-63syewy7/" \t "_blank" P Ferreira;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3w-63syewy8/" \t "_blank" D Gomes ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3x-63syewy9/" \t "_blank" P-119 The feasibility study of short hydration with oral rehydration therapy in chemotherapy with cisplatin plus gemcitabine for biliary tract cancer (KHBO-1302)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3y-63syewy0/" \t "_blank" T Ioka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu3z-63syewy1/" \t "_blank" D Sakai;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu40-63syewy8/" \t "_blank" H Wada;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu41-63syewy9/" \t "_blank" H Eguchi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu42-63syewy0/" \t "_blank" K Yanagihara ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu43-63syewy1/" \t "_blank" P-120 Comparison of different risk classification systems in patients with high risk gastrointestinal stromal tumors  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu44-63syewy2/" \t "_blank" Y Yin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu45-63syewy3/" \t "_blank" Z Cai;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu46-63syewy4/" \t "_blank" B Zhang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu47-63syewy5/" \t "_blank" C Shen  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu48-63syewy6/" \t "_blank" P-121 Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu49-63syewy7/" \t "_blank" N Takeuchi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4a-63syewy7/" \t "_blank" K Koike;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4b-63syewy8/" \t "_blank" S Yoshida;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4c-63syewy9/" \t "_blank" N Sekiguchi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4d-63syewy0/" \t "_blank" T Noguchi  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4e-63syewy1/" \t "_blank" P-122 Primary gastric diffuse large B cell lymphoma: A single center experience from developing country  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4f-63syewy2/" \t "_blank" A Gogia;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4g-63syewy3/" \t "_blank" V Raina ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4h-63syewy4/" \t "_blank" M Sharma  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4i-63syewy5/" \t "_blank" P-123 Quality of life by Karnofsky index in patients with gastrointestinal cancer subject to parenteral nutritional therapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4j-63syewy6/" \t "_blank" T Pessoa ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4k-63syewy7/" \t "_blank" A Pessoa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4l-63syewy8/" \t "_blank" P Aguiar;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4m-63syewy9/" \t "_blank" F Moreira;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4n-63syewy0/" \t "_blank" R Pessoa ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4o-63syewy1/" \t "_blank" P-124 De novo malignancies in patients after liver transplantation: A single centre experience  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4p-63syewy2/" \t "_blank" K Chmelova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4q-63syewy3/" \t "_blank" J Spicak  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4r-63syewy4/" \t "_blank" P-125 Laparoscopic liver resection for tumors in proximity to major vasculature and the impact of neo-adjuvant systemic therapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4s-63syewy5/" \t "_blank" M D'Hondt;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4t-63syewy6/" \t "_blank" E Willems;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4u-63syewy7/" \t "_blank" I Parmentier ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4v-63syewy8/" \t "_blank" H Pottel;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4w-63syewy9/" \t "_blank" C Verslype ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4x-63syewy0/" \t "_blank" P-126 Impact of revision surgery timing on overall survival in incidentally detected gall bladder cancer: An experience from tertiary care centre of Northern India  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4y-63syewy1/" \t "_blank" A Mishra;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu4z-63syewy2/" \t "_blank" M Gowda;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu50-63syewy9/" \t "_blank" S Bhoriwal;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu51-63syewy0/" \t "_blank" S Deo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu52-63syewy1/" \t "_blank" N Shukla ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu53-63syewy2/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu54-63syewy3/" \t "_blank" P-128 Surgical resection of primary tumor site is associated with prolonged survival in metastatic pancreatic neuroendocrine carcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu55-63syewy4/" \t "_blank" T Feng;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu56-63syewy5/" \t "_blank" S Ling  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu57-63syewy6/" \t "_blank" P-129 Comparing efficacy of 1-L Peg-Asc with prucalopride versus 2-L Peg-Asc for bowel preparation  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu58-63syewy7/" \t "_blank" S Jang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu59-63syewy8/" \t "_blank" Y Jeen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5a-63syewy8/" \t "_blank" S Choi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5b-63syewy9/" \t "_blank" J Lee ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5c-63syewy0/" \t "_blank" S Kim ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5d-63syewy1/" \t "_blank" P-130 A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5e-63syewy2/" \t "_blank" J Wei;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5f-63syewy3/" \t "_blank" J Yan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5g-63syewy4/" \t "_blank" S Su;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5h-63syewy5/" \t "_blank" J Shao;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5i-63syewy6/" \t "_blank" Y Zhao ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5j-63syewy7/" \t "_blank" P-131 Endoscopic detachable auxiliary manipulator in endoscopic submucosal dissection: Animal model studY  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5k-63syewy8/" \t "_blank" H Jeon;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5l-63syewy9/" \t "_blank" H Chun ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5m-63syewy0/" \t "_blank" B Keum;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5n-63syewy1/" \t "_blank" J Lee;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5o-63syewy2/" \t "_blank" S Choi ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5p-63syewy3/" \t "_blank" P-132 Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5q-63syewy4/" \t "_blank" V Domenyuk;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5r-63syewy5/" \t "_blank" X Liu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5s-63syewy6/" \t "_blank" D Magee;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5t-63syewy7/" \t "_blank" Z Gatalica ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5u-63syewy8/" \t "_blank" A Stark ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5v-63syewy9/" \t "_blank" P-133 The use of NLR, PLR and CA19.9 as prognostic markers for locally advanced pancreatic cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5w-63syewy0/" \t "_blank" A Dean ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5x-63syewy1/" \t "_blank" D Higgs;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5y-63syewy2/" \t "_blank" A Das;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu5z-63syewy3/" \t "_blank" S Fennessy;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu60-63syewy0/" \t "_blank" M Rogers-Seeley ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu61-63syewy1/" \t "_blank" P-134 Antibodies matter: A meta-analysis of the prognostic value of human equilibrative nucleoside transporter 1 (hENT1) antibodies in pancreatobiliary cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu62-63syewy2/" \t "_blank" D Yusuf;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu63-63syewy3/" \t "_blank" L Vos ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu64-63syewy4/" \t "_blank" A Lui;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu65-63syewy5/" \t "_blank" Z Abdelaziz;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu66-63syewy6/" \t "_blank" S Ghosh ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu67-63syewy7/" \t "_blank" P-135 The impact of inflammatory biomarkers on overall survival of patients with pancreatic cancer treated with chemoradiation  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu68-63syewy8/" \t "_blank" K Holub;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu69-63syewy9/" \t "_blank" C Conill  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6a-63syewy9/" \t "_blank" P-136 Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6b-63syewy0/" \t "_blank" A Cortellini;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6c-63syewy1/" \t "_blank" A Parisi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6d-63syewy2/" \t "_blank" K Cannita;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6e-63syewy3/" \t "_blank" O Venditti ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6f-63syewy4/" \t "_blank" F Pavese ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6g-63syewy5/" \t "_blank" P-137 Intraperitoneal chemotherapy for pancreatic cancer with peritoneal metastases: A single center retrospective analysis of 25 patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6h-63syewy6/" \t "_blank" Y Tsuji;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6i-63syewy7/" \t "_blank" T Takayama;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6j-63syewy8/" \t "_blank" N Okamura;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6k-63syewy9/" \t "_blank" J Sugiyama;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6l-63syewy0/" \t "_blank" S Oiwa ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6m-63syewy1/" \t "_blank" P-138 Predictive factors for early relapse and survival in resected pancreatic cancer: A single institution experience  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6n-63syewy2/" \t "_blank" C Saavedra Serrano;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6o-63syewy3/" \t "_blank" P Reguera Puertas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6p-63syewy4/" \t "_blank" O Martnez Saez ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6q-63syewy5/" \t "_blank" F Longo Muoz;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6r-63syewy6/" \t "_blank" A Barqun Garca ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6s-63syewy7/" \t "_blank" P-139 HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6t-63syewy8/" \t "_blank" A Ishiguro;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6u-63syewy9/" \t "_blank" Y Kawamoto;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6v-63syewy0/" \t "_blank" S Yuki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6w-63syewy1/" \t "_blank" S Nakano;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6x-63syewy2/" \t "_blank" M Yagisawa ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6y-63syewy3/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu6z-63syewy4/" \t "_blank" P-141 PanCO: An open-label, single-arm pilot study of Oncosil"! in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu70-63syewy1/" \t "_blank" M Harris;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu71-63syewy2/" \t "_blank" D Croagh;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu72-63syewy3/" \t "_blank" M Aghmesheh;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu73-63syewy4/" \t "_blank" A Nagrial ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu74-63syewy5/" \t "_blank" N Nguyen ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu75-63syewy6/" \t "_blank" P-142 Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu76-63syewy7/" \t "_blank" S Kokkali ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu77-63syewy8/" \t "_blank" M Drizou;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu78-63syewy9/" \t "_blank" E Tripodaki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu79-63syewy0/" \t "_blank" D Stefanou;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7a-63syewy0/" \t "_blank" E Magou ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7b-63syewy1/" \t "_blank" P-143 Safety of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients presenting with hyperbilirubinemia secondary to bile duct obstruction  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7c-63syewy2/" \t "_blank" M Sasaki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7d-63syewy3/" \t "_blank" H Imaoka ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7e-63syewy4/" \t "_blank" M Kan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7f-63syewy5/" \t "_blank" Y Suzuki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7g-63syewy6/" \t "_blank" G Kimura ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7h-63syewy7/" \t "_blank" P-144 Pancreatic ductal adenocarcinoma (PDAC) and type 2 diabetes mellitus: Cause or consequence? Analysis of the prevalence of alterations in glucose metabolism (AGM) in a patients cohort with PDAC  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7i-63syewy8/" \t "_blank" L Medina Rodriguez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7j-63syewy9/" \t "_blank" C Sanchez Cendra;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7k-63syewy0/" \t "_blank" M Pantin Gonzalez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7l-63syewy1/" \t "_blank" D Gutierrez Abad;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7m-63syewy2/" \t "_blank" I Juez Martel ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7n-63syewy3/" \t "_blank" P-145 FOLFIRINOX in pancreatic cancer: A careful review  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7o-63syewy4/" \t "_blank" E Una Cidon ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7p-63syewy5/" \t "_blank" P Alonso  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7q-63syewy6/" \t "_blank" P-146 Circulating tumor DNA (ctDNA) as a predictor of treatment for locally advanced pancreatic cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7r-63syewy7/" \t "_blank" G Botiralieva  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7s-63syewy8/" \t "_blank" P-147 Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7t-63syewy9/" \t "_blank" M McNulty ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7u-63syewy0/" \t "_blank" A Dean;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7v-63syewy1/" \t "_blank" A Das;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7w-63syewy2/" \t "_blank" M Gordon  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7x-63syewy3/" \t "_blank" P-148 Nimotuzumab bi-weekly/low dose combined to chemotherapy in advanced pancreatic cancer: A clinical study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7y-63syewy4/" \t "_blank" M Lima;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu7z-63syewy5/" \t "_blank" V Jennifer;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu80-63syewy2/" \t "_blank" C Dominguez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu81-63syewy3/" \t "_blank" G Robin ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu82-63syewy4/" \t "_blank" M Dunia ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu83-63syewy5/" \t "_blank" P-149 Risk factors and epidemiological features of pancreatic cancer in Iran  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu84-63syewy6/" \t "_blank" A Pourshams  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu85-63syewy7/" \t "_blank" P-150 Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu86-63syewy8/" \t "_blank" T Macarulla Mercad ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu87-63syewy9/" \t "_blank" A Wang-Gillam;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu88-63syewy0/" \t "_blank" L Chen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu89-63syewy1/" \t "_blank" J Blanc;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8a-63syewy1/" \t "_blank" K Lee ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8b-63syewy2/" \t "_blank" P-151 Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8c-63syewy3/" \t "_blank" G Lakatos;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8d-63syewy4/" \t "_blank" K Lee ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8e-63syewy5/" \t "_blank" J Siveke;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8f-63syewy6/" \t "_blank" J Blanc;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8g-63syewy7/" \t "_blank" T Macarulla Mercad ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8h-63syewy8/" \t "_blank" P-152 The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8i-63syewy9/" \t "_blank" T Macarulla Mercad;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8j-63syewy0/" \t "_blank" A Wang-Gillam;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8k-63syewy1/" \t "_blank" L Chen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8l-63syewy2/" \t "_blank" J Blanc;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8m-63syewy3/" \t "_blank" K Lee ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8n-63syewy4/" \t "_blank" P-153 Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8o-63syewy5/" \t "_blank" K Lee;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8p-63syewy6/" \t "_blank" G Bodoky;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8q-63syewy7/" \t "_blank" J Blanc;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8r-63syewy8/" \t "_blank" J Siveke;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8s-63syewy9/" \t "_blank" T Macarulla Mercad ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8t-63syewy0/" \t "_blank" P-154 Real life triplet FIr/FOx chemotherapy in first line metastatic pancreatic ductal adenocarcinoma: Recommended schedule for expected activity and safety and phase II study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8u-63syewy1/" \t "_blank" G Bruera;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8v-63syewy2/" \t "_blank" S Massacese ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8w-63syewy3/" \t "_blank" R Manetta;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8x-63syewy4/" \t "_blank" A Giordano;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8y-63syewy5/" \t "_blank" S Carducci ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu8z-63syewy6/" \t "_blank" P-155 Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu90-63syewy3/" \t "_blank" V Sahai;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu91-63syewy4/" \t "_blank" W Saif;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu92-63syewy5/" \t "_blank" A Kalyan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu93-63syewy6/" \t "_blank" P Philip ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu94-63syewy7/" \t "_blank" C Rocha-Lima ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu95-63syewy8/" \t "_blank" P-156 Effectiveness and costs of FOLFIRINOX in the treatment of advanced pancreatic cancer in a Portuguese oncology center  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu96-63syewy9/" \t "_blank" H Magalhes ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu97-63syewy0/" \t "_blank" J Lima;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu98-63syewy1/" \t "_blank" M Cassiano Neves;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu99-63syewy2/" \t "_blank" M Fontes e Sousa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9a-63syewy2/" \t "_blank" M Machado  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9b-63syewy3/" \t "_blank" P-157 Gemcitabine/nabpaclitaxel efficacy in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9c-63syewy4/" \t "_blank" V Michalaki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9d-63syewy5/" \t "_blank" A Poydorou;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9e-63syewy6/" \t "_blank" G Frangulidis ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9f-63syewy7/" \t "_blank" A Vezakis;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9g-63syewy8/" \t "_blank" E Karvouni ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9h-63syewy9/" \t "_blank" P-158 Correlation of neutrophil lymphocyte ratio, platelet lymphocyte ratio and rate of change of CA 19.9 in predicting outcome for metastatic pancreatic cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9i-63syewy0/" \t "_blank" A Dean;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9j-63syewy1/" \t "_blank" D Higgs;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9k-63syewy2/" \t "_blank" A Das;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9l-63syewy3/" \t "_blank" M Rogers-Seeley;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9m-63syewy4/" \t "_blank" S Fennessy ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9n-63syewy5/" \t "_blank" P-159 Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine + nab-paclitaxel  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9o-63syewy6/" \t "_blank" C Vivaldi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9p-63syewy7/" \t "_blank" C Cappelli;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9q-63syewy8/" \t "_blank" F Donati;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9r-63syewy9/" \t "_blank" L Fornaro;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9s-63syewy0/" \t "_blank" G Musettini ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9t-63syewy1/" \t "_blank" P-160 Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first line chemotherapy in routine practice  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9u-63syewy2/" \t "_blank" A Garca Velasco;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9v-63syewy3/" \t "_blank" T Macarulla;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9w-63syewy4/" \t "_blank" C Bugs Snchez ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9x-63syewy5/" \t "_blank" M Martn;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9y-63syewy6/" \t "_blank" C Garca ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wu9z-63syewy7/" \t "_blank" P-161 FOLFIRINOX versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wua0-63syewy3/" \t "_blank" I Cho;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wua1-63syewy4/" \t "_blank" H Kang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wua2-63syewy5/" \t "_blank" J Jo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wua3-63syewy6/" \t "_blank" H Lee;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wua4-63syewy7/" \t "_blank" M Chung ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wua5-63syewy8/" \t "_blank" P-162 Second line in pancreatic cancer: Resuming our experience and looking for prognostic factors  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wua6-63syewy9/" \t "_blank" B Anton;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wua7-63syewy0/" \t "_blank" F Longo Muoz;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wua8-63syewy1/" \t "_blank" D Gutierrez Abad;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wua9-63syewy2/" \t "_blank" M De Torres Olombrada;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuaa-63syewy2/" \t "_blank" I Juez Martel ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuab-63syewy3/" \t "_blank" P-163 Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre Zagreb  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuac-63syewy4/" \t "_blank" J Prejac;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuad-63syewy5/" \t "_blank" I Gorai;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuae-63syewy6/" \t "_blank" M Vidovi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuaf-63syewy7/" \t "_blank" H Golem;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuag-63syewy8/" \t "_blank" D Kekez ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuah-63syewy9/" \t "_blank" P-164 Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuai-63syewy0/" \t "_blank" V Pacheco-Barcia;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuaj-63syewy1/" \t "_blank" T France;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuak-63syewy2/" \t "_blank" G Zogopoulos;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wual-63syewy3/" \t "_blank" N Bouganim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuam-63syewy4/" \t "_blank" O Donnay ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuan-63syewy5/" \t "_blank" P-165 Clinical outcomes for modified FOLFIRINOX chemotherapy for pancreatic cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuao-63syewy6/" \t "_blank" D Holyoake;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuap-63syewy7/" \t "_blank" C Lo ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuaq-63syewy8/" \t "_blank" H Stubbings;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuar-63syewy9/" \t "_blank" T Roques  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuas-63syewy0/" \t "_blank" P-166 Questions of resolving cholestasis in metastatic cancer of the hepatobiliary system  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuat-63syewy1/" \t "_blank" S Khoshimov  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuau-63syewy2/" \t "_blank" P-167 Symptoms reported at initial diagnosis of (metastatic) pancreatic adenocarcinoma ([m]PAC) in routine clinical practice and variation in frequencies across Europe  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuav-63syewy3/" \t "_blank" D Melisi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuaw-63syewy4/" \t "_blank" B Westphalen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuax-63syewy5/" \t "_blank" Mellbring;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuay-63syewy6/" \t "_blank" A Carrato;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuaz-63syewy7/" \t "_blank" J Taieb ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wub0-63syewy4/" \t "_blank" P-168 Multiple dose pharmacokinetics of erlotinib when combined with gastric acid reducing agents: A comparison with a physiologically based pharmacokinetic model  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wub1-63syewy5/" \t "_blank" A Sahmanovic Hrgovcic ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wub2-63syewy6/" \t "_blank" A Gruber;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wub3-63syewy7/" \t "_blank" C Dittrich;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wub4-63syewy8/" \t "_blank" M Kitzmueller;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wub5-63syewy9/" \t "_blank" P Buchner ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wub6-63syewy0/" \t "_blank" P-169 Gemcitabine induced hemolytic uremic syndrome: Underestimated?  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wub7-63syewy1/" \t "_blank" E Una Cidon;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wub8-63syewy2/" \t "_blank" P Alonso  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wub9-63syewy3/" \t "_blank" P-170 Management of patients with unresectable HCC: A simulation-based assessment of medical oncologists practice choices  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuba-63syewy3/" \t "_blank" T Herrmann;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubb-63syewy4/" \t "_blank" A Carothers;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubc-63syewy5/" \t "_blank" G Littman;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubd-63syewy6/" \t "_blank" M Warters ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wube-63syewy7/" \t "_blank" C Cason ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubf-63syewy8/" \t "_blank" P-171 Analysis of echoendoscopic punctures of a solid pancreatic lesions in a private institution in Brazil  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubg-63syewy9/" \t "_blank" T Pessoa ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubh-63syewy0/" \t "_blank" A Pessoa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubi-63syewy1/" \t "_blank" P Aguiar;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubj-63syewy2/" \t "_blank" R Pessoa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubk-63syewy3/" \t "_blank" A Moura ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubl-63syewy4/" \t "_blank" P-172 Epidemiology, treatment modalities and prognostic factors of pancreatic cancer: A retrospective study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubm-63syewy5/" \t "_blank" W Khechine;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubn-63syewy6/" \t "_blank" I Belaid;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubo-63syewy7/" \t "_blank" F Ezzairi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubp-63syewy8/" \t "_blank" A El Ghali;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubq-63syewy9/" \t "_blank" A Bedioui ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubr-63syewy0/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubs-63syewy1/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubt-63syewy2/" \t "_blank" P-175 Clinical implication of inflammation markers for identifying radiotherapy candidates in inoperable locally advanced pancreas cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubu-63syewy3/" \t "_blank" W Cho ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubv-63syewy4/" \t "_blank" J Yu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubw-63syewy5/" \t "_blank" H Park;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubx-63syewy6/" \t "_blank" D Lim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuby-63syewy7/" \t "_blank" J Park ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wubz-63syewy8/" \t "_blank" P-176 Analysis of various clinical and pathological factors affecting survival in patients diagnosed with pancreatic adenocarcinoma: Single institute study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuc0-63syewy5/" \t "_blank" A Nagy  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuc1-63syewy6/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuc2-63syewy7/" \t "_blank" P-178 Clinical characteristic of pancreatic cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuc3-63syewy8/" \t "_blank" B Abdelkader El Hakim ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuc4-63syewy9/" \t "_blank" N Caid;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuc5-63syewy0/" \t "_blank" L Saoudi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuc6-63syewy1/" \t "_blank" R Benemla;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuc7-63syewy2/" \t "_blank" R Ramoul ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuc8-63syewy3/" \t "_blank" P-179 Surgical management of pancreatic tumors in children  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuc9-63syewy4/" \t "_blank" A Lukashenko;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuca-63syewy4/" \t "_blank" Y Ostapenko;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucb-63syewy5/" \t "_blank" O Kolesnik;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucc-63syewy6/" \t "_blank" N Chorna  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucd-63syewy7/" \t "_blank" P-180 Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma: An updated analysis  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuce-63syewy8/" \t "_blank" S Temraz ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucf-63syewy9/" \t "_blank" M Salim Hammoud;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucg-63syewy0/" \t "_blank" M Zorkot;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuch-63syewy1/" \t "_blank" W Albonji;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuci-63syewy2/" \t "_blank" H Dbouk ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucj-63syewy3/" \t "_blank" P-181 Pancreatic head resections: Impact factors, perioperative morbidity, mortality and long-term survival  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuck-63syewy4/" \t "_blank" B Ilijevec;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucl-63syewy5/" \t "_blank" S Potrc  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucm-63syewy6/" \t "_blank" P-182 Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucn-63syewy7/" \t "_blank" S Qin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuco-63syewy8/" \t "_blank" R Finn ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucp-63syewy9/" \t "_blank" M Kudo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucq-63syewy0/" \t "_blank" T Meyer;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucr-63syewy1/" \t "_blank" A Vogel ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucs-63syewy2/" \t "_blank" P-183 A pilot trial of PEGPH20 (Pegvorhyaluronidase alfa) in combination with avelumab (anti-PD-L1 MSB0010718C) in chemotherapy resistant pancreatic cancer (PDAC) - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuct-63syewy3/" \t "_blank" L Medina Rodriguez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucu-63syewy4/" \t "_blank" C Guilln-Ponce;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucv-63syewy5/" \t "_blank" J Feliu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucw-63syewy6/" \t "_blank" M Hidalgo  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucx-63syewy7/" \t "_blank" P-184 CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucy-63syewy8/" \t "_blank" T Bekaii-Saab ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wucz-63syewy9/" \t "_blank" T Okusaka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wud0-63syewy6/" \t "_blank" D Goldstein;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wud1-63syewy7/" \t "_blank" B ONeill;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wud2-63syewy8/" \t "_blank" J Tabernero ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wud3-63syewy9/" \t "_blank" P-185 PANOVA-3: A phase 3 study of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wud4-63syewy0/" \t "_blank" U Weinberg;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wud5-63syewy1/" \t "_blank" O Faber ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wud6-63syewy2/" \t "_blank" M Giladi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wud7-63syewy3/" \t "_blank" Z Bomzon;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wud8-63syewy4/" \t "_blank" G Lavy-Shahaf ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wud9-63syewy5/" \t "_blank" P-186 Chemotherapy for patients with advanced or metastatic pancreatic cancer (AMPC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuda-63syewy5/" \t "_blank" B Abdelkader El Hakim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudb-63syewy6/" \t "_blank" F Braneci;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudc-63syewy7/" \t "_blank" N Caid;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudd-63syewy8/" \t "_blank" L Saoudi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wude-63syewy9/" \t "_blank" R Ramoul ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudf-63syewy0/" \t "_blank" P-187 Erythrocyte membrane fatty acids as the potential biomarkers for detection of early-stage and progression of colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudg-63syewy1/" \t "_blank" M Kruchinina;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudh-63syewy2/" \t "_blank" A Gromov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudi-63syewy3/" \t "_blank" Y Prudnikova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudj-63syewy4/" \t "_blank" M Shashkov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudk-63syewy5/" \t "_blank" A Sokolova ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudl-63syewy6/" \t "_blank" P-188 LncRNA-ZFAS1 contributes to colon cancer progression through the miR-150-5p/VEGFA axis  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudm-63syewy7/" \t "_blank" X Chen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudn-63syewy8/" \t "_blank" S Wang  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudo-63syewy9/" \t "_blank" P-189 Retinoic acid-induced 2 (RAI2) is a potential tumor suppressor and RAI2 promoter methylation is a poor prognostic marker in colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudp-63syewy0/" \t "_blank" W Yan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudq-63syewy1/" \t "_blank" K Wu ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudr-63syewy2/" \t "_blank" Y Yang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuds-63syewy3/" \t "_blank" M Guo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudt-63syewy4/" \t "_blank" G Dai  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudu-63syewy5/" \t "_blank" P-190 The influence of GSTM1-null, TS-del6bp, XRCC1-A751C gene polymorphisms on overall survival in colorectal cancer patients related to the TNM parameters: A Romanian single-center study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudv-63syewy6/" \t "_blank" L Procopciuc;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudw-63syewy7/" \t "_blank" G Osian;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudx-63syewy8/" \t "_blank" M Iancu  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudy-63syewy9/" \t "_blank" P-191 Combined analysis of KRAS, NRAS, BRAF mutations and mismatch repair deficiency testing in Indian patients with metastatic colorectal carcinoma: A single centre experience  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wudz-63syewy0/" \t "_blank" T Sood;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wue0-63syewy7/" \t "_blank" A Rauthan ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wue1-63syewy8/" \t "_blank" P Patil;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wue2-63syewy9/" \t "_blank" S Kulkarni  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wue3-63syewy0/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wue4-63syewy1/" \t "_blank" P-193 RAS status in Algerian metastatic colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wue5-63syewy2/" \t "_blank" A Bensalem  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wue6-63syewy3/" \t "_blank" P-194 Transcribed ultraconserved regions Uc160 and Uc346 in colon cancer progression  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wue7-63syewy4/" \t "_blank" A Kottorou;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wue8-63syewy5/" \t "_blank" C Sirinian;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wue9-63syewy6/" \t "_blank" F Dimitrakopoulos;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuea-63syewy6/" \t "_blank" A Antonacopoulou ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wueb-63syewy7/" \t "_blank" T Makatsoris ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuec-63syewy8/" \t "_blank" P-195 Cost of illness for colorectal cancer at low middle income countries Egypt case  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wued-63syewy9/" \t "_blank" A Abotaleb  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuee-63syewy0/" \t "_blank" P-196 Anti-angiogenic action of leukotriene-C4 induced 15-hydroxyprostaglandin dehydrogenase in colon cancer cells is a TNF- dependent phenomenon  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuef-63syewy1/" \t "_blank" S Satapathy ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wueg-63syewy2/" \t "_blank" A Sjolander  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wueh-63syewy3/" \t "_blank" P-197 Repurposing ponatinib for the treatment of colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuei-63syewy4/" \t "_blank" F Tan ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuej-63syewy5/" \t "_blank" T Putoczki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuek-63syewy6/" \t "_blank" F Hollande;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuel-63syewy7/" \t "_blank" R Luwor  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuem-63syewy8/" \t "_blank" P-198 The management of locally advanced and metastatic colorectal cancer: A retrospective study of 77 cases  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuen-63syewy9/" \t "_blank" F Boudinar;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wueo-63syewy0/" \t "_blank" G Bettache;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuep-63syewy1/" \t "_blank" K Wahiba;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wueq-63syewy2/" \t "_blank" B Larbaoui  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuer-63syewy3/" \t "_blank" P-199 Colorectal cancer screening in Flanders: Advances in personalised screening  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wues-63syewy4/" \t "_blank" W van de Veerdonk;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuet-63syewy5/" \t "_blank" G Van Hal;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wueu-63syewy6/" \t "_blank" M Peeters ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuev-63syewy7/" \t "_blank" I Brabander;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuew-63syewy8/" \t "_blank" G Silversmit ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuex-63syewy9/" \t "_blank" P-200 Risk factors of colorectal cancer in Linxian, China: A nutrition intervention trial with 30 years follow-up  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuey-63syewy0/" \t "_blank" H Keskin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuez-63syewy1/" \t "_blank" A Etemadi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuf0-63syewy8/" \t "_blank" P Taylor  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuf1-63syewy9/" \t "_blank" P-201 Evaluation of the prognostic value of lymph-node ratio in patients with colon cancer in the oxaliplatin era  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuf2-63syewy0/" \t "_blank" B Bird;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuf3-63syewy1/" \t "_blank" D Connell;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuf4-63syewy2/" \t "_blank" D OConnor  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuf5-63syewy3/" \t "_blank" P-202 Competing risks analysis of microsatellite instability as a prognostic factor in colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuf6-63syewy4/" \t "_blank" K Spring;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuf7-63syewy5/" \t "_blank" J Toh;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuf8-63syewy6/" \t "_blank" P Chapuis ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuf9-63syewy7/" \t "_blank" L Bokey;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufa-63syewy7/" \t "_blank" C Chan ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufb-63syewy8/" \t "_blank" P-203 Survival and prognostic factors of non metastatic rectal adenocarcinoma: Analytic multifactor review of 91 cases  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufc-63syewy9/" \t "_blank" K Darif;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufd-63syewy0/" \t "_blank" Z Benbrahim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufe-63syewy1/" \t "_blank" M Benhami;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuff-63syewy2/" \t "_blank" I Ahalli;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufg-63syewy3/" \t "_blank" R Boujarnija ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufh-63syewy4/" \t "_blank" P-204 Prognostic value of neo-adjuvant treatment in localized rectal cancer about 78 cases  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufi-63syewy5/" \t "_blank" K Darif;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufj-63syewy6/" \t "_blank" Z Benbrahim ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufk-63syewy7/" \t "_blank" M Benhami;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufl-63syewy8/" \t "_blank" I Ahalli;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufm-63syewy9/" \t "_blank" R Boujarnija ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufn-63syewy0/" \t "_blank" P-205 Preoperative short course of radiotherapy in selected high risk patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufo-63syewy1/" \t "_blank" M Caro Gallarn;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufp-63syewy2/" \t "_blank" H Rosales Gonzlez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufq-63syewy3/" \t "_blank" J Jov Teixid;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufr-63syewy4/" \t "_blank" E Luguera Snchez ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufs-63syewy5/" \t "_blank" I Planas Toledano ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuft-63syewy6/" \t "_blank" P-206 Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufu-63syewy7/" \t "_blank" G Bruera;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufv-63syewy8/" \t "_blank" S Massacese;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufw-63syewy9/" \t "_blank" F Pepe;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufx-63syewy0/" \t "_blank" U Malapelle;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufy-63syewy1/" \t "_blank" A Dal Mas ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wufz-63syewy2/" \t "_blank" P-207 Clinico-pathological and molecular characterization of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wug0-63syewy9/" \t "_blank" M Schirripa ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wug1-63syewy0/" \t "_blank" P Biason;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wug2-63syewy1/" \t "_blank" F Cortiula;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wug3-63syewy2/" \t "_blank" M Pino;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wug4-63syewy3/" \t "_blank" F Urbano ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wug5-63syewy4/" \t "_blank" P-208 Autophagy (A) related proteins evaluation represents an independent survival factor of colorectal cancer (CRC) patients (pts)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wug6-63syewy5/" \t "_blank" M Karamouzis;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wug7-63syewy6/" \t "_blank" A Saetta;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wug8-63syewy7/" \t "_blank" E Koustas ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wug9-63syewy8/" \t "_blank" I Chatziandreou;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuga-63syewy8/" \t "_blank" I Giannopoulou ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugb-63syewy9/" \t "_blank" P-209 P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugc-63syewy0/" \t "_blank" M Puzzoni;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugd-63syewy1/" \t "_blank" L Demurtas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuge-63syewy2/" \t "_blank" P Ziranu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugf-63syewy3/" \t "_blank" E Lai ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugg-63syewy4/" \t "_blank" R Giampieri ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugh-63syewy5/" \t "_blank" P-210 Unexpected discordance in 5-year OS rates between Nx colon cancer patients and those in stages II plus III  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugi-63syewy6/" \t "_blank" I Tonev ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugj-63syewy7/" \t "_blank" N Conev;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugk-63syewy8/" \t "_blank" A Petrov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugl-63syewy9/" \t "_blank" I Donev  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugm-63syewy0/" \t "_blank" P-211 Serum angiogenesis associated proteins and clinical outcome in metastatic colorectal cancer patients receiving bevacizumab  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugn-63syewy1/" \t "_blank" G Marisi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugo-63syewy2/" \t "_blank" E Scarpi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugp-63syewy3/" \t "_blank" A Passardi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugq-63syewy4/" \t "_blank" O Nanni ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugr-63syewy5/" \t "_blank" F Pagan ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugs-63syewy6/" \t "_blank" P-212 CDX2 immunohistochemistry as a prognostic biomarker for colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugt-63syewy7/" \t "_blank" A Fatimilehin ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugu-63syewy8/" \t "_blank" C Mikropoulos;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugv-63syewy9/" \t "_blank" J Summers;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugw-63syewy0/" \t "_blank" L Rajakumar;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugx-63syewy1/" \t "_blank" M Hill  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugy-63syewy2/" \t "_blank" P-213 An evaluation of the clinical utility of a panel of variants in DPYD and ENOSF1 for predicting common capecitabine related toxicities  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wugz-63syewy3/" \t "_blank" C Palles;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuh0-63syewy0/" \t "_blank" S Fotheringham;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuh1-63syewy1/" \t "_blank" L Chegwidden ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuh2-63syewy2/" \t "_blank" M Lucas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuh3-63syewy3/" \t "_blank" G Mozolowski ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuh4-63syewy4/" \t "_blank" P-214 Bevacizumab combined with 1st line chemotherapy in elderly patients with metastatic colorectal cancer: Are there good prognostic indicators?  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuh5-63syewy5/" \t "_blank" C Borges;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuh6-63syewy6/" \t "_blank" J Simes;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuh7-63syewy7/" \t "_blank" C Lemos;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuh8-63syewy8/" \t "_blank" C Fernandes;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuh9-63syewy9/" \t "_blank" C Sarmento ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuha-63syewy9/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhb-63syewy0/" \t "_blank" P-216 Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhc-63syewy1/" \t "_blank" M Boisdron-Celle;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhd-63syewy2/" \t "_blank" J Metges;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhe-63syewy3/" \t "_blank" O Capitain;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhf-63syewy4/" \t "_blank" R Faroux ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhg-63syewy5/" \t "_blank" C Stampfli ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhh-63syewy6/" \t "_blank" P-217 ABCG2 and TOP-1 as predictive biomarkers and targets for therapy in colon cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhi-63syewy7/" \t "_blank" N Brnner ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhj-63syewy8/" \t "_blank" J Stenvang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhk-63syewy9/" \t "_blank" V Popovici;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhl-63syewy0/" \t "_blank" E Budinska  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhm-63syewy1/" \t "_blank" P-218 Biomarkers of oxidative stress in patient with colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhn-63syewy2/" \t "_blank" H Haddouche  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuho-63syewy3/" \t "_blank" P-219 Colorectal neuroendocrine carcinoma and colorectal mixed adeno-neuroendocrine carcinoma: A population-based study of the surveillance, epidemiology, and end results registry  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhp-63syewy4/" \t "_blank" M Liu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhq-63syewy5/" \t "_blank" H Zhang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhr-63syewy6/" \t "_blank" Y Yang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhs-63syewy7/" \t "_blank" X Fu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuht-63syewy8/" \t "_blank" K Nan ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhu-63syewy9/" \t "_blank" P-220 MTHFR, TSER and DPYD gene mutation is associated with toxicity and response in pre-operative chemo-radiotherapy for local advanced rectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhv-63syewy0/" \t "_blank" S Mancarella ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhw-63syewy1/" \t "_blank" O Pot;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhx-63syewy2/" \t "_blank" D De Giorgi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhy-63syewy3/" \t "_blank" M Schirinzi  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuhz-63syewy4/" \t "_blank" P-221 Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer: The optimization of pharmacological costs  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wui0-63syewy1/" \t "_blank" J Giuliani;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wui1-63syewy2/" \t "_blank" A Bonetti  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wui2-63syewy3/" \t "_blank" P-222 Is the PEG-G-CSF useful as the prevention for the severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab?  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wui3-63syewy4/" \t "_blank" H Osumi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wui4-63syewy5/" \t "_blank" E Shinozaki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wui5-63syewy6/" \t "_blank" T Wakatsuki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wui6-63syewy7/" \t "_blank" M Suenaga ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wui7-63syewy8/" \t "_blank" T Ichimura ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wui8-63syewy9/" \t "_blank" P-223 NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wui9-63syewy0/" \t "_blank" S Yuki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuia-63syewy0/" \t "_blank" Y Komatsu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuib-63syewy1/" \t "_blank" Y Kawamoto;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuic-63syewy2/" \t "_blank" H Nakatsumi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuid-63syewy3/" \t "_blank" N Takahashi ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuie-63syewy4/" \t "_blank" P-224 Analysis of clinical outcomes of two antiEGFR antibodies, cetuximab and panitumumab, in the 1st line chemotherapy of RAS wild metastatic colorectal cancer, by neutrophil-to-lymphocyte ratio (NLR) kinetics  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuif-63syewy5/" \t "_blank" D Manaka ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuig-63syewy6/" \t "_blank" R Nishitai;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuih-63syewy7/" \t "_blank" S Konishi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuii-63syewy8/" \t "_blank" T Ota;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuij-63syewy9/" \t "_blank" Y Nishikawa ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuik-63syewy0/" \t "_blank" P-225 The role of maintenance therapy in the first line treatment of metastatic colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuil-63syewy1/" \t "_blank" D Gridnev;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuim-63syewy2/" \t "_blank" A Popov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuin-63syewy3/" \t "_blank" E Vozny ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuio-63syewy4/" \t "_blank" V Makarov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuip-63syewy5/" \t "_blank" D Islamova ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuiq-63syewy6/" \t "_blank" P-226 HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuir-63syewy7/" \t "_blank" M Nakamura;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuis-63syewy8/" \t "_blank" Y Komatsu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuit-63syewy9/" \t "_blank" T Muranaka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuiu-63syewy0/" \t "_blank" M Yagisawa ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuiv-63syewy1/" \t "_blank" Y Kawamoto ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuiw-63syewy2/" \t "_blank" P-227 Analysis of the benefit of the adjuvant chemotherapy in stage II colon cancer according to the presence of classic poor risk factors: Our experience in Ramon y Cajal Hospital  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuix-63syewy3/" \t "_blank" C Saavedra Serrano;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuiy-63syewy4/" \t "_blank" M Villamayor Delgado;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuiz-63syewy5/" \t "_blank" E Corral de la Fuente;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuj0-63syewy2/" \t "_blank" A Barqun Garca;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuj1-63syewy3/" \t "_blank" J Serrano Domingo ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuj2-63syewy4/" \t "_blank" P-228 VOLTAGE: Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy (CRT) with capecitabine in patients with locally advanced rectal cancer (LARC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuj3-63syewy5/" \t "_blank" H Bando ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuj4-63syewy6/" \t "_blank" Y Tsukada;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuj5-63syewy7/" \t "_blank" K Inamori;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuj6-63syewy8/" \t "_blank" S Fukuoka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuj7-63syewy9/" \t "_blank" T Sasaki ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuj8-63syewy0/" \t "_blank" P-229 Long-term clinical outcomes in large colorectal polyps with indefinite or positive resection margin after endoscopic resection  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuj9-63syewy1/" \t "_blank" D Kang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuja-63syewy1/" \t "_blank" H Kim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujb-63syewy2/" \t "_blank" C Choi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujc-63syewy3/" \t "_blank" S Park;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujd-63syewy4/" \t "_blank" S Kim ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuje-63syewy5/" \t "_blank" P-230 Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujf-63syewy6/" \t "_blank" T Lewandowski;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujg-63syewy7/" \t "_blank" R Biernacka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujh-63syewy8/" \t "_blank" M Chmielowiec;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuji-63syewy9/" \t "_blank" M Gryziak  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujj-63syewy0/" \t "_blank" P-231 Clinical significance of microsatellite instability in gender-dependent patients with right-sided colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujk-63syewy1/" \t "_blank" J Choi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujl-63syewy2/" \t "_blank" J Kim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujm-63syewy3/" \t "_blank" S Han ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujn-63syewy4/" \t "_blank" M Park;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujo-63syewy5/" \t "_blank" S Park  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujp-63syewy6/" \t "_blank" P-232 Efficacy of adjuvant chemotherapy for elderly patients with colon cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujq-63syewy7/" \t "_blank" M Villamayor Delgado;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujr-63syewy8/" \t "_blank" C Saavedra Serrano;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujs-63syewy9/" \t "_blank" E Corral de la Fuente;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujt-63syewy0/" \t "_blank" A Barqun Garca;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuju-63syewy1/" \t "_blank" O Martnez Saez ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujv-63syewy2/" \t "_blank" P-233 Trifluridine/tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujw-63syewy3/" \t "_blank" M Kotaka ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujx-63syewy4/" \t "_blank" M Ogata;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujy-63syewy5/" \t "_blank" T Ogata;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wujz-63syewy6/" \t "_blank" Y Hatachi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuk0-63syewy3/" \t "_blank" H Yasui ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuk1-63syewy4/" \t "_blank" P-234 Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuk2-63syewy5/" \t "_blank" Z Wainberg;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuk3-63syewy6/" \t "_blank" J Strickler ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuk4-63syewy7/" \t "_blank" M Gordon;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuk5-63syewy8/" \t "_blank" M Barve;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuk6-63syewy9/" \t "_blank" L Wang ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuk7-63syewy0/" \t "_blank" P-235 Adjuvant chemotherapy for colorectal cancer using oxaliplatin induced irreversible sinusoidal obstruction syndrome  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuk8-63syewy1/" \t "_blank" K Hara;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuk9-63syewy2/" \t "_blank" T Yamada;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuka-63syewy2/" \t "_blank" M Koizumi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukb-63syewy3/" \t "_blank" S Shinji ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukc-63syewy4/" \t "_blank" Y Yokoyama ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukd-63syewy5/" \t "_blank" P-236 Clinical and pathological features in colorectal cancer associated to Lynch syndrome  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuke-63syewy6/" \t "_blank" O Higuera ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukf-63syewy7/" \t "_blank" A Rodriguez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukg-63syewy8/" \t "_blank" N Rodriguez-Salas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukh-63syewy9/" \t "_blank" L Ruiz-Gimnez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuki-63syewy0/" \t "_blank" A Gallego ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukj-63syewy1/" \t "_blank" P-237 Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukk-63syewy2/" \t "_blank" E Dell'Aquila;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukl-63syewy3/" \t "_blank" F Pantano ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukm-63syewy4/" \t "_blank" D Rossini;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukn-63syewy5/" \t "_blank" M Stellato;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuko-63syewy6/" \t "_blank" S Lonardi ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukp-63syewy7/" \t "_blank" P-238 Analysis of classical high risk factors in stage III colon cancer: Experience at University Hospital Ramon y Cajal (UHRyC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukq-63syewy8/" \t "_blank" J Serrano Domingo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukr-63syewy9/" \t "_blank" R Martn Huertas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuks-63syewy0/" \t "_blank" A Barqun Garca;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukt-63syewy1/" \t "_blank" E Corral de la Fuente ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuku-63syewy2/" \t "_blank" C Saavedra Serrano ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukv-63syewy3/" \t "_blank" P-239 Impact of adding oxaliplatin to fluoropyrimidines in the adjuvant therapy in stage II in colon cancer: Experience in Ramon y Cajal Universitary Hospital  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukw-63syewy4/" \t "_blank" R Martn Huertas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukx-63syewy5/" \t "_blank" J Serrano Domingo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuky-63syewy6/" \t "_blank" E Corral de la Fuente;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wukz-63syewy7/" \t "_blank" A Barqun Garca;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wul0-63syewy4/" \t "_blank" M Villamayor Delgado ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wul1-63syewy5/" \t "_blank" P-240 Benefit of the addition of oxaliplatin to 5-FU/leucovorin or capecitabine in adjuvant therapy for stage II/III colorectal cancer in elderly patients: Experience in Ramon y Cajal University Hospital.  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wul2-63syewy6/" \t "_blank" E Corral de la Fuente ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wul3-63syewy7/" \t "_blank" C Saavedra Serrano;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wul4-63syewy8/" \t "_blank" M Villamayor Delgado;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wul5-63syewy9/" \t "_blank" A Barqun Garca;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wul6-63syewy0/" \t "_blank" R Martn Huertas ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wul7-63syewy1/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wul8-63syewy2/" \t "_blank" P-242 International prospective multi-center clinical trial with adherence to surgical and pathological quality measures: Influence of body mass index (BMI) on outcome in colon cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wul9-63syewy3/" \t "_blank" M Protic;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wula-63syewy3/" \t "_blank" A Bilchik;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulb-63syewy4/" \t "_blank" A Nissan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulc-63syewy5/" \t "_blank" S Usaj Knezevic;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuld-63syewy6/" \t "_blank" B Kukic ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wule-63syewy7/" \t "_blank" P-243 Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulf-63syewy8/" \t "_blank" A Tsuji ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulg-63syewy9/" \t "_blank" M Nakamura;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulh-63syewy0/" \t "_blank" T Watanabe;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuli-63syewy1/" \t "_blank" D Manaka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulj-63syewy2/" \t "_blank" H Matsuoka ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulk-63syewy3/" \t "_blank" P-244 Dose finding phase Ib study of triplet plus cetuximab for patients with wild-type RAS gene metastatic colorectal cancer (TRICETSU study)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wull-63syewy4/" \t "_blank" H Satake;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulm-63syewy5/" \t "_blank" T Kotake ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuln-63syewy6/" \t "_blank" Y Okita;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulo-63syewy7/" \t "_blank" Y Hatachi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulp-63syewy8/" \t "_blank" H Yasui ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulq-63syewy9/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulr-63syewy0/" \t "_blank" P-246 Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuls-63syewy1/" \t "_blank" M Martnez-Villacampa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wult-63syewy2/" \t "_blank" S Besora Tavera;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulu-63syewy3/" \t "_blank" C Santos Vivas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulv-63syewy4/" \t "_blank" C Izquierdo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulw-63syewy5/" \t "_blank" J Bruna ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulx-63syewy6/" \t "_blank" P-247 Adding oxaliplatin (OX) do neoadjuvant therapy of locally advanced rectal cancer (LARC): Still promising option?  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuly-63syewy7/" \t "_blank" W Rogowski;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wulz-63syewy8/" \t "_blank" L Wyrwicz;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wum0-63syewy5/" \t "_blank" V Sulzyc-Bielicka  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wum1-63syewy6/" \t "_blank" P-248 G8 screening tool for treatment decision-making in elderly colorectal cancer patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wum2-63syewy7/" \t "_blank" J Marn;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wum3-63syewy8/" \t "_blank" G Soler;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wum4-63syewy9/" \t "_blank" M Martnez-Villacampa ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wum5-63syewy0/" \t "_blank" S Vzquez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wum6-63syewy1/" \t "_blank" C Santos Vivas ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wum7-63syewy2/" \t "_blank" P-249 A SEER analysis of increasing disparities in age-related cause specific survival (CSS) among patients with colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wum8-63syewy3/" \t "_blank" T Mehmood  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wum9-63syewy4/" \t "_blank" P-250 Capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer: Experience of the oncology department of the university hospital of Oran, Algeria  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuma-63syewy4/" \t "_blank" Z Behourah;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumb-63syewy5/" \t "_blank" A Bousahba;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumc-63syewy6/" \t "_blank" L Djellali  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumd-63syewy7/" \t "_blank" P-251 The prognostic ad predictive value of primary tumor sidedness in the mCRC pts  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wume-63syewy8/" \t "_blank" E Sezer;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumf-63syewy9/" \t "_blank" K Eser;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumg-63syewy0/" \t "_blank" A Onder;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumh-63syewy1/" \t "_blank" B Ozturk ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumi-63syewy2/" \t "_blank" V Ercolak ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumj-63syewy3/" \t "_blank" P-252 The evaluation of liver resection for colorectal cancer liver metastases  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumk-63syewy4/" \t "_blank" M Ogawa ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuml-63syewy5/" \t "_blank" K Haruki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumm-63syewy6/" \t "_blank" A Horiuchi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumn-63syewy7/" \t "_blank" H Shiba;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumo-63syewy8/" \t "_blank" Y Mitsuyama ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wump-63syewy9/" \t "_blank" P-253 A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumq-63syewy0/" \t "_blank" K Yamazaki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumr-63syewy1/" \t "_blank" H Yasui ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wums-63syewy2/" \t "_blank" K Yamaguchi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumt-63syewy3/" \t "_blank" Y Kagawa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumu-63syewy4/" \t "_blank" Y Kuboki ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumv-63syewy5/" \t "_blank" P-254 Ultrasonic monitoring of liver metastasis after radiofrequency thermoablation  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumw-63syewy6/" \t "_blank" S Khoshimov  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumx-63syewy7/" \t "_blank" P-255 Immediate and long-term results of liver resections with metastatic lesion  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumy-63syewy8/" \t "_blank" S Lukmonov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wumz-63syewy9/" \t "_blank" O Usmanov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wun0-63syewy6/" \t "_blank" M Ismailov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wun1-63syewy7/" \t "_blank" K Madatov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wun2-63syewy8/" \t "_blank" U Kurbankulov ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wun3-63syewy9/" \t "_blank" P-256 Treatment efficacy and survival analysis of extremely elderly (80 years of age or older) patients with metastatic colorectal cancer: Single institute retrospective study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wun4-63syewy0/" \t "_blank" Y Liang ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wun5-63syewy1/" \t "_blank" C Wei;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wun6-63syewy2/" \t "_blank" J Tsai;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wun7-63syewy3/" \t "_blank" Y Jeng;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wun8-63syewy4/" \t "_blank" K Chen ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wun9-63syewy5/" \t "_blank" P-257 Improvement of metastatic colorectal cancer patient survival: Single institution experience  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuna-63syewy5/" \t "_blank" E Fenocchio;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunb-63syewy6/" \t "_blank" F Colombi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunc-63syewy7/" \t "_blank" M Calella ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wund-63syewy8/" \t "_blank" R Filippi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wune-63syewy9/" \t "_blank" I Depetris ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunf-63syewy0/" \t "_blank" P-258 HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wung-63syewy1/" \t "_blank" Y Shindo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunh-63syewy2/" \t "_blank" S Yuki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuni-63syewy3/" \t "_blank" M Yagisawa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunj-63syewy4/" \t "_blank" Y Kawamoto;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunk-63syewy5/" \t "_blank" Y Tsuji ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunl-63syewy6/" \t "_blank" P-259 Variability of current global practice patterns in the management of metastatic colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunm-63syewy7/" \t "_blank" T Bekaii-Saab;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunn-63syewy8/" \t "_blank" K Marcello;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuno-63syewy9/" \t "_blank" G Fisher;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunp-63syewy0/" \t "_blank" S Kopetz;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunq-63syewy1/" \t "_blank" J Strickler ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunr-63syewy2/" \t "_blank" P-260 Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI: Interim results of the non-interventional AIO study QoLiTrap  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuns-63syewy3/" \t "_blank" M Zahn;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunt-63syewy4/" \t "_blank" F Scholten;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunu-63syewy5/" \t "_blank" R von Moos;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunv-63syewy6/" \t "_blank" J Thaler ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunw-63syewy7/" \t "_blank" R Hofheinz  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunx-63syewy8/" \t "_blank" P-261 HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuny-63syewy9/" \t "_blank" K Hatanaka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wunz-63syewy0/" \t "_blank" S Yuki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuo0-63syewy7/" \t "_blank" S Nakano;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuo1-63syewy8/" \t "_blank" K Sawada;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuo2-63syewy9/" \t "_blank" K Harada ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuo3-63syewy0/" \t "_blank" P-262 Trial-level analysis of early tumor shrinkage and disease control rate as intermediate end points of first-line medical treatment in randomized studies of metastatic colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuo4-63syewy1/" \t "_blank" G Colloca ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuo5-63syewy2/" \t "_blank" A Venturino;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuo6-63syewy3/" \t "_blank" D Guarneri  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuo7-63syewy4/" \t "_blank" P-263 Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuo8-63syewy5/" \t "_blank" A Avallone;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuo9-63syewy6/" \t "_blank" G Nasti;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuoa-63syewy6/" \t "_blank" G Rosati;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuob-63syewy7/" \t "_blank" C Carlomagno ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuoc-63syewy8/" \t "_blank" C Romano ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuod-63syewy9/" \t "_blank" P-264 HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuoe-63syewy0/" \t "_blank" T Honda;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuof-63syewy1/" \t "_blank" S Yuki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuog-63syewy2/" \t "_blank" T Muranaka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuoh-63syewy3/" \t "_blank" H Nakatsumi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuoi-63syewy4/" \t "_blank" Y Tsuji ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuoj-63syewy5/" \t "_blank" P-265 Treatment choices in metastatic colorectal cancer according to sidedness and RAS/BRAF status: A national survey by the Brazilian Group of Gastrointestinal Tumors (GTG)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuok-63syewy6/" \t "_blank" R Peixoto ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuol-63syewy7/" \t "_blank" R Riechelmann;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuom-63syewy8/" \t "_blank" G Prolla;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuon-63syewy9/" \t "_blank" R Weschenfelder;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuoo-63syewy0/" \t "_blank" J Rego ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuop-63syewy1/" \t "_blank" P-266 Retrospective analysis of clinical factors associated with a greater benefit with Trifluridine and Tipiracil in metastasic colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuoq-63syewy2/" \t "_blank" N Rodriguez-Salas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuor-63syewy3/" \t "_blank" M Soriano Segura ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuos-63syewy4/" \t "_blank" A Jimenez-Gordo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuot-63syewy5/" \t "_blank" R Molina;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuou-63syewy6/" \t "_blank" J Cmara ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuov-63syewy7/" \t "_blank" P-267 The prognostic impact of sidedness in RAS wild-type colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuow-63syewy8/" \t "_blank" N Tavares;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuox-63syewy9/" \t "_blank" A Costa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuoy-63syewy0/" \t "_blank" D Almeida;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuoz-63syewy1/" \t "_blank" S Meireles ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wup0-63syewy8/" \t "_blank" C Fernandes ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wup1-63syewy9/" \t "_blank" P-268 Advanced colorectal cancer and risk factors for survival  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wup2-63syewy0/" \t "_blank" D Kaidarova ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wup3-63syewy1/" \t "_blank" K Smagulova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wup4-63syewy2/" \t "_blank" S Yesentaeva;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wup5-63syewy3/" \t "_blank" Y Ishkinin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wup6-63syewy4/" \t "_blank" Y Ukolova ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wup7-63syewy5/" \t "_blank" P-269 Dynamics of the monoclonal antibodies (MABs) treatment rate and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia from 2013 to 2016  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wup8-63syewy6/" \t "_blank" M Fedyanin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wup9-63syewy7/" \t "_blank" H Elsnukaeva ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupa-63syewy7/" \t "_blank" E Polyanskaya;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupb-63syewy8/" \t "_blank" A Popova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupc-63syewy9/" \t "_blank" I Pokataev ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupd-63syewy0/" \t "_blank" P-270 Association between duration of oxaliplatin-free interval and effect of reintroduction of oxaliplatin-containing chemotherapy in patients with metastatic colorectal cancer (mCRC)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupe-63syewy1/" \t "_blank" M Fedyanin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupf-63syewy2/" \t "_blank" A Tryakin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupg-63syewy3/" \t "_blank" A Bulanov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuph-63syewy4/" \t "_blank" A Popova ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupi-63syewy5/" \t "_blank" E Ignatova ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupj-63syewy6/" \t "_blank" P-271 Prognostic impact of K-RAS mutational status and primary tumour location in patients undergoing resection for colorectal cancer liver metastases: A METHEPAR analysis (multicentre study in Argentina)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupk-63syewy7/" \t "_blank" J OConnor;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupl-63syewy8/" \t "_blank" E Huertas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupm-63syewy9/" \t "_blank" F Sanchez Loria;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupn-63syewy0/" \t "_blank" F Brancato;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupo-63syewy1/" \t "_blank" J Grondona ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupp-63syewy2/" \t "_blank" P-272 Understanding of metastatic colorectal cancer (mCRC) in the real world: Initial results from a European survey on the unmet needs of patients living with metastatic colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupq-63syewy3/" \t "_blank" Z Maravic ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupr-63syewy4/" \t "_blank" L Wyrwicz;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wups-63syewy5/" \t "_blank" B Karczmarek-Borowska;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupt-63syewy6/" \t "_blank" E Espn Basany;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupu-63syewy7/" \t "_blank" A Carrato ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupv-63syewy8/" \t "_blank" P-273 Recruitment for a survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC): Lessons from a European study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupw-63syewy9/" \t "_blank" Z Maravic;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupx-63syewy0/" \t "_blank" J Stanisic Trenevski;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupy-63syewy1/" \t "_blank" J Bokros ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wupz-63syewy2/" \t "_blank" A Ruiz Casado;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuq0-63syewy9/" \t "_blank" C Gonzlez de Pedro ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuq1-63syewy0/" \t "_blank" P-274 The clinical effectiveness and safety of re-induction oxaliplatin, irinotecan and fluorouracil (FOLFOXIRI regimen) for the treatment of metastatic colorectal cancer after two lines of chemotherapy (oxaliplatin- and irinotecan-based regimens)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuq2-63syewy1/" \t "_blank" E Ledin;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuq3-63syewy2/" \t "_blank" A Mochalova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuq4-63syewy3/" \t "_blank" Y Zaitseva  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuq5-63syewy4/" \t "_blank" P-275 Selective internal radiation therapy (SIRT) with yttrium-90 microspheres and peri-procedural FOLFIRI/irinotecan in pre-treated colorectal liver metastases patients: An analysis of outcomes from a UK Cancer Centre between 2009 and 2017  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuq6-63syewy5/" \t "_blank" G Wilson;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuq7-63syewy6/" \t "_blank" D Bentley ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuq8-63syewy7/" \t "_blank" S Mullamitha;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuq9-63syewy8/" \t "_blank" M Braun;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqa-63syewy8/" \t "_blank" M Nasralla ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqb-63syewy9/" \t "_blank" P-276 Raltitrexed as salvage therapy for metastatic colorectal cancer: A multicenter retrospective study  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqc-63syewy0/" \t "_blank" I Ghanem;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqd-63syewy1/" \t "_blank" A Viudez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqe-63syewy2/" \t "_blank" E Garca-Torralba;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqf-63syewy3/" \t "_blank" J Torres-Tenor ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqg-63syewy4/" \t "_blank" A Carmona ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqh-63syewy5/" \t "_blank" P-277 Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study)  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqi-63syewy6/" \t "_blank" C Pericay;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqj-63syewy7/" \t "_blank" J Gallego;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqk-63syewy8/" \t "_blank" A Fernandez Montes;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuql-63syewy9/" \t "_blank" H Oliveres;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqm-63syewy0/" \t "_blank" H Asensio-Martnez ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqn-63syewy1/" \t "_blank" P-278 Prognostic factors in metastatic colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqo-63syewy2/" \t "_blank" M Silva;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqp-63syewy3/" \t "_blank" I Guerreiro ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqq-63syewy4/" \t "_blank" S Abreu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqr-63syewy5/" \t "_blank" D Marques  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqs-63syewy6/" \t "_blank" P-279 Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqt-63syewy7/" \t "_blank" C Sales;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqu-63syewy8/" \t "_blank" I Julio;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqv-63syewy9/" \t "_blank" A Rosinha;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqw-63syewy0/" \t "_blank" D Marques;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqx-63syewy1/" \t "_blank" F Carneiro ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqy-63syewy2/" \t "_blank" WITHDRAWN  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuqz-63syewy3/" \t "_blank" P-281 The impact of primary tumor location in patients with resected colorectal liver metastasis  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wur0-63syewy0/" \t "_blank" V Pacheco-Barcia;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wur1-63syewy1/" \t "_blank" O Donnay;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wur2-63syewy2/" \t "_blank" R Mondjar Sols;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wur3-63syewy3/" \t "_blank" R Serrano ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wur4-63syewy4/" \t "_blank" E Martin ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wur5-63syewy5/" \t "_blank" P-282 RAS status in metastatic colorectal cancer: What is the relationship to epidemiological and anatomo-clinical factors?  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wur6-63syewy6/" \t "_blank" M Haffadi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wur7-63syewy7/" \t "_blank" N Tawfiq;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wur8-63syewy8/" \t "_blank" M Karkouri;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wur9-63syewy9/" \t "_blank" Z Bouchbika;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wura-63syewy9/" \t "_blank" N Benchakroun ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurb-63syewy0/" \t "_blank" P-283 Skin disorders and primary tumor location as a prognostic factor of cetuximab plus chemotherapy in the treatment of advanced colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurc-63syewy1/" \t "_blank" T Shinya;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurd-63syewy2/" \t "_blank" S Tamotsu ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wure-63syewy3/" \t "_blank" K Fujikawa;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurf-63syewy4/" \t "_blank" T Kana;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurg-63syewy5/" \t "_blank" F Yuta ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurh-63syewy6/" \t "_blank" P-284 Characteristics of colorectal cancer in the elderly patients about 60 cases  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuri-63syewy7/" \t "_blank" H Aliane;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurj-63syewy8/" \t "_blank" S Ghomari-Bezzar;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurk-63syewy9/" \t "_blank" A Belhadj;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurl-63syewy0/" \t "_blank" N Madani ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurm-63syewy1/" \t "_blank" N Charif  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurn-63syewy2/" \t "_blank" P-285 Optimizing the use of EGFR antibodies across the continuum of care in mCRC: Effect of online education on clinician knowledge, competence and confidence  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuro-63syewy3/" \t "_blank" G Fisher;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurp-63syewy4/" \t "_blank" W Guerra;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurq-63syewy5/" \t "_blank" C Day;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurr-63syewy6/" \t "_blank" C Montagut  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurs-63syewy7/" \t "_blank" P-286 Integrating a paradigm shift in the treatment of metastatic colorectal cancer: Effect of online CME on oncologists' knowledge and competence  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurt-63syewy8/" \t "_blank" T Herrmann;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuru-63syewy9/" \t "_blank" D Cameron ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurv-63syewy0/" \t "_blank" A Carothers;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurw-63syewy1/" \t "_blank" T Bekaii-Saab  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurx-63syewy2/" \t "_blank" P-287 Treatment based on tumor sidedness in mCRC: Effect of online education on clinician knowledge, competence and confidence  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wury-63syewy3/" \t "_blank" G Fisher;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wurz-63syewy4/" \t "_blank" W Guerra;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wus0-63syewy1/" \t "_blank" C Day;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wus1-63syewy2/" \t "_blank" M Ducreux  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wus2-63syewy3/" \t "_blank" P-288 Causes of death in a cohort of early stage colorectal cancer patients at a regional centre in Australia  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wus3-63syewy4/" \t "_blank" L Lim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wus4-63syewy5/" \t "_blank" W Faisal;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wus5-63syewy6/" \t "_blank" M Wuttke ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wus6-63syewy7/" \t "_blank" G Chong  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wus7-63syewy8/" \t "_blank" P-289 Prognostic factors for early recurrences following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wus8-63syewy9/" \t "_blank" N Chandran;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wus9-63syewy0/" \t "_blank" G Tan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusa-63syewy0/" \t "_blank" C Chia;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusb-63syewy1/" \t "_blank" M Teo  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusc-63syewy2/" \t "_blank" P-290 Simultaneous versus staged resections of liver metastases in patients with advanced colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusd-63syewy3/" \t "_blank" O Kolesnik;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuse-63syewy4/" \t "_blank" A Lukashenko;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusf-63syewy5/" \t "_blank" Y Ostapenko ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusg-63syewy6/" \t "_blank" N Chorna  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wush-63syewy7/" \t "_blank" P-291 The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusi-63syewy8/" \t "_blank" P Ziranu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusj-63syewy9/" \t "_blank" L Demurtas;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusk-63syewy0/" \t "_blank" M Puzzoni;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusl-63syewy1/" \t "_blank" F Loupakis;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusm-63syewy2/" \t "_blank" B Daniele ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusn-63syewy3/" \t "_blank" P-292 A phase II study of dose-escalation of regorafenib for patients with previously treated metastatic colorectal cancer DEREGULATE study - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuso-63syewy4/" \t "_blank" K Kawaguchi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusp-63syewy5/" \t "_blank" R Nishitai;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusq-63syewy6/" \t "_blank" D Manaka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusr-63syewy7/" \t "_blank" T Ota;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuss-63syewy8/" \t "_blank" Y Nishikawa ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wust-63syewy9/" \t "_blank" P-293 Comorbidities (CM) and potential impact in outcomes of advanced colorectal cancer patients (ACC) in Argentina: EVIREPRO real life program - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusu-63syewy0/" \t "_blank" A Schmilovich;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusv-63syewy1/" \t "_blank" F Ramello ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusw-63syewy2/" \t "_blank" M Malicki;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusx-63syewy3/" \t "_blank" N Colombo Berra;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusy-63syewy4/" \t "_blank" S Rojo ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wusz-63syewy5/" \t "_blank" P-294 Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wut0-63syewy2/" \t "_blank" T Kato;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wut1-63syewy3/" \t "_blank" H Satake;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wut2-63syewy4/" \t "_blank" K Oba;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wut3-63syewy5/" \t "_blank" Y Kagawa ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wut4-63syewy6/" \t "_blank" H Yasui ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wut5-63syewy7/" \t "_blank" P-295 A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wut6-63syewy8/" \t "_blank" T Yoshino;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wut7-63syewy9/" \t "_blank" S Siena;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wut8-63syewy0/" \t "_blank" R Dalal;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wut9-63syewy1/" \t "_blank" Y Okuda;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuta-63syewy1/" \t "_blank" E Yamamoto ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutb-63syewy2/" \t "_blank" P-296 ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutc-63syewy3/" \t "_blank" Z Wainberg ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutd-63syewy4/" \t "_blank" L Wang;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wute-63syewy5/" \t "_blank" H Yue;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutf-63syewy6/" \t "_blank" M Motwani;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutg-63syewy7/" \t "_blank" S Kasichayanula ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuth-63syewy8/" \t "_blank" P-297 CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuti-63syewy9/" \t "_blank" M Shah;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutj-63syewy0/" \t "_blank" A Grothey ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutk-63syewy1/" \t "_blank" N Tebbutt;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutl-63syewy2/" \t "_blank" R Xu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutm-63syewy3/" \t "_blank" T Yoshino ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutn-63syewy4/" \t "_blank" P-298 A phase II study of avelumab in MSI-H metastatic colorectal cancer patients - Trial in progress  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuto-63syewy5/" \t "_blank" D Proszynski;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutp-63syewy6/" \t "_blank" M Winiarek;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutq-63syewy7/" \t "_blank" K Marcisz-Grzanka;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutr-63syewy8/" \t "_blank" J Krynski ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuts-63syewy9/" \t "_blank" J Zwolinski ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutt-63syewy0/" \t "_blank" P-299 Predictive factors of complete pathological response in operated patients with locally advanced rectal cancer after chemoradiotherapy neoadjuvant treatment in Peru  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutu-63syewy1/" \t "_blank" R Motta;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutv-63syewy2/" \t "_blank" P Ybazeta;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutw-63syewy3/" \t "_blank" O Cordova;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutx-63syewy4/" \t "_blank" S Quiroz;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuty-63syewy5/" \t "_blank" A Figueroa ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wutz-63syewy6/" \t "_blank" P-300 Predictive value of circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CT-RT): Preliminary results  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuu0-63syewy3/" \t "_blank" P Ravenda ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuu1-63syewy4/" \t "_blank" G Gregato;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuu2-63syewy5/" \t "_blank" M Rotundo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuu3-63syewy6/" \t "_blank" S Frassoni;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuu4-63syewy7/" \t "_blank" V Dell'Acqua ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuu5-63syewy8/" \t "_blank" P-301 CRP/albumin ratio can be a predictor of response to neoadjuvant chemoradiotherapy (CRT) in rectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuu6-63syewy9/" \t "_blank" T Yetisyigit;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuu7-63syewy0/" \t "_blank" S Seber;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuu8-63syewy1/" \t "_blank" A Yolcu  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuu9-63syewy2/" \t "_blank" P-302 Pathological complete response after chemoradiotherapy in locally advanced rectal cancer: Capecitabine or 5-fluorouracil? Which is better?  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuua-63syewy2/" \t "_blank" X Hernndez-Yage;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuub-63syewy3/" \t "_blank" E Canals-Subirats ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuc-63syewy4/" \t "_blank" G Mateu Esquerda;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuud-63syewy5/" \t "_blank" C Aun Sanz;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuue-63syewy6/" \t "_blank" A Maroto Genover ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuf-63syewy7/" \t "_blank" P-303 Food intake and nutritional status of colorectal cancer patients undergoing radio-chemotherapy in Sardjito hospital  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuug-63syewy8/" \t "_blank" M Purba;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuh-63syewy9/" \t "_blank" H Winarti;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuui-63syewy0/" \t "_blank" R Pangastuti  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuj-63syewy1/" \t "_blank" P-304 Preoperative chemoradiation in locally advanced rectal cancer: A single center experience  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuk-63syewy2/" \t "_blank" L Oliveira;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuul-63syewy3/" \t "_blank" A Rolo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuum-63syewy4/" \t "_blank" C Carvalho ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuun-63syewy5/" \t "_blank" I Faustino;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuo-63syewy6/" \t "_blank" C Alpoim ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuup-63syewy7/" \t "_blank" P-305 The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer patients who received preoperative chemoradiation and total mesorectal excision  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuq-63syewy8/" \t "_blank" S Sung;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuur-63syewy9/" \t "_blank" J Lee;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuus-63syewy0/" \t "_blank" S Kim;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuut-63syewy1/" \t "_blank" J Lee  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuu-63syewy2/" \t "_blank" P-306 The relationship between primary tumor regression grade and lymph nodes status in local advanced rectal cancer after neoadjuvant chemoradiation therapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuv-63syewy3/" \t "_blank" H Ju;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuw-63syewy4/" \t "_blank" L Liu ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuux-63syewy5/" \t "_blank" W Wu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuy-63syewy6/" \t "_blank" Y Cai;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuuz-63syewy7/" \t "_blank" X Lu  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuv0-63syewy4/" \t "_blank" P-307 Preoperative predictors for pathologic response and prognosis of rectal cancer after neoadjuvant chemoradiation  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuv1-63syewy5/" \t "_blank" G Yoo;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuv2-63syewy6/" \t "_blank" J Yu;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuv3-63syewy7/" \t "_blank" H Park;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuv4-63syewy8/" \t "_blank" D Choi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuv5-63syewy9/" \t "_blank" W Cho ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuv6-63syewy0/" \t "_blank" P-308 Comparison of incidence and survival outcomes in mucinous and signet-ring cell colorectal cancers with classical adenocarcinoma: A SEER analysis  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuv7-63syewy1/" \t "_blank" T Mehmood  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuv8-63syewy2/" \t "_blank" P-309 Quality improvement in the management of rectal cancer in a large healthcare system in the United States  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuv9-63syewy3/" \t "_blank" W Sause  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuva-63syewy3/" \t "_blank" P-310 Diagnosis and selection of method of combined treatment of local-distributed cancer of the rectum with invasion into organs of the genitals  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvb-63syewy4/" \t "_blank" S Lukmonov ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvc-63syewy5/" \t "_blank" O Usmanov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvd-63syewy6/" \t "_blank" K Madatov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuve-63syewy7/" \t "_blank" U Allazarov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvf-63syewy8/" \t "_blank" U Kurbankulov ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvg-63syewy9/" \t "_blank" P-311 Comparison between the toxicity profile of fluorouracil versus capecitabine concomitant with radiotherapy in patients with non-metastatic rectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvh-63syewy0/" \t "_blank" A Lotfy;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvi-63syewy1/" \t "_blank" M Yassin ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvj-63syewy2/" \t "_blank" G Rashwan;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvk-63syewy3/" \t "_blank" A Nagy  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvl-63syewy4/" \t "_blank" P-312 Role of consolidative radiation therapy after surgery in patients with stage IV rectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvm-63syewy5/" \t "_blank" T Mehmood  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvn-63syewy6/" \t "_blank" P-313 Nonstandard hypofraction radiotherapy in neoadjuvant chemo-radiation therapy of locally advanced rectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvo-63syewy7/" \t "_blank" A Abdujapparov ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvp-63syewy8/" \t "_blank" S Tkachev;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvq-63syewy9/" \t "_blank" F Djuraev;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvr-63syewy0/" \t "_blank" Y Ten  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvs-63syewy1/" \t "_blank" P-314 Prone vs supine position in patients with rectal cancer treated with volumetric arc therapy and concurrent chemotherapy  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvt-63syewy2/" \t "_blank" L Diaz Gomez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvu-63syewy3/" \t "_blank" A Seguro Fernandez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvv-63syewy4/" \t "_blank" P Ramirez Daffos;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvw-63syewy5/" \t "_blank" J Tisaire ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvx-63syewy6/" \t "_blank" J Jaen Olasolo  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvy-63syewy7/" \t "_blank" P-315 The role of palliative re-irradiation in management of rectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuvz-63syewy8/" \t "_blank" T Janjua ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuw0-63syewy5/" \t "_blank" M Hingorani;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuw1-63syewy6/" \t "_blank" R Cooper;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuw2-63syewy7/" \t "_blank" P Hatfield;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuw3-63syewy8/" \t "_blank" N Casanova ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuw4-63syewy9/" \t "_blank" P-316 Is there any association of dose received by pelvic bone marrow in preoperative radiotherapy in rectal cancer with hematological toxicity of subsequent oxaliplatin-based chemotherapy?  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuw5-63syewy0/" \t "_blank" M Spalek;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuw6-63syewy1/" \t "_blank" W Michalski ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuw7-63syewy2/" \t "_blank" K Bujko;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuw8-63syewy3/" \t "_blank" L Wyrwicz  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuw9-63syewy4/" \t "_blank" P-317 A single centre experience of in-field recurrence following pre-operative radio(chemo)therapy in patients with rectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwa-63syewy4/" \t "_blank" O Coen;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwb-63syewy5/" \t "_blank" L Karsera;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwc-63syewy6/" \t "_blank" N Tambe;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwd-63syewy7/" \t "_blank" R Roy  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwe-63syewy8/" \t "_blank" P-318 Laparoscopic technologies in the treatment of patients with locally advanced rectal cancer: The possibilities and prospects  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwf-63syewy9/" \t "_blank" S Khoshimov  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwg-63syewy0/" \t "_blank" P-319 Long term efficacy results from the phase II CRAB trial: Neoadjuvant bevacizumab, capecitabine and radiotherapy in locally advanced rectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwh-63syewy1/" \t "_blank" V Velenik;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwi-63syewy2/" \t "_blank" M Omejc;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwj-63syewy3/" \t "_blank" J Ocvirk;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwk-63syewy4/" \t "_blank" I Edhemovi ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwl-63syewy5/" \t "_blank" F Anderluh ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwm-63syewy6/" \t "_blank" P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwn-63syewy7/" \t "_blank" K Johung ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwo-63syewy8/" \t "_blank" B Kann;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwp-63syewy9/" \t "_blank" J Lacy;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwq-63syewy0/" \t "_blank" S Stein;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwr-63syewy1/" \t "_blank" J Kortmansky ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuws-63syewy2/" \t "_blank" P-321 Profile of neurotoxicity of oxaliplatin in young versus elderly patients treated for colorectal carcinoma  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwt-63syewy3/" \t "_blank" H Aliane;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwu-63syewy4/" \t "_blank" S Ghomari-Bezzar  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwv-63syewy5/" \t "_blank" P-322 First study in North Africa: Screening colorectal cancer  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuww-63syewy6/" \t "_blank" C Mazouzi;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwx-63syewy7/" \t "_blank" K Bouzid  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwy-63syewy8/" \t "_blank" P-323 Perioperative treatment of gastric cancer: FLOT or not  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuwz-63syewy9/" \t "_blank" F Djuraev;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wux0-63syewy6/" \t "_blank" A Abdujapparov;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wux1-63syewy7/" \t "_blank" N Atakhanova  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wux2-63syewy8/" \t "_blank" P-324 Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wux3-63syewy9/" \t "_blank" S Veiga;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wux4-63syewy0/" \t "_blank" X Ge;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wux5-63syewy1/" \t "_blank" C Mercer ;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wux6-63syewy2/" \t "_blank" M Hernndez lvarez;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wux7-63syewy3/" \t "_blank" H Thomas ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wux8-63syewy4/" \t "_blank" P-325 Gut microbial community diversity is associated with systemic vascular endothelial growth factor A levels among colorectal cancer patients  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wux9-63syewy5/" \t "_blank" A Holowatyj;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuxa-63syewy5/" \t "_blank" W Stephens;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuxb-63syewy6/" \t "_blank" C Warby;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuxc-63syewy7/" \t "_blank" K Buhrke;  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuxd-63syewy8/" \t "_blank" B Gigic ...  INCLUDEPICTURE "https://ecp.yusercontent.com/mail?url=http%3A%2F%2Fmedia.emailcampaigns.net%2Fmedia%2F52%2F528555%2Fspacer_img.gif&t=1529806487&ymreqid=83814193-ffa6-e80f-1328-590000010000&sig=SRjkg0DhPD9JMWUW_oyuPw--%7EC" \* MERGEFORMATINET   Author Index  HYPERLINK "http://click.skem1.com/click/bbu3-q26rk-f9wuxe-63syewy9/" \t "_blank" Author Index  A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P)  HYPERLINK "https://clinicaltrials.gov/ct2/show/NCT02993731" https://clinicaltrials.gov/ct2/show/NCT02993731  INCLUDEPICTURE "https://clinicaltrials.gov/ct2/html/images/warning.png" \* MERGEFORMATINET The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.  HYPERLINK "https://clinicaltrials.gov/ct2/about-studies/learn" \l "Considerations" Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our  HYPERLINK "https://clinicaltrials.gov/ct2/about-site/disclaimer" disclaimer for details. ClinicalTrials.gov Identifier: NCT02993731Recruitment Status : Recruiting First Posted : December 15, 2016 Last Update Posted : April 11, 2018 See  HYPERLINK "https://clinicaltrials.gov/ct2/show/study/NCT02993731" \l "contacts" Contacts and Locations Sponsor: Boston Biomedical, Inc Information provided by (Responsible Party): Boston Biomedical, Inc Study Details  HYPERLINK "https://clinicaltrials.gov/ct2/show/record/NCT02993731" Tabular View  HYPERLINK "https://clinicaltrials.gov/ct2/show/results/NCT02993731" No Results Posted  HYPERLINK "https://clinicaltrials.gov/ct2/about-site/disclaimer" \o "Disclaimer - opens new window" Disclaimer  HYPERLINK "https://clinicaltrials.gov/ct2/help/how-read-study" \o "How to Read a Study Record - opens new window" How to Read a Study Record Study Description Brief Summary: This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma. Condition or disease Intervention/treatment Phase Carcinoma, Pancreatic Ductal Drug: Napabucasin Drug: Nab-paclitaxel Drug: Gemcitabine Phase 3  Study Design Study Type :Interventional (Clinical Trial) Estimated Enrollment :1132 participantsAllocation:RandomizedIntervention Model:Parallel AssignmentMasking:None (Open Label)Primary Purpose:TreatmentOfficial Title:A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic AdenocarcinomaStudy Start Date :December 2016Estimated Primary Completion Date :December 2020Resource links provided by the National Library of Medicine  INCLUDEPICTURE "https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" \* MERGEFORMATINET   HYPERLINK "https://druginfo.nlm.nih.gov/drugportal" \o "Drug Information Portal" Drug Information available for:  HYPERLINK "https://druginfo.nlm.nih.gov/drugportal/name/Paclitaxel" \o "Paclitaxel at Drug Information Portal" Paclitaxel  HYPERLINK "https://druginfo.nlm.nih.gov/drugportal/name/Gemcitabine" \o "Gemcitabine at Drug Information Portal" Gemcitabine  HYPERLINK "https://druginfo.nlm.nih.gov/drugportal/name/Gemcitabine+hydrochloride" \o "Gemcitabinehydrochloride at Drug Information Portal" Gemcitabinehydrochloride  HYPERLINK "https://clinicaltrials.gov/ct2/info/fdalinks" \o "Show FDA resources page" U.S. FDA Resources Arms and Interventions Arm Intervention/treatment Experimental: Arm 1: Napabucasin plus Nab-paclitaxel with Gemcitabine Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.Drug: Napabucasin Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours. Other Names: BBI-608 BBI608 BB608 Drug: Nab-paclitaxel Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion. Other Name: Abraxane Drug: Gemcitabine Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion. Other Name: Gemzar Active Comparator: Arm 2: Nab-paclitaxel with Gemcitabine Patients randomized to this arm will receive weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.Drug: Nab-paclitaxel Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion. Other Name: Abraxane Drug: Gemcitabine Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion. Other Name: Gemzar  Outcome Measures Primary Outcome Measures : Overall Survival [TimeFrame:36 months] To assess the effect of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine on the Overall Survival of patients with metastatic pancreatic ductal adenocarcinoma. Secondary Outcome Measures : Overall Survival in biomarker positive patients [TimeFrame:36 months] To assess the effect of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine on the Overall Survival of patients with metastatic pancreatic ductal adenocarcinoma in biomarker positive patients. This biomarker-positive sub-population is defined as those patients with phospho-STAT3 positivity based on immunohistochemical (IHC) staining of Formalin Fixed Paraffin Embedded (FFPE) tumor tissue. Progression Free Survival [TimeFrame:36 months] To assess the effect of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine on the Progression Free Survival (PFS) of patients with metastatic pancreatic ductal adenocarcinoma. PFS is defined as the time from randomization to the first objective documentation of disease progression or death due to any cause. Progression Free Survival in biomarker positive patients [TimeFrame:36 months] To assess the effect of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine on the Progression Free Survival (PFS) of patients with metastatic pancreatic ductal adenocarcinoma in biomarker positive patients. PFS is defined as the time from randomization to the first objective documentation of disease progression or death due to any cause. This biomarker-positive sub-population is defined as those patients with phospho-STAT3 positivity based on immunohistochemical (IHC) staining of Formalin Fixed Paraffin Embedded (FFPE) tumor tissue. Overall Response Rate [TimeFrame:36 months] To assess the effect of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine on the Overall Response Rate (ORR) of patients with metastatic pancreatic ductal adenocarcinoma. ORR is evaluated using RECIST 1.1. Disease Control Rate [TimeFrame:36 months] To assess the effect of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine on the Disease Control Rate (DCR) of patients with metastatic pancreatic ductal adenocarcinoma. DCR is defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1. Overall Response Rate in biomarker positive patients [TimeFrame:36 months] To assess the effect of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine on the Overall Response Rate (ORR) of patients with metastatic pancreatic ductal adenocarcinoma in biomarker positive patients. ORR is evaluated using RECIST 1.1. This biomarker-positive sub-population is defined as those patients with phospho-STAT3 positivity based on immunohistochemical (IHC) staining of Formalin Fixed Paraffin Embedded (FFPE) tumor tissue. Disease Control Rate in biomarker positive patients [TimeFrame:36 months] To assess the effect of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine on the Disease Control Rate (DCR) of patients with metastatic pancreatic ductal adenocarcinoma. DCR is defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1. This biomarker-positive sub-population is defined as those patients with phospho-STAT3 positivity based on immunohistochemical (IHC) staining of Formalin Fixed Paraffin Embedded (FFPE) tumor tissue. Quality of Life (QoL) [TimeFrame:36 months] QoL will be measured using the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC-QLQ-C30) in patients with metastatic pancreatic ductal adenocarcinoma with napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine. Number of Patients with Adverse Events [TimeFrame:36 months] All patients who have received at least one dose of napabucasin will be included in the safety analysis according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 4.0. The incidence of adverse events will be summarized by type of adverse event and severity. Eligibility Criteria Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information,  HYPERLINK "https://clinicaltrials.gov/ct2/about-studies/learn" \o "Learn About Clinical Studies" Learn About Clinical Studies. Ages Eligible for Study: 18 Years and older (Adult, Older Adult)Sexes Eligible for Study: AllAccepts Healthy Volunteers: NoCriteria Inclusion Criteria: Written, signed consent for trial participation must be obtained from the patient appropriately in accordance with applicable International Conference on Harmonization (ICH) guidelines and local and regulatory requirements prior to the performance of any study specific procedure. Must have histologically or cytologically confirmed advanced pancreatic ductal adenocarcinoma (PDAC) that is metastatic. The definitive diagnosis of metastatic PDAC will be made by integrating the histopathological data within the context of the clinical and radiographic data. Patients with islet cell neoplasms are excluded. Must not have previously received chemotherapy or any investigational agent for the treatment of PDAC. A fluoropyrimidine or gemcitabine administered as a radiation sensitizer in the adjuvant setting is allowed for as long as last dose was administered > 6 months prior to randomization and no lingering toxicities are present. Nab-paclitaxel with gemcitabine therapy is appropriate for the patient and recommended by the Investigator. Patient has one or more metastatic tumors evaluable by CT scan with contrast (or MRI, if patient is allergic to CT contrast media) per RECIST 1.1. Imaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as necessary to document all sites of disease must be performed within 14 days prior to randomization. Qualifying scans performed as part of standard of care prior to patient signature of the study informed consent will be acceptable as baseline scanning as long as scanning is performed < 14 days prior to randomization. Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, assessed within 14 days prior to randomization. Two observers qualified to perform assessment of the performance status will be required to perform this assessment. If discrepant, the one with the most deteriorated performance status will be considered true. Must have life-expectancy of > 12 weeks. Must be e" 18 years of age. Due to increased risk of sepsis in patients >80 years old, candidate patients in this age group should be thoroughly evaluated prior to study randomization to ensure they are fit to receive chemotherapy. In addition to all of the inclusion/exclusion criteria listed, clinical judgment should be used regarding patients' susceptibility to infection (including but not limited to presence of ascites or diabetes mellitus increasing risk of infection). Furthermore, the expected stability of their performance status while receiving repeat weekly chemotherapy cycles should be given special attention. Patients in this age group should not be randomized on the study should there be any hesitation on any of these considerations. For male or female patients of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 180 days after the final dose of nab-paclitaxel and gemcitabine or for 30 days for female patients and for 90 days for male patients, after the final napabucasin dose if nab-paclitaxel and gemcitabine were not administered. Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within 5 days prior to randomization. Patient has adequate biological parameters as demonstrated by the following blood counts at baseline (obtained < 14 days prior to randomization; laboratory testing performed as part of standard of care prior to patient signature of informed consent for the study will be acceptable as baseline laboratory work as long as testing is performed < 14 days prior to randomization): Absolute neutrophil count (ANC) > 1.5 x 10^9/L Platelet count > 100,000/mm^3 (100 x 10^9/L). Must not have required transfusion of platelets within 1 week of baseline platelet count assessment. Hemoglobin (HgB) > 9 g/dL. Must not have required transfusion of red blood cells within 1 week of baseline Hgb assessment. Patient has the following blood chemistry levels at baseline (obtained < 14 days prior to randomization; laboratory testing performed as part of standard of care prior to patient signature of informed consent for the study will be acceptable as baseline laboratory work as long as testing is performed < 14 days prior to randomization): AST (SGOT) and ALT (SGPT) d" 2.5 institutional upper limit of normal (ULN) [d" 5 ULN in presence of liver metastases] Total bilirubin d" 1.5 x institutional ULN. If total bilirubin is > ULN and < 1.5 x ULN, it must be non-rising for at least 7 days. Serum creatinine wi()    N O P Q R X  ȹȮȹzsohYhh\hIwfH`q hIwhIwhL hUQhn hUQhap hUQhEhUQh,1fHq hUQhL hUQhWhvqGhYc0JjhYcU hYchYcjhYcUhYchL%hUQhL%0JjhUQhL%UjhUQhL%U hUQhL% hUQh1L"Q R  n o   ab#$2gd~ngd~ngdIwgdn    | T U ^ m o u      $ X w ]㿰ͩͿͩͿ}v hUQhShUQhfHq hUQh hUQh^iehUQhBfHq hUQhaph8ZhBfH`q hUQhB hUQh1 hUQhEhUQhLfHq hUQhL hUQhIwhIw hIwhIwhs)#op@AO`abh"#$*#$%&۾žž۞{r{{r{{r{hUQh~n0JhUQh~n0JjhUQh~n0JUhUQh~nOJQJ^J!hph~nB*OJQJ^JphhUQhG5fHq hUQhG5 hUQhc?h8ZhSfH`q hUQhL hUQh^ie hUQhShUQhSfHq ,&@AKLMNhiopqr    &'/012DyzSTU   ڸکhUQh~n0JOJQJ^JjhUQh~nUjhUQh~nUhUQh~n0J hUQh~nhUQh~n0JjhUQh~n0JUhUQh~n0J@2 B_Z t!!!!"$T% &gdSgdS & F[$\$gd~n [$\$gd~ngd~n dd[$\$gd~ngd~njq{q\G)hh~nOJQJ^JfH`q )hOh~nOJQJ^JfHq h~nOJQJ^J)hUQh~nOJQJ^JfH`q )hFh~nOJQJ^JfHq )hh~nOJQJ^JfHq hUQh~n0JOJQJ^J)hUQh~nOJQJ^JfHq )heh~nOJQJ^JfHq hUQh~nOJQJ^J(/6;>CGy)3EVl 2!3!q!r!!qj_j_V_jhUQh~n0JjhUQh~nU hUQh~nhUQh~n0JOJQJ^J)heh~nOJQJ^JfH`q )hgh~nOJQJ^JfHq )hh~nOJQJ^JfH`q )hOh~nOJQJ^JfHq h~nOJQJ^J)hUQh~nOJQJ^JfHq hUQh~nOJQJ^J!!!!!!!!!!!""""""""""##### #+#,#-#.#H#I#R#S#T#U#o#p#{#|#}#~###################µhUQhS0JhUQhS0JjhUQhS0JUhUQhSOJQJ^JhSOJQJ^J!hZGhSB*OJQJ^Jph hUQhShUQh~n0J hUQh~njhUQh~nU;#$$$$$ $#$$$1$2$3$4$$$$$$$$$$$$(%)%R%S%l%m%%%%&& & &r&s&w&x&y&&' ((˼ϳϥϖt)hhSOJQJ^JfHq hUQhSOJQJ^JhUQhS0JOJQJ^JjhUQhSUhUQhS0JhUQhSfHq hS hUQhSjhUQhSUhUQhS0JjhUQhS0JUhUQhS0J- &y&+>0000L112B3369 ;< = = ==?r@(Agd&0M0N0000000ݷݢݢݢݢݢ݄yypyi hUQhzhUQhS0JjhUQhSU hUQhS-hUQhSOJPJQJ^JfHq )hUQhSOJQJ^JfHq hUQhS0JOJQJ^J-hhSOJPJQJ^JfHq hUQhSOJQJ^J)hhSOJQJ^JfHq "000L1M1g1h1q1r1s1t11111111111111111111(2)2`2a22222222?3@3B3C3333333ʸʸʸʸhUQhz0JOJQJ^JjLhUQhzUjhUQhzUhUQhz0J hUQhzhUQhz0JhUQhz0JjhUQhz0JUhUQhzOJQJ^JhzOJQJ^J!h.hzB*OJQJ^Jph236677888899:: ;;;;;<<<<=== = ===@=F====󤙤|r|]|]|)hYh&>>>!>">(>)>*>+>E>F>N>O>P>Q>k>l>t>u>v>w>>>>>>>>>>>>>>>>>>>??????.?/?8?9?:?;?U?V?]?^?_?`?????????@@F@οζhUQh&DDDDDEHHHHHH4I6IIIII6J8JOLWLMǺǺǺhUQh&`ccFeUeVeeeeeeeeeɴɥɴɐ{tm`hUQhWOJQJ^J hUQh&{]|gdw$4gd5Ie dd[$\$gd5Iegd5Iegd5IegdW dd[$\$gdOgdWjjjjjjj+k,k-k.k/kkkkkkkkAltl|lllnnnnbndnfnhnnnnnnnvqxqzqżvggggggghUQhWOJPJQJ^J)h#hWOJQJ^JfHq )hhWOJQJ^JfHq hUQhWOJQJ^JhUQhW0JOJQJ^JhUQhW0JjhUQhWUhUQhO0Jj; hUQhOUjhUQhOU hUQhO hUQhW(zq|qss,tNttt+u:u;uuuuuuuuCvDv^v_vovpvqvrvvvvvvvv䤙yl_lRl_l_lRl_l_hUQh5Ie0JmHsHhUQh5Ie0JmHsHjhUQh5Ie0JUhpOJQJ^JhUQh5IeOJQJ^JhUQhW0JjhUQhWU hUQhW)h]|hWOJQJ^JfHq )hphWOJQJ^JfHq hUQhW0JOJQJ^JhUQhWOJQJ^JhUQhWOJPJQJ^J vvvvvvvvvvvvww wwww*w+w5w6w7w8wRwSwcwdwewfwwwwwwwwwwwwwwwwwww)x*x.x7x8x9x@xAxSxxxxxxxyyCyͲͲ͹ͲͲhUQh5Ie0Jh){F{_{l{]|e|f|q|||||~~~~HJLNjlnpVXZ\ǺǺǺhUQh5IeOJPJQJ^J)hh5IeOJQJ^JfHq hUQh5IeOJQJ^JhUQh5Ie0JOJQJ^J hUQh5IehUQh5Ie0JjhUQh5IeUj hUQh5IeU7ƒԃT~$& %&-./0ݿݸypygypypygypyhUQhw$40JhUQhw$40JjhUQhw$40JUhpzOJQJ^JhUQhw$4OJQJ^J hUQhrLhUQh5Ie0JjhUQh5IeU hUQh5IehUQh5Ie0JOJQJ^JhUQh5IeOJPJQJ^JhUQh5IeOJQJ^J)hZGh5IeOJQJ^JfHq (0JKSTUVpqyz{|ˆʈˈ̈ӈԈST}~2356oԲԣhUQhw$4OJPJQJ^JhUQhw$4OJQJ^JhUQhw$40JOJQJ^Jj1hUQhw$4UjhUQhw$4UhUQhw$40J hUQhw$4 hpz0JhUQhw$40JjhUQhw$40JUhUQhw$40J4Ԉ5p8wٜ^_`ßn$%1ʯVWXgd}Ggd}Ggd }gd }gd }gdw$4 dd[$\$gdpzgdw$4opD8@Al4vʗ̗02tvwXYST[\^_`şş阍}v hUQhc hUQhrLhUQhw$40JjhUQhw$4U hUQhw$4-h5lhw$4OJPJQJ^JfHq hUQhw$40JOJQJ^J)h5lhw$4OJQJ^JfHq hUQhw$4OJPJQJ^JhUQhw$4OJQJ^JhGu/OJQJ^J)`egx45GHIJdetuvwŸß՟ BClm󲥲}r}rirhUQh }0JjhUQh }U hUQh }hUQh }0JhUQh }mHsHhUQh }0JmHsHhUQh }0JmHsHjhUQh }0JU)hIcjh }OJQJ^JfHq )hsIh }OJQJ^JfHq hsIOJQJ^JhUQh }OJQJ^J)mڠ۠ܠ!"%219ʯKLSTVWXŰǰȰȻȻ}pieie]jh}GUh}G h}Gh}Gh}Gh}GOJQJ^Jh}Gh}G0JOJQJ^JhW hUQhc)h8@h }OJQJ^JfHq hUQh }OJPJQJ^JhUQh }OJQJ^JhUQh }0JOJQJ^JhUQh }0JjhUQh }UjhUQh }U hUQh }$Ȱ԰9;<=Hrs+fhR͹ FGGnḰ̫̖̫lWW)hCh}GOJQJ^JfHq )hth}GOJQJ^JfHq )hZh}GOJQJ^JfHq )hM?h}GOJQJ^JfHq )h6?;h}GOJQJ^JfHq h}Gh}G0J5\h}Gh}GOJQJ^Jhh}G0Jjh}GUj{h}GU h}Gh}Gh}G!Hsȴh Ggs[# & Fdd[$\$gd}G & Fdd[$\$gd}Ggd}Ggd}GVX_ lsb23456fݼݠݠ݋݋݋ݼ|xqjcUhUQhW5CJ$\aJ$ hUQhL hUQh&$$If\"& 0634aytVi d$IfgdW $$Ifa$gdWgkd>$$If&0634aytW^U $IfgdWkd{?$$If\"& 0634aytVicq d$IfgdW $$Ifa$gdWgkdI@$$If&0634aytW^U $IfgdWkd@$$If\"& 0634aytViQhz d$IfgdW $$Ifa$gdWgkdA$$If&0634aytWz{|^U $IfgdWkd?B$$If\"& 0634aytVi|} d$IfgdW $$Ifa$gdWgkd C$$If&0634aytW^U $IfgdWkdC$$If\"& 0634aytVidt d$IfgdW $$Ifa$gdWgkdoD$$If&0634aytW^U $IfgdWkdE$$If\"& 0634aytVibu d$IfgdW $$Ifa$gdWgkdE$$If&0634aytW^U $IfgdWkdeF$$If\"& 0634aytVi d$IfgdW $$Ifa$gdWgkd3G$$If&0634aytW^U $IfgdWkdG$$If\"& 0634aytVi!Pgy d$IfgdW $$Ifa$gdWgkdH$$If&0634aytWyz{^U $IfgdWkd)I$$If\"& 0634aytVi{| d$IfgdW $$Ifa$gdWgkdI$$If&0634aytW^U $IfgdWkdJ$$If\"& 0634aytViU_q d$IfgdW $$Ifa$gdWgkdYK$$If&0634aytWqrs^U $IfgdWkdK$$If\"& 0634aytVist|  d$IfgdW $$Ifa$gdWgkdL$$If&0634aytW ^U $IfgdWkdOM$$If\"& 0634aytVi Uo d$IfgdW $$Ifa$gdWgkdN$$If&0634aytW^U $IfgdWkdN$$If\"& 0634aytVi&.@ d$IfgdW $$Ifa$gdWgkdO$$If&0634aytW@AB^U $IfgdWkdP$$If\"& 0634aytViBCK' d$IfgdW $$Ifa$gdWgkdP$$If&0634aytW'()^U $IfgdWkduQ$$If\"& 0634aytVi)*2 d$IfgdW $$Ifa$gdWgkdCR$$If&0634aytW^U $IfgdWkdR$$If\"& 0634aytVi?Pb d$IfgdW $$Ifa$gdWgkdS$$If&0634aytWbcd^U $IfgdWkd9T$$If\"& 0634aytVidem$6 d$IfgdW $$Ifa$gdWgkdU$$If&0634aytW678^U $IfgdWkdU$$If\"& 0634aytVi89A d$IfgdW $$Ifa$gdWgkdiV$$If&0634aytW^U $IfgdWkdV$$If\"& 0634aytViq d$IfgdW $$Ifa$gdWgkdW$$If&0634aytW^U $IfgdWkd_X$$If\"& 0634aytVi'9 d$IfgdW $$Ifa$gdWgkd-Y$$If&0634aytW9:;^U $IfgdWkdY$$If\"& 0634aytVi;<D d$IfgdW $$Ifa$gdWgkdZ$$If&0634aytW^U $IfgdWkd#[$$If\"& 0634aytVi:HZ d$IfgdW $$Ifa$gdWgkd[$$If&0634aytWZ[\^U $IfgdWkd\$$If\"& 0634aytVi\]e  d$IfgdW $$Ifa$gdWgkdS]$$If&0634aytW ^U $IfgdWkd]$$If\"& 0634aytVi  d$IfgdW $$Ifa$gdWgkd^$$If&0634aytW^U $IfgdWkdI_$$If\"& 0634aytVi! d$IfgdW $$Ifa$gdWgkd`$$If&0634aytW^U $IfgdWkd`$$If\"& 0634aytVio} d$IfgdW $$Ifa$gdWgkdya$$If&0634aytW^U $IfgdWkd b$$If\"& 0634aytViXbt d$IfgdW $$Ifa$gdWgkdb$$If&0634aytWtuv^U $IfgdWkdoc$$If\"& 0634aytVivw d$IfgdW $$Ifa$gdWgkd=d$$If&0634aytW^U $IfgdWkdd$$If\"& 0634aytVi r d$IfgdW $$Ifa$gdWgkde$$If&0634aytW^U $IfgdWkd3f$$If\"& 0634aytVi  d$IfgdW $$Ifa$gdWgkdg$$If&0634aytW^U $IfgdWkdg$$If\"& 0634aytVi' d$IfgdW $$Ifa$gdWgkdch$$If&0634aytW^U $IfgdWkdh$$If\"& 0634aytVi d$IfgdW $$Ifa$gdWgkdi$$If&0634aytW^U $IfgdWkdYj$$If\"& 0634aytVi,BT d$IfgdW $$Ifa$gdWgkd'k$$If&0634aytWTUV^U $IfgdWkdk$$If\"& 0634aytViVW_$ d$IfgdW $$Ifa$gdWgkdl$$If&0634aytW$%&^U $IfgdWkdm$$If\"& 0634aytVi&'/ d$IfgdW $$Ifa$gdWgkdm$$If&0634aytW^U $IfgdWkdn$$If\"& 0634aytViFVh d$IfgdW $$Ifa$gdWgkdMo$$If&0634aytWhij^U $IfgdWkdo$$If\"& 0634aytVijks * d$IfgdW $$Ifa$gdWgkdp$$If&0634aytW*+,^U $IfgdWkdCq$$If\"& 0634aytVi,-5 d$IfgdW $$Ifa$gdWgkdr$$If&0634aytW^U $IfgdWkdr$$If\"& 0634aytVi=Oa d$IfgdW $$Ifa$gdWgkdss$$If&0634aytWabc^U $IfgdWkdt$$If\"& 0634aytVicdl d$IfgdW $$Ifa$gdWgkdt$$If&0634aytW^U $IfgdWkdiu$$If\"& 0634aytViCQc d$IfgdW $$Ifa$gdWgkd7v$$If&0634aytWcde^U $IfgdWkdv$$If\"& 0634aytViefn d$IfgdW $$Ifa$gdWgkdw$$If&0634aytW^U $IfgdWkd-x$$If\"& 0634aytVi+= d$IfgdW $$Ifa$gdWgkdx$$If&0634aytW=>?^U $IfgdWkdy$$If\"& 0634aytVi?@H d$IfgdW $$Ifa$gdWgkd]z$$If&0634aytW^U $IfgdWkdz$$If\"& 0634aytVi(6H d$IfgdW $$Ifa$gdWgkd{$$If&0634aytWHIJ^U $IfgdWkdS|$$If\"& 0634aytViJKS5?Q d$IfgdW $$Ifa$gdWgkd!}$$If&0634aytWQRS^U $IfgdWkd}$$If\"& 0634aytViST\ d$IfgdW $$Ifa$gdWgkd~$$If&0634aytW^U $IfgdWkd$$If\"& 0634aytViM\n d$IfgdW $$Ifa$gdWgkd$$If&0634aytWnop^U $IfgdWkdy$$If\"& 0634aytVipqy + =  d$IfgdW $$Ifa$gdWgkdG$$If&0634aytW= > ? ^U $IfgdWkdہ$$If\"& 0634aytVi? @ H     d$IfgdW $$Ifa$gdWgkd$$If&0634aytW   ^U $IfgdWkd=$$If\"& 0634aytVi   J ] o  d$IfgdW $$Ifa$gdWgkd $$If&0634aytWo p q ^U $IfgdWkd$$If\"& 0634aytViq r z     d$IfgdW $$Ifa$gdWgkdm$$If&0634aytW   ^U $IfgdWkd$$If\"& 0634aytVi       d$IfgdW $$Ifa$gdWgkdφ$$If&0634aytW   ^U $IfgdWkdc$$If\"& 0634aytVi       d$IfgdW $$Ifa$gdWgkd1$$If&0634aytW   ^U $IfgdWkdň$$If\"& 0634aytVi   O Y k  d$IfgdW $$Ifa$gdWgkd$$If&0634aytWk l m ^U $IfgdWkd'$$If\"& 0634aytVim n v    d$IfgdW $$Ifa$gdWgkd$$If&0634aytW^U $IfgdWkd$$If\"& 0634aytVi d$IfgdW $$Ifa$gdWgkdW$$If&0634aytW^U $IfgdWkd$$If\"& 0634aytVie| d$IfgdW $$Ifa$gdWgkd$$If&0634aytW^U $IfgdWkdM$$If\"& 0634aytVio d$IfgdW $$Ifa$gdWgkd$$If&0634aytW^U $IfgdWkd$$If\"& 0634aytVi  d$IfgdW $$Ifa$gdWgkd}$$If&0634aytW  ^U $IfgdWkd$$If\"& 0634aytVi d$IfgdW $$Ifa$gdWgkdߑ$$If&0634aytW^U $IfgdWkds$$If\"& 0634aytVi"/A d$IfgdW $$Ifa$gdWgkdA$$If&0634aytWABC^U $IfgdWkdՓ$$If\"& 0634aytViCDM d$IfgdW $$Ifa$gdWgkd$$If&0634aytW^U $IfgdWkd7$$If\"& 0634aytViFXj d$IfgdW $$Ifa$gdWgkd$$If&0634aytWjkl^U $IfgdWkd$$If\"& 0634aytVilmv$ d$IfgdW $$Ifa$gdWgkdg$$If&0634aytW$%&^U $IfgdWkd$$If\"& 0634aytVi&'0 d$IfgdW $$Ifa$gdWgkdɘ$$If&0634aytW^U $IfgdWkd]$$If\"& 0634aytViZhz d$IfgdW $$Ifa$gdWgkd+$$If&0634aytWz{|^U $IfgdWkd$$If\"& 0634aytVi|}  d$IfgdW $$Ifa$gdWgkd$$If&0634aytW !^U $IfgdWkd!$$If\"& 0634aytVi!"+ d$IfgdW $$Ifa$gdWgkd$$If&0634aytW^U $IfgdWkd$$If\"& 0634aytVi>N` d$IfgdW $$Ifa$gdWgkdQ$$If&0634aytW`ab^U $IfgdWkd$$If\"& 0634aytVibcl d$IfgdW $$Ifa$gdWgkd$$If&0634aytW  ^U $IfgdWkdG$$If\"& 0634aytVi   d$IfgdW $$Ifa$gdWgkd$$If&0634aytW^U $IfgdWkd$$If\"& 0634aytViy d$IfgdW $$Ifa$gdWgkdw$$If&0634aytW^U $IfgdWkd $$If\"& 0634aytVi(: d$IfgdW $$Ifa$gdWgkd٣$$If&0634aytW:;<^U $IfgdWkdm$$If\"& 0634aytVi<=F d$IfgdW $$Ifa$gdWgkd;$$If&0634aytW^U $IfgdWkdϥ$$If\"& 0634aytVikt d$IfgdW $$Ifa$gdWgkd$$If&0634aytW^U $IfgdWkd1$$If\"& 0634aytVi d$IfgdW $$Ifa$gdWgkd$$If&0634aytW^U $IfgdWkd$$If\"& 0634aytVi! d$IfgdW $$Ifa$gdWgkda$$If&0634aytW^U $IfgdWkd$$If\"& 0634aytVi d$IfgdW $$Ifa$gdWgkdê$$If&0634aytW^U $IfgdWkdW$$If\"& 0634aytVi]p d$IfgdW $$Ifa$gdWgkd%$$If&0634aytW^U $IfgdWkd$$If\"& 0634aytVi"4 d$IfgdW $$Ifa$gdWgkd$$If&0634aytW456^U $IfgdWkd$$If\"& 0634aytVi67@ d$IfgdW $$Ifa$gdWgkd$$If&0634aytW^U $IfgdWkd}$$If\"& 0634aytVif t   d$IfgdW $$Ifa$gdWgkdK$$If&0634aytW   ^U $IfgdWkd߰$$If\"& 0634aytVi   ^!l!~! d$IfgdW $$Ifa$gdWgkd$$If&0634aytW~!!!^U $IfgdWkdA$$If\"& 0634aytVi!!!!"" d$IfgdW $$Ifa$gdWgkd$$If&0634aytW"""^U $IfgdWkd$$If\"& 0634aytVi""$"""" d$IfgdW $$Ifa$gdWgkdq$$If&0634aytW"""^U $IfgdWkd$$If\"& 0634aytVi"""~### d$IfgdW $$Ifa$gdWgkdӵ$$If&0634aytW###^U $IfgdWkdg$$If\"& 0634aytVi####$$ d$IfgdW $$Ifa$gdWgkd5$$If&0634aytW$$$^U $IfgdWkdɷ$$If\"& 0634aytVi$$!$$$$ d$IfgdW $$Ifa$gdWgkd$$If&0634aytW$$$^U $IfgdWkd+$$If\"& 0634aytVi$$$m%%% d$IfgdW $$Ifa$gdWgkd$$If&0634aytW%%%^U $IfgdWkd$$If\"& 0634aytVi%%%&&&8& d$IfgdW $$Ifa$gdWgkd[$$If&0634aytW8&9&:&^U $IfgdWkd$$If\"& 0634aytVi:&;&D&&&& d$IfgdW $$Ifa$gdWgkd$$If&0634aytW&&&^U $IfgdWkdQ$$If\"& 0634aytVi&' '''' d$IfgdW $$Ifa$gdWgkd$$If&0634aytW'''^U $IfgdWkd$$If\"& 0634aytVi'''a(u(( d$IfgdW $$Ifa$gdWgkd$$If&0634aytW(((^U $IfgdWkd$$If\"& 0634aytVi((())/) d$IfgdW $$Ifa$gdWgkd$$If&0634aytW/)0)1)^U $IfgdWkdw$$If\"& 0634aytVi1)2);)))) d$IfgdW $$Ifa$gdWgkdE$$If&0634aytW)))^U $IfgdWkd$$If\"& 0634aytVi)))*** d$IfgdW $$Ifa$gdWgkd$$If&0634aytW***^U $IfgdWkd;$$If\"& 0634aytVi***+++ d$IfgdW $$Ifa$gdWgkd $$If&0634aytW+++^U $IfgdWkd$$If\"& 0634aytVi+++,,', d$IfgdW $$Ifa$gdWgkdk$$If&0634aytW',(,),^U $IfgdWkd$$If\"& 0634aytVi),*,3,,,, d$IfgdW $$Ifa$gdWgkd$$If&0634aytW,,,^U $IfgdWkda$$If\"& 0634aytVi,,-|--- d$IfgdW $$Ifa$gdWgkd/$$If&0634aytW---^U $IfgdWkd$$If\"& 0634aytVi--- .3.E. d$IfgdW $$Ifa$gdWgkd$$If&0634aytWE.F.G.^U $IfgdWkd%$$If\"& 0634aytViG.H.Q.... d$IfgdW $$Ifa$gdWgkd$$If&0634aytW...^U $IfgdWkd$$If\"& 0634aytVi...\/k/}/ d$IfgdW $$Ifa$gdWgkdU$$If&0634aytW}/~//^U $IfgdWkd$$If\"& 0634aytVi///0+0=0 d$IfgdW $$Ifa$gdWgkd$$If&0634aytW=0>0?0^U $IfgdWkdK$$If\"& 0634aytVi?0@0I0k0|00 d$IfgdW $$Ifa$gdWgkd$$If&0634aytW000^U $IfgdWkd$$If\"& 0634aytVi000 11+1 d$IfgdW $$Ifa$gdWgkd{$$If&0634aytW+1,1-1^U $IfgdWkd$$If\"& 0634aytVi-1.171111 d$IfgdW $$Ifa$gdWgkd$$If&0634aytW111^U $IfgdWkdq$$If\"& 0634aytVi111{222 d$IfgdW $$Ifa$gdWgkd?$$If&0634aytW222^U $IfgdWkd$$If\"& 0634aytVi222Q3a3s3 d$IfgdW $$Ifa$gdWgkd$$If&0634aytWs3t3u3^U $IfgdWkd5$$If\"& 0634aytViu3v3334&4 d$IfgdW $$Ifa$gdWgkd$$If&0634aytW&4'4(4^U $IfgdWkd$$If\"& 0634aytVi(4)424444 d$IfgdW $$Ifa$gdWgkde$$If&0634aytW444^U $IfgdWkd$$If\"& 0634aytVi444555 d$IfgdW $$Ifa$gdWgkd$$If&0634aytW555^U $IfgdWkd[$$If\"& 0634aytVi555566 d$IfgdW $$Ifa$gdWgkd)$$If&0634aytW666^U $IfgdWkd$$If\"& 0634aytVi66 6o666 d$IfgdW $$Ifa$gdWgkd$$If&0634aytW666^U $IfgdWkd$$If\"& 0634aytVi66677$7 d$IfgdW $$Ifa$gdWgkd$$If&0634aytW$7%7&7^U $IfgdWkd$$If\"& 0634aytVi&7'707m7{77 d$IfgdW $$Ifa$gdWgkdO$$If&0634aytW777^U $IfgdWkd$$If\"& 0634aytVi777778 d$IfgdW $$Ifa$gdWgkd$$If&0634aytW888^U $IfgdWkdE$$If\"& 0634aytVi888888 d$IfgdW $$Ifa$gdWgkd$$If&0634aytW888^U $IfgdWkd$$If\"& 0634aytVi888'969H9 d$IfgdW $$Ifa$gdWgkdu$$If&0634aytWH9I9J9^U $IfgdWkd $$If\"& 0634aytViJ9K9T9999 d$IfgdW $$Ifa$gdWgkd$$If&0634aytW999^U $IfgdWkdk$$If\"& 0634aytVi999:1:C: d$IfgdW $$Ifa$gdWgkd9$$If&0634aytWC:D:E:^U $IfgdWkd$$If\"& 0634aytViE:F:O:I;W;i; d$IfgdW $$Ifa$gdWgkd$$If&0634aytWi;j;k;^U $IfgdWkd/$$If\"& 0634aytVik;l;u;;<< d$IfgdW $$Ifa$gdWgkd$$If&0634aytW<<<^U $IfgdWkd$$If\"& 0634aytVi<<&<<<< d$IfgdW $$Ifa$gdWgkd_$$If&0634aytW<<<^U $IfgdWkd$$If\"& 0634aytVi<= =t=== d$IfgdW $$Ifa$gdWgkd$$If&0634aytW===^U $IfgdWkdU$$If\"& 0634aytVi===>.>@> d$IfgdW $$Ifa$gdWgkd#$$If&0634aytW@>A>B>^U $IfgdWkd$$If\"& 0634aytViB>C>L>>>> d$IfgdW $$Ifa$gdWgkd$$If&0634aytW>>>^U $IfgdWkd$$If\"& 0634aytVi>>>N?b?t? d$IfgdW $$Ifa$gdWgkd$$If&0634aytWt?u?v?^U $IfgdWkd{$$If\"& 0634aytViv?w?? @@/@ d$IfgdW $$Ifa$gdWgkdI$$If&0634aytW/@0@1@^U $IfgdWkd$$If\"& 0634aytVi1@2@;@@@@ d$IfgdW $$Ifa$gdWgkd$$If&0634aytW@@@^U $IfgdWkd?$$If\"& 0634aytVi@@@.A;AMA d$IfgdW $$Ifa$gdWgkd $$If&0634aytWMANAOA^U $IfgdWkd$$If\"& 0634aytViOAPAYAAAA d$IfgdW $$Ifa$gdWgkdo$$If&0634aytWAAA^U $IfgdWkd$$If\"& 0634aytViAABBBB d$IfgdW $$Ifa$gdWgkd$$If&0634aytWBBB^U $IfgdWkde$$If\"& 0634aytViBBBCCC d$IfgdW $$Ifa$gdWgkd3$$If&0634aytWCCC^U $IfgdWkd$$If\"& 0634aytViCCCFDVDhD d$IfgdW $$Ifa$gdWgkd$$If&0634aytWhDiDjD^U $IfgdWkd)$$If\"& 0634aytVijDkDtDPEaEsE d$IfgdW $$Ifa$gdWgkd$$If&0634aytWsEtEuE^U $IfgdWkd$$If\"& 0634aytViuEvEE.FAFSF d$IfgdW $$Ifa$gdWgkdY$$If&0634aytWSFTFUF^U $IfgdWkd$$If\"& 0634aytViUFVF_F6GEGWG d$IfgdW $$Ifa$gdWgkd$$If&0634aytWWGXGYG^U $IfgdWkdO$$If\"& 0634aytViYGZGcGGGG d$IfgdW $$Ifa$gdWgkd$$If&0634aytWGGG^U $IfgdWkd$$If\"& 0634aytViGGHwHHH d$IfgdW $$Ifa$gdWgkd$$If&0634aytWHHH^U $IfgdWkd$$If\"& 0634aytViHHHHHI d$IfgdW $$Ifa$gdWgkd$$If&0634aytWIII^U $IfgdWkdu$$If\"& 0634aytViIIIIII d$IfgdW $$Ifa$gdWgkdC$$If&0634aytWIII^U $IfgdWkd$$If\"& 0634aytViIIIOJ]JoJ d$IfgdW $$Ifa$gdWgkd$$If&0634aytWoJpJqJ^U $IfgdWkd9$$If\"& 0634aytViqJrJ{JJJJ d$IfgdW $$Ifa$gdWgkd$$If&0634aytWJJJ^U $IfgdWkd$$If\"& 0634aytViJJJKKK d$IfgdW $$Ifa$gdWgkdi$$If&0634aytWKKL^U $IfgdWkd$$If\"& 0634aytViLL LLLL d$IfgdW $$Ifa$gdWgkd$$If&0634aytWLLL^U $IfgdWkd_ $$If\"& 0634aytViLLLWMoMM d$IfgdW $$Ifa$gdWgkd- $$If&0634aytWMMM^U $IfgdWkd $$If\"& 0634aytViMMMTNoNN d$IfgdW $$Ifa$gdWgkd $$If&0634aytWNNN^U $IfgdWkd# $$If\"& 0634aytViNNN?OOOaO d$IfgdW $$Ifa$gdWgkd $$If&0634aytWaObOcO^U $IfgdWkd $$If\"& 0634aytVicOdOmO7PFPXP d$IfgdW $$Ifa$gdWgkdS$$If&0634aytWXPYPZP^U $IfgdWkd$$If\"& 0634aytViZP[PdPPPQ d$IfgdW $$Ifa$gdWgkd$$If&0634aytWQQQ^U $IfgdWkdI$$If\"& 0634aytViQQQqQQQ d$IfgdW $$Ifa$gdWgkd$$If&0634aytWQQQ^U $IfgdWkd$$If\"& 0634aytViQQQmRRR d$IfgdW $$Ifa$gdWgkdy$$If&0634aytWRRR^U $IfgdWkd $$If\"& 0634aytViRRRRR S d$IfgdW $$Ifa$gdWgkd$$If&0634aytW S S S^U $IfgdWkdo$$If\"& 0634aytVi S SS_SoSS d$IfgdW $$Ifa$gdWgkd=$$If&0634aytWSSS^U $IfgdWkd$$If\"& 0634aytViSSSFTTTfT d$IfgdW $$Ifa$gdWgkd$$If&0634aytWfTgThT^U $IfgdWkd3$$If\"& 0634aytVihTiTrTU+U=U d$IfgdW $$Ifa$gdWgkd$$If&0634aytW=U>U?U^U $IfgdWkd$$If\"& 0634aytVi?U@UIUUUU d$IfgdW $$Ifa$gdWgkdc$$If&0634aytWUUU^U $IfgdWkd$$If\"& 0634aytViUUUVVV d$IfgdW $$Ifa$gdWgkd$$If&0634aytWVVV^U $IfgdWkdY$$If\"& 0634aytViVVVW&W8W d$IfgdW $$Ifa$gdWgkd'$$If&0634aytW8W9W:W^U $IfgdWkd$$If\"& 0634aytVi:W;WDWWXX d$IfgdW $$Ifa$gdWgkd$$If&0634aytWXXX^U $IfgdWkd$$If\"& 0634aytViXXXXXX d$IfgdW $$Ifa$gdWgkd$$If&0634aytWXXX^U $IfgdWkd$$If\"& 0634aytViXXXYYY d$IfgdW $$Ifa$gdWgkdM $$If&0634aytWYYY^U $IfgdWkd $$If\"& 0634aytViYYYZZZ d$IfgdW $$Ifa$gdWgkd!$$If&0634aytWZZZ^U $IfgdWkdC"$$If\"& 0634aytViZZZ\[l[~[ d$IfgdW $$Ifa$gdWgkd#$$If&0634aytW~[[[^U $IfgdWkd#$$If\"& 0634aytVi[[[b\q\\ d$IfgdW $$Ifa$gdWgkds$$$If&0634aytW\\\^U $IfgdWkd%$$If\"& 0634aytVi\\\\\\ d$IfgdW $$Ifa$gdWgkd%$$If&0634aytW\\\^U $IfgdWkdi&$$If\"& 0634aytVi\\]]]] d$IfgdW $$Ifa$gdWgkd7'$$If&0634aytW]]]^U $IfgdWkd'$$If\"& 0634aytVi]]]^^^ d$IfgdW $$Ifa$gdWgkd($$If&0634aytW^^^^U $IfgdWkd-)$$If\"& 0634aytVi^^^{___ d$IfgdW $$Ifa$gdWgkd)$$If&0634aytW___^U $IfgdWkd*$$If\"& 0634aytVi___e`u`` d$IfgdW $$Ifa$gdWgkd]+$$If&0634aytW```^U $IfgdWkd+$$If\"& 0634aytVi```a*aa^U $IfgdWkdS-$$If\"& 0634aytVi>a?aHa:bObab d$IfgdW $$Ifa$gdWgkd!.$$If&0634aytWabbbcb^U $IfgdWkd.$$If\"& 0634aytVicbdbmbXchczc d$IfgdW $$Ifa$gdWgkd/$$If&0634aytWzc{c|c^U $IfgdWkd0$$If\"& 0634aytVi|c}cccc d d$IfgdW $$Ifa$gdWgkd0$$If&0634aytW d d d^U $IfgdWkdy1$$If\"& 0634aytVi d ddddd d$IfgdW $$Ifa$gdWgkdG2$$If&0634aytWdee^U $IfgdWkd2$$If\"& 0634aytViee ezeee d$IfgdW $$Ifa$gdWgkd3$$If&0634aytWeee^U $IfgdWkd=4$$If\"& 0634aytVieeeff+f d$IfgdW $$Ifa$gdWgkd 5$$If&0634aytW+f,f-f^U $IfgdWkd5$$If\"& 0634aytVi-f.f7ffff d$IfgdW $$Ifa$gdWgkdm6$$If&0634aytWfff^U $IfgdWkd7$$If\"& 0634aytVifffjgygg d$IfgdW $$Ifa$gdWgkd7$$If&0634aytWggg^U $IfgdWkdc8$$If\"& 0634aytVigggggh d$IfgdW $$Ifa$gdWgkd19$$If&0634aytWhhh^U $IfgdWkd9$$If\"& 0634aytVihhhhhh d$IfgdW $$Ifa$gdWgkd:$$If&0634aytWhhh^U $IfgdWkd';$$If\"& 0634aytVihhhmizii d$IfgdW $$Ifa$gdWgkd;$$If&0634aytWiii^U $IfgdWkd<$$If\"& 0634aytViiiijj0j d$IfgdW $$Ifa$gdWgkdW=$$If&0634aytW0j1j2j^U $IfgdWkd=$$If\"& 0634aytVi2j3j$$If&0634aytWjjj^U $IfgdWkdM?$$If\"& 0634aytVijjjkkk d$IfgdW $$Ifa$gdWgkd@$$If&0634aytWkkk^U $IfgdWkd@$$If\"& 0634aytVikkklll d$IfgdW $$Ifa$gdWgkd}A$$If&0634aytWlll^U $IfgdWkdB$$If\"& 0634aytVilllVmjm|m d$IfgdW $$Ifa$gdWgkdB$$If&0634aytW|m}m~m^U $IfgdWkdsC$$If\"& 0634aytVi~mmmn,n>n d$IfgdW $$Ifa$gdWgkdAD$$If&0634aytW>n?n@n^U $IfgdWkdD$$If\"& 0634aytVi@nAnJnnoo d$IfgdW $$Ifa$gdWgkdE$$If&0634aytWooo^U $IfgdWkd7F$$If\"& 0634aytVioo#oooo d$IfgdW $$Ifa$gdWgkdG$$If&0634aytWooo^U $IfgdWkdG$$If\"& 0634aytVioooppp d$IfgdW $$Ifa$gdWgkdgH$$If&0634aytWppp^U $IfgdWkdH$$If\"& 0634aytVipppqqq d$IfgdW $$Ifa$gdWgkdI$$If&0634aytWqqq^U $IfgdWkd]J$$If\"& 0634aytViqqqjrrr d$IfgdW $$Ifa$gdWgkd+K$$If&0634aytWrrr^U $IfgdWkdK$$If\"& 0634aytVirrr ss.s d$IfgdW $$Ifa$gdWgkdL$$If&0634aytW.s/s0s^U $IfgdWkd!M$$If\"& 0634aytVi0s1s:ssss d$IfgdW $$Ifa$gdWgkdM$$If&0634aytWsss^U $IfgdWkdN$$If\"& 0634aytVisssottt d$IfgdW $$Ifa$gdWgkdQO$$If&0634aytWttt^U $IfgdWkdO$$If\"& 0634aytVitttt uu d$IfgdW $$Ifa$gdWgkdP$$If&0634aytWuuu^U $IfgdWkdGQ$$If\"& 0634aytViuu(uuuu d$IfgdW $$Ifa$gdWgkdR$$If&0634aytWuuu^U $IfgdWkdR$$If\"& 0634aytViuuvrvvv d$IfgdW $$Ifa$gdWgkdwS$$If&0634aytWvvv^U $IfgdWkd T$$If\"& 0634aytVivvvww(w d$IfgdW $$Ifa$gdWgkdT$$If&0634aytW(w)w*w^U $IfgdWkdmU$$If\"& 0634aytVi*w+w4wwww d$IfgdW $$Ifa$gdWgkd;V$$If&0634aytWwww^U $IfgdWkdV$$If\"& 0634aytViwwwexyxx d$IfgdW $$Ifa$gdWgkdW$$If&0634aytWxxx^U $IfgdWkd1X$$If\"& 0634aytVixxxyy-y d$IfgdW $$Ifa$gdWgkdX$$If&0634aytW-y.y/y^U $IfgdWkdY$$If\"& 0634aytVi/y0y9y~yyy d$IfgdW $$Ifa$gdWgkdaZ$$If&0634aytWyyy^U $IfgdWkdZ$$If\"& 0634aytViyyyezuzz d$IfgdW $$Ifa$gdWgkd[$$If&0634aytWzzz^U $IfgdWkdW\$$If\"& 0634aytVizzz{{0{ d$IfgdW $$Ifa$gdWgkd%]$$If&0634aytW0{1{2{^U $IfgdWkd]$$If\"& 0634aytVi2{3{<{{{{ d$IfgdW $$Ifa$gdWgkd^$$If&0634aytW{{{^U $IfgdWkd_$$If\"& 0634aytVi{{{l|{|| d$IfgdW $$Ifa$gdWgkd_$$If&0634aytW|||^U $IfgdWkd}`$$If\"& 0634aytVi|||}}1} d$IfgdW $$Ifa$gdWgkdKa$$If&0634aytW1}2}3}^U $IfgdWkda$$If\"& 0634aytVi3}4}=}v}}} d$IfgdW $$Ifa$gdWgkdb$$If&0634aytW}}}}}E~^\\SH $Ifgdyu:K$ $Ifgdyu:kdAc$$If\"& 0634aytVi}}~~~C~D~E~F~G~H~I~J~Q~R~S~FGHINO𴩚}n}n_n}Kkdh$IfK$L$T`&634aT $Ifgdyu:K$Rkdg$IfK$L$T &  634ap TIJSTVWghpqv|}pqrs޿zzkzjjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****f[ $Ifgdyu:K$<kdh$IfK$L$T&634aT $$Ifa$gdyu:K$Okd_h$IfK$L$T0h%&h634aTvwyzz<>kdi$IfK$L$T&634aT<kdi$IfK$L$T&634aT $Ifgdyu:K$>kd#i$IfK$L$T`&634aTz{|tuwRG $Ifgdyu:K$RkdOk$IfK$L$T &  634ap T $Ifgdyu:K$Akd9j$IfK$L$T&634aT $$Ifa$gdyu:K$wxRTUVgY $$Ifa$gdyu:K$Okd*l$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdk$IfK$L$T`&634aTsxy˃̃у҃PQRZ[  lmwxz{ͅ΅օׅمڅ,-56;AB56ҿzzjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ,VWYZ;<>z><kdLm$IfK$L$T&634aT>kdl$IfK$L$T`&634aT $Ifgdyu:K$<kdl$IfK$L$T&634aT>?@A9rg $Ifgdyu:K$Akdn$IfK$L$T&634aT $$Ifa$gdyu:K$>kdm$IfK$L$T&634aT678=>HIJRS ghrsuvȉɉщ҉ԉՉ'(23³ ³֌}j}}j}}j}}j}}j$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjXnhyu:h< LCJUaJ)9:<=JLcXX $Ifgdyu:K$>kdo$IfK$L$T`&634aT $Ifgdyu:K$Rkdo$IfK$L$T &  634ap TLMNOQf[ $Ifgdyu:K$<kdep$IfK$L$T&634aT $$Ifa$gdyu:K$Okdo$IfK$L$T0h%&h634aTQR89;<z<>kdqq$IfK$L$T&634aT<kdq$IfK$L$T&634aT $Ifgdyu:K$>kdp$IfK$L$T`&634aT38>?2345:;<=>FG    _`ijlm͍΍э峤}}j}}}j}}}j}}}j}$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j#rhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho)<=>679RG $Ifgdyu:K$Rkdr$IfK$L$T &  634ap T $Ifgdyu:K$Akdq$IfK$L$T&634aT $$Ifa$gdyu:K$9:>@ABgY $$Ifa$gdyu:K$Okds$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdbs$IfK$L$T`&634aTBCEF124z><kdt$IfK$L$T&634aT>kdt$IfK$L$T`&634aT $Ifgdyu:K$<kd0t$IfK$L$T&634aTэҍ$%+,178+,-.34:;<DEST[\^_ݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***juhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*4567/rg $Ifgdyu:K$Akdu$IfK$L$T&634aT $$Ifa$gdyu:K$>kdcXX $Ifgdyu:K$>kd-w$IfK$L$T`&634aT $Ifgdyu:K$Rkdv$IfK$L$T &  634ap T>?@ACf[ $Ifgdyu:K$<kdw$IfK$L$T&634aT $$Ifa$gdyu:K$Okdw$IfK$L$T0h%&h634aTCD !z<>kdy$IfK$L$T&634aT<kdx$IfK$L$T&634aT $Ifgdyu:K$>kdOx$IfK$L$T`&634aT#$ rsxy jkʿ~k~k~X%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jyhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho!"#RG $Ifgdyu:K$Rkd{z$IfK$L$T &  634ap T $Ifgdyu:K$Akdey$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$OkdV{$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdz$IfK$L$T`&634aTz><kdx|$IfK$L$T&634aT>kd|$IfK$L$T`&634aT $Ifgdyu:K$<kd{$IfK$L$T&634aTkrsvwɔʔԔՔהؔ*+9:<=      de³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j}hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH% rg $Ifgdyu:K$Akd0}$IfK$L$T&634aT $$Ifa$gdyu:K$>kd|$IfK$L$T&634aT ]_cXX $Ifgdyu:K$>kd~$IfK$L$T`&634aT $Ifgdyu:K$RkdF~$IfK$L$T &  634ap Tejk[\]ef˜ØŘƘ$%(){|ٙڙ89ABGMN޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&_`abdf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd!$IfK$L$T0h%&h634aTdeGHJKz<>kd$IfK$L$T&634aT<kdC$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTKLMEFHRG $Ifgdyu:K$Rkd$IfK$L$T &  634ap T $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$NABCDIJcdijlmŜƜȜɜ$%'(z{ם؝ôáô~k~~k~~k~~k~~k$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jOhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ*HI   gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT  z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd\$IfK$L$T&634aT=>CDpqvwyz̠͠Ԡՠנؠ*+/02ôҠ~~kkkk$hyu:h< L0J>*B* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*rg $Ifgdyu:K$AkdƄ$IfK$L$T&634aT $$Ifa$gdyu:K$>kdh$IfK$L$T&634aTcXX $Ifgdyu:K$>kdY$IfK$L$T`&634aT $Ifgdyu:K$Rkd܅$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd'$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kd3$IfK$L$T&634aT<kdه$IfK$L$T&634aT $Ifgdyu:K$>kd{$IfK$L$T`&634aT23ɣʣ&')*|}ݤޤDݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*RG $Ifgdyu:K$Rkd$IfK$L$T &  634ap T $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$ãģţgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$$IfK$L$T`&634aTţƣȣɣz><kd$IfK$L$T&634aT>kdF$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTDENOQR ŧƧʿ~k~k~X%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphorg $Ifgdyu:K$Akd\$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTcXX $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Rkdr$IfK$L$T &  634ap T§ħf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OkdM$IfK$L$T0h%&h634aTħŧz<>kdɏ$IfK$L$T&634aT<kdo$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT !#$vw֨רݨި34;<?@³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j{hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%RG $Ifgdyu:K$Rkd=$IfK$L$T &  634ap T $Ifgdyu:K$Akd'$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTīū!"$%wxج٬67@ACD޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&ëīz><kd:$IfK$L$T&634aT>kdܒ$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTrg $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT˯̯ͯկ֯()2367GHRSUôáôzczzczzczzcz,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jFhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ&ͯϯcXX $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Rkd$IfK$L$T &  634ap TϯЯѯүԯf[ $Ifgdyu:K$<kdS$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTԯկz<>kd_$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTUV  XYٳvgvTgTvgA%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphoRG $Ifgdyu:K$RkdӘ$IfK$L$T &  634ap T $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdP$IfK$L$T`&634aTz><kdК$IfK$L$T&634aT>kdr$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTYfgij´Ŵƴ#$&'yzյֵ޵ߵ޶߶9:³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jܛhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%rg $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd*$IfK$L$T&634aTcXX $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Rkd$IfK$L$T &  634ap T:?@OP\]_`$%'(z{׹ع޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okdy$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd=$IfK$L$T`&634aTRG $Ifgdyu:K$Rkdi$IfK$L$T &  634ap T $Ifgdyu:K$AkdS$IfK$L$T&634aT $$Ifa$gdyu:K$ABGH$%wxܼݼ;<EFHIôáôzczzczzczzcz,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ& gY $$Ifa$gdyu:K$OkdD$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT !#$ z><kdf$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT   bchi#$%-.ٳvgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jrhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho  rg $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT  %'cXX $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Rkd4$IfK$L$T &  634ap T'()*,f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT,-z<>kd$IfK$L$T&634aT<kd1$IfK$L$T&634aT $Ifgdyu:K$>kdӥ$IfK$L$T`&634aTEFOPRSklqrٳvgvTg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j=hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho RG $Ifgdyu:K$Rkd$IfK$L$T &  634ap T $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okdڨ$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd|$IfK$L$T`&634aTr0134LM]^`aʿrccjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***&z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdJ$IfK$L$T&634aTrg $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdV$IfK$L$T&634aT#$$%./12FGSTVW³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ&cXX $Ifgdyu:K$>kdG$IfK$L$T`&634aT $Ifgdyu:K$Rkdʫ$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kd!$IfK$L$T&634aT<kdǭ$IfK$L$T&634aT $Ifgdyu:K$>kdi$IfK$L$T`&634aT[\]ef³vgvTgTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jӮhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJphoRG $Ifgdyu:K$Rkd$IfK$L$T &  634ap T $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$]_`agY $$Ifa$gdyu:K$Okdp$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTabdeDEGz><kd$IfK$L$T&634aT>kd4$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT$%(){|78>?DJK>?@AFG/01ʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*GHIJBrg $Ifgdyu:K$AkdJ$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTBCEF13cXX $Ifgdyu:K$>kdݳ$IfK$L$T`&634aT $Ifgdyu:K$Rkd`$IfK$L$T &  634ap T34568f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd;$IfK$L$T0h%&h634aT89z<>kd$IfK$L$T&634aT<kd]$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT19:EFKLNO  hΨvghyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jihyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ(RG $Ifgdyu:K$Rkd+$IfK$L$T &  634ap T $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$kmnogY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aThinoijkst./:;=>OPYZ_efYZ[ʿzzkj4hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph****oprs_`bz><kd($IfK$L$T&634aT>kdʸ$IfK$L$T`&634aT $Ifgdyu:K$<kdv$IfK$L$T&634aTbcde]rg $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT[\ab !st}~45?@BC ѯ¯囌yyyyy$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJ-]^`acXX $Ifgdyu:K$>kds$IfK$L$T`&634aT $Ifgdyu:K$Rkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kdA$IfK$L$T&634aT $$Ifa$gdyu:K$Okdѻ$IfK$L$T0h%&h634aT z<>kdM$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTRG $Ifgdyu:K$Rkd$IfK$L$T &  634ap T $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$WX]^ !"*+}~?@VWYZ³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ&"$%&gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd>$IfK$L$T`&634aT&')*"#%z><kd$IfK$L$T&634aT>kd`$IfK$L$T`&634aT $Ifgdyu:K$<kd $IfK$L$T&634aT"()$%wx}~'()12³vgvTgTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%&'( rg $Ifgdyu:K$Akdv$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT !#$)+cXX $Ifgdyu:K$>kd $IfK$L$T`&634aT $Ifgdyu:K$Rkd$IfK$L$T &  634ap T+,-.0f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okdg$IfK$L$T0h%&h634aT01  z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd+$IfK$L$T`&634aTBCMNPQ  abghʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*   RG $Ifgdyu:K$RkdW$IfK$L$T &  634ap T $Ifgdyu:K$AkdA$IfK$L$T&634aT $$Ifa$gdyu:K$ gY $$Ifa$gdyu:K$Okd2$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kdT$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTYZdehi"#%&xy>?D~k$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j`hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ*rg $Ifgdyu:K$Akd $IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTcXX $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Rkd"$IfK$L$T &  634ap TDEqr~34?@BC  𾪛yyjyj+hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***)f[ $Ifgdyu:K$<kdm$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kdy$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT  RG $Ifgdyu:K$Rkd$IfK$L$T &  634ap T $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdj$IfK$L$T`&634aTYZ_` !st~45?@BC ҿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ) z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd8$IfK$L$T&634aT  rg $Ifgdyu:K$Akd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdD$IfK$L$T&634aT  YZ_` (){|89CDFG³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ& "cXX $Ifgdyu:K$>kd5$IfK$L$T`&634aT $Ifgdyu:K$Rkd$IfK$L$T &  634ap T"#$%'f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT'(z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdW$IfK$L$T`&634aT      efklLMNVW첣ufuSfSufDhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosHRG $Ifgdyu:K$Rkd$IfK$L$T &  634ap T $Ifgdyu:K$Akdm$IfK$L$T&634aT $$Ifa$gdyu:K$NPQRgY $$Ifa$gdyu:K$Okd^$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTRSUVWXZz><kd$IfK$L$T&634aT>kd"$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT  qr>?QRW]^QRST[ostghijrʿj/hyu:h< LCJUaJ#hyu:h< L5B*CJ\aJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*Z[\]Urg $Ifgdyu:K$Akd8$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTUVWXZg\ $Ifgdyu:K$9kd$$IfT&64ayt< LT $$Ifa$gdyu:RkdN$IfK$L$T &  634ap TZ[oprskz<>kd$IfK$L$T`&634aT<kdw$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T&634aTklnoqh] $Ifgdyu:K$>kdn$IfK$L$Th&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tqr(*+,gY $$Ifa$gdyu:K$Okd*$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTrs&'(01=>DEGHݿzzkzjXhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph****,-/0z><kdL$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T}~9:BCFGYZfglrsfghʿzzkj#hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph****f[ $Ifgdyu:K$<kde$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTlmopz<>kdq$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTpqrjkm\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$hinoKLMUVefpqst&'127=>12ѯ¯囌yyyyy$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJ-mnMOPQgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdb$IfK$L$T`&634aTQRTU78:z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd0$IfK$L$T&634aT:;<=5wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd<$IfK$L$T&634aT2349:=>QRTU fgpq³ ³֌}j}}j}}j}}j}}j$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ)5689h]] $Ifgdyu:K$>kd-$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTvwyzz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdO$IfK$L$T`&634aTqv|}pqrsxy[\]ef*+-.峤}j}S}j}j}S}j}j},hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho z{|tuw\Q $Ifgdyu:K$Mkd{$IfK$L$T &  634ap T $Ifgdyu:K$<kde$IfK$L$T&634aT $$Ifa$gdyu:K$wx]_`agY $$Ifa$gdyu:K$OkdV$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTabdeN O Q z><kdx$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT@ A H I N T U H I J K P Q     < = > F G ³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH Q R S T L wl $Ifgdyu:K$<kd0$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTL M O P > @ h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$MkdF$IfK$L$T &  634ap T@ A B C E f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd!$IfK$L$T0h%&h634aTE F 4 5 7 8 z<>kd$IfK$L$T&634aT<kdC$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTG             Z [ o p r s       % & . / 4 : ; ./0167𾯾}j$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jOhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho)8 9 : 235\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$56gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT~=>GHJKǸ}j}S}j}j}S}j},hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LB* CJaJphohyu:h< LCJaJhyu:h< LB*CJaJph*** z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd\$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdh$IfK$L$T&634aTh]] $Ifgdyu:K$>kdY$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd'$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTuvxyz<>kd3$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd{$IfK$L$T`&634aTK   `aopu{|opqrwx/01첣ufuSfSuf$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH yz{stv\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$vw1345gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$$IfK$L$T`&634aT5689z><kd$IfK$L$T&634aT>kdF$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT19:MNTUXY   nΨvghyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ(wl $Ifgdyu:K$<kd\$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTegh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkdr$IfK$L$T &  634ap Tnouvcdemn !+,./>?JKPVWJKLʿzzkj{hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph****ghijlf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OkdM$IfK$L$T0h%&h634aTlmPQSTz<>kd$IfK$L$T&634aT<kdo$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTTUVNOQ\Q $Ifgdyu:K$Mkd=$IfK$L$T &  634ap T $Ifgdyu:K$<kd'$IfK$L$T&634aT $$Ifa$gdyu:K$LMRStuv~34>?ABTU]^cѯ¯囈qqqqq,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJ)QRvxyzgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz{}~cdfz><kd:$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTfghiawl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTcij]^_`ef           Q!R!\!]!_!`!!!!!!!"״~o~\~o~o~\~o~o~\~o~o$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jFhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH$abde  h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T     f[ $Ifgdyu:K$<kdS$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT  """"z<>kd_$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT""""" "r"s"{"|""""{#|#}#~#######*$+$,$4$5$$$ʿ~k~k~X%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho"""###\Q $Ifgdyu:K$Mkd $IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$##,$.$/$0$gY $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT $Ifgdyu:K$>kdP $IfK$L$T`&634aT0$1$3$4$& & &z><kd $IfK$L$T&634aT>kdr $IfK$L$T`&634aT $Ifgdyu:K$<kd $IfK$L$T&634aT$$$$$$$$$$$A%B%H%I%L%M%%%%%%%%%&&&&&'''' ' ']'^'³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH% & & &&'wl $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$>kd* $IfK$L$T&634aT'' ' '''h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd $IfK$L$T &  634ap T^'d'e''''''C(D(L(M(O(P((((((())))))d)e)l)m)o)p))))))))****޿zzkzjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****'''''f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okdy$IfK$L$T0h%&h634aT''))))z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd=$IfK$L$T`&634aT)))***\Q $Ifgdyu:K$Mkdi$IfK$L$T &  634ap T $Ifgdyu:K$<kdS$IfK$L$T&634aT $$Ifa$gdyu:K$**++++gY $$Ifa$gdyu:K$OkdD$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT***$+%+++,++++++8,9,C,D,G,H,,,,,,,,,-- - -\-]-g-h-j-k-------ҿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ)++++---z><kdf$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT----.wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT--...... /!/'/(//////"0#030406070000000001111W1X1e1f1³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jrhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&....//h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd4$IfK$L$T &  634ap T/////f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT//1111z<>kd$IfK$L$T&634aT<kd1$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTf1h1i11111111222222 3!3'3(333333첣ufuSfSuf$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j=hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH111222\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$223333gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd|$IfK$L$T`&634aT3333555z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdJ$IfK$L$T&634aT34 4(4)4+4,4~444444444444C5D5L5M5P5Q55555555666666 7 7첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'55556wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdV$IfK$L$T&634aT6666z7|7h]] $Ifgdyu:K$>kdG$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T 777x7y7z7777777777888@8A8C8D888888888999 9[9\9e9f9k9q9r9e:f:g:h:޿zzkzjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****|7}7~777f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT77k9l9n9o9z<>kd!$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdi$IfK$L$T`&634aTo9p9q9i:j:l:\Q $Ifgdyu:K$Mkd $IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$l:m:;;;;gY $$Ifa$gdyu:K$Okdp!$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd!$IfK$L$T`&634aTh:m:n:::::;;;;;;;<<<<W<X<a<b<e<f<<<<<<<==$=%='=(=z={=====ҿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ);;;;===z><kd"$IfK$L$T&634aT>kd4"$IfK$L$T`&634aT $Ifgdyu:K$<kd!$IfK$L$T&634aT====>wl $Ifgdyu:K$<kdJ#$IfK$L$T&634aT $$Ifa$gdyu:K$>kd"$IfK$L$T&634aT==>>>>>>>>>>?????@@&@'@)@*@|@}@@@@@@@@@@@KALA\A]A³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j#hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&>>>>??h]] $Ifgdyu:K$>kd$$IfK$L$T`&634aT $Ifgdyu:K$Mkd`$$IfK$L$T &  634ap T?????f[ $Ifgdyu:K$<kd%$IfK$L$T&634aT $$Ifa$gdyu:K$Okd;%$IfK$L$T0h%&h634aT??AAAAz<>kd&$IfK$L$T&634aT<kd]&$IfK$L$T&634aT $Ifgdyu:K$>kd%$IfK$L$T`&634aT]A_A`AAAAAAAABBBBBBBBCCCCCC#D$D첣whTEThyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j *hyu:h< LCJUaJ#hyu:h< L5B*CJ\aJph***ji'hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosHAAABBB\P $$Ifa$gdyu:Mkd+($IfK$L$T &  634ap T $Ifgdyu:K$<kd'$IfK$L$T&634aT $$Ifa$gdyu:K$BBBBBBB}A<kdT)$IfK$L$T&634aT>kd($IfK$L$T&634aT $Ifgdyu:K$9kd($$IfT&64ayt< LTBBCCChMkd*$IfK$L$T &  634ap T $Ifgdyu:K$>kd)$IfK$L$T`&634aTCCCCDDxmm $Ifgdyu:K$>kd+$IfK$L$T`&634aT $Ifgdyu:K$>kdK+$IfK$L$Th&634aT$D)D*DDDDDDEE E EEEEF F F FFFcFdFiFjFFFFFFJGKG޿zzkz޿X%hyu:h< LB* CJaJmHphosHj5.hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***DDDDDf[ $Ifgdyu:K$<kdw,$IfK$L$T&634aT $$Ifa$gdyu:K$Okd,$IfK$L$T0h%&h634aTDDEEEEz<>kd-$IfK$L$T&634aT<kd)-$IfK$L$T&634aT $Ifgdyu:K$>kd,$IfK$L$T`&634aTEEE F FF\Q $Ifgdyu:K$Mkd.$IfK$L$T &  634ap T $Ifgdyu:K$<kd-$IfK$L$T&634aT $$Ifa$gdyu:K$FFFFFFgY $$Ifa$gdyu:K$Okd/$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdt/$IfK$L$T`&634aTFFFFHHHz><kd0$IfK$L$T&634aT>kd0$IfK$L$T`&634aT $Ifgdyu:K$<kdB0$IfK$L$T&634aTKGUGVGXGYGGGGGGG H HHHHHgHhHrHsHuHvHHHHHHHHIIIIII*J+J³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j2hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%HHHHIwl $Ifgdyu:K$<kd1$IfK$L$T&634aT $$Ifa$gdyu:K$>kdN1$IfK$L$T&634aTIIIIJJh]] $Ifgdyu:K$>kd?3$IfK$L$T`&634aT $Ifgdyu:K$Mkd2$IfK$L$T &  634ap T+J0J1JJJJJJJJJJJJIKJKNKOKQKRKKKKKKKLLLL L L]L^LdLeLjLpLqL޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&JJJJJf[ $Ifgdyu:K$<kd 4$IfK$L$T&634aT $$Ifa$gdyu:K$Okd3$IfK$L$T0h%&h634aTJJjLkLmLnLz<>kd5$IfK$L$T&634aT<kd4$IfK$L$T&634aT $Ifgdyu:K$>kda4$IfK$L$T`&634aTnLoLpLhMiMkM\Q $Ifgdyu:K$Mkd6$IfK$L$T &  634ap T $Ifgdyu:K$<kdw5$IfK$L$T&634aT $$Ifa$gdyu:K$qLdMeMfMgMlMmMMMMMNNNNNbNcNmNnNqNrNNNNNNN"O#O1O2O4O5OOOOOOOOOOôáô~k~~k~~k~~k~~k$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j5hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ*kMlMN N N NgY $$Ifa$gdyu:K$Okdh7$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd 7$IfK$L$T`&634aT N NNNOOOz><kd8$IfK$L$T&634aT>kd,8$IfK$L$T`&634aT $Ifgdyu:K$<kd7$IfK$L$T&634aTOOOOOPPPPPPLQMQRQSQQQQQQMRNRbRcReRfRRRRRRRSôҠ~~kTkkTkk,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j9hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho OOOOPwl $Ifgdyu:K$<kdB9$IfK$L$T&634aT $$Ifa$gdyu:K$>kd8$IfK$L$T&634aTPPPPQQh]] $Ifgdyu:K$>kd:$IfK$L$T`&634aT $Ifgdyu:K$MkdX:$IfK$L$T &  634ap TQQQQQf[ $Ifgdyu:K$<kd;$IfK$L$T&634aT $$Ifa$gdyu:K$Okd3;$IfK$L$T0h%&h634aTQQSSSSz<>kd<$IfK$L$T&634aT<kdU<$IfK$L$T&634aT $Ifgdyu:K$>kd;$IfK$L$T`&634aTSS S!S#S$SvSwSSSSSSSSSSSSTTTTTT?U@UEUFUUUUU³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***ja=hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho SSSTTT\Q $Ifgdyu:K$Mkd#>$IfK$L$T &  634ap T $Ifgdyu:K$<kd =$IfK$L$T&634aT $$Ifa$gdyu:K$TTUUUUgY $$Ifa$gdyu:K$Okd>$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd>$IfK$L$T`&634aTUUUU/W0W2Wz><kd @$IfK$L$T&634aT>kd?$IfK$L$T`&634aT $Ifgdyu:K$<kdn?$IfK$L$T&634aTUUVVV V V V^V_ViVjVlVmVVVVVVV W!W-W.W/W5W6W)X*X+X,X1X2XXXXXXXXXX)Yݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j,Ahyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*2W3W4W5W-Xwl $Ifgdyu:K$<kd@$IfK$L$T&634aT $$Ifa$gdyu:K$>kdz@$IfK$L$T&634aT-X.X0X1XXXh]] $Ifgdyu:K$>kdkB$IfK$L$T`&634aT $Ifgdyu:K$MkdA$IfK$L$T &  634ap TXXXXXf[ $Ifgdyu:K$<kd9C$IfK$L$T&634aT $$Ifa$gdyu:K$OkdB$IfK$L$T0h%&h634aTXXZZZZz<>kdED$IfK$L$T&634aT<kdC$IfK$L$T&634aT $Ifgdyu:K$>kdC$IfK$L$T`&634aT)Y*Y4Y5Y7Y8YYYYYYYYYYYYYNZOZZZ[Z]Z^ZZZZZZZZ[[[[[[\\\\\\ʿ~k~k$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jDhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho*ZZZ[[[\Q $Ifgdyu:K$MkdE$IfK$L$T &  634ap T $Ifgdyu:K$<kdD$IfK$L$T&634aT $$Ifa$gdyu:K$[[\\\\gY $$Ifa$gdyu:K$OkdF$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd6F$IfK$L$T`&634aT\\\\\\\\\\M]N]U]V]X]Y]]]]]]]^ ^^^^^l^m^u^v^w^}^~^q_r_s_t_y_z_ѾѧѾѾѧѾѾѧѾѾѧѾѾѧѾzf&jhyu:h< LB*CJUaJph***jHhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***(\\\\w^x^z^z><kdG$IfK$L$T&634aT>kdXG$IfK$L$T`&634aT $Ifgdyu:K$<kdG$IfK$L$T&634aTz^{^|^}^u_wl $Ifgdyu:K$<kdnH$IfK$L$T&634aT $$Ifa$gdyu:K$>kdH$IfK$L$T&634aTu_v_x_y_e`g`h]] $Ifgdyu:K$>kdJ$IfK$L$T`&634aT $Ifgdyu:K$MkdI$IfK$L$T &  634ap Tz_____c`d`e`m`n```````"a#a.a/a1a2aaaaaaaaaaaaaAbBbJbKbPbVb𾪗qhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***'g`h`i`j`l`f[ $Ifgdyu:K$<kdJ$IfK$L$T&634aT $$Ifa$gdyu:K$Okd_J$IfK$L$T0h%&h634aTl`m`PbQbSbTbz<>kdK$IfK$L$T&634aT<kdK$IfK$L$T&634aT $Ifgdyu:K$>kd#K$IfK$L$T`&634aTTbUbVbNcOcQc\Q $Ifgdyu:K$MkdOM$IfK$L$T &  634ap T $Ifgdyu:K$<kd9L$IfK$L$T&634aT $$Ifa$gdyu:K$VbWbJcKcLcMcRcSccccddddddeeeeee&f'f+f,f-f3f4f'g(g)g*g/g0g³ ³}j}}j}[jXPhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jLhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ#QcRcddddgY $$Ifa$gdyu:K$Okd*N$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdM$IfK$L$T`&634aTdddd-f.f0fz><kdLO$IfK$L$T&634aT>kdN$IfK$L$T`&634aT $Ifgdyu:K$<kdN$IfK$L$T&634aT0f1f2f3f+gwl $Ifgdyu:K$<kdP$IfK$L$T&634aT $$Ifa$gdyu:K$>kdO$IfK$L$T&634aT+g,g.g/gghh]] $Ifgdyu:K$>kdQ$IfK$L$T`&634aT $Ifgdyu:K$MkdQ$IfK$L$T &  634ap T0gggggggghhYhZh_h`hbhchhhhhhhii'i(i+i,i~iiiiiiiiiiiiijj𾪛yyjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph****hhhhhf[ $Ifgdyu:K$<kdeR$IfK$L$T&634aT $$Ifa$gdyu:K$OkdQ$IfK$L$T0h%&h634aThhiiiiz<>kdqS$IfK$L$T&634aT<kdS$IfK$L$T&634aT $Ifgdyu:K$>kdR$IfK$L$T`&634aTiiijjj\Q $Ifgdyu:K$MkdT$IfK$L$T &  634ap T $Ifgdyu:K$<kdS$IfK$L$T&634aT $$Ifa$gdyu:K$jjjjjHkIkRkSkTk\k]kckdkWlXlYlZl_l`llllllllmmZm[mjmkmmmnmm³ ³֑³ ³nn[nn$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphojWhyu:h< LCJUaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJj#Thyu:h< LCJUaJ#jjTkVkWkXkgY $$Ifa$gdyu:K$OkdU$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdbU$IfK$L$T`&634aTXkYk[k\k]k^k`kz><kdV$IfK$L$T&634aT>kdV$IfK$L$T`&634aT $Ifgdyu:K$<kd0V$IfK$L$T&634aT`kakbkck[lwl $Ifgdyu:K$<kdW$IfK$L$T&634aT $$Ifa$gdyu:K$>kdkd-Y$IfK$L$T`&634aT $Ifgdyu:K$MkdX$IfK$L$T &  634ap Tmmmmmf[ $Ifgdyu:K$<kdY$IfK$L$T&634aT $$Ifa$gdyu:K$OkdY$IfK$L$T0h%&h634aTmmnnnoz<>kd[$IfK$L$T&634aT<kdZ$IfK$L$T&634aT $Ifgdyu:K$>kdOZ$IfK$L$T`&634aTmmmmmm!n"n0n1n4n5nnnnnnnnnnnnooooooooQpRpWpXpppppp5q6q*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j[hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho*oooooo\Q $Ifgdyu:K$Mkd{\$IfK$L$T &  634ap T $Ifgdyu:K$<kde[$IfK$L$T&634aT $$Ifa$gdyu:K$ooppppgY $$Ifa$gdyu:K$OkdV]$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd\$IfK$L$T`&634aTpppprrrz><kdx^$IfK$L$T&634aT>kd^$IfK$L$T`&634aT $Ifgdyu:K$<kd]$IfK$L$T&634aT*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j_hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*rrrrswl $Ifgdyu:K$<kd0_$IfK$L$T&634aT $$Ifa$gdyu:K$>kd^$IfK$L$T&634aTssssVtXth]] $Ifgdyu:K$>kd`$IfK$L$T`&634aT $Ifgdyu:K$MkdF`$IfK$L$T &  634ap TXtYtZt[t]tf[ $Ifgdyu:K$<kda$IfK$L$T&634aT $$Ifa$gdyu:K$Okd!a$IfK$L$T0h%&h634aT]t^t7v8v:v;vz<>kdb$IfK$L$T&634aT<kdCb$IfK$L$T&634aT $Ifgdyu:K$>kda$IfK$L$T`&634aT^t_tttttttuuuuuukulutuuuwuxuuuuuuu'v(v1v2v7v=v>v1w2w3w4w9w:wwwwwݿ~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jOchyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*;vkdd$IfK$L$T`&634aTwwwwwxRxSx\x]x_x`xxxxxxxyyyy!y"ytyuyyyyyyyyyyyyzzzzzzʿzzkzjghyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph****wwwwyyyz><kdf$IfK$L$T&634aT>kde$IfK$L$T`&634aT $Ifgdyu:K$<kd\e$IfK$L$T&634aTyyyyzwl $Ifgdyu:K$<kdf$IfK$L$T&634aT $$Ifa$gdyu:K$>kdhf$IfK$L$T&634aTzzzz||h]] $Ifgdyu:K$>kdYh$IfK$L$T`&634aT $Ifgdyu:K$Mkdg$IfK$L$T &  634ap Tz5{6{;{<{{{|| |[|\|f|g|i|j||||||||}}}}}}~~!~"~~~~~~𾪛yyjyjjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***%|||||f[ $Ifgdyu:K$<kd'i$IfK$L$T&634aT $$Ifa$gdyu:K$Okdh$IfK$L$T0h%&h634aT||||||z<>kd3j$IfK$L$T&634aT<kdi$IfK$L$T&634aT $Ifgdyu:K$>kd{i$IfK$L$T`&634aT|||}}}\Q $Ifgdyu:K$Mkdk$IfK$L$T &  634ap T $Ifgdyu:K$<kdj$IfK$L$T&634aT $$Ifa$gdyu:K$}}~~~~gY $$Ifa$gdyu:K$Okdl$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$l$IfK$L$T`&634aT~~~~z><kdm$IfK$L$T&634aT>kdFm$IfK$L$T`&634aT $Ifgdyu:K$<kdl$IfK$L$T&634aT~fgqrtu%&,-/0첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jnhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'wl $Ifgdyu:K$<kd\n$IfK$L$T&634aT $$Ifa$gdyu:K$>kdm$IfK$L$T&634aT35h]] $Ifgdyu:K$>kdo$IfK$L$T`&634aT $Ifgdyu:K$Mkdro$IfK$L$T &  634ap T123;<RS`abhi\]^_de޿rccTcj{rhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph*** 5678:f[ $Ifgdyu:K$<kdp$IfK$L$T&634aT $$Ifa$gdyu:K$OkdMp$IfK$L$T0h%&h634aT:;bcefz<>kdq$IfK$L$T&634aT<kdoq$IfK$L$T&634aT $Ifgdyu:K$>kdq$IfK$L$T`&634aTfgh`ac\Q $Ifgdyu:K$Mkd=s$IfK$L$T &  634ap T $Ifgdyu:K$<kd'r$IfK$L$T&634aT $$Ifa$gdyu:K$cd !gY $$Ifa$gdyu:K$Okdt$IfK$L$T0h%&h634aT $Ifgdyu:K$>kds$IfK$L$T`&634aTe%&xyۅ܅?@JKMN𾪗qhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***'!"$%z><kd:u$IfK$L$T&634aT>kdt$IfK$L$T`&634aT $Ifgdyu:K$<kdt$IfK$L$T&634aTwl $Ifgdyu:K$<kdu$IfK$L$T&634aT $$Ifa$gdyu:K$>kdu$IfK$L$T&634aTlmrs   `apqstƉljӉԉ։׉)*67³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jFvhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&h]] $Ifgdyu:K$>kdw$IfK$L$T`&634aT $Ifgdyu:K$Mkdw$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kdSx$IfK$L$T&634aT $$Ifa$gdyu:K$Okdw$IfK$L$T0h%&h634aTz<>kd_y$IfK$L$T&634aT<kdy$IfK$L$T&634aT $Ifgdyu:K$>kdx$IfK$L$T`&634aT79:JKLTU  첣ufuSfSuf$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jzhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH \Q $Ifgdyu:K$Mkdz$IfK$L$T &  634ap T $Ifgdyu:K$<kdy$IfK$L$T&634aT $$Ifa$gdyu:K$LNOPgY $$Ifa$gdyu:K$Okd{$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdP{$IfK$L$T`&634aTPQSTstvz><kd|$IfK$L$T&634aT>kdr|$IfK$L$T`&634aT $Ifgdyu:K$<kd|$IfK$L$T&634aT fgqrsyzmnopuvȎɎΎώ!"tu|}³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j}hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH vwxyqwl $Ifgdyu:K$<kd}$IfK$L$T&634aT $$Ifa$gdyu:K$>kd*}$IfK$L$T&634aTqrtuh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd~$IfK$L$T &  634ap T f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okdy$IfK$L$T0h%&h634aT !z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd=$IfK$L$T`&634aTҏӏޏߏ45=>@A WX첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH!\Q $Ifgdyu:K$Mkdi$IfK$L$T &  634ap T $Ifgdyu:K$<kdS$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$OkdD$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTX]^op~Փ֓ߓ56>?AB޿zzkzjrhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****z><kdf$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd4$IfK$L$T &  634ap T   fglmԗ՗֗ޗߗ12@ADEҿ~~k~~~k~~~k~$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphoj=hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ*    f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kd1$IfK$L$T&634aT $Ifgdyu:K$>kdӇ$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$֗ؗٗڗgY $$Ifa$gdyu:K$Okdڊ$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd|$IfK$L$T`&634aTڗۗݗޗřƙșz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdJ$IfK$L$T&634aTST\]_`ř˙̙šǚȚ !`abjk𾯾}j}j}W%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho șəʙ˙Úwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdV$IfK$L$T&634aTÚĚƚǚbdh]] $Ifgdyu:K$>kdG$IfK$L$T`&634aT $Ifgdyu:K$Mkdʍ$IfK$L$T &  634ap Tdefgif[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTijz<>kd!$IfK$L$T&634aT<kdǏ$IfK$L$T&634aT $Ifgdyu:K$>kdi$IfK$L$T`&634aT ĜƜڜܜ01;<>?³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jӐhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$.246gY $$Ifa$gdyu:K$Okdp$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT*,.>@NOTUWX  bcghiopcdef޿zzkzjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****68<>ijlz><kd$IfK$L$T&634aT>kd4$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTlmnogwl $Ifgdyu:K$<kdJ$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTghjk}h]] $Ifgdyu:K$>kdݕ$IfK$L$T`&634aT $Ifgdyu:K$Mkd`$IfK$L$T &  634ap TfklĤŤ{|}إ٥ޥߥ45;<?@JKQRW]^QRҿzzjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ,f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd;$IfK$L$T0h%&h634aTWXZ[z<>kd$IfK$L$T&634aT<kd]$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT[\]UVX\Q $Ifgdyu:K$Mkd+$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$RSTYZ9:;CD  YZ_³ ³֌}j}}j}[³ j4hyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjihyu:h< LCJUaJ#XY;=>?gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT?@BCz><kd($IfK$L$T&634aT>kdʚ$IfK$L$T`&634aT $Ifgdyu:K$<kdv$IfK$L$T&634aT  wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTh]] $Ifgdyu:K$>kds$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T_`ūƫ!"$%wx}~ح٭ޭ߭JKLTU𾪛yyjyjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***"«īf[ $Ifgdyu:K$<kdA$IfK$L$T&634aT $$Ifa$gdyu:K$Okdѝ$IfK$L$T0h%&h634aTīūz<>kdM$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$LNOPgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd>$IfK$L$T`&634aTPQSTްz><kd$IfK$L$T&634aT>kd`$IfK$L$T`&634aT $Ifgdyu:K$<kd $IfK$L$T&634aTU $&ʰ̰ڰܰްijklqrIJŲʲ˲opq첣ufuSfSuf$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jʣhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH mwl $Ifgdyu:K$<kdv$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTmnpqqsh]] $Ifgdyu:K$>kd $IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tstuvxf[ $Ifgdyu:K$<kdץ$IfK$L$T&634aT $$Ifa$gdyu:K$Okdg$IfK$L$T0h%&h634aTxy^_abz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd+$IfK$L$T`&634aTqyz̳ͳֳ׳ٳڳ,-67:;RS\]^deXYZ[`aΨvghyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ(bcd\]_\Q $Ifgdyu:K$MkdW$IfK$L$T &  634ap T $Ifgdyu:K$<kdA$IfK$L$T&634aT $$Ifa$gdyu:K$_`lnopgY $$Ifa$gdyu:K$Okd2$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdԨ$IfK$L$T`&634aTjkltuǷȷҷӷշַ()1245JKRSX^ʿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***&pqstXY[z><kdT$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT[\]^Vwl $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT^_RSTUZ[HIJRS   ^_cdfg³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j`hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&VWYZJLh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd"$IfK$L$T &  634ap TLMNOQf[ $Ifgdyu:K$<kdm$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTQR#$&'z<>kdy$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTüļ#)* %&xy~KL첣ufuSfSufDhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j+hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'()!"$\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd׮$IfK$L$T&634aT $$Ifa$gdyu:K$$%gY $$Ifa$gdyu:K$OkdȰ$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdj$IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd8$IfK$L$T&634aTLTUXYopxy{|89>?stuʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdD$IfK$L$T&634aTuwh]] $Ifgdyu:K$>kd5$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Twxyz|f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT|}Z[]^z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdW$IfK$L$T`&634aTu}~/078:;QRXYZ`aTUVW\]~k$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ*^_`XY[\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kdm$IfK$L$T&634aT $$Ifa$gdyu:K$[\gY $$Ifa$gdyu:K$Okd^$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTklyz}~78GHJK𾪛yyjyjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***)z><kd$IfK$L$T&634aT>kd"$IfK$L$T`&634aT $Ifgdyu:K$<kdθ$IfK$L$T&634aTwl $Ifgdyu:K$<kd8$IfK$L$T&634aT $$Ifa$gdyu:K$>kdڹ$IfK$L$T&634aTh]] $Ifgdyu:K$>kd˻$IfK$L$T`&634aT $Ifgdyu:K$MkdN$IfK$L$T &  634ap TlmrsQRZ[\bcVWXY^_456>?ҿzzkzҿX%hyu:h< LB* CJaJmHphosHjWhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ"f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd)$IfK$L$T0h%&h634aT\]_`z<>kd$IfK$L$T&634aT<kdK$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT`abZ[]\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$]^689:gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT:;=>z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdd$IfK$L$T&634aTJKQRUV     fg³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j"hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho&wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdp$IfK$L$T&634aTh]] $Ifgdyu:K$>kda$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tglm%&./12DEMNPQ޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&f[ $Ifgdyu:K$<kd/$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kd;$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$ |}~:;DEGHôáôzczzczzczzcz,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ&~gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd,$IfK$L$T`&634aTijlz><kd$IfK$L$T&634aT>kdN$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT [\cdiopcdefklJKMUVٳvgvTgTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpholmnogwl $Ifgdyu:K$<kdd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTghjkMOh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkdz$IfK$L$T &  634ap TOPQRTf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OkdU$IfK$L$T0h%&h634aTTUz<>kd$IfK$L$T&634aT<kdw$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT     cdijDEFNOʿ~k~k~X%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho  \Q $Ifgdyu:K$MkdE$IfK$L$T &  634ap T $Ifgdyu:K$<kd/$IfK$L$T&634aT $$Ifa$gdyu:K$FHIJgY $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTJKMNNOQz><kdB$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT !st>?HINTUHIJKPQ³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jNhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%QRSTLwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTLMOP/1h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T-./78YZlmop-.BCHNO޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&12346f[ $Ifgdyu:K$<kd[$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT67HIKLz<>kdg$IfK$L$T&634aT<kd $IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTLMNFGI\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OBCDEJK stu}~ôáôôáôoo\oo$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphojhyu:h< LCJUaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$IJgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdX$IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kdz$IfK$L$T`&634aT $Ifgdyu:K$<kd&$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd2$IfK$L$T&634aTuwh]] $Ifgdyu:K$>kd#$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Twxyz|f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT|}z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdE$IfK$L$T`&634aT12=>@AVW\]𾯾}j}j}$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho"\Q $Ifgdyu:K$Mkdq$IfK$L$T &  634ap T $Ifgdyu:K$<kd[$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$OkdL$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kdn$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTLMTUWXefpqst*첣ub%hyu:h< LB*CJaJmHph***sH&jhyu:h< LB*CJUaJph***jzhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH&wl $Ifgdyu:K$<kd&$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT]_h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd<$IfK$L$T &  634ap T*+01[\]ef³}rcrcTcrEhyu:h< LB*CJaJph***jEhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJmHsH%hyu:h< LB*CJaJmHph***sH,hyu:h< L0J>*B*CJaJmHph***sH&jhyu:h< LB*CJUaJph***_`abdf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTdez<>kd$IfK$L$T&634aT<kd9$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$xz{|gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTvwx/09:<=޿rccTcjhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph*** |}z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdR$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd^$IfK$L$T&634aTh]] $Ifgdyu:K$>kdO$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T  Z[`a678@AMNXY[𾯾}}j}}}j}}}j}$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphojhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LB* CJaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***)f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT z<>kd)$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdq$IfK$L$T`&634aT   \Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$8:;<gY $$Ifa$gdyu:K$Okdx$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT<=?@z><kd$IfK$L$T&634aT>kd<$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT[\"#qrwx23=>@Aݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho* !"wl $Ifgdyu:K$<kdR$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkdh$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OkdC$IfK$L$T0h%&h634aT\]_`z<>kd$IfK$L$T&634aT<kde$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTRSZ[\bcVWXY^_ !)*|}ʿ~k~k~X%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jqhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho`abZ[]\Q $Ifgdyu:K$Mkd3$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$]^!#$%gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT%&()z><kd0$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd~$IfK$L$T&634aT}@AJKMNjk³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j<hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTh]] $Ifgdyu:K$>kd{$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tkpq+,5689LMTUWX޿zzkzjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****f[ $Ifgdyu:K$<kdI$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kdU$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdF$IfK$L$T`&634aT-.01BCTUV\]PQҿrccjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ&VWYz><kd$IfK$L$T&634aT>kdh$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTYZ[\Twl $Ifgdyu:K$<kd~$IfK$L$T&634aT $$Ifa$gdyu:K$>kd $IfK$L$T&634aTQRSXY>?@HISTYZ\] ³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ&TUWX@Bh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap TBCDEGf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okdo$IfK$L$T0h%&h634aTGHz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd3$IfK$L$T`&634aT  lmrs>?NOQR³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho \Q $Ifgdyu:K$Mkd_$IfK$L$T &  634ap T $Ifgdyu:K$<kdI$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd:$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kd\$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT  qr      @ A F G   ٳvgvTgTv$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho  wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT      h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd*$IfK$L$T &  634ap T    + , 6 7 8 > ? 2 3 4 5 : ;     9 : ; C D             MNSTѯ堑}}jj}ѯѯѯ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***j3 hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***)     f[ $Ifgdyu:K$<kdu$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT  8 9 ; < z<>kd $IfK$L$T&634aT<kd' $IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT< = > 6 7 9 \Q $Ifgdyu:K$Mkd $IfK$L$T &  634ap T $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$9 : ; = > ? gY $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT $Ifgdyu:K$>kdr $IfK$L$T`&634aT? @ B C z><kd $IfK$L$T&634aT>kd $IfK$L$T`&634aT $Ifgdyu:K$<kd@ $IfK$L$T&634aTTVW    ghmn-.89;<𾯾}j}j}$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho)wl $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$>kdL $IfK$L$T&634aTh]] $Ifgdyu:K$>kd=$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd_$IfK$L$T`&634aTOPYZ\]Jݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kdu$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okdf$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kd*$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTJKTUWX  lmz{z{|}345=>ʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho*~wl $Ifgdyu:K$<kd@$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT~57h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$MkdV$IfK$L$T &  634ap T789:<f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd1$IfK$L$T0h%&h634aT<=z<>kd$IfK$L$T&634aT<kdS$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTMNSTDENOQR  ݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j_hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*\Q $Ifgdyu:K$Mkd!$IfK$L$T &  634ap T $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdl$IfK$L$T&634aT  ^_jkmn!"'($%(){|ݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j*hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdx$IfK$L$T&634aTh]] $Ifgdyu:K$>kdi$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd7$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT    z<>kdC $IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT8 9 D E G H        !!!!!!!!"""""""""####X#Y#^#ʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho*   !!!\Q $Ifgdyu:K$Mkd!$IfK$L$T &  634ap T $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$!!""""gY $$Ifa$gdyu:K$Okd"$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd4"$IfK$L$T`&634aT""""|$}$$z><kd#$IfK$L$T&634aT>kdV#$IfK$L$T`&634aT $Ifgdyu:K$<kd#$IfK$L$T&634aT^#_#b#c#######$$$$$$o$p$v$w$|$$$v%w%x%y%~%%%%%%\&]&^&f&g&&&&&&ݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j$hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*$$$$z%wl $Ifgdyu:K$<kdl$$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$$IfK$L$T&634aTz%{%}%~%^&`&h]] $Ifgdyu:K$>kd%$IfK$L$T`&634aT $Ifgdyu:K$Mkd%$IfK$L$T &  634ap T`&a&b&c&e&f[ $Ifgdyu:K$<kd&$IfK$L$T&634aT $$Ifa$gdyu:K$Okd]&$IfK$L$T0h%&h634aTe&f&?(@(B(C(z<>kd'$IfK$L$T&634aT<kd'$IfK$L$T&634aT $Ifgdyu:K$>kd!'$IfK$L$T`&634aT&&'' '!'#'$'v'w'~''''''''''5(6(=(>(?(E(F(9):);)<)A)B)))))*****ݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j(hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho)C(D(E(=)>)@)\Q $Ifgdyu:K$MkdM)$IfK$L$T &  634ap T $Ifgdyu:K$<kd7($IfK$L$T&634aT $$Ifa$gdyu:K$@)A)** * *gY $$Ifa$gdyu:K$Okd(*$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd)$IfK$L$T`&634aT * * **+++z><kdJ+$IfK$L$T&634aT>kd*$IfK$L$T`&634aT $Ifgdyu:K$<kd*$IfK$L$T&634aT*a*b*g*h*k*l*******++"+#+%+&+x+y+~+++++++++++,,,,,,6-7-첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jV,hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'++++,wl $Ifgdyu:K$<kd,$IfK$L$T&634aT $$Ifa$gdyu:K$>kd+$IfK$L$T&634aT,,,,--h]] $Ifgdyu:K$>kd-$IfK$L$T`&634aT $Ifgdyu:K$Mkd-$IfK$L$T &  634ap T7-<-=------------K.L.R.S.U.V.......// / ///b/c/h/i/n/t/u/h0i0j0k0޿zzkzj!0hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****-----f[ $Ifgdyu:K$<kdc.$IfK$L$T&634aT $$Ifa$gdyu:K$Okd-$IfK$L$T0h%&h634aT--n/o/q/r/z<>kdo/$IfK$L$T&634aT<kd/$IfK$L$T&634aT $Ifgdyu:K$>kd.$IfK$L$T`&634aTr/s/t/l0m0o0\Q $Ifgdyu:K$Mkd0$IfK$L$T &  634ap T $Ifgdyu:K$<kd/$IfK$L$T&634aT $$Ifa$gdyu:K$o0p0p1r1s1t1gY $$Ifa$gdyu:K$Okd1$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd`1$IfK$L$T`&634aTk0p0q00000n1o1p1x1y1111111+2,2627292:2222222222222L3M3U3V3[3a3ҿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ)t1u1w1x1[3\3^3z><kd2$IfK$L$T&634aT>kd2$IfK$L$T`&634aT $Ifgdyu:K$<kd.2$IfK$L$T&634aT^3_3`3a3Y4wl $Ifgdyu:K$<kd3$IfK$L$T&634aT $$Ifa$gdyu:K$>kd:3$IfK$L$T&634aTa3b3U4V4W4X4]4^44444g5h5i5q5r5555555!6"6'6(6*6+6}6~666666666666³ ³}j}}j}}j}}j}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j3hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ)Y4Z4\4]4i5k5h]] $Ifgdyu:K$>kd+5$IfK$L$T`&634aT $Ifgdyu:K$Mkd4$IfK$L$T &  634ap Tk5l5m5n5p5f[ $Ifgdyu:K$<kd5$IfK$L$T&634aT $$Ifa$gdyu:K$Okd5$IfK$L$T0h%&h634aTp5q56666z<>kd7$IfK$L$T&634aT<kd6$IfK$L$T&634aT $Ifgdyu:K$>kdM6$IfK$L$T`&634aT666777\Q $Ifgdyu:K$Mkdy8$IfK$L$T &  634ap T $Ifgdyu:K$<kdc7$IfK$L$T&634aT $$Ifa$gdyu:K$677777798:8?8@888888999999m9n9s9t9v9w999999ôáôzczzczzcz,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j7hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ 778888gY $$Ifa$gdyu:K$OkdT9$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd8$IfK$L$T`&634aT8888999z><kdv:$IfK$L$T&634aT>kd:$IfK$L$T`&634aT $Ifgdyu:K$<kd9$IfK$L$T&634aT9999:wl $Ifgdyu:K$<kd.;$IfK$L$T&634aT $$Ifa$gdyu:K$>kd:$IfK$L$T&634aT999::::::%;&;+;,;l;m;n;v;w;;;;;;;(<)<1<2<4<5<<<<״~k~T~k~k~T~k~k~T,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j;hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH ::::n;p;h]] $Ifgdyu:K$>kd<$IfK$L$T`&634aT $Ifgdyu:K$MkdD<$IfK$L$T &  634ap Tp;q;r;s;u;f[ $Ifgdyu:K$<kd=$IfK$L$T&634aT $$Ifa$gdyu:K$Okd=$IfK$L$T0h%&h634aTu;v;X=Y=[=\=z<>kd>$IfK$L$T&634aT<kdA>$IfK$L$T&634aT $Ifgdyu:K$>kd=$IfK$L$T`&634aT<<<<<<<<<<H=I=R=S=X=^=_=R>S>T>U>Z>[>>>>>>>>>>L?ٳvgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jM?hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho \=]=^=V>W>Y>\Q $Ifgdyu:K$Mkd@$IfK$L$T &  634ap T $Ifgdyu:K$<kd>$IfK$L$T&634aT $$Ifa$gdyu:K$Y>Z>>>>>gY $$Ifa$gdyu:K$Okd@$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd@$IfK$L$T`&634aT>>>>@@@z><kd B$IfK$L$T&634aT>kdA$IfK$L$T`&634aT $Ifgdyu:K$<kdZA$IfK$L$T&634aTL?M?U?V?Y?Z??????? @ @@@@@k@l@v@w@y@z@@@@@@@@AAAAAA1B2B³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jChyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho&@@@@Awl $Ifgdyu:K$<kdB$IfK$L$T&634aT $$Ifa$gdyu:K$>kdfB$IfK$L$T&634aTAAAABBh]] $Ifgdyu:K$>kdWD$IfK$L$T`&634aT $Ifgdyu:K$MkdC$IfK$L$T &  634ap T2B7B8BBBBBBCC*C+C,C2C3C&D'D(D)D.D/DDDDDEEE E E]E^E޿zzkz޿X%hyu:h< LB* CJaJmHphosHjFhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***BBBBBf[ $Ifgdyu:K$<kd%E$IfK$L$T&634aT $$Ifa$gdyu:K$OkdD$IfK$L$T0h%&h634aTBB,C-C/C0Cz<>kd1F$IfK$L$T&634aT<kdE$IfK$L$T&634aT $Ifgdyu:K$>kdyE$IfK$L$T`&634aT0C1C2C*D+D-D\Q $Ifgdyu:K$MkdG$IfK$L$T &  634ap T $Ifgdyu:K$<kdF$IfK$L$T&634aT $$Ifa$gdyu:K$-D.DEEEEgY $$Ifa$gdyu:K$OkdH$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd"H$IfK$L$T`&634aTEE E EFFFz><kdI$IfK$L$T&634aT>kdDI$IfK$L$T`&634aT $Ifgdyu:K$<kdH$IfK$L$T&634aT^EcEdEfEgEEEEEEEFFFFFFpFqFuFvFxFyFFFFFFFFGGGGGG-H.H³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jJhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%FFFFGwl $Ifgdyu:K$<kdZJ$IfK$L$T&634aT $$Ifa$gdyu:K$>kdI$IfK$L$T&634aTGGGGwHyHh]] $Ifgdyu:K$>kdK$IfK$L$T`&634aT $Ifgdyu:K$MkdpK$IfK$L$T &  634ap T.H3H4HuHvHwHHHHHHHHH1I2I>I?IAIBIIIIIIIIIJJJJWJXJ_J`JaJgJhJ޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&yHzH{H|H~Hf[ $Ifgdyu:K$<kdL$IfK$L$T&634aT $$Ifa$gdyu:K$OkdKL$IfK$L$T0h%&h634aT~HHaJbJdJeJz<>kdM$IfK$L$T&634aT<kdmM$IfK$L$T&634aT $Ifgdyu:K$>kdM$IfK$L$T`&634aTeJfJgJ_K`KbK\Q $Ifgdyu:K$Mkd;O$IfK$L$T &  634ap T $Ifgdyu:K$<kd%N$IfK$L$T&634aT $$Ifa$gdyu:K$hJ[K\K]K^KcKdKKKKKLLLLLaLbLjLkLmLnLLLLLLL M!M*M+M-M.MMMMMMôáôzczzczzczzcz,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jyNhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ&bKcKLL L LgY $$Ifa$gdyu:K$OkdP$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdO$IfK$L$T`&634aT L L LLMMMz><kd8Q$IfK$L$T&634aT>kdP$IfK$L$T`&634aT $Ifgdyu:K$<kdP$IfK$L$T&634aTMMMMMMMMMNNNNNNFOGOLOMOOOOOOOOٳvgvTgTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jDRhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphoMMMMNwl $Ifgdyu:K$<kdQ$IfK$L$T&634aT $$Ifa$gdyu:K$>kdQ$IfK$L$T&634aTNNNNOOh]] $Ifgdyu:K$>kdS$IfK$L$T`&634aT $Ifgdyu:K$MkdS$IfK$L$T &  634ap TOOOOOf[ $Ifgdyu:K$<kdQT$IfK$L$T&634aT $$Ifa$gdyu:K$OkdS$IfK$L$T0h%&h634aTOOQQQQz<>kd]U$IfK$L$T&634aT<kdU$IfK$L$T&634aT $Ifgdyu:K$>kdT$IfK$L$T`&634aTOOPPPUPVPbPcPePfPPPPPPPQQQ Q#Q$QvQwQ~QQQQQ~RRRRRRRRRRGSHSISʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jVhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*QQQRRR\Q $Ifgdyu:K$MkdV$IfK$L$T &  634ap T $Ifgdyu:K$<kdU$IfK$L$T&634aT $$Ifa$gdyu:K$RRISKSLSMSgY $$Ifa$gdyu:K$OkdW$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdNW$IfK$L$T`&634aTMSNSPSQS4U5U7Uz><kdX$IfK$L$T&634aT>kdpX$IfK$L$T`&634aT $Ifgdyu:K$<kdX$IfK$L$T&634aTISQSRSSSSSSSTT TTTTcTdTmTnTpTqTTTTTTT#U$U.U/U4U:U;U.V/V0V1V6V7VVΨvghyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jYhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ(7U8U9U:U2Vwl $Ifgdyu:K$<kdY$IfK$L$T&634aT $$Ifa$gdyu:K$>kd(Y$IfK$L$T&634aT2V3V5V6VsWuWh]] $Ifgdyu:K$>kd[$IfK$L$T`&634aT $Ifgdyu:K$MkdZ$IfK$L$T &  634ap TVVVVqWrWsW{W|WWWWWWW+X,X6X7X:X;XXXXXXXXXXXXXOYPYVYWY\YbYʿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***&uWvWwWxWzWf[ $Ifgdyu:K$<kd[$IfK$L$T&634aT $$Ifa$gdyu:K$Okdw[$IfK$L$T0h%&h634aTzW{W\Y]Y_Y`Yz<>kd\$IfK$L$T&634aT<kd\$IfK$L$T&634aT $Ifgdyu:K$>kd;\$IfK$L$T`&634aT`YaYbYZZ[Z]Z\Q $Ifgdyu:K$Mkdg^$IfK$L$T &  634ap T $Ifgdyu:K$<kdQ]$IfK$L$T&634aT $$Ifa$gdyu:K$bYcYVZWZXZYZ^Z_ZZZZZZZZZZ?[@[K[L[N[O[[[[[[[[\ \ \ \ \_\`\h\i\³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j]hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&]Z^ZZZZZgY $$Ifa$gdyu:K$OkdB_$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd^$IfK$L$T`&634aTZZZZ\\\z><kdd`$IfK$L$T&634aT>kd`$IfK$L$T`&634aT $Ifgdyu:K$<kd_$IfK$L$T&634aTi\l\m\\\\\\\\]]]]]]^^$^%^^^^^^ _ _첣ufuSfSufDhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jpahyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH\\\\]wl $Ifgdyu:K$<kda$IfK$L$T&634aT $$Ifa$gdyu:K$>kd`$IfK$L$T&634aT]]]]^^h]] $Ifgdyu:K$>kdb$IfK$L$T`&634aT $Ifgdyu:K$Mkd2b$IfK$L$T &  634ap T^^^^^f[ $Ifgdyu:K$<kd}c$IfK$L$T&634aT $$Ifa$gdyu:K$Okd c$IfK$L$T0h%&h634aT^^````z<>kdd$IfK$L$T&634aT<kd/d$IfK$L$T&634aT $Ifgdyu:K$>kdc$IfK$L$T`&634aT _____i_j_p_q_s_t_______#`$`)`*`,`-````````aaaaaaaaaabʿ~k~k$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j;ehyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho(```aaa\Q $Ifgdyu:K$Mkde$IfK$L$T &  634ap T $Ifgdyu:K$<kdd$IfK$L$T&634aT $$Ifa$gdyu:K$aabbbbgY $$Ifa$gdyu:K$Okdf$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdzf$IfK$L$T`&634aTbbbbbbbcccccc%d&d0d1d3d4dddddddddddddBeCeMeNeSeYeZeMf³rrrrrcjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***,hyu:h< L0J>*B*CJPJQJaJph***&bbbbSeTeVez><kdg$IfK$L$T&634aT>kdg$IfK$L$T`&634aT $Ifgdyu:K$<kdHg$IfK$L$T&634aTVeWeXeYeQfwl $Ifgdyu:K$<kdh$IfK$L$T&634aT $$Ifa$gdyu:K$>kdTh$IfK$L$T&634aTMfNfOfPfUfVfffffGgHgIgQgRggggggghh h hhhbhchjhkhlhrh³ ³֌ybyybyybyShyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjihyu:h< LCJUaJjhyu:h< LCJUaJ QfRfTfUfIgKgh]] $Ifgdyu:K$>kdEj$IfK$L$T`&634aT $Ifgdyu:K$Mkdi$IfK$L$T &  634ap TKgLgMgNgPgf[ $Ifgdyu:K$<kdk$IfK$L$T&634aT $$Ifa$gdyu:K$Okdj$IfK$L$T0h%&h634aTPgQglhmhohphz<>kdl$IfK$L$T&634aT<kdk$IfK$L$T&634aT $Ifgdyu:K$>kdgk$IfK$L$T`&634aTphqhrhjikimi\Q $Ifgdyu:K$Mkdm$IfK$L$T &  634ap T $Ifgdyu:K$<kd}l$IfK$L$T&634aT $$Ifa$gdyu:K$rhshfigihiiinioiiiiiojpjqjyjzjjjjjjj.k/k5k6k8k9kkkkkkkkkkkkkEl³ ³}j}}j}}j}}j}}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jlhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ)miniqjsjtjujgY $$Ifa$gdyu:K$Okdnn$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdn$IfK$L$T`&634aTujvjxjyjSlTlVlz><kdo$IfK$L$T&634aT>kd2o$IfK$L$T`&634aT $Ifgdyu:K$<kdn$IfK$L$T&634aTElFlMlNlSlYlZlMmNmOmPmUmVmmmmmLnMnNnVnWnnnnnnno oooooiojosotovowooooʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jphyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho*VlWlXlYlQmwl $Ifgdyu:K$<kdHp$IfK$L$T&634aT $$Ifa$gdyu:K$>kdo$IfK$L$T&634aTQmRmTmUmNnPnh]] $Ifgdyu:K$>kdq$IfK$L$T`&634aT $Ifgdyu:K$Mkd^q$IfK$L$T &  634ap TPnQnRnSnUnf[ $Ifgdyu:K$<kdr$IfK$L$T&634aT $$Ifa$gdyu:K$Okd9r$IfK$L$T0h%&h634aTUnVn9p:pkds$IfK$L$T&634aT<kd[s$IfK$L$T&634aT $Ifgdyu:K$>kdr$IfK$L$T`&634aToooo)p*p3p4p9p?p@p3q4q5q6q;q*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jgthyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho=p>p?p7q8q:q\Q $Ifgdyu:K$Mkd)u$IfK$L$T &  634ap T $Ifgdyu:K$<kdt$IfK$L$T&634aT $$Ifa$gdyu:K$:q;qrrrrgY $$Ifa$gdyu:K$Okdv$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdu$IfK$L$T`&634aTrrr r t t tz><kd&w$IfK$L$T&634aT>kdv$IfK$L$T`&634aT $Ifgdyu:K$<kdtv$IfK$L$T&634aTtrrrrrrrrrrr6s7s?s@sBsCssssssssstt tttuuuu u u^u_u³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j2xhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH% t tttuwl $Ifgdyu:K$<kdw$IfK$L$T&634aT $$Ifa$gdyu:K$>kdw$IfK$L$T&634aTuu u uuuh]] $Ifgdyu:K$>kdqy$IfK$L$T`&634aT $Ifgdyu:K$Mkdx$IfK$L$T &  634ap T_udueuuuuuuvvvv!v"vtvuv}v~vvvvvvvvv3w4w:w;w=w>wwwwwwww޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&uuuuuf[ $Ifgdyu:K$<kd?z$IfK$L$T&634aT $$Ifa$gdyu:K$Okdy$IfK$L$T0h%&h634aTuuwwwwz<>kdK{$IfK$L$T&634aT<kdz$IfK$L$T&634aT $Ifgdyu:K$>kdz$IfK$L$T`&634aTwwwxxx\Q $Ifgdyu:K$Mkd|$IfK$L$T &  634ap T $Ifgdyu:K$<kd{$IfK$L$T&634aT $$Ifa$gdyu:K$wxxxxxxxxxxKyLyMyUyVyyyyyyyzzzzzzdzeznzozqzrzzzzzzz${%{+{ôáô~k~~k~~k~~k~~k$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j{hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ*xxMyOyPyQygY $$Ifa$gdyu:K$Okd}$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd<}$IfK$L$T`&634aTQyRyTyUy1{2{4{z><kd~$IfK$L$T&634aT>kd^~$IfK$L$T`&634aT $Ifgdyu:K$<kd ~$IfK$L$T&634aT+{,{1{7{8{+|,|-|.|3|4|||||}}} } }_}`}k}l}o}p}}}}}}}}~~~~ôҠ~~kk\jhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$4{5{6{7{/|wl $Ifgdyu:K$<kdt$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT/|0|2|3|}}h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T}}} } }f[ $Ifgdyu:K$<kdՁ$IfK$L$T&634aT $$Ifa$gdyu:K$Okde$IfK$L$T0h%&h634aT } }}}}}z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd)$IfK$L$T`&634aT}}}~~~\Q $Ifgdyu:K$MkdU$IfK$L$T &  634ap T $Ifgdyu:K$<kd?$IfK$L$T&634aT $$Ifa$gdyu:K$~~iklmgY $$Ifa$gdyu:K$Okd0$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd҄$IfK$L$T`&634aT~~~$%*+ghiqr'(4578JKRSTZҿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ)mnpqTUWz><kdR$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTWXYZRwl $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTZ[NOPQVWĂłlmyz³ ³³ ³nn[n$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphoj)hyu:h< LCJUaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j^hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ#RSUVh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd $IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kdk$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT‚z<>kdw$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT‚ÂĂ\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kdՊ$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okdƌ$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdh$IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd6$IfK$L$T&634aTz|}υЅօׅمڅ,-679:UV[\'𾯾}j}j}$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho)wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdB$IfK$L$T&634aT!h]] $Ifgdyu:K$>kd3$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T!"#$&f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT&'z<>kd $IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdU$IfK$L$T`&634aT'(z{։׉܉݉߉2378:;HINOݿ~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kdk$IfK$L$T&634aT $$Ifa$gdyu:K$#%&'gY $$Ifa$gdyu:K$Okd\$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTO!"#+,~ۍ܍?@GHJK   ʿzzkzjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph****'(*+ z><kd~$IfK$L$T&634aT>kd $IfK$L$T`&634aT $Ifgdyu:K$<kd̔$IfK$L$T&634aT wl $Ifgdyu:K$<kd6$IfK$L$T&634aT $$Ifa$gdyu:K$>kdؕ$IfK$L$T&634aT  h]] $Ifgdyu:K$>kdɗ$IfK$L$T`&634aT $Ifgdyu:K$MkdL$IfK$L$T &  634ap Tbchi [\bcefÑđƑǑ#$&'yzܒݒ𾪗qhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***'f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd'$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kdI$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>?DE”ʔ˔$%(){|וؕܕݕߕ2378³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jUhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&”ĔŔƔgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTƔǔɔʔz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdb$IfK$L$T&634aT8:;CDEMN첣ufuSfSuf$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosHwl $Ifgdyu:K$<kd̝$IfK$L$T&634aT $$Ifa$gdyu:K$>kdn$IfK$L$T&634aTEGh]] $Ifgdyu:K$>kd_$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap TGHIJLf[ $Ifgdyu:K$<kd-$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTLM/023z<>kd9$IfK$L$T&634aT<kdߠ$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTNZ[fgjkșə˙̙)*/56)*+,12첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'345-.0\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$01gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd*$IfK$L$T`&634aTST_`bc rs|}޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&z><kd$IfK$L$T&634aT>kdL$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kdb$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT|}~ן؟ݟޟefgop àʠˠ͠Π !,-/0ôáôzczzczzczzcz,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ&gih]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkdx$IfK$L$T &  634ap Tijklnf[ $Ifgdyu:K$<kdç$IfK$L$T&634aT $$Ifa$gdyu:K$OkdS$IfK$L$T0h%&h634aTnoz<>kdϨ$IfK$L$T&634aT<kdu$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT\Q $Ifgdyu:K$MkdC$IfK$L$T &  634ap T $Ifgdyu:K$<kd-$IfK$L$T&634aT $$Ifa$gdyu:K$DEJKOP^_ab¤!"#)*״~o~\~o~o~\~o~o~\~o$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH$gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT#$&z><kd@$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT&'()!wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT* %&xy~QRS[\pqz{}~ШѨۨܨިߨ12:ôáô~k~~k~~k~~k~~k$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jLhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ*!"$%SUh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap TUVWXZf[ $Ifgdyu:K$<kdY$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTZ[@ACDz<>kde$IfK$L$T&634aT<kd $IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT:;@FG:;<=BC  ijqrtuǫȫӫԫ֫׫)ôҠ~~kTkkTkk,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho DEF>?A\Q $Ifgdyu:K$Mkdٱ$IfK$L$T &  634ap T $Ifgdyu:K$<kdð$IfK$L$T&634aT $$Ifa$gdyu:K$ABgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdV$IfK$L$T`&634aTz><kdֳ$IfK$L$T&634aT>kdx$IfK$L$T`&634aT $Ifgdyu:K$<kd$$IfK$L$T&634aT)*0134KLQR³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd0$IfK$L$T&634aTh]] $Ifgdyu:K$>kd!$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdC$IfK$L$T`&634aTZ[efhiƯǯɯʯ()+,~ٳvgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho(\Q $Ifgdyu:K$Mkdo$IfK$L$T &  634ap T $Ifgdyu:K$<kdY$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$OkdJ$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTSTYZCDKLMSTGH޿zzkz޿zzjxhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&z><kdl$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kd$$IfK$L$T&634aT $$Ifa$gdyu:K$>kdƻ$IfK$L$T&634aTh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd:$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTMNPQz<>kd$IfK$L$T&634aT<kd7$IfK$L$T&634aT $Ifgdyu:K$>kdپ$IfK$L$T`&634aTQRSKLN\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$HIJOP:;<DEZ[efhiɸʸ̸͸ )*³ ³֌}j}}j}}j}}j}}j$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjChyu:h< LCJUaJ)NO<>?@gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT@ACD/02z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdP$IfK$L$T&634aT*/56)*+,12NOYZ\]峤}j}S}j}j}S}j}j},hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho 2345-wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd\$IfK$L$T&634aT-.01h]] $Ifgdyu:K$>kdM$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kd'$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdo$IfK$L$T`&634aT!"pqvwHI³vgvTgTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH !\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okdv$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTۿܿ޿z><kd$IfK$L$T&634aT>kd:$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTIPQSThirsuvȿɿտֿۿ01:;<DEʿ~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*޿߿wl $Ifgdyu:K$<kdP$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT<>h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkdf$IfK$L$T &  634ap T>?@ACf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OkdA$IfK$L$T0h%&h634aTCDEFHIz<>kd$IfK$L$T&634aT<kdc$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTIJKCDF\Q $Ifgdyu:K$Mkd1$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$EKL?@ABGH>?FGIJ   _`iôáôzczzczzczzc,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***johyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ&FGgY $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kd.$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd|$IfK$L$T&634aTijlm%&/019:@A4ٳvgvTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j:hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphowl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT13h]] $Ifgdyu:K$>kdy$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T34568f[ $Ifgdyu:K$<kdG$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT89:;=>z<>kdS$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT>?@89;\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$4567<=   ghoprs#$-.01³ ³֌}j}}j}}j}}j}}j$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ);< gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdD$IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kdf$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTdefglmZ[\de%&ôҠ~~kk\jhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hwl $Ifgdyu:K$<kd|$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aThikl\^h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T^_`acf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okdm$IfK$L$T0h%&h634aTcd "#z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd1$IfK$L$T`&634aT#$% \Q $Ifgdyu:K$Mkd]$IfK$L$T &  634ap T $Ifgdyu:K$<kdG$IfK$L$T&634aT $$Ifa$gdyu:K$ !gY $$Ifa$gdyu:K$Okd8$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT!"tuz{01<=?@RS]^abҿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ)z><kdZ$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT   ^_ghjk"#%&x³ ³}j}}j}}j}}j}}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jfhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ)h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd($IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kds$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kd%$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTxyFGHPQʿ~k~k~XA,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j1hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$HJKLgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdp$IfK$L$T`&634aTLMOP./1z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd>$IfK$L$T&634aT   `ahilm !().45()*+01첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH#1234,wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdJ$IfK$L$T&634aT,-/0')h]] $Ifgdyu:K$>kd;$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T%&'/0=>DEGH  ޿zzkzjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****)*+,.f[ $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT./  z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd]$IfK$L$T`&634aT   \Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kds$IfK$L$T&634aT $$Ifa$gdyu:K$ gY $$Ifa$gdyu:K$Okdd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT abgh349:<=IJPQRXYLMNOTUҿzzkzjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ*RSUz><kd$IfK$L$T&634aT>kd($IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTUVWXPwl $Ifgdyu:K$<kd>$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTPQST"$h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$MkdT$IfK$L$T &  634ap TU !"*+}~<=FGIJ  𾪛yyjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph****$%&')f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd/$IfK$L$T0h%&h634aT)*   z<>kd$IfK$L$T&634aT<kdQ$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT  \Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$  _`ef$%,-/0³ ³֌}j}}j}}j}[j(hyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJj]hyu:h< LCJUaJ#  gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdj$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdv$IfK$L$T&634aTABGH#$'(z{89BCEFѯ¯囈qqqqq,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJ)h]] $Ifgdyu:K$>kdg$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd5$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kdA$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$[\]ef"#$*+״~o~\~o~o~\~o$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH ]_`agY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd2$IfK$L$T`&634aTabde$%'z><kd$IfK$L$T&634aT>kdT$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT'()*"wl $Ifgdyu:K$<kdj$IfK$L$T&634aT $$Ifa$gdyu:K$>kd $IfK$L$T&634aT !&'yzVW`acd#$'(z{³ ³֌}j}}j}}j}}j}}j$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ)"#%&h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd[$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kd}$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT?@EF@AIJLM峤}j}S}j}j}S}j}j},hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho \Q $Ifgdyu:K$MkdK$IfK$L$T &  634ap T $Ifgdyu:K$<kd5$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd&$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kdH$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT   ^_degh()*2³vgvTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jThyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosHwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT*,h]] $Ifgdyu:K$>kd $IfK$L$T`&634aT $Ifgdyu:K$Mkd $IfK$L$T &  634ap T,-./1f[ $Ifgdyu:K$<kda $IfK$L$T&634aT $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT123467z<>kdm $IfK$L$T&634aT<kd $IfK$L$T&634aT $Ifgdyu:K$>kd $IfK$L$T`&634aT239:-./056lmstvw峤}}j}}}j}[jhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho#789124\Q $Ifgdyu:K$Mkd $IfK$L$T &  634ap T $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$45gY $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT $Ifgdyu:K$>kd^ $IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd,$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd8$IfK$L$T&634aTh]] $Ifgdyu:K$>kd)$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T'(-.DEKLNO [\abgmnabҿzzjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ,f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTghjkz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdK$IfK$L$T`&634aTklmefh\Q $Ifgdyu:K$Mkdw$IfK$L$T &  634ap T $Ifgdyu:K$<kda$IfK$L$T&634aT $$Ifa$gdyu:K$bcdijrst|}+,1245?@FG³ ³֌}j}}j}}j}}j}}j$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ)hitvwxgY $$Ifa$gdyu:K$OkdR$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTxy{|LMOz><kdt$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTGLRSFGHINO   hioprs#$峤}j}S}j}j}S}j}j},hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho OPQRJwl $Ifgdyu:K$<kd,$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTJKMN h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$MkdB$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kd?$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT$*+-.>?DE³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jKhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH \Q $Ifgdyu:K$Mkd $IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kd $IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdX$IfK$L$T&634aTZ[efhi "#uv: ; 첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdd$IfK$L$T&634aT  h]] $Ifgdyu:K$>kdU $IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T; @ A            W X _ ` b c             r s          ޿zzkzj"hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****     f[ $Ifgdyu:K$<kd#!$IfK$L$T&634aT $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT      z<>kd/"$IfK$L$T&634aT<kd!$IfK$L$T&634aT $Ifgdyu:K$>kdw!$IfK$L$T`&634aT      \Q $Ifgdyu:K$Mkd#$IfK$L$T &  634ap T $Ifgdyu:K$<kd"$IfK$L$T&634aT $$Ifa$gdyu:K$  ~    gY $$Ifa$gdyu:K$Okd~$$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd $$IfK$L$T`&634aT       | } ~         78=>ABRSZ[`fҿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ)    `acz><kd%$IfK$L$T&634aT>kdB%$IfK$L$T`&634aT $Ifgdyu:K$<kd$$IfK$L$T&634aTcdef^wl $Ifgdyu:K$<kdX&$IfK$L$T&634aT $$Ifa$gdyu:K$>kd%$IfK$L$T&634aTfgZ[\]bc456>?³ ³}j}}j}[jw*hyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j&hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ#^_ab68h]] $Ifgdyu:K$>kd'$IfK$L$T`&634aT $Ifgdyu:K$Mkdn'$IfK$L$T &  634ap T89:;=f[ $Ifgdyu:K$<kd($IfK$L$T&634aT $$Ifa$gdyu:K$OkdI($IfK$L$T0h%&h634aT=>z<>kd)$IfK$L$T&634aT<kdk)$IfK$L$T&634aT $Ifgdyu:K$>kd )$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd9+$IfK$L$T &  634ap T $Ifgdyu:K$<kd#*$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd,$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd+$IfK$L$T`&634aTOPUVOP\]_`qr|}𾪗qhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***'z><kd6-$IfK$L$T&634aT>kd,$IfK$L$T`&634aT $Ifgdyu:K$<kd,$IfK$L$T&634aTwl $Ifgdyu:K$<kd-$IfK$L$T&634aT $$Ifa$gdyu:K$>kd-$IfK$L$T&634aT78=> '(*+}~>?IJLM³ ³}j}}j}}j}}j}}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jB.hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ)h]] $Ifgdyu:K$>kd/$IfK$L$T`&634aT $Ifgdyu:K$Mkd/$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kdO0$IfK$L$T&634aT $$Ifa$gdyu:K$Okd/$IfK$L$T0h%&h634aTz<>kd[1$IfK$L$T&634aT<kd1$IfK$L$T&634aT $Ifgdyu:K$>kd0$IfK$L$T`&634aTxyzʿ~k~k~XA,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j 2hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho\Q $Ifgdyu:K$Mkd2$IfK$L$T &  634ap T $Ifgdyu:K$<kd1$IfK$L$T&634aT $$Ifa$gdyu:K$z|}~gY $$Ifa$gdyu:K$Okd3$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdL3$IfK$L$T`&634aT~z><kd4$IfK$L$T&634aT>kdn4$IfK$L$T`&634aT $Ifgdyu:K$<kd4$IfK$L$T&634aT>?PQST qr첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j5hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH#wl $Ifgdyu:K$<kd5$IfK$L$T&634aT $$Ifa$gdyu:K$>kd&5$IfK$L$T&634aTegh]] $Ifgdyu:K$>kd7$IfK$L$T`&634aT $Ifgdyu:K$Mkd6$IfK$L$T &  634ap Tcdemn! " , - / 0             >!?!I!J!O!U!V!޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&ghijlf[ $Ifgdyu:K$<kd7$IfK$L$T&634aT $$Ifa$gdyu:K$Okdu7$IfK$L$T0h%&h634aTlmO!P!R!S!z<>kd8$IfK$L$T&634aT<kd8$IfK$L$T&634aT $Ifgdyu:K$>kd98$IfK$L$T`&634aTS!T!U!M"N"P"\Q $Ifgdyu:K$Mkde:$IfK$L$T &  634ap T $Ifgdyu:K$<kdO9$IfK$L$T&634aT $$Ifa$gdyu:K$V!I"J"K"L"Q"R""""""""""######$$($*$%%%%%?&@&H&I&K&L&ôáôôáôoo\oo$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphojn=hyu:h< LCJUaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j9hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$P"Q"""""gY $$Ifa$gdyu:K$Okd@;$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd:$IfK$L$T`&634aT"""""""z><kdb<$IfK$L$T&634aT>kd<$IfK$L$T`&634aT $Ifgdyu:K$<kd;$IfK$L$T&634aT""""#wl $Ifgdyu:K$<kd=$IfK$L$T&634aT $$Ifa$gdyu:K$>kd<$IfK$L$T&634aT####%%h]] $Ifgdyu:K$>kd>$IfK$L$T`&634aT $Ifgdyu:K$Mkd0>$IfK$L$T &  634ap T%%%%%f[ $Ifgdyu:K$<kd{?$IfK$L$T&634aT $$Ifa$gdyu:K$Okd ?$IfK$L$T0h%&h634aT%%''''z<>kd@$IfK$L$T&634aT<kd-@$IfK$L$T&634aT $Ifgdyu:K$>kd?$IfK$L$T`&634aTL&&&&&&&&& ' ' ' '_'`'i'j'm'n''''''''(((((($)%)*)+))))))𾯾}j}j}$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j9Ahyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho('''(((\Q $Ifgdyu:K$MkdA$IfK$L$T &  634ap T $Ifgdyu:K$<kd@$IfK$L$T&634aT $$Ifa$gdyu:K$(())))gY $$Ifa$gdyu:K$OkdB$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdxB$IfK$L$T`&634aT))))+++z><kdC$IfK$L$T&634aT>kdC$IfK$L$T`&634aT $Ifgdyu:K$<kdFC$IfK$L$T&634aT))))***V*W*_*`*b*c*******++"+#+%+&+x+y++++++,,,,,,,,첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jEhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'++++,wl $Ifgdyu:K$<kdD$IfK$L$T&634aT $$Ifa$gdyu:K$>kdRD$IfK$L$T&634aT,,,,z-|-h]] $Ifgdyu:K$>kdCF$IfK$L$T`&634aT $Ifgdyu:K$MkdE$IfK$L$T &  634ap T,,,x-y-z---------4.5.=.>.A.B.............O/P/X/Y/^/d/e/X0Y0Z0[0޿zzkzjHhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****|-}-~---f[ $Ifgdyu:K$<kdG$IfK$L$T&634aT $$Ifa$gdyu:K$OkdF$IfK$L$T0h%&h634aT--^/_/a/b/z<>kdH$IfK$L$T&634aT<kdG$IfK$L$T&634aT $Ifgdyu:K$>kdeG$IfK$L$T`&634aTb/c/d/\0]0_0\Q $Ifgdyu:K$MkdI$IfK$L$T &  634ap T $Ifgdyu:K$<kd{H$IfK$L$T&634aT $$Ifa$gdyu:K$_0`0}1111gY $$Ifa$gdyu:K$OkdlJ$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdJ$IfK$L$T`&634aT[0`0a00000{1|1}111111111A2B2R2S2U2V222222233!3"3$3%3w3x33333344ҿzzjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ,1111333z><kdK$IfK$L$T&634aT>kd0K$IfK$L$T`&634aT $Ifgdyu:K$<kdJ$IfK$L$T&634aT33334wl $Ifgdyu:K$<kdFL$IfK$L$T&634aT $$Ifa$gdyu:K$>kdK$IfK$L$T&634aT444444444555"5#5u5v55555555555566³ ³֌ybyybyShyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjLhyu:h< LCJUaJ444455h]] $Ifgdyu:K$>kdM$IfK$L$T`&634aT $Ifgdyu:K$Mkd\M$IfK$L$T &  634ap T5555!5f[ $Ifgdyu:K$<kdN$IfK$L$T&634aT $$Ifa$gdyu:K$Okd7N$IfK$L$T0h%&h634aT!5"55555z<>kdO$IfK$L$T&634aT<kdYO$IfK$L$T&634aT $Ifgdyu:K$>kdN$IfK$L$T`&634aT555666\Q $Ifgdyu:K$Mkd'Q$IfK$L$T &  634ap T $Ifgdyu:K$<kdP$IfK$L$T&634aT $$Ifa$gdyu:K$666668797>7?77777777 8 8 888999 999a9b9g9h9999::³ ³֌}j}[³ ³֌j0Thyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjePhyu:h< LCJUaJ#667777gY $$Ifa$gdyu:K$OkdR$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdQ$IfK$L$T`&634aT7777 8 88z><kd$S$IfK$L$T&634aT>kdR$IfK$L$T`&634aT $Ifgdyu:K$<kdrR$IfK$L$T&634aT8888 9wl $Ifgdyu:K$<kdS$IfK$L$T&634aT $$Ifa$gdyu:K$>kd~S$IfK$L$T&634aT 9 9 9999h]] $Ifgdyu:K$>kdoU$IfK$L$T`&634aT $Ifgdyu:K$MkdT$IfK$L$T &  634ap T99:::f[ $Ifgdyu:K$<kd=V$IfK$L$T&634aT $$Ifa$gdyu:K$OkdU$IfK$L$T0h%&h634aT::|;};;;z<>kdIW$IfK$L$T&634aT<kdV$IfK$L$T&634aT $Ifgdyu:K$>kdV$IfK$L$T`&634aT:W:X:a:b:e:f:::::::;;;;;;q;r;z;{;|;;;v<w<x<y<~<<<<<<?=@=A=I=J==𾯾}j}j}$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jWhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho);;;z<{<}<\Q $Ifgdyu:K$MkdX$IfK$L$T &  634ap T $Ifgdyu:K$<kdW$IfK$L$T&634aT $$Ifa$gdyu:K$}<~<A=C=D=E=gY $$Ifa$gdyu:K$OkdY$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd:Y$IfK$L$T`&634aTE=F=H=I=)?*?,?z><kdZ$IfK$L$T&634aT>kd\Z$IfK$L$T`&634aT $Ifgdyu:K$<kdZ$IfK$L$T&634aT========>>>>Z>[>f>g>i>j>>>>>>>??#?$?)?/?0?#@$@%@&@+@,@~@@@@@@ʿ~k~k$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j[hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho*,?-?.?/?'@wl $Ifgdyu:K$<kdr[$IfK$L$T&634aT $$Ifa$gdyu:K$>kd[$IfK$L$T&634aT'@(@*@+@@@h]] $Ifgdyu:K$>kd]$IfK$L$T`&634aT $Ifgdyu:K$Mkd\$IfK$L$T &  634ap T@@@@(A)A4A5A6AD?DEDFDѯ堑}}jj}ѯѯѯ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***j_hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***)@@@@@f[ $Ifgdyu:K$<kd]$IfK$L$T&634aT $$Ifa$gdyu:K$Okdc]$IfK$L$T0h%&h634aT@@6A7A9A:Az<>kd^$IfK$L$T&634aT<kd^$IfK$L$T&634aT $Ifgdyu:K$>kd'^$IfK$L$T`&634aT:A;Akd`$IfK$L$T`&634aTCCCCEEEz><kdPb$IfK$L$T&634aT>kda$IfK$L$T`&634aT $Ifgdyu:K$<kda$IfK$L$T&634aTFDHDIDDDDDDDDDDEE E EEFFFFFZF[F`FaFFFFFFPGQGZG[G]G^GGGGGG𾯾}j}j}$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j\chyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho)E E E EFwl $Ifgdyu:K$<kdc$IfK$L$T&634aT $$Ifa$gdyu:K$>kdb$IfK$L$T&634aTFFFFFFh]] $Ifgdyu:K$>kdd$IfK$L$T`&634aT $Ifgdyu:K$Mkdd$IfK$L$T &  634ap TFFFFFf[ $Ifgdyu:K$<kdie$IfK$L$T&634aT $$Ifa$gdyu:K$Okdd$IfK$L$T0h%&h634aTFFHHHHz<>kduf$IfK$L$T&634aT<kdf$IfK$L$T&634aT $Ifgdyu:K$>kde$IfK$L$T`&634aTGG HHHHHHlHmHtHuHwHxHHHHHHHHIIIIII9J:J?J@JKKK#K$KvKwKKKKKKݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j'ghyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*HHHIII\Q $Ifgdyu:K$Mkdg$IfK$L$T &  634ap T $Ifgdyu:K$<kdf$IfK$L$T&634aT $$Ifa$gdyu:K$IIKKKKgY $$Ifa$gdyu:K$Okdh$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdfh$IfK$L$T`&634aTK K"K#K M MMz><kdi$IfK$L$T&634aT>kdi$IfK$L$T`&634aT $Ifgdyu:K$<kd4i$IfK$L$T&634aTKKKKKKDLELKLLLNLOLLLLLLLLMMM MMMNNNN NN`NaNfNgNNNNNNNOOOTOʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jjhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho*MMMM Nwl $Ifgdyu:K$<kdj$IfK$L$T&634aT $$Ifa$gdyu:K$>kd@j$IfK$L$T&634aT N N N NNNh]] $Ifgdyu:K$>kd1l$IfK$L$T`&634aT $Ifgdyu:K$Mkdk$IfK$L$T &  634ap TNNNNNf[ $Ifgdyu:K$<kdl$IfK$L$T&634aT $$Ifa$gdyu:K$Okdl$IfK$L$T0h%&h634aTNNPPPPz<>kd n$IfK$L$T&634aT<kdm$IfK$L$T&634aT $Ifgdyu:K$>kdSm$IfK$L$T`&634aTTOUOWOXOOOOOOO P PPPPPgPhPpPqPsPtPPPPPPPPQQQQQQ5R6R;R*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jnhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*PPPQQQ\Q $Ifgdyu:K$Mkdo$IfK$L$T &  634ap T $Ifgdyu:K$<kdin$IfK$L$T&634aT $$Ifa$gdyu:K$QQRRRRgY $$Ifa$gdyu:K$OkdZp$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdo$IfK$L$T`&634aTRRRRTTTz><kd|q$IfK$L$T&634aT>kdq$IfK$L$T`&634aT $Ifgdyu:K$<kdp$IfK$L$T&634aTRRCSDSLSMSOSPSSSSSSSTTTTTTeTfTpTqTsTtTTTTTTTTUUUUUU,V-V2V3Vݿ~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jrhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*TTTTUwl $Ifgdyu:K$<kd4r$IfK$L$T&634aT $$Ifa$gdyu:K$>kdq$IfK$L$T&634aTUUUUWWh]] $Ifgdyu:K$>kds$IfK$L$T`&634aT $Ifgdyu:K$MkdJs$IfK$L$T &  634ap T3VVWW W W\W]WdWeWgWhWWWWWWWXX X!X#X$XvXwXXXXXXXXXXXXYYYYYYʿzzkzjSvhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph****WWWWWf[ $Ifgdyu:K$<kdt$IfK$L$T&634aT $$Ifa$gdyu:K$Okd%t$IfK$L$T0h%&h634aTW WXXXXz<>kdu$IfK$L$T&634aT<kdGu$IfK$L$T&634aT $Ifgdyu:K$>kdt$IfK$L$T`&634aTXXXYYY\Q $Ifgdyu:K$Mkdw$IfK$L$T &  634ap T $Ifgdyu:K$<kdu$IfK$L$T&634aT $$Ifa$gdyu:K$YYZZZZgY $$Ifa$gdyu:K$Okdw$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdw$IfK$L$T`&634aTY>Z?ZDZEZZZZZZ[["[#[&['[y[z[[[[[[[[[[[=\>\N\O\Q\R\\\\\\\𾪗qhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***'ZZZZ\\\z><kdy$IfK$L$T&634aT>kdx$IfK$L$T`&634aT $Ifgdyu:K$<kd`x$IfK$L$T&634aT\\\\]wl $Ifgdyu:K$<kdy$IfK$L$T&634aT $$Ifa$gdyu:K$>kdly$IfK$L$T&634aT\\]]]]]]^^ ^ ^^^^^^^^^^^^?_@_J_K_M_N_______````³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jzhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&]]]]^^h]] $Ifgdyu:K$>kd]{$IfK$L$T`&634aT $Ifgdyu:K$Mkdz$IfK$L$T &  634ap T^^^^^f[ $Ifgdyu:K$<kd+|$IfK$L$T&634aT $$Ifa$gdyu:K$Okd{$IfK$L$T0h%&h634aT^^v`w`y`z`z<>kd7}$IfK$L$T&634aT<kd|$IfK$L$T&634aT $Ifgdyu:K$>kd|$IfK$L$T`&634aT```e`f`p`q`v`|`}`paqarasaxayaaaaalbmbnbvbwbbb첣ufuSfSufDhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j}hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosHz`{`|`tauawa\Q $Ifgdyu:K$Mkd~$IfK$L$T &  634ap T $Ifgdyu:K$<kd}$IfK$L$T&634aT $$Ifa$gdyu:K$waxanbpbqbrbgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd($IfK$L$T`&634aTrbsbubvbWdXdZdz><kd$IfK$L$T&634aT>kdJ$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTbbbbb&c'c.c/c1c2cccccccccccccFdGdQdRdWd]d^dQeReSeTeYeZeeeee_f`fafʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*Zd[d\d]dUewl $Ifgdyu:K$<kd`$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTUeVeXeYeafcfh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkdv$IfK$L$T &  634ap Tcfdfefffhff[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OkdQ$IfK$L$T0h%&h634aThfifOhPhRhShz<>kd̈́$IfK$L$T&634aT<kds$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTafifjfffffffgg(g)g+g,g~gggggggggggg=h>hIhJhOhUhVhIiJiKiLiQiRiiΨvghyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ(ShThUhMiNiPi\Q $Ifgdyu:K$MkdA$IfK$L$T &  634ap T $Ifgdyu:K$<kd+$IfK$L$T&634aT $$Ifa$gdyu:K$PiQiRjVjXjZjgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTiiiijjNjPjRjbjdjk k*k,k0k2kkkkkkkMlNl]l^lalblllllllmmmm"mٳʨjjjjj,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ,hyu:h< L0J>*B*CJPJQJaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***'Zj\j`jbj"m#m%mz><kd>$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT%m&m'm(m nwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT"m(m)mnnnn$n%nwnxn}n~nnnnooXoYo^o_oaobooooooopppppplp״~o~\~o~o~\~o~o~\~o~o$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jJhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH$ n!n#n$nnnh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd $IfK$L$T &  634ap Tnoooof[ $Ifgdyu:K$<kdW$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTooppppz<>kdc$IfK$L$T&634aT<kd $IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTlpmprpspupvppppppppqqqqqq+r,r1r2rrrrrrrrʿ~k~k~X%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphopppqqq\Q $Ifgdyu:K$Mkd׍$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$qqrrrrgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdT$IfK$L$T`&634aTrrrrtttz><kdԏ$IfK$L$T&634aT>kdv$IfK$L$T`&634aT $Ifgdyu:K$<kd"$IfK$L$T&634aTrrrrrIsJsWsXsZs[ssssssstt*t+t-t.ttttttttuuuuuuuu³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%ttttuwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd.$IfK$L$T&634aTuuuuvvh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap TuuuvvvvvAwBwJwKwMwNwwxxxxxxxxxxx~yyyyyyzz%z&z+z1z2z%{&{'{({޿zzkzjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****vvvvvf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd}$IfK$L$T0h%&h634aTvv+z,z.z/zz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdA$IfK$L$T`&634aT/z0z1z){*{,{\Q $Ifgdyu:K$Mkdm$IfK$L$T &  634ap T $Ifgdyu:K$<kdW$IfK$L$T&634aT $$Ifa$gdyu:K$,{-{%|'|(|)|gY $$Ifa$gdyu:K$OkdH$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT({-{.{{{{{#|$|%|-|.|||||||||||||F}G}S}T}V}W}}}}}}} ~ ~~~~~ҿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ))|*|,|-|~~~z><kdj$IfK$L$T&634aT>kd $IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT~~~~wl $Ifgdyu:K$<kd"$IfK$L$T&634aT $$Ifa$gdyu:K$>kdė$IfK$L$T&634aT~ ~notu)*,-ۀ܀=>FGHNO³ ³}j}}j}}j}}j}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jvhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ)h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd8$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTHIKLz<>kd$IfK$L$T&634aT<kd5$IfK$L$T&634aT $Ifgdyu:K$>kdך$IfK$L$T`&634aTLMNFGI\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OBCDEJKTU`abhi\]^_de_`aiôáô~k~\ôáôj hyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jAhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$IJgY $$Ifa$gdyu:K$Okdޝ$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTbcez><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdN$IfK$L$T&634aTefgh`wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdZ$IfK$L$T&634aT`acdach]] $Ifgdyu:K$>kdK$IfK$L$T`&634aT $Ifgdyu:K$MkdΠ$IfK$L$T &  634ap Tcdefhf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aThiMNPQz<>kd%$IfK$L$T&634aT<kdˢ$IfK$L$T&634aT $Ifgdyu:K$>kdm$IfK$L$T`&634aTijŅƅȅɅ()+,~߆?@GHMSTGHIJOPݿ~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jףhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*QRSKLN\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$NOGIJKgY $$Ifa$gdyu:K$Okdt$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTEFGOPnoyz|}ϊЊ݊ފ34=>CIJ=>?@EFʿzzkzjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph****KLNOCDFz><kd$IfK$L$T&634aT>kd8$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTFGHIAwl $Ifgdyu:K$<kdN$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTABDEߌh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkdd$IfK$L$T &  634ap TF݌ތߌ:;FGIJ𾪗qbbSbjmhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph*** f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd?$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kda$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd/$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$y{|}gY $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTwxyԏՏߏ56ABDEXY`aflm`abchiʿzzkzj8hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph****}~fgiz><kd,$IfK$L$T&634aT>kdέ$IfK$L$T`&634aT $Ifgdyu:K$<kdz$IfK$L$T&634aTijkldwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTdegh)+h]] $Ifgdyu:K$>kdw$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Ti’'()12CDLMOP  𾪗qhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***'+,-.0f[ $Ifgdyu:K$<kdE$IfK$L$T&634aT $$Ifa$gdyu:K$Okdհ$IfK$L$T0h%&h634aT01z<>kdQ$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT \Q $Ifgdyu:K$Mkdų$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$    dejkЖіҖږۖ-.89;<NOYZ³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&ҖԖՖ֖gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdB$IfK$L$T`&634aT֖זٖږ˜z><kdµ$IfK$L$T&634aT>kdd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTZ\]ŘƘ™ ()/0#$첣ufuSufDhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jζhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH˜ØĘŘwl $Ifgdyu:K$<kdz$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT "h]] $Ifgdyu:K$>kd $IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T"#$%'f[ $Ifgdyu:K$<kd۸$IfK$L$T&634aT $$Ifa$gdyu:K$Okdk$IfK$L$T0h%&h634aT'()*,-z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd/$IfK$L$T`&634aT-./'(*\Q $Ifgdyu:K$Mkd[$IfK$L$T &  634ap T $Ifgdyu:K$<kdE$IfK$L$T&634aT $$Ifa$gdyu:K$$%&+,~rst|}ϝН³ ³֑³ ³n[n%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphojdhyu:h< LCJUaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ*+gY $$Ifa$gdyu:K$Okd6$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdػ$IfK$L$T`&634aTz><kdX$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTtvh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd&$IfK$L$T &  634ap Tvwxy{f[ $Ifgdyu:K$<kdq$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT{|MNPQz<>kd}$IfK$L$T&634aT<kd#$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTН՝֝ٝڝ,-1245@AGHMSTGHIJOP³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j/hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%QRSKLN\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$NO@BCDgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdn$IfK$L$T`&634aT>?@HI    c޿zzkz޿zz\zjhyu:h< LCJUaJjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***$DEGHz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd<$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdH$IfK$L$T&634aTh]] $Ifgdyu:K$>kd9$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T   f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT  z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd[$IfK$L$T`&634aT  \Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kdq$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okdb$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTcdij   `aghjkƥǥɥʥ&')*|}ʿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***&z><kd$IfK$L$T&634aT>kd&$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kd<$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT%&xyۨܨ=>HIKL³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$MkdR$IfK$L$T &  634ap T !"$f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd-$IfK$L$T0h%&h634aT$%z<>kd$IfK$L$T&634aT<kdO$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTuvwҫӫ۫ܫ߫23BCδà~~j[jHj[j[jHj$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j[hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$wyz{gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT{|~efhz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdh$IfK$L$T&634aTCEFWX_`ekl_`abgh&'(01𾯾}j}j}$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j&hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho)hijkcwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdt$IfK$L$T&634aTcdfg(*h]] $Ifgdyu:K$>kde$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T*+,-/f[ $Ifgdyu:K$<kd3$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT/0z<>kd?$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTCDIJ-./78ݿ~k~k~X%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$/123gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd0$IfK$L$T`&634aT3467 z><kd$IfK$L$T&634aT>kdR$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTDEKLNO   bc³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH% wl $Ifgdyu:K$<kdh$IfK$L$T&634aT $$Ifa$gdyu:K$>kd $IfK$L$T&634aT  h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd~$IfK$L$T &  634ap Tchi#$vw߶EFMNPQ޿rccjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***" "f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OkdY$IfK$L$T0h%&h634aT"#z<>kd$IfK$L$T&634aT<kd{$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT\Q $Ifgdyu:K$MkdI$IfK$L$T &  634ap T $Ifgdyu:K$<kd3$IfK$L$T&634aT $$Ifa$gdyu:K$  ͹ιϹ׹ع*+89<=QR[\^_³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ&ϹѹҹӹgY $$Ifa$gdyu:K$Okd$$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTӹԹֹ׹ûĻƻz><kdF$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTûɻʻżƼٽڽ۽67³vgvTgTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jRhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJphoƻǻȻɻwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT¼ļż۽ݽh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tݽ޽߽f[ $Ifgdyu:K$<kd_$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTȿɿ˿̿z<>kdk$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT7ABDEUV^_ab¿ÿȿοϿ#$rstʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*̿Ϳο\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$tvwxgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd\$IfK$L$T`&634aTxy{|ghjz><kd$IfK$L$T&634aT>kd~$IfK$L$T`&634aT $Ifgdyu:K$<kd*$IfK$L$T&634aTt|};<EFHIXYabgmnabcdij~k$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ*jklmewl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd6$IfK$L$T&634aTefhiCEh]] $Ifgdyu:K$>kd'$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap TABCKL   `amnpq$%/05;</012𾪛yyjyjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***)EFGHJf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTJK5689z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdI$IfK$L$T`&634aT9:;346\Q $Ifgdyu:K$Mkdu$IfK$L$T &  634ap T $Ifgdyu:K$<kd_$IfK$L$T&634aT $$Ifa$gdyu:K$67gY $$Ifa$gdyu:K$OkdP$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT278DEKLNOҿzzkzҿj~hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ*z><kdr$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kd*$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd@$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTijlmz<>kd$IfK$L$T&634aT<kd=$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTLMQRUV  abghiopcdefkl{|}ݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jIhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*mnoghj\Q $Ifgdyu:K$Mkd $IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$jk}gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdV$IfK$L$T&634aT;<CDFG cݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdb$IfK$L$T&634aTh]] $Ifgdyu:K$>kdS$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd!$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT/023z<>kd-$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdu$IfK$L$T`&634aTcdmnqr"#-./56)*+,12ʿ~k~ʿ\jhyu:h< LCJUaJ$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho$345-.0\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$01gY $$Ifa$gdyu:K$Okd|$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kd@$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kdV$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT()*23<=>FGѯ¯囌yjѯ¯juhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJ"*,h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkdl$IfK$L$T &  634ap T,-./1f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OkdG$IfK$L$T0h%&h634aT12z<>kd$IfK$L$T&634aT<kdi$IfK$L$T&634aT $Ifgdyu:K$>kd $IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd7$IfK$L$T &  634ap T $Ifgdyu:K$<kd!$IfK$L$T&634aT $$Ifa$gdyu:K$>@ABgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTBCEF>?Az><kd4 $IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTG [\mnpq+,89>DE89:;@A첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j@ hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'ABCD<wl $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$>kd $IfK$L$T&634aT<=?@h]] $Ifgdyu:K$>kd $IfK$L$T`&634aT $Ifgdyu:K$Mkd $IfK$L$T &  634ap TFGQRSYZMNOPUVvxz02HJPR ޿zzkz޿zj hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****f[ $Ifgdyu:K$<kdM $IfK$L$T&634aT $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aTSTVWz<>kdY $IfK$L$T&634aT<kd $IfK$L$T&634aT $Ifgdyu:K$>kd $IfK$L$T`&634aTWXYQRT\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$TUz~gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdJ$IfK$L$T`&634aT   z><kd$IfK$L$T&634aT>kdl$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT  wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$$IfK$L$T&634aT  ^_de [\fgij%&'ôáôzczzczzczzcz,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ&  h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okds$IfK$L$T0h%&h634aT'(*+z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd7$IfK$L$T`&634aT+,-%&(\Q $Ifgdyu:K$Mkdc$IfK$L$T &  634ap T $Ifgdyu:K$<kdM$IfK$L$T&634aT $$Ifa$gdyu:K$'-.!"#$)*|}FGQRTU g״~o~\~o~o~\~o~o~\~o~o$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH$()gY $$Ifa$gdyu:K$Okd>$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTtuwz><kd`$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTghrstz{nopqvw%&xyʿ~k~k~XA,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jlhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphowxyzrwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTrsuvh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd.$IfK$L$T &  634ap T !"$f[ $Ifgdyu:K$<kdy$IfK$L$T&634aT $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT$%z<>kd$IfK$L$T&634aT<kd+$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT@AJKNOkl첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j7hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH#\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdv$IfK$L$T`&634aTlqr:;CDFG  ޿rccTcj!hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph*** z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdD$IfK$L$T&634aT  wl $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$>kdP $IfK$L$T&634aTh]] $Ifgdyu:K$>kdA"$IfK$L$T`&634aT $Ifgdyu:K$Mkd!$IfK$L$T &  634ap TYZ_`()/023GHMN𾪛yyjyj$hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***)f[ $Ifgdyu:K$<kd#$IfK$L$T&634aT $$Ifa$gdyu:K$Okd"$IfK$L$T0h%&h634aTz<>kd$$IfK$L$T&634aT<kd#$IfK$L$T&634aT $Ifgdyu:K$>kdc#$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd%$IfK$L$T &  634ap T $Ifgdyu:K$<kdy$$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okdj&$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd &$IfK$L$T`&634aTz><kd'$IfK$L$T&634aT>kd.'$IfK$L$T`&634aT $Ifgdyu:K$<kd&$IfK$L$T&634aT lmrsuv)*1245~k$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j(hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ*wl $Ifgdyu:K$<kdD($IfK$L$T&634aT $$Ifa$gdyu:K$>kd'$IfK$L$T&634aTbdh]] $Ifgdyu:K$>kd)$IfK$L$T`&634aT $Ifgdyu:K$MkdZ)$IfK$L$T &  634ap T`abjk'(*+}~<=IJOUVIJKL𾪛yyjyjc,hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***)defgif[ $Ifgdyu:K$<kd*$IfK$L$T&634aT $$Ifa$gdyu:K$Okd5*$IfK$L$T0h%&h634aTijOPRSz<>kd+$IfK$L$T&634aT<kdW+$IfK$L$T&634aT $Ifgdyu:K$>kd*$IfK$L$T`&634aTSTUMNP\Q $Ifgdyu:K$Mkd%-$IfK$L$T &  634ap T $Ifgdyu:K$<kd,$IfK$L$T&634aT $$Ifa$gdyu:K$PQgY $$Ifa$gdyu:K$Okd.$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd-$IfK$L$T`&634aTLQR  \]degh'(*+}~ҿzzjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ, z><kd"/$IfK$L$T&634aT>kd.$IfK$L$T`&634aT $Ifgdyu:K$<kdp.$IfK$L$T&634aTwl $Ifgdyu:K$<kd/$IfK$L$T&634aT $$Ifa$gdyu:K$>kd|/$IfK$L$T&634aTDEJKVWijlm$%67:;³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJj.0hyu:h< LCJUaJ&h]] $Ifgdyu:K$>kdm1$IfK$L$T`&634aT $Ifgdyu:K$Mkd0$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd;2$IfK$L$T&634aT $$Ifa$gdyu:K$Okd1$IfK$L$T0h%&h634aTz<>kdG3$IfK$L$T&634aT<kd2$IfK$L$T&634aT $Ifgdyu:K$>kd2$IfK$L$T`&634aTWX³vgvTgTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j3hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho\Q $Ifgdyu:K$Mkd4$IfK$L$T &  634ap T $Ifgdyu:K$<kd3$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd5$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd85$IfK$L$T`&634aTz><kd6$IfK$L$T&634aT>kdZ6$IfK$L$T`&634aT $Ifgdyu:K$<kd6$IfK$L$T&634aTX`acd "#uv<=BCʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j7hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*wl $Ifgdyu:K$<kdp7$IfK$L$T&634aT $$Ifa$gdyu:K$>kd7$IfK$L$T&634aTh]] $Ifgdyu:K$>kd9$IfK$L$T`&634aT $Ifgdyu:K$Mkd8$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd9$IfK$L$T&634aT $$Ifa$gdyu:K$Okda9$IfK$L$T0h%&h634aTz<>kd:$IfK$L$T&634aT<kd:$IfK$L$T&634aT $Ifgdyu:K$>kd%:$IfK$L$T`&634aT()4589KLRSUV       Ψvghyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j;hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ(   \Q $Ifgdyu:K$MkdQ<$IfK$L$T &  634ap T $Ifgdyu:K$<kd;;$IfK$L$T&634aT $$Ifa$gdyu:K$      gY $$Ifa$gdyu:K$Okd,=$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd<$IfK$L$T`&634aT               P Q Y Z \ ]          ! # $ v w     ʿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***&       z><kdN>$IfK$L$T&634aT>kd=$IfK$L$T`&634aT $Ifgdyu:K$<kd=$IfK$L$T&634aT     wl $Ifgdyu:K$<kd?$IfK$L$T&634aT $$Ifa$gdyu:K$>kd>$IfK$L$T&634aT            YZdegh ³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jZ?hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&    h]] $Ifgdyu:K$>kd@$IfK$L$T`&634aT $Ifgdyu:K$Mkd@$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kdgA$IfK$L$T&634aT $$Ifa$gdyu:K$Okd@$IfK$L$T0h%&h634aTz<>kdsB$IfK$L$T&634aT<kdB$IfK$L$T&634aT $Ifgdyu:K$>kdA$IfK$L$T`&634aT #$vwNOPXY첣ufuSfSufDhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j%Chyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH\Q $Ifgdyu:K$MkdC$IfK$L$T &  634ap T $Ifgdyu:K$<kdB$IfK$L$T&634aT $$Ifa$gdyu:K$PRSTgY $$Ifa$gdyu:K$OkdD$IfK$L$T0h%&h634aT $Ifgdyu:K$>kddD$IfK$L$T`&634aTTUWXz><kdE$IfK$L$T&634aT>kdE$IfK$L$T`&634aT $Ifgdyu:K$<kd2E$IfK$L$T&634aT  hiqrtu&',-ʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jFhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho&wl $Ifgdyu:K$<kdF$IfK$L$T&634aT $$Ifa$gdyu:K$>kd>F$IfK$L$T&634aTh]] $Ifgdyu:K$>kd/H$IfK$L$T`&634aT $Ifgdyu:K$MkdG$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kdH$IfK$L$T&634aT $$Ifa$gdyu:K$OkdH$IfK$L$T0h%&h634aTz<>kd J$IfK$L$T&634aT<kdI$IfK$L$T&634aT $Ifgdyu:K$>kdQI$IfK$L$T`&634aT cdlmop#$+,/0첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jJhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'\Q $Ifgdyu:K$Mkd}K$IfK$L$T &  634ap T $Ifgdyu:K$<kdgJ$IfK$L$T&634aT $$Ifa$gdyu:K$79:;gY $$Ifa$gdyu:K$OkdXL$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdK$IfK$L$T`&634aT567?@ [\efhi$%&,- !"#޿zzkzjNhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****;<>?&')z><kdzM$IfK$L$T&634aT>kdM$IfK$L$T`&634aT $Ifgdyu:K$<kdL$IfK$L$T&634aT)*+,$wl $Ifgdyu:K$<kd2N$IfK$L$T&634aT $$Ifa$gdyu:K$>kdM$IfK$L$T&634aT$%'(  h]] $Ifgdyu:K$>kdO$IfK$L$T`&634aT $Ifgdyu:K$MkdHO$IfK$L$T &  634ap T#(){| efnoqr)*67:;ҿzzjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ,  f[ $Ifgdyu:K$<kdP$IfK$L$T&634aT $$Ifa$gdyu:K$Okd#P$IfK$L$T0h%&h634aTz<>kdQ$IfK$L$T&634aT<kdEQ$IfK$L$T&634aT $Ifgdyu:K$>kdP$IfK$L$T`&634aT\Q $Ifgdyu:K$MkdS$IfK$L$T &  634ap T $Ifgdyu:K$<kdQ$IfK$L$T&634aT $$Ifa$gdyu:K$  S T Y Z      C!D!L!M!O!P!!!!!!!"" " " " "_"`"k"l"n"o""³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjQRhyu:h< LCJUaJ&     gY $$Ifa$gdyu:K$OkdS$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdS$IfK$L$T`&634aT    """z><kdU$IfK$L$T&634aT>kdT$IfK$L$T`&634aT $Ifgdyu:K$<kd^T$IfK$L$T&634aT"""""""######'$($1$2$3$;$<$B$C$6%7%³vgvTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jVhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho""""#wl $Ifgdyu:K$<kdU$IfK$L$T&634aT $$Ifa$gdyu:K$>kdjU$IfK$L$T&634aT####3$5$h]] $Ifgdyu:K$>kd[W$IfK$L$T`&634aT $Ifgdyu:K$MkdV$IfK$L$T &  634ap T5$6$7$8$:$f[ $Ifgdyu:K$<kd)X$IfK$L$T&634aT $$Ifa$gdyu:K$OkdW$IfK$L$T0h%&h634aT:$;$<$=$?$@$z<>kd5Y$IfK$L$T&634aT<kdX$IfK$L$T&634aT $Ifgdyu:K$>kd}X$IfK$L$T`&634aT@$A$B$:%;%=%\Q $Ifgdyu:K$MkdZ$IfK$L$T &  634ap T $Ifgdyu:K$<kdY$IfK$L$T&634aT $$Ifa$gdyu:K$7%8%9%>%?%%%%%&&& &&`&a&q&r&t&u&&&&&&&&'''1'2'4'5'''''''''''³ ³֌}j}}j}}j}}j}}j$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjYhyu:h< LCJUaJ)=%>%&&& &gY $$Ifa$gdyu:K$Okd[$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd&[$IfK$L$T`&634aT & & & &'''z><kd\$IfK$L$T&634aT>kdH\$IfK$L$T`&634aT $Ifgdyu:K$<kd[$IfK$L$T&634aT''''((((((M)N)S)T))))))** * ***b*c*m*n*p*q*******$+%+/+0+1+峤}}j}}}j}}}j}}}j}$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j]hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho)''''(wl $Ifgdyu:K$<kd^]$IfK$L$T&634aT $$Ifa$gdyu:K$>kd]$IfK$L$T&634aT(((())h]] $Ifgdyu:K$>kd^$IfK$L$T`&634aT $Ifgdyu:K$Mkdt^$IfK$L$T &  634ap T)))))f[ $Ifgdyu:K$<kd_$IfK$L$T&634aT $$Ifa$gdyu:K$OkdO_$IfK$L$T0h%&h634aT))1+2+4+5+z<>kd`$IfK$L$T&634aT<kdq`$IfK$L$T&634aT $Ifgdyu:K$>kd`$IfK$L$T`&634aT5+6+7+/,0,2,\Q $Ifgdyu:K$Mkd?b$IfK$L$T &  634ap T $Ifgdyu:K$<kd)a$IfK$L$T&634aT $$Ifa$gdyu:K$1+7+8++,,,-,.,3,4,,,,,,,,,,*-+-6-7-8->-?-2.3.4.5.:.;.....A/B/ôáô~k~\ôájHehyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j}ahyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$2,3,,,,,gY $$Ifa$gdyu:K$Okdc$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdb$IfK$L$T`&634aT,,,,8-9-;-z><kdkdc$IfK$L$T`&634aT $Ifgdyu:K$<kdc$IfK$L$T&634aT;-<-=->-6.wl $Ifgdyu:K$<kdd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdd$IfK$L$T&634aT6.7.9.:.C/E/h]] $Ifgdyu:K$>kdf$IfK$L$T`&634aT $Ifgdyu:K$Mkd f$IfK$L$T &  634ap TB/C/K/L/////////0000X0Y0_0`0b0c000000011111"1#1222222q2r2ѯѯѯѯѯ堑}}&jhyu:h< LB*CJUaJph***jihyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph****E/F/G/H/J/f[ $Ifgdyu:K$<kdUg$IfK$L$T&634aT $$Ifa$gdyu:K$Okdf$IfK$L$T0h%&h634aTJ/K/111 1z<>kdah$IfK$L$T&634aT<kdh$IfK$L$T&634aT $Ifgdyu:K$>kdg$IfK$L$T`&634aT 1!1"1222\Q $Ifgdyu:K$Mkdi$IfK$L$T &  634ap T $Ifgdyu:K$<kdh$IfK$L$T&634aT $$Ifa$gdyu:K$22 3 3 33gY $$Ifa$gdyu:K$Okdj$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdRj$IfK$L$T`&634aTr2w2x23 3 333e3f3r3s3v3w3333333&4'424345464444444455޿rccjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***"3333444z><kdk$IfK$L$T&634aT>kdtk$IfK$L$T`&634aT $Ifgdyu:K$<kd k$IfK$L$T&634aT44445wl $Ifgdyu:K$<kdl$IfK$L$T&634aT $$Ifa$gdyu:K$>kd,l$IfK$L$T&634aT555555555m6n6o6w6x6666666+7,7576777=7>71828384898:8888³ ³֌}j}}j}[³ jphyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjlhyu:h< LCJUaJ#5555o6q6h]] $Ifgdyu:K$>kdn$IfK$L$T`&634aT $Ifgdyu:K$Mkdm$IfK$L$T &  634ap Tq6r6s6t6v6f[ $Ifgdyu:K$<kdn$IfK$L$T&634aT $$Ifa$gdyu:K$Okd{n$IfK$L$T0h%&h634aTv6w67787:7;7z<>kdo$IfK$L$T&634aT<kdo$IfK$L$T&634aT $Ifgdyu:K$>kd?o$IfK$L$T`&634aT;7<7=7586888\Q $Ifgdyu:K$Mkdkq$IfK$L$T &  634ap T $Ifgdyu:K$<kdUp$IfK$L$T&634aT $$Ifa$gdyu:K$8898+9-9.9/9gY $$Ifa$gdyu:K$OkdFr$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdq$IfK$L$T`&634aT88)9*9+93949999999999999F:G:R:S:U:V::::::: ; ;;;; ;!;<<<<𾪛yyjyjtthyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***)/9092939;;;z><kdhs$IfK$L$T&634aT>kd s$IfK$L$T`&634aT $Ifgdyu:K$<kdr$IfK$L$T&634aT;;; ;<wl $Ifgdyu:K$<kd t$IfK$L$T&634aT $$Ifa$gdyu:K$>kds$IfK$L$T&634aT<<<<:=<=h]] $Ifgdyu:K$>kdu$IfK$L$T`&634aT $Ifgdyu:K$Mkd6u$IfK$L$T &  634ap T<<<o<p<u<v<8=9=:=B=C============>R>S>]>^>`>a>>>>>>>??!?"?'?-?.?!@"@ҿzzjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ,<===>=?=A=f[ $Ifgdyu:K$<kdv$IfK$L$T&634aT $$Ifa$gdyu:K$Okdv$IfK$L$T0h%&h634aTA=B='?(?*?+?z<>kdw$IfK$L$T&634aT<kd3w$IfK$L$T&634aT $Ifgdyu:K$>kdv$IfK$L$T`&634aT+?,?-?%@&@(@\Q $Ifgdyu:K$Mkdy$IfK$L$T &  634ap T $Ifgdyu:K$<kdw$IfK$L$T&634aT $$Ifa$gdyu:K$"@#@$@)@*@|@}@@@OAPAQAYAZAAAAAAA B BBBBBmBnBwBxBzB{BBBBBBB)C*C5C6C³ ³֌}j}}j}}j}}j}}j$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJj?xhyu:h< LCJUaJ)(@)@QASATAUAgY $$Ifa$gdyu:K$Okdy$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd~y$IfK$L$T`&634aTUAVAXAYA;CCz><kdz$IfK$L$T&634aT>kdz$IfK$L$T`&634aT $Ifgdyu:K$<kdLz$IfK$L$T&634aT6C;CACBC5D6D7D8D=D>DDDDDDDDDDOEPEYEZE\E]EEEEEEE FFFFFFlFmFvFwFyF峤}}j}}}j}}}j}}}j}$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j |hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho)>C?C@CAC9Dwl $Ifgdyu:K$<kd{$IfK$L$T&634aT $$Ifa$gdyu:K$>kdX{$IfK$L$T&634aT9D:DkdI}$IfK$L$T`&634aT $Ifgdyu:K$Mkd|$IfK$L$T &  634ap TDDDDDf[ $Ifgdyu:K$<kd~$IfK$L$T&634aT $$Ifa$gdyu:K$Okd}$IfK$L$T0h%&h634aTDDFFFFz<>kd#$IfK$L$T&634aT<kd~$IfK$L$T&634aT $Ifgdyu:K$>kdk~$IfK$L$T`&634aTyFzFFFFFFFFGGGGGG2H3H8H9HIIIIIqIrI|I}IIIIIIIII2J3J=J>J@JAJJݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*FFFGGG\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$GGIIIIgY $$Ifa$gdyu:K$Okdr$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTIIIIKK Kz><kd$IfK$L$T&634aT>kd6$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTJJJJJJJJKKK K KLLLLL L[L\LaLbLMMMMMmMnMʿ~k~k~X%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho K K K KLwl $Ifgdyu:K$<kdL$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTLLLLMMh]] $Ifgdyu:K$>kd߄$IfK$L$T`&634aT $Ifgdyu:K$Mkdb$IfK$L$T &  634ap TMMMMMf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd=$IfK$L$T0h%&h634aTMM,O-O/O0Oz<>kd$IfK$L$T&634aT<kd_$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTnMMMMMMMMMMMANBNWNXNZN[NNNNNNNOO&O'O,O2O3O&P'P(P)P.P/PPP³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jkhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%0O1O2O*P+P-P\Q $Ifgdyu:K$Mkd-$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$-P.P`QbQcQdQgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTPPP^Q_Q`QhQiQQQQQQQRR$R%R'R(RzR{RRRRRRRRRRR:S;SCSDSISOSPSCTDTETFT޿zzkzj6hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****dQeQgQhQISJSLSz><kd*$IfK$L$T&634aT>kd̉$IfK$L$T`&634aT $Ifgdyu:K$<kdx$IfK$L$T&634aTLSMSNSOSGTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTGTHTJTKT%U'Uh]] $Ifgdyu:K$>kdu$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap TFTKTLTTTTT#U$U%U-U.UUUUUUUUUUUUU9V:V@VAVDVEVVVVVVVVVVVWWҿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ)'U(U)U*U,Uf[ $Ifgdyu:K$<kdC$IfK$L$T&634aT $$Ifa$gdyu:K$Okdӌ$IfK$L$T0h%&h634aT,U-UWWWWz<>kdO$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTWWWWWX\Q $Ifgdyu:K$MkdÏ$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$WWWWWWXXUXVX[X\XXXXXX(Y)Y6Y7Y9Y:YYYYYYYYYYYYZRZSZ\Z]Z³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&XXXXXXgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd@$IfK$L$T`&634aTXXXX^Z_ZaZz><kd$IfK$L$T&634aT>kdb$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT]Z^ZdZeZX[Y[Z[[[`[a[[[[[-\.\/\7\8\\\\\\\\\\\\\C]D]δà~~jjSjjjSjjj,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j̒hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH aZbZcZdZ\[wl $Ifgdyu:K$<kdx$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT\[][_[`[/\1\h]] $Ifgdyu:K$>kd $IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T1\2\3\4\6\f[ $Ifgdyu:K$<kdٔ$IfK$L$T&634aT $$Ifa$gdyu:K$Okdi$IfK$L$T0h%&h634aT6\7\^^ ^ ^z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd-$IfK$L$T`&634aTD]I]J]M]N]]]]]]]]]^^^ ^ ^_____ _[_\_a_b______³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH ^ ^ ^___\Q $Ifgdyu:K$MkdY$IfK$L$T &  634ap T $Ifgdyu:K$<kdC$IfK$L$T&634aT $$Ifa$gdyu:K$______gY $$Ifa$gdyu:K$Okd4$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd֗$IfK$L$T`&634aT____aaaz><kdV$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT_````` `r`s```````````GaHaXaYa[a\aaaaaaaabbbbbbcc첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jbhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'aaaabwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTbbbbcch]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$$IfK$L$T &  634ap Tcc cccccc ddddddmdndudvdxdyddddddd)e*e3e4e6e7eeeeeeeeffff޿zzkzj-hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****cccccf[ $Ifgdyu:K$<kdo$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTcceeeez<>kd{$IfK$L$T&634aT<kd!$IfK$L$T&634aT $Ifgdyu:K$>kdÜ$IfK$L$T`&634aTeeefff\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kdٝ$IfK$L$T&634aT $$Ifa$gdyu:K$ffgggggY $$Ifa$gdyu:K$Okdʟ$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdl$IfK$L$T`&634aTfffffffgggggggh h h h^h_hjhkhnhohhhhhhh i!i(i)i+i,i~iiiiiiҿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ)ggggiiiz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd:$IfK$L$T&634aTiiiijwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdF$IfK$L$T&634aTiijjjjjjjjjjYkZk[kckdkkkkkkklllll lrlsl|l}lllllllll2m³ ³}j}}j}}j}}j}}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ)jjjj[k]kh]] $Ifgdyu:K$>kd7$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T]k^k_k`kbkf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTbkckCmDmFmGmz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdY$IfK$L$T`&634aT2m3m=m>mCmImJm=n>n?n@nEnFnnnnnnnnnnPoQoZo[oʿ~k~k~XA,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jåhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphoGmHmImAnBnDn\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kdo$IfK$L$T&634aT $$Ifa$gdyu:K$DnEnnnnngY $$Ifa$gdyu:K$Okd`$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTnnnnpppz><kd$IfK$L$T&634aT>kd$$IfK$L$T`&634aT $Ifgdyu:K$<kdЧ$IfK$L$T&634aT[o^o_ooooooopp%p&p(p)p{p|ppppppppppppqqqqqqErFr첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH#ppppqwl $Ifgdyu:K$<kd:$IfK$L$T&634aT $$Ifa$gdyu:K$>kdܨ$IfK$L$T&634aTqqqq+s-sh]] $Ifgdyu:K$>kdͪ$IfK$L$T`&634aT $Ifgdyu:K$MkdP$IfK$L$T &  634ap TFrKrLr)s*s+s3s4sssssssssssssKtLtUtVtXtYttttttt u uuuu"u#u޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&-s.s/s0s2sf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd+$IfK$L$T0h%&h634aT2s3suuu uz<>kd$IfK$L$T&634aT<kdM$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT u!u"uvvv\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$#uvvvvvvqvrvwvxvvvvvvOwPwawbwdwewwwwwwwxx/x0x2x3xxxxxxôáôzczzczzczzcz,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jYhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ&vvvvvvgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTvvvv y yyz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdf$IfK$L$T&634aTxxxxyy yyyzzzz zz`zazfzgzz{{ { {\{]{m{n{p{q{{{{ٳvgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j$hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho yyyy zwl $Ifgdyu:K$<kdа$IfK$L$T&634aT $$Ifa$gdyu:K$>kdr$IfK$L$T&634aT z z z z{{h]] $Ifgdyu:K$>kdc$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T{{{{{f[ $Ifgdyu:K$<kd1$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT{ {}}}}z<>kd=$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT{{{{+|,|A|B|D|E|||||||||}}}} }~~~~~~n~o~t~u~ٳvgvTg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho }}}~~~\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$~~=?@AgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd.$IfK$L$T`&634aTu~;<=EFnoـڀ@AQRW]^QRʿrccjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***&ABDEWXZz><kd$IfK$L$T&634aT>kdP$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTZ[\]Uwl $Ifgdyu:K$<kdf$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTRSTYZǂȂÃă΄τЄ؄ل+,4578³ ³֑³ ³nn[nn$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphojhyu:h< LCJUaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ#UVXYh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd|$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kdǺ$IfK$L$T&634aT $$Ifa$gdyu:K$OkdW$IfK$L$T0h%&h634aT‚Ăłz<>kdӻ$IfK$L$T&634aT<kdy$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTłƂǂƒ\Q $Ifgdyu:K$MkdG$IfK$L$T &  634ap T $Ifgdyu:K$<kd1$IfK$L$T&634aT $$Ifa$gdyu:K$ƒÃЄ҄ӄԄgY $$Ifa$gdyu:K$Okd"$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdĽ$IfK$L$T`&634aTԄՄׄ؄z><kdD$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTIJYZ\]ÆĆ?@Gʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jPhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho*†Æwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd]$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTЊъӊԊz<>kdi$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTGHKL   `aijlmʊˊЊ֊׊ʋˋ̋͋ҋӋ%&+,ݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*ԊՊ֊΋ϋы\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$ыҋgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdZ$IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kd|$IfK$L$T`&634aT $Ifgdyu:K$<kd($IfK$L$T&634aTpqyz}~Ѝэ؍ٍۍ܍./89;<ݿ~k$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd4$IfK$L$T&634aTh]] $Ifgdyu:K$>kd%$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T   [\ab)*,-Ǹ}j}S}j}j}S}j},hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LB* CJaJphohyu:h< LCJaJhyu:h< LB*CJaJph*** f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT  z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdG$IfK$L$T`&634aT   \Q $Ifgdyu:K$Mkds$IfK$L$T &  634ap T $Ifgdyu:K$<kd]$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$OkdN$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kdp$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTJKVWYZ첣ufuSfSuf$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j|hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH wl $Ifgdyu:K$<kd($IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd>$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kd;$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTDENOQR iΨvgvTgT$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jGhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ \Q $Ifgdyu:K$Mkd $IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$kmnogY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTijkstƘǘΘϘјҘ$%,-/0OP^_djk^_`afҾvvgvjhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***(oprsdegz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdT$IfK$L$T&634aTghijbwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd`$IfK$L$T&634aTbcef>@h]] $Ifgdyu:K$>kdQ$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tfg<=>FGžʞ˞()+,~ݿzzkzݿjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph****@ABCEf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTEFz<>kd+$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kds$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$žĞŞƞgY $$Ifa$gdyu:K$Okdz$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTƞǞɞʞz><kd$IfK$L$T&634aT>kd>$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTߟABGH𾯾}j}j}W%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJphowl $Ifgdyu:K$<kdT$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkdj$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OkdE$IfK$L$T0h%&h634aT{|~z<>kd$IfK$L$T&634aT<kdg$IfK$L$T&634aT $Ifgdyu:K$>kd $IfK$L$T`&634aTPQWXZ[  kluv{uvwx}~ФѤ³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jshyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%yz|\Q $Ifgdyu:K$Mkd5$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$|}!#$%gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTѤ֤פ !)*|}ۥܥ:;EFHI ޿zzkzj>hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****%&()  z><kd2$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT    !#h]] $Ifgdyu:K$>kd}$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T `afg !)*|}ݩީ<=HIKL ҿzzjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ,#$%&(f[ $Ifgdyu:K$<kdK$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT()  z<>kdW$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT   \Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$ abgh &'"#uv{|ƮǮȮЮѮ³ ³֌}j}[³ ³֌jhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJj hyu:h< LCJUaJ# gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdH$IfK$L$T`&634aT !#z><kd$IfK$L$T&634aT>kdj$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT#$%&wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd"$IfK$L$T&634aT!"Ȯʮh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tʮˮ̮ͮϮf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okdq$IfK$L$T0h%&h634aTϮЮz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd5$IfK$L$T`&634aTѮ#$./12EFOPRS𾯾}j}$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho)\Q $Ifgdyu:K$Mkda$IfK$L$T &  634ap T $Ifgdyu:K$<kdK$IfK$L$T&634aT $$Ifa$gdyu:K$²òIJgY $$Ifa$gdyu:K$Okd<$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTȲɲ#$'(z{ֳ׳ݳ޳34:;=>ʿrccjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***&IJŲDzȲz><kd^$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTTUV^_ !st}~Էշ޷߷4³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjjhyu:h< LCJUaJ&VXh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd,$IfK$L$T &  634ap TXYZ[]f[ $Ifgdyu:K$<kdw$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT]^EFHIz<>kd$IfK$L$T&634aT<kd)$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT45?@EKL?@ABGHLMNVW³vgvTgTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j5hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJphoIJKCDF\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$FGNPQRgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdt$IfK$L$T`&634aTRSUV568z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdB$IfK$L$T&634aT efpqstƻǻѻһԻջ'(/05;</01278ʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*89:;3wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdN$IfK$L$T&634aT3467h]] $Ifgdyu:K$>kd?$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kda$IfK$L$T`&634aTOP]^`a¾ !st|}ҿӿ޿߿9:?~k$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ*\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kdw$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okdh$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd $IfK$L$T`&634aT?@DEKLNO cdlmpq𾪗qbjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&z><kd$IfK$L$T&634aT>kd,$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kdB$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT%&+,&'1245CDLMOP³ ³֌ybyybyybyyby,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ&h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$MkdX$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd3$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kdU$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTP  !"첣ufuSfSuf@%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jahyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH\Q $Ifgdyu:K$Mkd# $IfK$L$T &  634ap T $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT $Ifgdyu:K$>kd $IfK$L$T`&634aTz><kd $IfK$L$T&634aT>kd $IfK$L$T`&634aT $Ifgdyu:K$<kdn $IfK$L$T&634aT"+,/0FGLM³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j, hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH wl $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$>kdz $IfK$L$T&634aT h]] $Ifgdyu:K$>kdk $IfK$L$T`&634aT $Ifgdyu:K$Mkd $IfK$L$T &  634ap T    f[ $Ifgdyu:K$<kd9$IfK$L$T&634aT $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aTz<>kdE$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTcdnoqr"#+,./IJ첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$    gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd6$IfK$L$T`&634aTJOP delmop *+-.޿zzkzjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph**** z><kd$IfK$L$T&634aT>kdX$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kdn$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap TEFKLPQZ[^_!"tuҿrhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ)f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd_$IfK$L$T0h%&h634aTz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd#$IfK$L$T`&634aT\Q $Ifgdyu:K$MkdO$IfK$L$T &  634ap T $Ifgdyu:K$<kd9$IfK$L$T&634aT $$Ifa$gdyu:K$<=BC,->?AB  bckl³ ³ybyybyybyyb,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ&gY $$Ifa$gdyu:K$Okd*$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kdL$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTlno%&+,qrs{|./첣ufuSfSuf$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jXhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTsuh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tuvwxzf[ $Ifgdyu:K$<kde$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTz{`acdz<>kdq$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT/679:NOZ[`fgZ[\]bc³vgvT$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j#hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH def^_a\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$abgY $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT $Ifgdyu:K$>kdb $IfK$L$T`&634aTQR]^ab#$&'yz𾪛yyjyj"hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***)z><kd!$IfK$L$T&634aT>kd!$IfK$L$T`&634aT $Ifgdyu:K$<kd0!$IfK$L$T&634aTwl $Ifgdyu:K$<kd"$IfK$L$T&634aT $$Ifa$gdyu:K$>kd<"$IfK$L$T&634aTh]] $Ifgdyu:K$>kd-$$IfK$L$T`&634aT $Ifgdyu:K$Mkd#$IfK$L$T &  634ap T?@EFBCMNPQkltuwxҿzzjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ,f[ $Ifgdyu:K$<kd$$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$$IfK$L$T0h%&h634aTz<>kd&$IfK$L$T&634aT<kd%$IfK$L$T&634aT $Ifgdyu:K$>kdO%$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd{'$IfK$L$T &  634ap T $Ifgdyu:K$<kde&$IfK$L$T&634aT $$Ifa$gdyu:K$0167FGQRTUghpqtu³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJj&hyu:h< LCJUaJ&gY $$Ifa$gdyu:K$OkdV($IfK$L$T0h%&h634aT $Ifgdyu:K$>kd'$IfK$L$T`&634aTz><kdx)$IfK$L$T&634aT>kd)$IfK$L$T`&634aT $Ifgdyu:K$<kd($IfK$L$T&634aT-.34WX³vgvTgTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j*hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJphowl $Ifgdyu:K$<kd0*$IfK$L$T&634aT $$Ifa$gdyu:K$>kd)$IfK$L$T&634aTh]] $Ifgdyu:K$>kd+$IfK$L$T`&634aT $Ifgdyu:K$MkdF+$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd,$IfK$L$T&634aT $$Ifa$gdyu:K$Okd!,$IfK$L$T0h%&h634aTz<>kd-$IfK$L$T&634aT<kdC-$IfK$L$T&634aT $Ifgdyu:K$>kd,$IfK$L$T`&634aTXbcef()+,~EFKLʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jO.hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*\Q $Ifgdyu:K$Mkd/$IfK$L$T &  634ap T $Ifgdyu:K$<kd-$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd/$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd/$IfK$L$T`&634aT   z><kd1$IfK$L$T&634aT>kd0$IfK$L$T`&634aT $Ifgdyu:K$<kd\0$IfK$L$T&634aT  _`ijmn !679:VW\~k$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j2hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ*wl $Ifgdyu:K$<kd1$IfK$L$T&634aT $$Ifa$gdyu:K$>kdh1$IfK$L$T&634aTh]] $Ifgdyu:K$>kdY3$IfK$L$T`&634aT $Ifgdyu:K$Mkd2$IfK$L$T &  634ap T\]ABKLNO  lmz{}~𾪗qbjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&f[ $Ifgdyu:K$<kd'4$IfK$L$T&634aT $$Ifa$gdyu:K$Okd3$IfK$L$T0h%&h634aTz<>kd35$IfK$L$T&634aT<kd4$IfK$L$T&634aT $Ifgdyu:K$>kd{4$IfK$L$T`&634aT\Q $Ifgdyu:K$Mkd6$IfK$L$T &  634ap T $Ifgdyu:K$<kd5$IfK$L$T&634aT $$Ifa$gdyu:K$?@EF789ABTU_`agh[\³ ³֌}j}}j}}j}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJj5hyu:h< LCJUaJjhyu:h< LCJUaJ#9;<=gY $$Ifa$gdyu:K$Okd7$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$7$IfK$L$T`&634aT=>@Aabdz><kd8$IfK$L$T&634aT>kdF8$IfK$L$T`&634aT $Ifgdyu:K$<kd7$IfK$L$T&634aTdefg_wl $Ifgdyu:K$<kd\9$IfK$L$T&634aT $$Ifa$gdyu:K$>kd8$IfK$L$T&634aT\]^cd cdmnqr'(/023³ ³֌}j}}j}}j}}j}}j$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJj9hyu:h< LCJUaJ)_`bch]] $Ifgdyu:K$>kd:$IfK$L$T`&634aT $Ifgdyu:K$Mkdr:$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd;$IfK$L$T&634aT $$Ifa$gdyu:K$OkdM;$IfK$L$T0h%&h634aTz<>kd<$IfK$L$T&634aT<kdo<$IfK$L$T&634aT $Ifgdyu:K$>kd<$IfK$L$T`&634aTTUV^_op峤}j}S}j}j}S}j}j},hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j{=hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho \Q $Ifgdyu:K$Mkd=>$IfK$L$T &  634ap T $Ifgdyu:K$<kd'=$IfK$L$T&634aT $$Ifa$gdyu:K$VXYZgY $$Ifa$gdyu:K$Okd?$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd>$IfK$L$T`&634aTZ[]^MNPz><kd:@$IfK$L$T&634aT>kd?$IfK$L$T`&634aT $Ifgdyu:K$<kd?$IfK$L$T&634aTp=>GHMSTGHIJOPopqyz³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jFAhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH PQRSKwl $Ifgdyu:K$<kd@$IfK$L$T&634aT $$Ifa$gdyu:K$>kd@$IfK$L$T&634aTKLNOqsh]] $Ifgdyu:K$>kdB$IfK$L$T`&634aT $Ifgdyu:K$MkdB$IfK$L$T &  634ap Tstuvxf[ $Ifgdyu:K$<kdSC$IfK$L$T&634aT $$Ifa$gdyu:K$OkdB$IfK$L$T0h%&h634aTxyoprsz<>kd_D$IfK$L$T&634aT<kdD$IfK$L$T&634aT $Ifgdyu:K$>kdC$IfK$L$T`&634aTz,-679:VWijouvijklqr첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jEhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'stumnp\Q $Ifgdyu:K$MkdE$IfK$L$T &  634ap T $Ifgdyu:K$<kdD$IfK$L$T&634aT $$Ifa$gdyu:K$pqgY $$Ifa$gdyu:K$OkdF$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdPF$IfK$L$T`&634aTZ[bcef#$&'yz  ޿rccjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***"z><kdG$IfK$L$T&634aT>kdrG$IfK$L$T`&634aT $Ifgdyu:K$<kdG$IfK$L$T&634aT wl $Ifgdyu:K$<kdH$IfK$L$T&634aT $$Ifa$gdyu:K$>kd*H$IfK$L$T&634aT         O P Q Y Z             i j s t v w       ) ³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjHhyu:h< LCJUaJ&    Q S h]] $Ifgdyu:K$>kdJ$IfK$L$T`&634aT $Ifgdyu:K$MkdI$IfK$L$T &  634ap TS T U V X f[ $Ifgdyu:K$<kdJ$IfK$L$T&634aT $$Ifa$gdyu:K$OkdyJ$IfK$L$T0h%&h634aTX Y : ; = > z<>kdK$IfK$L$T&634aT<kdK$IfK$L$T&634aT $Ifgdyu:K$>kd=K$IfK$L$T`&634aT) * 4 5 : @ A 4 5 6 7 < =          ³vgvTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jLhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho> ? @ 8 9 ; \Q $Ifgdyu:K$MkdiM$IfK$L$T &  634ap T $Ifgdyu:K$<kdSL$IfK$L$T&634aT $$Ifa$gdyu:K$; <     gY $$Ifa$gdyu:K$OkdDN$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdM$IfK$L$T`&634aT       z><kdfO$IfK$L$T&634aT>kdO$IfK$L$T`&634aT $Ifgdyu:K$<kdN$IfK$L$T&634aT    wl $Ifgdyu:K$<kdP$IfK$L$T&634aT $$Ifa$gdyu:K$>kdO$IfK$L$T&634aTZ[\de'(*+}~E³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjrPhyu:h< LCJUaJ&\^h]] $Ifgdyu:K$>kdQ$IfK$L$T`&634aT $Ifgdyu:K$Mkd4Q$IfK$L$T &  634ap T^_`acf[ $Ifgdyu:K$<kdR$IfK$L$T&634aT $$Ifa$gdyu:K$OkdR$IfK$L$T0h%&h634aTcdTUWXz<>kdS$IfK$L$T&634aT<kd1S$IfK$L$T&634aT $Ifgdyu:K$>kdR$IfK$L$T`&634aTEFNOTZ[NOPQVW%&'/0³vgvTgTvgEhyu:h< LB* CJaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j=Thyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJphoXYZRSU\Q $Ifgdyu:K$MkdT$IfK$L$T &  634ap T $Ifgdyu:K$<kdS$IfK$L$T&634aT $$Ifa$gdyu:K$UV')*+gY $$Ifa$gdyu:K$OkdU$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd|U$IfK$L$T`&634aT+,./z><kdV$IfK$L$T&634aT>kdV$IfK$L$T`&634aT $Ifgdyu:K$<kdJV$IfK$L$T&634aTBCMNPQ notuʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jXhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B* CJaJpho*wl $Ifgdyu:K$<kdW$IfK$L$T&634aT $$Ifa$gdyu:K$>kdVW$IfK$L$T&634aTh]] $Ifgdyu:K$>kdGY$IfK$L$T`&634aT $Ifgdyu:K$MkdX$IfK$L$T &  634ap T   f[ $Ifgdyu:K$<kdZ$IfK$L$T&634aT $$Ifa$gdyu:K$OkdY$IfK$L$T0h%&h634aT  z<>kd![$IfK$L$T&634aT<kdZ$IfK$L$T&634aT $Ifgdyu:K$>kdiZ$IfK$L$T`&634aT `aijlm !+,./@AF~k$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j[hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ*\Q $Ifgdyu:K$Mkd\$IfK$L$T &  634ap T $Ifgdyu:K$<kd[$IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okdp]$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd]$IfK$L$T`&634aTFGNO_`bc"#uv~z𾪗qbjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&z><kd^$IfK$L$T&634aT>kd4^$IfK$L$T`&634aT $Ifgdyu:K$<kd]$IfK$L$T&634aT~wl $Ifgdyu:K$<kdJ_$IfK$L$T&634aT $$Ifa$gdyu:K$>kd^$IfK$L$T&634aTz{|}tuv~019:<=  ³ ³֌}j}}j}}j}}j}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJj_hyu:h< LCJUaJjhyu:h< LCJUaJ)~vxh]] $Ifgdyu:K$>kd`$IfK$L$T`&634aT $Ifgdyu:K$Mkd``$IfK$L$T &  634ap Txyz{}f[ $Ifgdyu:K$<kda$IfK$L$T&634aT $$Ifa$gdyu:K$Okd;a$IfK$L$T0h%&h634aT}~z<>kdb$IfK$L$T&634aT<kd]b$IfK$L$T&634aT $Ifgdyu:K$>kda$IfK$L$T`&634aT   \Q $Ifgdyu:K$Mkd+d$IfK$L$T &  634ap T $Ifgdyu:K$<kdc$IfK$L$T&634aT $$Ifa$gdyu:K$     M!N!S!T!!!!!!=">"H"I"K"L""""""""# # ###a#b#o#p#q#w#x#k$l$³ ³֌}j}}j}}j}}j}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjichyu:h< LCJUaJ(  !!!!gY $$Ifa$gdyu:K$Okde$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdd$IfK$L$T`&634aT!!!!q#r#t#z><kd(f$IfK$L$T&634aT>kde$IfK$L$T`&634aT $Ifgdyu:K$<kdve$IfK$L$T&634aTt#u#v#w#o$wl $Ifgdyu:K$<kdf$IfK$L$T&634aT $$Ifa$gdyu:K$>kdf$IfK$L$T&634aTl$m$n$s$t$$$$$E%F%G%O%P%%%%%%%&& & & &&`&a&f&g&i&j&&&&&&&&''³ ³֌}j}}j}}j}}j}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJj4ghyu:h< LCJUaJ(o$p$r$s$G%I%h]] $Ifgdyu:K$>kdsh$IfK$L$T`&634aT $Ifgdyu:K$Mkdg$IfK$L$T &  634ap TI%J%K%L%N%f[ $Ifgdyu:K$<kdAi$IfK$L$T&634aT $$Ifa$gdyu:K$Okdh$IfK$L$T0h%&h634aTN%O%&&&&z<>kdMj$IfK$L$T&634aT<kdi$IfK$L$T&634aT $Ifgdyu:K$>kdi$IfK$L$T`&634aT&&&'''\Q $Ifgdyu:K$Mkdk$IfK$L$T &  634ap T $Ifgdyu:K$<kdj$IfK$L$T&634aT $$Ifa$gdyu:K$'''''((#($((((((((((((D)E)M)N)P)Q)))))))** * * ***++³ ³֌}j}}j}}j}}j}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjjhyu:h< LCJUaJ(''((((gY $$Ifa$gdyu:K$Okdl$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd>l$IfK$L$T`&634aT(((( ***z><kdm$IfK$L$T&634aT>kd`m$IfK$L$T`&634aT $Ifgdyu:K$<kd m$IfK$L$T&634aT**** +wl $Ifgdyu:K$<kdvn$IfK$L$T&634aT $$Ifa$gdyu:K$>kdn$IfK$L$T&634aT+ + +++b+c+h+i+",#,$,,,-,,,,,,,,,,,,,<-=-C-D-F-G--------..³ ³֌}j}}j}}j}}j}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjnhyu:h< LCJUaJ( + +++$,&,h]] $Ifgdyu:K$>kd p$IfK$L$T`&634aT $Ifgdyu:K$Mkdo$IfK$L$T &  634ap T&,',(,),+,f[ $Ifgdyu:K$<kdp$IfK$L$T&634aT $$Ifa$gdyu:K$Okdgp$IfK$L$T0h%&h634aT+,,,----z<>kdq$IfK$L$T&634aT<kdq$IfK$L$T&634aT $Ifgdyu:K$>kd+q$IfK$L$T`&634aT---...\Q $Ifgdyu:K$MkdWs$IfK$L$T &  634ap T $Ifgdyu:K$<kdAr$IfK$L$T&634aT $$Ifa$gdyu:K$.........b/c/d/l/m/////// 0!0-0.0001000000000000³ ³֌ybyybyybyyby,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjrhyu:h< LCJUaJ$..d/f/g/h/gY $$Ifa$gdyu:K$Okd2t$IfK$L$T0h%&h634aT $Ifgdyu:K$>kds$IfK$L$T`&634aTh/i/k/l/000z><kdTu$IfK$L$T&634aT>kdt$IfK$L$T`&634aT $Ifgdyu:K$<kdt$IfK$L$T&634aT00001wl $Ifgdyu:K$<kd v$IfK$L$T&634aT $$Ifa$gdyu:K$>kdu$IfK$L$T&634aT000111111F2G2L2M2=3>3?3G3H3333333334444Z4[4d4e4g4h44״~o~\~o~o~\~o~o~\~o~o$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j`vhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH$1111?3A3h]] $Ifgdyu:K$>kdw$IfK$L$T`&634aT $Ifgdyu:K$Mkd"w$IfK$L$T &  634ap TA3B3C3D3F3f[ $Ifgdyu:K$<kdmx$IfK$L$T&634aT $$Ifa$gdyu:K$Okdw$IfK$L$T0h%&h634aTF3G3+5,5.5/5z<>kdyy$IfK$L$T&634aT<kdy$IfK$L$T&634aT $Ifgdyu:K$>kdx$IfK$L$T`&634aT44444455%5&5+51525%6&6'6(6-6.66666"7#7$7,7-7777777777777C8D8L8ʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j+zhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho*/50515)6*6,6\Q $Ifgdyu:K$Mkdz$IfK$L$T &  634ap T $Ifgdyu:K$<kdy$IfK$L$T&634aT $$Ifa$gdyu:K$,6-6$7&7'7(7gY $$Ifa$gdyu:K$Okd{$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdj{$IfK$L$T`&634aT(7)7+7,7999z><kd|$IfK$L$T&634aT>kd|$IfK$L$T`&634aT $Ifgdyu:K$<kd8|$IfK$L$T&634aTL8M8O8P888888888 9 9999 : : : :::e:f:k:l: ; ; ;;;f;g;t;u;w;x;;;;;;ݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j}hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*9999:wl $Ifgdyu:K$<kd}$IfK$L$T&634aT $$Ifa$gdyu:K$>kdD}$IfK$L$T&634aT:::: ; ;h]] $Ifgdyu:K$>kd5$IfK$L$T`&634aT $Ifgdyu:K$Mkd~$IfK$L$T &  634ap T ;;;;;f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT;;<<==z<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdW$IfK$L$T`&634aT;;+<,<5<6<8<9<<<<<<<<<<<<======>>S>T>Y>Z>???#?$?v?w?}?~????ݿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho*======\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kdm$IfK$L$T&634aT $$Ifa$gdyu:K$=>????gY $$Ifa$gdyu:K$Okd^$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT? ?"?#?@@@z><kd$IfK$L$T&634aT>kd"$IfK$L$T`&634aT $Ifgdyu:K$<kd΃$IfK$L$T&634aT??????2@3@8@9@;@<@@@@@@@@@@@@AAAAAAAAQBRBWBXBBBBCCʿ~k~k~$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJhyu:h< LB* CJaJpho$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJpho'@AAAAwl $Ifgdyu:K$<kd8$IfK$L$T&634aT $$Ifa$gdyu:K$>kdڄ$IfK$L$T&634aTAAAABBh]] $Ifgdyu:K$>kdˆ$IfK$L$T`&634aT $Ifgdyu:K$MkdN$IfK$L$T &  634ap TBBBBCf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd)$IfK$L$T0h%&h634aTCCDDDDz<>kd$IfK$L$T&634aT<kdK$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTCUCVC_C`CbCcCCCCCCCDDDDDDqDrDyDzD|D}DDDDDDDDEEEEEE5F6F첣ufuhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jWhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho%hyu:h< LB* CJaJmHphosH'DDDEEE\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$EEFFFGgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT6F;F*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph****GGGGHHHz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdd$IfK$L$T&634aTHHHHIwl $Ifgdyu:K$<kdΌ$IfK$L$T&634aT $$Ifa$gdyu:K$>kdp$IfK$L$T&634aTIIII6K8Kh]] $Ifgdyu:K$>kda$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap TIII=J>JCJDJ4K5K6K>K?KKKKKKKKKKKKKOLPLYLZL\L]LLLLLLL M MMMM M!MNNҿzzjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJ,8K9K:K;K=Kf[ $Ifgdyu:K$<kd/$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT=K>KMMMMz<>kd;$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTMM MNNN\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$NNNNNoNpNuNvNNNNNN2O3O?O@OBOCOOOOOOOOOP P P P^P_PhPiPlPmPP³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ&NNNNNNgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd,$IfK$L$T`&634aTNNNNPPPz><kd$IfK$L$T&634aT>kdN$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTPPPPPPPQQQQQQ&R'R,R-RRRRRR-S.S³vgvTgTvgA%hyu:h< LB* CJaJmHphosH$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJphoPPPPQwl $Ifgdyu:K$<kdd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTQQQQRRh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkdz$IfK$L$T &  634ap TRRRRRf[ $Ifgdyu:K$<kdŖ$IfK$L$T&634aT $$Ifa$gdyu:K$OkdU$IfK$L$T0h%&h634aTRRTTTTz<>kdї$IfK$L$T&634aT<kdw$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT.S5S6S8S9SSSSSSSSSSSSSKTLTTTUTWTXTTTTTTTTUUUUUUVV³vgvhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho,hyu:h< L0J>*B* CJaJmHphosH%TTTUUU\Q $Ifgdyu:K$MkdE$IfK$L$T &  634ap T $Ifgdyu:K$<kd/$IfK$L$T&634aT $$Ifa$gdyu:K$UUVVVVgY $$Ifa$gdyu:K$Okd $IfK$L$T0h%&h634aT $Ifgdyu:K$>kd™$IfK$L$T`&634aTVVVVVVVV,W-W6W7W:W;WWWWWWWWWWWWWMXNXXXYX[X\XXXXXXXX޿rcjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***&VVVVXXXz><kdB$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTXXXXYwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTXYYYYYYZZZZZZZZZZZZZZZE[F[M[N[P[Q[[[[[[[[\\ôáô~k~~k~~k~$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jNhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$YYYYZZh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap TZZZZZf[ $Ifgdyu:K$<kd[$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTZZ[[[[z<>kdg$IfK$L$T&634aT<kd $IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT[[[\\\\Q $Ifgdyu:K$Mkd۠$IfK$L$T &  634ap T $Ifgdyu:K$<kdş$IfK$L$T&634aT $$Ifa$gdyu:K$\\\\\]]] ]]]]]]]]^^^^X^Y^j^k^n^o^^^^^^^(_)_5_6_8_9__³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ&\\]]]]gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdX$IfK$L$T`&634aT]]]]___z><kdآ$IfK$L$T&634aT>kdz$IfK$L$T`&634aT $Ifgdyu:K$<kd&$IfK$L$T&634aT_______``````````qarasa{a|aaaaaaa,b-b6b7b9b³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho ____`wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd2$IfK$L$T&634aT````sauah]] $Ifgdyu:K$>kd#$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tuavawaxazaf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTza{abbbbz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kdE$IfK$L$T`&634aT9b:bbbbbbbbccccccccccPdQdRdZd[dddddddeeeٳvgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho bbbccc\Q $Ifgdyu:K$Mkdq$IfK$L$T &  634ap T $Ifgdyu:K$<kd[$IfK$L$T&634aT $$Ifa$gdyu:K$ccRdTdUdVdgY $$Ifa$gdyu:K$OkdL$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTVdWdYdZd=f>f@fz><kdn$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTeeeekeleveweze{eeeeeee.f/f7f8f=fCfDf7g8g9g:g?g@gggggٳvgvTg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jzhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho @fAfBfCf;gwl $Ifgdyu:K$<kd&$IfK$L$T&634aT $$Ifa$gdyu:K$>kdȪ$IfK$L$T&634aT;gg?gHhJhh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd<$IfK$L$T &  634ap TgFhGhHhPhQhhhhhhhiiii i i\i]ibicieifiiiiiiiijjjjjjkkkkkkʿzzkzjEhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph****JhKhLhMhOhf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTOhPhiiiiz<>kd$IfK$L$T&634aT<kd9$IfK$L$T&634aT $Ifgdyu:K$>kdۭ$IfK$L$T`&634aTiiijjj\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$jjkkkkgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTkkkkllllllklllqlrlulvlllllll#m$m)m*m,m-mmmmmmmmnnnnnnѾѧѾѾѧѾѾѧѾѾѧѾѾѧѾzf&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***(kkkkmmmz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdR$IfK$L$T&634aTmmmmnwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd^$IfK$L$T&634aTnnnnSoUoh]] $Ifgdyu:K$>kdO$IfK$L$T`&634aT $Ifgdyu:K$Mkdҳ$IfK$L$T &  634ap TnnnnnQoRoSo[o\ooooooo p pppppepfplpmpoppppppppp q!q&q'q,q2q𾪗qhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***'UoVoWoXoZof[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTZo[o,q-q/q0qz<>kd)$IfK$L$T&634aT<kdϵ$IfK$L$T&634aT $Ifgdyu:K$>kdq$IfK$L$T`&634aT0q1q2q*r+r-r\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$2q3q&r'r(r)r.r/rrrrrsss"s#susvssssss{t|t}t~tttttttEuFu³ ³}j}[³ jhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j۶hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJ#-r.rssssgY $$Ifa$gdyu:K$Okdx$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTss!s"ssssz><kd$IfK$L$T&634aT>kd<$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTsssstwl $Ifgdyu:K$<kdR$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTttttGuIuh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkdh$IfK$L$T &  634ap TFuGuOuPuuuuuuuuvvvvvvwwwwwwwwwwwwwwxRxSx\x]x_x`xxxxxѯ堑}}jj}ѯѯѯ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***jqhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***)IuJuKuLuNuf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$OkdC$IfK$L$T0h%&h634aTNuOuuuuuz<>kd$IfK$L$T&634aT<kde$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTuuuvvv\Q $Ifgdyu:K$Mkd3$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$vvwwwwgY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTwwwwyyyz><kd0$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd~$IfK$L$T&634aTxxxyyyy!y"ytyuyyyyyyzzzzzzzzzz{{|{}{{{{{{{{{6|7|?|@|C|𾯾}j}j}$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j<hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho)yyyyzwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTzzzz}{{h]] $Ifgdyu:K$>kd{$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T{{{{{f[ $Ifgdyu:K$<kdI$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT{{|}}}z<>kdU$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTC|D||||||||||||}}}}}}~~T~U~Z~[~~~~~~ !'(ݿ~k~k~ݿ$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho&}}}}}~\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$~~~~~~gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdF$IfK$L$T`&634aT~~~~!"$z><kd$IfK$L$T&634aT>kdh$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT$%&'wl $Ifgdyu:K$<kd~$IfK$L$T&634aT $$Ifa$gdyu:K$>kd $IfK$L$T&634aT#$vw|}HIWX[\notuv|}pq³ ³֌}j}}j}}j}}j}$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ( "#h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okdo$IfK$L$T0h%&h634aTvwyzz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd3$IfK$L$T`&634aTz{|tuw\Q $Ifgdyu:K$Mkd_$IfK$L$T &  634ap T $Ifgdyu:K$<kdI$IfK$L$T&634aT $$Ifa$gdyu:K$qrsxy˃̃у҃IJKST   rsمڅ:³ ³֌ybyybyybyybyy,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ&wxKMNOgY $$Ifa$gdyu:K$Okd:$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTOPRSKLNz><kd\$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT:;IJKQREFGHMNHIQRUV³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho NOPQIwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTIJLMh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd*$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kdu$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTۉ܉މ߉z<>kd$IfK$L$T&634aT<kd'$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT  ijtuwxʉˉՉ։ۉՊ֊׊؊݊ފ0167ٳvgvTgTv$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j3hyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho ߉يڊ܊\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$܊݊gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kdr$IfK$L$T`&634aTKLTUWX kluvw}~qrstyz͎̎ѾѧѾѾѧѾѾѧѾѾѧѾzff&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***$wxzz><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd@$IfK$L$T&634aTz{|}uwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdL$IfK$L$T&634aTuvxyQSh]] $Ifgdyu:K$>kd=$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T͎ҎӎOPQYZ  ijqrtuǐȐ͐ΐϐՐ֐ɑʑ޿rccjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph***$hyu:h< L0J>*B*CJaJph***"STUVXf[ $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTXYϐАҐӐz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd_$IfK$L$T`&634aTӐԐՐ͑ΑБ\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kdu$IfK$L$T&634aT $$Ifa$gdyu:K$ʑˑ̑ёґ$%*+   fglm ³ ³֌}j}[³ ³֌jhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJpho$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LCJaJjhyu:h< LCJUaJjhyu:h< LCJUaJ#БёgY $$Ifa$gdyu:K$Okdf$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTz><kd$IfK$L$T&634aT>kd*$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kd@$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aTh]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$MkdV$IfK$L$T &  634ap Tf[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd1$IfK$L$T0h%&h634aTؗڗޗz<>kd$IfK$L$T&634aT<kdS$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT [\efhiÕĕƕǕ24DFJL ̗ΗؗABGH𾯾}j}$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***j_hyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJ$hyu:h< L0J>*B* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LB* CJaJpho)\Q $Ifgdyu:K$Mkd!$IfK$L$T &  634ap T $Ifgdyu:K$<kd $IfK$L$T&634aT $$Ifa$gdyu:K$gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTH™!"tu{|~њҚؚٚۚܚ./679:ʿzzkzj*hyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph****z><kd$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kdl$IfK$L$T&634aTwl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kdx$IfK$L$T&634aTfhh]] $Ifgdyu:K$>kdi$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap Tdefnoʝ˝͝Ν !1239:-./056𾪗qbbSbjhyu:h< LCJUaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***&jhyu:h< LB*CJUaJph***hyu:h< LB*CJaJph*** hijkmf[ $Ifgdyu:K$<kd7$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTmn3467z<>kdC$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT789124\Q $Ifgdyu:K$Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$45ɟ˟̟͟gY $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aT $Ifgdyu:K$>kd4$IfK$L$T`&634aTǟȟɟџҟ$%./12!"#+,~ʿzzkzʿX%hyu:h< LB* CJaJmHphosHjhyu:h< LCJUaJjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJhyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***$hyu:h< L0J>*B*CJaJph***"͟ΟПџz><kd$IfK$L$T&634aT>kdV$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aTwl $Ifgdyu:K$<kdl$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT#%h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T%&'(*f[ $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$Okd]$IfK$L$T0h%&h634aT*+RSUVz<>kd$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd!$IfK$L$T`&634aT~ޢߢCDPQRXYLMNOTU$³vgvTgTvg$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***jhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH%hyu:h< LB* CJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH&jhyu:h< LB* CJUaJpho VWXPQS\Q $Ifgdyu:K$MkdM$IfK$L$T &  634ap T $Ifgdyu:K$<kd7$IfK$L$T&634aT $$Ifa$gdyu:K$ST gY $$Ifa$gdyu:K$Okd($IfK$L$T0h%&h634aT $Ifgdyu:K$>kd$IfK$L$T`&634aT !#$   z><kdJ$IfK$L$T&634aT>kd$IfK$L$T`&634aT $Ifgdyu:K$<kd$IfK$L$T&634aT$%wxե֥ڥۥݥޥ`brtz| "8:HJNP  ©ٚqjVhyu:h< LCJUaJhyu:h< LCJaJjhyu:h< LCJUaJhyu:h< LCJaJmHsH0hyu:h< L0J>*B* CJPJaJmHphosH,hyu:h< L0J>*B* CJaJmHphosH%hyu:h< LB* CJaJmHphosH&jhyu:h< LB* CJUaJpho'  wl $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$>kd$IfK$L$T&634aT  h]] $Ifgdyu:K$>kd$IfK$L$T`&634aT $Ifgdyu:K$Mkd$IfK$L$T &  634ap T  ^_deLMXY[\mnvwyz̫ͫԫիګԬլݿzzjhyu:h< LCJUaJ$hyu:h< L0J>*B* CJaJphohyu:h< LB* CJaJpho&jhyu:h< LB* CJUaJphohyu:h< LCJaJ$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***+f[ $Ifgdyu:K$<kdc$IfK$L$T&634aT $$Ifa$gdyu:K$Okd$IfK$L$T0h%&h634aTګ۫ݫޫz<>kdo$IfK$L$T&634aT<kd$IfK$L$T&634aT $Ifgdyu:K$>kd$IfK$L$T`&634aTޫ߫ج٬ڬ\P $$Ifa$gdyu:Mkd$IfK$L$T &  634ap T $Ifgdyu:K$<kd$IfK$L$T&634aT $$Ifa$gdyu:K$լ֬׬ެCDPQRYZ[\ !"QRTְ֊|od]OdFd]hUQhUQ0JjhUQhUQU hUQhUQjhUQhUQUhUQhOJQJ^J hUQhW hUQh< Lh< L$hyu:h< L0J>*B*CJaJph***hyu:h< LB*CJaJph***&jhyu:h< LB*CJUaJph***#hyu:h< L5B*CJ\aJph***hyu:h< LCJaJjhyu:h< LCJUaJj!hyu:h< LCJUaJڬ۬ݬެx7Akd $IfK$L$T&634aTCkd$IfK$L$T&634aT $Ifgdyu:K$9kd`$$IfT&64ayt< LTRSToa $$Ifa$gdyu:K$<kd$IfK$L$T&634aT $Ifgdyu:K$>kdf$IfK$L$T`&634aT $Ifgdyu:K$TUVWXYth/9kd$$IfT&64ayt< LT $$Ifa$gdyu:Akdr$IfK$L$T&634aT $$Ifa$gdyu:K$<kd$IfK$L$T&634aTYZ[\STذٰ`>kdr$$If634aytNkd$$If0&634ayt$IfgdUQgd TUxyͯίNOװذٰ.?CD%&jkwxyzѲҲż$hUQh0J>*B*CJaJphhUQhCJaJjhUQhCJUaJhUQhB*CJaJphhUQh0JhUQhCJaJhUQh0JhUQhaJjahUQhU hUQhjhUQhU2ٰ?ѱ%yӲF׳ -DM gd & Fdd[$\$gdgd>kd$$If634ayt $IfgdҲӲԲ9:DEFGճֳ9:st|}~ɵԵյֵ()*23DEFVW`abqr°°hUQh0JhUQhaJhUQhCJaJhUQh5\aJhUQh0J5\hUQh0JjhUQhU hUQhE:RG d$If[$\$kd>$$IfF W106    34ab yt$dd$If[$\$a$ -DM gd:t}~dWWWO$If -DM gdkd$$IfF W1"06    34ab yt d$If[$\$ֵXUkd$$If0m&"62 234ayt$If $$Ifa$=kd$$If4m634ayt)@Ukd $$If0m&"62 234ayt$If $$Ifa$Ukd$$If0m&"62 234ayt)*3EFWa@Ukd$$If0m&"62 234ayt$If $$Ifa$Ukd$$If0m&"62 234aytabr@Ukd$$If0m&"62 234ayt$If $$Ifa$Ukdx$$If0m&"62 234ayt567DEFABRScdԸո߸TU`abc  fgyzͻλѾȽȴȴȴȴȴhUQh5\aJhUQh0J5\hUQh0Jj\hUQhUjhUQhUhUQh0JhUQh0JhUQhCJaJhUQhaJ hUQh=7EF@3 -DM gdUkd$$If0m&"62 234ayt$If $$Ifa$Ukdj$$If0m&"62 234ayt|}λnh_ $Ifgd$If{kd $$If<0+'0634<abyt $$Ifa$ -DM gd λGT\ci#8L & Fdd$If[$\$gd $Ifgd$If ?ҾWjk~u~uu~uu~ $Ifgd$If{kd $$If<0+'0634<abyt ѾҾjklHIfghijklz/lııĒUh(PhfHq hUQhOJQJ^J"hUQh0J6OJQJ]^J%jhUQh0JOJQJU^JhUQh0JOJQJ^JhUQh0JhUQh0JhUQhCJaJ hUQhhUQhaJ2klm~uhhhR & FTd-DM \$gd -DM gd-DM gd{kdf $$If<0+'0634<abytY*,[# Y;mn & FTd-DM \$gd -DM gdTd-DM \$^gdnijkl $$Ifa$=kd $$If4M 634ayt$If -DM gd -DM gd DUkd $$If0M "62 234ayt$If $$Ifa$Ukdq $$If0M "62 234ayt.u)MD4rrrrrrrrrr & FTd-DM \$gdxx-DM [$\$gd -DM gdUkdo $$If0M "62 234ayt /^lR7T0 & FTd-DM \$gdx-DM [$\$^gd & FTd-DM \$gd & Fx-DM [$\$gdthin normal limits or calculated clearance > 60 mL/min/1.73 m^2 for patients with serum creatinine levels above or below the institutional normal value. If using creatinine clearance, actual body weight should be used for calculating creatinine clearance (eg. Using the Cockcroft-Gault formula). For patients with a Body Mass Index (BMI) > 30 kg/m^2, lean body weight should be used instead. Patient not on anticoagulation has acceptable coagulation studies (obtained < 14 days prior to randomization; laboratory testing performed as part of standard of care prior to patient signature of informed consent for the study will be acceptable as baseline laboratory work as long as testing is performed < 14 days prior to randomization) as demonstrated by prothrombin time (PT) and partial thromboplastin time (PTT) below or within normal limits (+15%). Patients on anticoagulation must have coagulation values within the therapeutic range appropriate for the anti-coagulation indication. Patient has no clinically significant abnormalities on urinalysis results (obtained < 14 days prior to randomization; laboratory testing performed as part of standard of care prior to patient signature of informed consent for the study will be acceptable as baseline laboratory work as long as testing is performed < 14 days prior to randomization). Patient must have adequate nutritional status with Body Mass Index (BMI) > 18 kg/m^2 and body weight of > 40 kg with serum albumin > 3 g/dL. Baseline laboratory evaluations must be done within 14 days prior to randomization and some must be repeated < 72 hours prior to randomization. Patients requiring biliary stent placement must have biliary stent placed > 7 days prior to screening. Pain symptoms should be stable (of tolerable Grade 2 or less). Only patients with available archival tumor tissue must consent to provision of, and Investigator(s) must confirm access to and agree to submit a representative formalin fixed paraffin block of tumor tissue in order that the specific correlative marker assays (Correlative Studies) of this protocol may be conducted. Submission of the tissue does not have to occur prior to randomization. Where local center regulations prohibit submission of blocks of tumor tissue, two 2 mm cores of tumor from the block and 5-20 unstained slides of whole sections of representative tumor tissue are preferred. Where it is not possible to obtain two 2 mm cores of tumor from the block, 5-20 unstained slides of representative tumor tissue are also acceptable. Where no previously resected or biopsied tumor tissue exists or is available, on the approval of the Sponsor/designated CRO, the patient may still be considered eligible for the study. Patient must consent to provision of a sample of blood in order that the specific correlative marker assays (Correlative Studies) may be conducted. Patients must be accessible for treatment and follow up. Patients registered on this trial must receive protocol treatment and be followed at the participating center. This implies there must be reasonable geographical limits placed on patients being considered for this trial. Investigators must ensure that the patients randomized on this trial will be available for complete documentation of the treatment, response assessment, adverse events, and follow-up. Protocol treatment is to begin within 2 calendar days of patient randomization for patients randomized to Arm 1. Patients randomized to Arm 2 must begin protocol treatment within 7 calendar days of randomization. The patient is not receiving therapy in a concurrent clinical study and the patient agrees not to participate in other interventional clinical studies during their participation in this trial while on study treatment. Patients participating in surveys or observational studies are eligible to participate in this study. Exclusion Criteria: Patients with no evidence of metastatic disease as well as patients with a local recurrence following surgical resection of primary lesion. Patient has experienced a decline in ECOG performance status between Baseline visit and within 72 hours prior to randomization. Patient has a > 20% decrease in serum albumin level between Baseline visit and within 72 hours prior to randomization. Patient has a > 10% decrease in weight between Baseline visit and within 72 hours prior to randomization. Any prior anti-cancer chemotherapy, biologic or investigational therapy for PDAC. Patients receiving immunotherapy for non-cancer related treatment within < 4 weeks of first planned dose of study treatment will be excluded. A fluoropyrimidine or gemcitabine administered as a radiation sensitizer in the adjuvant setting is allowed for as long as last dose was administered > 6 months prior to randomization. Major surgery within 4 weeks prior to randomization. Any known brain or leptomeningeal metastases are excluded, even if treated. Patients with clinically significant ascites or pleural effusions. Women who are pregnant or breastfeeding. Women should not breastfeed while taking study treatment and for 4 weeks after the last dose of napabucasin or while undergoing treatment with nab-paclitaxel and gemcitabine and for 180 days after the last dose of nab-paclitaxel and gemcitabine. Gastrointestinal disorder(s) which, in the opinion of the Principal Investigator, would significantly impede the absorption of an oral agent (e.g. active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection). Unable or unwilling to swallow napabucasin capsules daily. Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements. History of cardiac disease: congestive heart failure (CHF) > New York Heart Association (NYHA) Class II; active coronary artery disease, myocardial infarction or coronary stenting within 6 months prior to randomization; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted). Current uncontrolled hypertension (systolic blood pressure [BP] > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management) as well as prior history of hypertensive crisis or hypertensive encephalopathy. Significant vascular disease (e.g., aortic aneurysm, aortic dissection, symptomatic peripheral vascular disease including claudication, Leo Buerger's disease). Treated peripheral vascular disease that is stable for at least 6 months is allowed. Evidence of bleeding diathesis or clinically significant coagulopathy. Major surgical procedure (including open biopsy, significant traumatic injury, etc.) within 28 days, or anticipation of the need for major surgical procedure during the course of the study as well as minor surgical procedure (excluding placement of a vascular access device or bone marrow biopsy) within 7 days prior to randomization. Patients with clinically significant abnormalities on urinalysis at < 14 days prior to randomization. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to randomization. Ongoing serious, non-healing wound, ulcer, or bone fracture. Known infection with Human Immunodeficiency Virus (HIV), and/or active infection with hepatitis B, or hepatitis C. History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies. History of hemolytic-uremic syndrome. History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa). Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders that could compromise the patient's safety or the study data integrity. Known hypersensitivity to gemcitabine, taxanes or any of their excipients, or the patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of the product or comparator Summary of Product Characteristics or Prescribing Information. Possible hypersensitivity to napabucasin or one of the excipients which include the azo dyes sunset yellow and allura red. Neurosensory neuropathy > grade 2 at baseline. Uncontrolled chronic diarrhea > grade 2 at baseline. Patients being treated with Warfarin. Patients with active, uncontrolled bacterial, viral or fungal infection(s) requiring systemic therapy Patients with a history of other malignancies except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated by surgery alone or surgery plus radiotherapy with no evidence of disease continuously for > 5 years. Any active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy. Any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol, including patients with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol. Patients planning to take a vacation for 14 or more consecutive days during the course of the study are ineligible. Contacts and Locations Goto Information from the National Library of Medicine  INCLUDEPICTURE "https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" \* MERGEFORMATINET  To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02993731 Contacts Contact: Boston Biomedical617-674-6800  HYPERLINK "https://clinicaltrials.gov/ct2/show/study/NCT02993731?show_locs=Y" \l "locn" \o "Show 189 study locations" Show 189 Study Locations  Sponsors and Collaborators Boston Biomedical, Inc Investigators OverallOfficial:Boston BiomedicalMore Information Responsible Party:Boston Biomedical, IncClinicalTrials.gov Identifier: HYPERLINK "https://clinicaltrials.gov/show/NCT02993731" \o "Current version of study NCT02993731 on ClinicalTrials.gov" NCT02993731  HYPERLINK "https://clinicaltrials.gov/ct2/archive/NCT02993731" \o "Historical versions of study NCT02993731 on ClinicalTrials.gov Archive Site" History of Changes Other Study ID Numbers:CanStem111P First Posted:December 15, 2016  HYPERLINK "https://clinicaltrials.gov/ct2/keydates/NCT02993731" \o "View key record dates for NCT02993731" Key Record Dates Last Update Posted:April 11, 2018 Last Verified:April 2018  Keywords provided by Boston Biomedical, Inc: Neoplasms Neoplasms by Site Digestive System Neoplasms Endocrine Gland Neoplasms Pancreatic Neoplasms Adenocarcinoma Neoplasms, Glandular and EpithelialNeoplasms by Histologic Type Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Albumin-Bound Paclitaxel Gemcitabine Additional relevant MeSH terms: Adenocarcinoma Carcinoma, Pancreatic Ductal Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Carcinoma, Ductal Neoplasms, Ductal, Lobular, and Medullary Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System DiseasesPaclitaxel Gemcitabine Albumin-Bound Paclitaxel Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antimetabolites Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents 'f QRSMN\]vw  "#󾬾정쌕؃정쌕정hUQh0JhUQhaJhUQhCJaJhUQh5\aJ"hUQh0J6OJQJ]^JhUQh0JOJQJ^Jj hUQhUjhUQhUhUQh0J hUQhhUQhOJQJ^J3'3f.q & FTd-DM \$gd & Fx-DM [$\$gd & FTd-DM \$gdx-DM [$\$gd & FTd-DM \$gd3gi>Z & FTd-DM \$gd & FTd-DM \$gd & Fx-DM [$\$gdZ N $$Ifa$ -DM gd -DM gd & FTd-DM \$gd $Iftkd $$If4\u <Pd634aytxqdddd[[[[ $$Ifa$ -DM gdkd$$If\u <Pd""62x222x2234ayt $Iftkd$$If4\ 634aytqdddYY $x$Ifa$ -DM gdkdW$$If\ ""62x222x2234ayt #$CwSUkdz$$If04 "62 234aytx$IfNkd$$If404 634ayt#$BCDabtuvwx./?@ABCVWfghvwNO_`hUQh5\aJhUQh0JjhUQhUhUQhaJ hUQhhUQhCJaJ C R8mail?url=http%3A%2F%2Fmedia<{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ? C R8mail?url=http%3A%2F%2Fmedia={$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v @ C R8mail?url=http%3A%2F%2Fmedia>{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v A C R8mail?url=http%3A%2F%2Fmedia?{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v B C R8mail?url=http%3A%2F%2Fmedia@{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v C C R8mail?url=http%3A%2F%2FmediaA{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v D C R8mail?url=http%3A%2F%2FmediaB{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v E C R8mail?url=http%3A%2F%2FmediaC{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v F C R8mail?url=http%3A%2F%2FmediaD{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v G C R8mail?url=http%3A%2F%2FmediaE{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v H C R8mail?url=http%3A%2F%2FmediaF{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v I C R8mail?url=http%3A%2F%2FmediaG{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v J C R8mail?url=http%3A%2F%2FmediaH{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v K C R8mail?url=http%3A%2F%2FmediaI{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v L C R8mail?url=http%3A%2F%2FmediaJ{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v M C R8mail?url=http%3A%2F%2FmediaK{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v N C R8mail?url=http%3A%2F%2FmediaL{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v O C R8mail?url=http%3A%2F%2FmediaM{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v P C R8mail?url=http%3A%2F%2FmediaN{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v Q C R8mail?url=http%3A%2F%2FmediaO{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v R C R8mail?url=http%3A%2F%2FmediaP{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v S C R8mail?url=http%3A%2F%2FmediaQ{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v T C R8mail?url=http%3A%2F%2FmediaR{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v U C R8mail?url=http%3A%2F%2FmediaS{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v V C R8mail?url=http%3A%2F%2FmediaT{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v W C R8mail?url=http%3A%2F%2FmediaU{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v X C R8mail?url=http%3A%2F%2FmediaV{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v Y C R8mail?url=http%3A%2F%2FmediaW{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v Z C R8mail?url=http%3A%2F%2FmediaX{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v [ C R8mail?url=http%3A%2F%2FmediaY{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v \ C R8mail?url=http%3A%2F%2FmediaZ{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ] C R8mail?url=http%3A%2F%2Fmedia[{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ^ C R8mail?url=http%3A%2F%2Fmedia\{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v _ C R8mail?url=http%3A%2F%2Fmedia]{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ` C R8mail?url=http%3A%2F%2Fmedia^{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v a C R8mail?url=http%3A%2F%2Fmedia_{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v b C R8mail?url=http%3A%2F%2Fmedia`{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v c C R8mail?url=http%3A%2F%2Fmediaa{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v d C R8mail?url=http%3A%2F%2Fmediab{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v e C R8mail?url=http%3A%2F%2Fmediac{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v f C R8mail?url=http%3A%2F%2Fmediad{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v g C R8mail?url=http%3A%2F%2Fmediae{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v h C R8mail?url=http%3A%2F%2Fmediaf{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v i C R8mail?url=http%3A%2F%2Fmediag{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v j C R8mail?url=http%3A%2F%2Fmediah{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v k C R8mail?url=http%3A%2F%2Fmediai{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v l C R8mail?url=http%3A%2F%2Fmediaj{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v m C R8mail?url=http%3A%2F%2Fmediak{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v n C R8mail?url=http%3A%2F%2Fmedial{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v o C R8mail?url=http%3A%2F%2Fmediam{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v p C R8mail?url=http%3A%2F%2Fmedian{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v q C R8mail?url=http%3A%2F%2Fmediao{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v r C R8mail?url=http%3A%2F%2Fmediap{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v s C R8mail?url=http%3A%2F%2Fmediaq{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v t C R8mail?url=http%3A%2F%2Fmediar{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v u C R8mail?url=http%3A%2F%2Fmedias{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v v C R8mail?url=http%3A%2F%2Fmediat{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v w C R8mail?url=http%3A%2F%2Fmediau{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v x C R8mail?url=http%3A%2F%2Fmediav{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v y C R8mail?url=http%3A%2F%2Fmediaw{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v z C R8mail?url=http%3A%2F%2Fmediax{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v { C R8mail?url=http%3A%2F%2Fmediay{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v | C R8mail?url=http%3A%2F%2Fmediaz{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v } C R8mail?url=http%3A%2F%2Fmedia{{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ~ C R8mail?url=http%3A%2F%2Fmedia|{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia}{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia~{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v   C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v   C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v   C R8mail?url=http%3A%2F%2Fmedia {$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v   C R8mail?url=http%3A%2F%2Fmedia {$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v   C R8mail?url=http%3A%2F%2Fmedia {$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia {$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia {$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v  C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v   C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ! C R8mail?url=http%3A%2F%2Fmedia{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v " C R8mail?url=http%3A%2F%2Fmedia {$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v # C R8mail?url=http%3A%2F%2Fmedia!{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v $ C R8mail?url=http%3A%2F%2Fmedia"{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v % C R8mail?url=http%3A%2F%2Fmedia#{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v & C R8mail?url=http%3A%2F%2Fmedia${$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ' C R8mail?url=http%3A%2F%2Fmedia%{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ( C R8mail?url=http%3A%2F%2Fmedia&{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ) C R8mail?url=http%3A%2F%2Fmedia'{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v * C R8mail?url=http%3A%2F%2Fmedia({$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v + C R8mail?url=http%3A%2F%2Fmedia){$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v , C R8mail?url=http%3A%2F%2Fmedia*{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v - C R8mail?url=http%3A%2F%2Fmedia+{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v . C R8mail?url=http%3A%2F%2Fmedia,{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v / C R8mail?url=http%3A%2F%2Fmedia-{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v 0 C R8mail?url=http%3A%2F%2Fmedia.{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v 1 C R8mail?url=http%3A%2F%2Fmedia/{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v 2 C R8mail?url=http%3A%2F%2Fmedia0{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v 3 C R8mail?url=http%3A%2F%2Fmedia1{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v 4 C R8mail?url=http%3A%2F%2Fmedia2{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v 5 C R8mail?url=http%3A%2F%2Fmedia3{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v 6 C R8mail?url=http%3A%2F%2Fmedia4{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v 7 C R8mail?url=http%3A%2F%2Fmedia5{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v 8 C R8mail?url=http%3A%2F%2Fmedia6{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v 9 C R8mail?url=http%3A%2F%2Fmedia7{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v : C R8mail?url=http%3A%2F%2Fmedia8{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ; C R8mail?url=http%3A%2F%2Fmedia9{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v < C R8mail?url=http%3A%2F%2Fmedia:{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v = C R8mail?url=http%3A%2F%2Fmedia;{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v > C R8mail?url=http%3A%2F%2Fmedia<{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ? C R8mail?url=http%3A%2F%2Fmedia={$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v @ C R8mail?url=http%3A%2F%2Fmedia>{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v A C R8mail?url=http%3A%2F%2Fmedia?{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v B C R8mail?url=http%3A%2F%2Fmedia@{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v C C R8mail?url=http%3A%2F%2FmediaA{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v D C R8mail?url=http%3A%2F%2FmediaB{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v E C R8mail?url=http%3A%2F%2FmediaC{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v F C R8mail?url=http%3A%2F%2FmediaD{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v G C R8mail?url=http%3A%2F%2FmediaE{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v H C R8mail?url=http%3A%2F%2FmediaF{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v I C R8mail?url=http%3A%2F%2FmediaG{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v J C R8mail?url=http%3A%2F%2FmediaH{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v K C R8mail?url=http%3A%2F%2FmediaI{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v L C R8mail?url=http%3A%2F%2FmediaJ{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v M C R8mail?url=http%3A%2F%2FmediaK{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v N C R8mail?url=http%3A%2F%2FmediaL{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v O C R8mail?url=http%3A%2F%2FmediaM{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v P C R8mail?url=http%3A%2F%2FmediaN{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v Q C R8mail?url=http%3A%2F%2FmediaO{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v R C R8mail?url=http%3A%2F%2FmediaP{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v S C R8mail?url=http%3A%2F%2FmediaQ{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v T C R8mail?url=http%3A%2F%2FmediaR{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v U C R8mail?url=http%3A%2F%2FmediaS{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v V C R8mail?url=http%3A%2F%2FmediaT{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v W C R8mail?url=http%3A%2F%2FmediaU{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v X C R8mail?url=http%3A%2F%2FmediaV{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v Y C R8mail?url=http%3A%2F%2FmediaW{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v Z C R8mail?url=http%3A%2F%2FmediaX{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v [ C R8mail?url=http%3A%2F%2FmediaY{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v \ C R8mail?url=http%3A%2F%2FmediaZ{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ] C R8mail?url=http%3A%2F%2Fmedia[{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ^ C R8mail?url=http%3A%2F%2Fmedia\{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v _ C R8mail?url=http%3A%2F%2Fmedia]{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v ` C R8mail?url=http%3A%2F%2Fmedia^{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v a C R8mail?url=http%3A%2F%2Fmedia_{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v b C R8mail?url=http%3A%2F%2Fmedia`{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v c C R8mail?url=http%3A%2F%2Fmediaa{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v d C R8mail?url=http%3A%2F%2Fmediab{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v e C R8mail?url=http%3A%2F%2Fmediac{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v f C R8mail?url=http%3A%2F%2Fmediad{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v g C R8mail?url=http%3A%2F%2Fmediae{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v h C R8mail?url=http%3A%2F%2Fmediaf{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v i C R8mail?url=http%3A%2F%2Fmediag{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v j C R8mail?url=http%3A%2F%2Fmediah{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v k C R8mail?url=http%3A%2F%2Fmediai{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v l C R8mail?url=http%3A%2F%2Fmediaj{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v m C R8mail?url=http%3A%2F%2Fmediak{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v n C R8mail?url=http%3A%2F%2Fmedial{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v o C R8mail?url=http%3A%2F%2Fmediam{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v p C R8mail?url=http%3A%2F%2Fmedian{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v q C R8mail?url=http%3A%2F%2Fmediao{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v r C R8mail?url=http%3A%2F%2Fmediap{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v s C R8mail?url=http%3A%2F%2Fmediaq{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v t C R8mail?url=http%3A%2F%2Fmediar{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v u C R8mail?url=http%3A%2F%2Fmedias{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v v C R8mail?url=http%3A%2F%2Fmediat{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v w C R8mail?url=http%3A%2F%2Fmediau{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v x C R8mail?url=http%3A%2F%2Fmediav{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v y C R8mail?url=http%3A%2F%2Fmediaw{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v z C R8mail?url=http%3A%2F%2Fmediax{$IfK$L$!vh5&#v&:V   6,534 p T\$IfK$L$!vh5&#v&:V `6,534 Tn$IfK$L$!vh5h%5h#vh%#vh:V 6,55h34 TR$IfK$L$!vh5&#v&:V 6534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TDd v { C R8mail?url=http%3A%2F%2Fmediay{$IfK$L$!vh5&#v&:V   6,534 p TL$$If!vh5&#v&:V 654 yt< LT\$IfK$L$!vh5&#v&:V 6,534 TX$IfK$L$!vh5&#v&:V 6,534 T\$IfK$L$!vh5&#v&:V `6,534 TX$IfK$L$!vh5&#v&:V 6,534 TR$IfK$L$!vh5&#v&:V 6534 TR$IfK$L$!vh5&#v&:V 6534 TL$$If!vh5&#v&:V 654 yt< LTMDyK 0https://clinicaltrials.gov/ct2/show/NCT02993731yK xhttps://clinicaltrials.gov/ct2/show/NCT02993731yX;H,]ą'cDd ooN  C *warningzu$$If!vh5+5$#v+#v$:V 6,5534ytd$$If!vh5"#v":V 6,534ytd$$If!vh5"#v":V 6,534yt$$If!vh5J 5I5#vJ #vI#v:V 06,5/ 34yt$$If!vh5J 5I5#vJ #vI#v:V 0659/ 34yt_$$If!vh5m#vm:V 46,534 ytw$$If!vh5m5c#vm#vc:V 6592 234 ytw$$If!vh5m5c#vm#vc:V 6592 234 ytw$$If!vh5m5c#vm#vc:V 6592 234 ytw$$If!vh5m5c#vm#vc:V 6592 234 ytw$$If!vh5m5c#vm#vc:V 6592 234 ytw$$If!vh5m5c#vm#vc:V 6592 234 ytw$$If!vh5m5c#vm#vc:V 6592 234 ytw$$If!vh5m5c#vm#vc:V 6592 234 ytw$$If!vh5m5c#vm#vc:V 6592 234 ytDd ood  C @&NIH_NLM_ABRV_BLK_4$$If!vh5v5#vv#v:V <06,5/ 34<yt$$If!vh5v5#vv#v:V <065/ 34<yt$$If!vh5v5#vv#v:V <065/ 34<yt_$$If!vh5M #vM :V 46,534 yt}$$If!vh5M 5#vM #v:V 6,592 234 yt}$$If!vh5M 5#vM #v:V 6,592 234 yt}$$If!vh5M 5#vM #v:V 6,592 234 ytDd ood  C @&NIH_NLM_ABRV_BLK_4~$$If!vh5u 555#vu #v#v:V 46,534 yt$$If!vh5u 555#vu #v#v:V 6,592x222x2234 yt~$$If!vh5 555#v #v#v:V 46,534 yt$$If!vh5 555#v #v#v:V 6,592x222x2234 yth$$If!vh54 5#v4 #v:V 46,534 ytw$$If!vh54 5#v4 #v:V 6592 234 ytw$$If!vh54 5#v4 #v:V 6592 234 ytw$$If!vh54 5#v4 #v:V 6592 234 ytw$$If!vh54 5#v4 #v:V 6592 234 ytw$$If!vh54 5#v4 #v:V 6592 234 ytw$$If!vh54 5#v4 #v:V 6592 234 ytb$$If!vh5h5h#vh:V 46,5 34 ytk$$If!vh5h5h#vh:V 652 234 ytb$$If!vh5h5h#vh:V 46,5 34 ytk$$If!vh5h5h#vh:V 652 234 ytL@L Normal$CJOJQJ^J_HaJmH sH tH ^@^ =v Heading 1dd@&[$\$5CJ0KH$OJQJ\^JaJ0J@J }G Heading 3$<@&5CJ\aJDA@D Default Paragraph FontRi@R  Table Normal4 l4a (k@(No List6U@6  R Hyperlink >*B*ph4O4 =val-author-name.X@. =vEmphasis6]R^@"R =v Normal (Web)dd[$\$OJQJ^JaJ*W@1* =vStrong5\VOBV LDefault 7$8$H$!B*CJ_HaJmH phsH tH  OQ term&Oa& header24Oq4 }Gezstring-field% QRnoab# $ 2 B_ZtT y p$$$$~%&&t''*-<./<0=0>0123Z448<?h@@@@A6CCDEGKORRRRSTDUUiV@W+Y\]h^i^j^_ aaEbb d)ejxkkkklmKnoporbuzO{c||||}9~~̈́΋qIpD(˥0ӨL<[\]^_#Wst~ŭƭǭȭЭMYklmnv$ İְƱ%7IJKLT nz)5GHIJRֵcs 0BCDEM·˷ȸڸ۸ܸݸ̹͹ιϹ׹'1CDEFN  )!"#$, erԽѾ߾}+,-.7z);<=>F-?@ABJy%~ !3456>~OWijklt+>PQRS[ hy;M_`abj  !"*BPbcdemcq"4567?-?@ABJ()*+3$3EFGHP!"#$,Uk}~.;MNOPXo4ASTUV^ fx !"#+lzFTfghiqQ_qrst|^hz{|}vITfghiq#s#x&89:;D#5678AKXjklmv o;MNOPY"6HIJKTgw1234= BQcdefo,>?@AJ%&'(1<K]^_`i !/ABCDM ,>?@AJ!;Oabcdm&'()2 :FXYZ[d->PQRS\%&'(16\nopqz        H T f g h i r        4 B T U V W `               z       '=OPQR[ +=>?@I);MNOPY&89:;DP_qrst}DZlmnoxr1CDEFO&'()2BWijkluw6FXYZ[dWdvwxy!"#$-  oyW j | } ~   _!n!!!!!!!" "!"""#",""""""""#&#8#9#:#;#D#######$x$$$$$$$$ %%%%%'%&&'&(&)&*&3&&&&&&&&'''''''}(((((((h)x))))))`*o******+'+9+:+;+<+E++++++++,,,,,,,-!-3-4-5-6-?--------o.}......E/T/f/g/h/i/r///////00000000>1O1a1b1c1d1m12)2;2<2=2>2G2223333333333334444444555555566666666 777 7!7*7777777788888889999999:::::::C;S;e;f;g;h;q;c<x<<<<<<=======>!>3>4>5>6>?>??(?)?*?+?4????????,@B@T@U@V@W@`@@@@@@@AAAAAAAA B(B:B;Bp6q7q9q:qrrrrrrrptqtstttutvtnuouquru1v3v4v5v6v8v9vxxxxxxyyyyyyyyyyy{{{{{{||||}}}}}}}ڀۀ݀ހʃ˃̓΃σЃȄɄ˄̄·χч҇Ӈԇ͈̈ψЈߋ݌ތ&()*+-.    !"$%EGHIJLM679:;<4578NPQRSUV?@BCDE=>@AmnpqrsklnoZ\]^_ab<=?@AB:;=>ACDEFHI+,./01)*,-KMNOPRSKLNOPQIJLMRTUVWYZ5689:;3467')*+,./?ABCDFG-.0123+,./ACDEFHI-.0123+,./IKLMNPQ9:<=>?78:;wyz{|~~QSTUVXYvxyz{}~`acdef^_abwxz{|}uvxygijklno]^`abc[\^_Z\]^_abBCEFGH@ACDyz|}~wxz{UWXYZ\]124567/023                            78:;<=5 6 8 9 !!!!!! !""#######$$$$$$$$&&&&&&''''0(2(3(4(5(7(8( *!*#*$*%*&*++!+"+,,,, ,",#,......///////////X1Y1[1\1]1^1V2W2Y2Z22222222444444555566666668888889999:::::::y<z<|<}<~<<w=x=z={=E>G>H>I>J>L>M>??????@@@@@@@@@@@BBBBBBCCCC)D+D,D-D.D0D1D2D3D5D6D7D8D0E1E3E4EEEEEEEEGGGGGGHHHHIIIIIIIKKKKKKLLLL+M-M.M/M0M2M3M O OOOOO P P PPPPPPPPPRRRRRRSSSSTTTTTTTUUUUUUVVVVWWWWWWWdYeYgYhYiYjYbZcZeZfZ[ [ [ [ [[[7\8\:\;\<\=\5]6]8]9]]]]]]]]______````xaza{a|a}aaarcscucvcwcxcpdqdsdtd!e#e$e%e&e(e)eHfIfKfLfMfNfFgGgIgJggggggggiiiiiijjjjkkkkkkk|m}mmmmmzn{n}n~nnnnnnnnnnnnnnooooppppppprrrrrrssss7t9t:t;tt?t3v4v6v7v8v9v1w2w4w5w*x,x-x.x/x1x2xyyyzzzzzzz|||||||}}}}}}~~~~PRSTUWX߄            {|~yz|} ΠРѠҠӠՠ֠bdefgijKLNOPQIJLMޮDzɲʲ˲̲βϲ޵ߵACDEFHIJKMNOPHIKL mnpqrsklno[\^_`aYZ\]3467891245oqrstvwhjklmopSTVWXYQRTUY[\]^`a{}~hjklmopjlmnoqr[\^_`aYZ\]&()*+-.deghijbcefY[\]^`aABDEFG?@BC9;<=>@Ayz|}~wxz{+-./023               | }     z { } ~ L N O P Q S T hiklmnfgij    tuwxyzrsuv[]^_`bcpqstuvnoqr       """"""####1$3$4$5$6$8$9$&&& &!&"&'''''''''''))))))**** , ,,,,,,------....|/~//////a1b1d1e1f1g1_2`2b2c2H3J3K3L3M3O3P35 5"5#5$5%566 6!666666668888889999:::::::;;;;;;<<<<=======??????@@@@AAAAAAACCCCCCDDDDEEEEEEEGGGGGGHHHH6I8I9I:I;I=I>IK K"K#K$K%KLL L!LLLLLLLLNNNNNNOOOOPPPPPPPOQPQRQSQTQUQMRNRPRQRRRRRRRRTTTTTTUUUU5V7V8V9V:VV?VAVBVCVDV?AB~iklmnpqSTVWXYQRTU~bcefgh`acd !"#%&                       ~    EGHIJLM-.0123+,./:;=>?@89;<       !"#$&' !!!!!!""""#######%%%%%%&&&&((( ( ( ( ())))))****+++++++------....///////z1{1}1~111x2y2{2|2r3t3u3v3w3y3z3[5\5^5_5`5a5Y6Z6\6]6e7g7h7i7j7l7m7S9T9V9W9X9Y9Q:R:T:U:-;/;0;1;2;4;5;&='=)=*=+=,=$>%>'>(>?????? ?@@@@@@AAAABBBBBBBDDDDDDEEEEFFFFFFFHHHHHHIIIIJJJJJJJLLLLLLMMMMhNjNkNlNmNoNpNOOOOOOPPPPQQQQQQQRR R R R RSSS STT T T T TTUUUUUUVVVVWWWWWWWYYYYYYZZZZ[[[[[[[L\M\O\P\Q\R\J]K]M]N]^ ^!^"^#^%^&^ ` ````` a a a aaaaaaaaccccccddddweyeze{e|e~eedgeggghgigjgbhchehfhhhhhhhhhhhhhhiiii/j1j2j3j4j6j7j8j9j;jj6k7k9k:klllll l!lmmmmmmnnnnoooooooIpJpLpMpNpOpGqHqJqKqqqqqqqqqqqqqqrrrr=s?s@sAsBsDsEs0u1u3u4u5u6u.v/v1v2vvvvvvvvNxOxQxRxSxTxLyMyOyPyzzz z!z#z$z | | ||||} } } }}}}}}}}~~~~~~Ԁր׀؀ـۀ܀„ÄĄńDŽȄTUWXYZRSUVtvwxy{|hiklmnfgijmnpqrsklno !     ڕەݕޕߕٖؖۖܖOPRSTUMNPQ:<=>?AB  "$%&')*HIKLMNFGIJPRSTUWXԢբעآ٢ڢңӣգ֣5789:<=>?ABCD<=?@ϥѥҥӥԥ֥ץ78:;<=5689HJKLMOP̱ͱϱбѱұʲ˲Ͳβ¶ĶŶƶǶɶʶrtuvwyzWYZ[\^_9:<=>?78:;    :<=>?ABJKMNOPHIKLrtuvwyz\]_`abZ[]^79:;<>?013456./12CEFGHJK-.0123+,./vwyz{|tuwxNPQRSUV5689:;3467wxz{|}uvxyKMNOPRStvwxy{|;<>?@A9:<=                                !!!!!!!######$$$$r%t%u%v%w%y%z%''''' '(((((((((((******++++Q,S,T,U,V,X,Y,i.j.l.m.n.o.g/h/j/k/W0Y0Z0[0\0^0_0<2=2?2@2A2B2:3;3=3>3G4I4J4K4L4N4O4061636465666.7/717278888888999999::::;;;;;;;======>>>>???????AAAAAABBBBCCCCCCCEEEEEEFFFFGGGGGGGIIIIIIJJJJKKKKKKKMMMNNNNNNN]O_O`OaObOdOeOfOgOiOjOkOlOdPePgPhPuQwQxQyQzQ|Q}QbScSeSfSgShS`TaTcTdTUUUUUUUuWvWxWyWzW{WsXtXvXwX[Y]Y^Y_Y`YbYcYA[B[D[E[F[G[?\@\B\C\\\\\\\\\\\\\\]]]]]^_^`^a^b^d^e^_```b`c`d`e`]a^a`aaa-b/b0b1b2b4b5b]c^c`cacbccc[d\d^d_deeeeeee g g g ggghh h hhhhhhhhJiKiMiNiOiPiHjIjKjLjgkikjkkklknkokllllllmmmmn?n@nAnCnDn p!p#p$p%p&pqq!q"qqqqqqqqssssssttttuuuuuuuwwwwwwxxxx\y^y_y`yaycydyyyyyyyzzzzm{o{p{q{r{t{u{^}_}a}b}c}d}\~]~_~`~eghijlmBCEFGH@ACDڈۈ݈ވ߈؉ىۉ܉uvxyz{stvwprstuwxVWYZ[\TUWXkmnoprsvxyz{}~uvxyz{stvw    ~}~{|~    NPQRSUV;<>?@A9:<=*+-./0()+,@BCDEGHIJLMNOGHJK 9;<=>@A%&()*+#$&' "#mnpqrsklno245679:FGIJKLDEGH                           |~vwyz{|tuwxwyz{|~`!a!c!d!e!f!^"_"a"b"v#x#y#z#{#}#~#f%g%i%j%k%l%d&e&g&h&,'.'/'0'1'3'4'R(S(U(V(W(X(P)Q)S)T):*<*=*>*?*A*B*G,H,J,K,L,M,E-F-H-I-...... .@/A/C/D/E/F/>0?0A0B0000000022222233334444444e6f6h6i6j6k6c7d7f7g7Z8\8]8^8_8a8b8+:,:.:/:0:1:);*;,;-;;;;;;;<======>>>>???????&@'@)@*@+@,@$A%A'A(AAAAAAAAQBRBTBUBVBWBOCPCRCSC:DD?DADBD-F.F0F1F2F3F+G,G.G/G"H$H%H&H'H)H*HIIIIIIJJJJ_KaKbKcKdKfKgKKKKKKKLLLLMMMMMMMOOOO O!OPPPPPPPPPPPRRRRRRSSSSTTTTTTTVVVVVV~WWWWXXXXXXXZZZ Z!Z"Z[[[[[[[[[[[t]u]w]x]y]z]r^s^u^v^M_O_P_Q_R_T_U_______````aaaaaaaccccccdddd^e`eaebeceeefeDgEgGgHgIgJgBhChEhFh i iiiiiiiiiiiijjjjnkpkqkrkskukvk4l5l7l8l9l:l2m3m5m6mmmmmmmmnnnnnnooooppppppprrrrrrsssstttttttvvvvvv}w~wwwwwwwwwwwwwwwwwwxxxxxZyQ{R{}{~{{{{T|U|^|v|||||}x}}|~~~~"#$1234Acd{΀π؀܁!"9:?WXs%ȇ݇w0EY#$@k?@^bQϒѓyȕ>n()\-WXuyzӠbΣGpb٫[ԭbڰ]´I4ķ+j nC#dR,g\X`$S7p.#$%&'(CPQRS()*+,->PQRSdefghi| #$%&IJlmno"#$'000000000000000000000000000$ 0$ 0$ 0$ 0$ 0$ 0$  0$  0$  0$  0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 000000000000$0$0$0$0$0$0$0$0$0$0$00>00>00>00>00>00>00>00>00>00>00>000@0@0@0@0@0@0@0@0@0@0@00R0R0R0R0R0R0R0R0R0R0R00j^0j^0j^0j^0j^0j^0j^0j^0j^0j^0j^00k0k0k0k0k0k0k0k0k0k0k0k00|0|0|0|0|0|0|0|0|000(00q0q(000(00I0I0I0I(000(0 0 0 0 0(0 0 0 0 0 0 00000000_0_0_0_0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_0_0_0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_ 0_0_0_00y0y0y 0y 0y 0y 0y 0y0y0y0y 0y 0y0y0y0y0y 0y 0y 0y 0y 0y0y0y0y0y0y0y 0y 0y 0y 0y 0y 0y 0y 0y0y0y0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y0y0y0y0y0y0y 0y 0y 0y0y 0y0y0y 0y 0y 0y0y0y0y0y0y0y0y 0y 0y0y 0y0y0y0y0y0y0y 0y 0y0y0y0y 0y0y0y0y 0y0y 0y0y 0y0y 0y0y 0y0y 0y0y 0y0y 0y0y 0y0y0y0y0y0y0y0y0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0 y 0 y 0]y 0]y 0]y 0 y 0y 0y 0y 0 y0y 0 y 0y 0y 0y 0y 0y 0y 0y 0y 0y0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0y 0 y 0 y 0 y 0.y 0.y 0.y 0.y 0.y 0.y 0.y 0.y 0.y 0 .y 0 .y 0 .y 0 .y 0 y 0 y 0y 0y 0y 0y 0y 0y000000000 0 0 0 0 0 0 0 0 0 00000 0 0 0 0 0 0 0 0 0 0000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00QRnoab# 2 ZtT  p$$$~%&&t''*-<./<0>0123Z448<?h@@@A6CCDEGKORRRSTDUUiV@W+Y\]h^j^_ aaEbb d)ejxkkklmKnopobuzO{c|||}9~~̈́΋qIpD(˥0ӨL<[_#Wst~ŭƭǭȭЭMYklmnv$ İְƱ%7IJKLT nz)5GHIJRֵcs 0BCDEM·˷ȸڸ۸ܸݸ̹͹ιϹ׹'1CDEFN  )!"#$, erԽѾ߾}+,-.7z);<=>F-?@ABJy%~ !3456>~OWijklt+>PQRS[ hy;M_`abj  !"*BPbcdemcq"4567?-?@ABJ()*+3$3EFGHP!"#$,Uk}~.;MNOPXo4ASTUV^ fx !"#+lzFTfghiqQ_qrst|^hz{|}vITfghiq#s#x&89:;D#5678AKXjklmv o;MNOPY"6HIJKTgw1234= BQcdefo,>?@AJ%&'(1<K]^_`i !/ABCDM ,>?@AJ!;Oabcdm&'()2 :FXYZ[d->PQRS\%&'(16\nopqz        H T f g h i r        4 B T U V W `               z       '=OPQR[ +=>?@I);MNOPY&89:;DP_qrst}DZlmnoxr1CDEFO&'()2BWijkluw6FXYZ[dWdvwxy!"#$-  oyW j | } ~   _!n!!!!!!!" "!"""#",""""""""#&#8#9#:#;#D#######$x$$$$$$$$ %%%%%'%&&'&(&)&*&3&&&&&&&&'''''''}(((((((h)x))))))`*o******+'+9+:+;+<+E++++++++,,,,,,,-!-3-4-5-6-?--------o.}......E/T/f/g/h/i/r///////00000000>1O1a1b1c1d1m12)2;2<2=2>2G2223333333333334444444555555566666666 777 7!7*7777777788888889999999:::::::C;S;e;f;g;h;q;c<x<<<<<<=======>!>3>4>5>6>?>??(?)?*?+?4????????,@B@T@U@V@W@`@@@@@@@AAAAAAAA B(B:B;Bp6q7q9q:qrrrrrrrptqtstttutvtnuouquru1v3v4v5v6v8v9vxxxxxxyyyyyyyyyyy{{{{{{||||}}}}}}}ڀۀ݀ހʃ˃̓΃σЃȄɄ˄̄·χч҇Ӈԇ͈̈ψЈߋ݌ތ&()*+-.    !"$%EGHIJLM679:;<4578NPQRSUV?@BCDE=>@AmnpqrsklnoZ\]^_ab<=?@AB:;=>ACDEFHI+,./01)*,-KMNOPRSKLNOPQIJLMRTUVWYZ5689:;3467')*+,./?ABCDFG-.0123+,./ACDEFHI-.0123+,./IKLMNPQ9:<=>?78:;wyz{|~~QSTUVXYvxyz{}~`acdef^_abwxz{|}uvxygijklno]^`abc[\^_Z\]^_abBCEFGH@ACDyz|}~wxz{UWXYZ\]124567/023                            78:;<=5 6 8 9 !!!!!! !""#######$$$$$$$$&&&&&&''''0(2(3(4(5(7(8( *!*#*$*%*&*++!+"+,,,, ,",#,......///////////X1Y1[1\1]1^1V2W2Y2Z22222222444444555566666668888889999:::::::y<z<|<}<~<<w=x=z={=E>G>H>I>J>L>M>??????@@@@@@@@@@@BBBBBBCCCC)D+D,D-D.D0D1D2D3D5D6D7D8D0E1E3E4EEEEEEEEGGGGGGHHHHIIIIIIIKKKKKKLLLL+M-M.M/M0M2M3M O OOOOO P P PPPPPPPPPRRRRRRSSSSTTTTTTTUUUUUUVVVVWWWWWWWdYeYgYhYiYjYbZcZeZfZ[ [ [ [ [[[7\8\:\;\<\=\5]6]8]9]]]]]]]]______````xaza{a|a}aaarcscucvcwcxcpdqdsdtd!e#e$e%e&e(e)eHfIfKfLfMfNfFgGgIgJggggggggiiiiiijjjjkkkkkkk|m}mmmmmzn{n}n~nnnnnnnnnnnnnnooooppppppprrrrrrssss7t9t:t;tt?t3v4v6v7v8v9v1w2w4w5w*x,x-x.x/x1x2xyyyzzzzzzz|||||||}}}}}}~~~~PRSTUWX߄            {|~yz|} ΠРѠҠӠՠ֠bdefgijKLNOPQIJLMޮDzɲʲ˲̲βϲ޵ߵACDEFHIJKMNOPHIKL mnpqrsklno[\^_`aYZ\]3467891245oqrstvwhjklmopSTVWXYQRTUY[\]^`a{}~hjklmopjlmnoqr[\^_`aYZ\]&()*+-.deghijbcefY[\]^`aABDEFG?@BC9;<=>@Ayz|}~wxz{+-./023               | }     z { } ~ L N O P Q S T hiklmnfgij    tuwxyzrsuv[]^_`bcpqstuvnoqr       """"""####1$3$4$5$6$8$9$&&& &!&"&'''''''''''))))))**** , ,,,,,,------....|/~//////a1b1d1e1f1g1_2`2b2c2H3J3K3L3M3O3P35 5"5#5$5%566 6!666666668888889999:::::::;;;;;;<<<<=======??????@@@@AAAAAAACCCCCCDDDDEEEEEEEGGGGGGHHHH6I8I9I:I;I=I>IK K"K#K$K%KLL L!LLLLLLLLNNNNNNOOOOPPPPPPPOQPQRQSQTQUQMRNRPRQRRRRRRRRTTTTTTUUUU5V7V8V9V:VV?VAVBVCVDV?AB~iklmnpqSTVWXYQRTU~bcefgh`acd !"#%&                       ~    EGHIJLM-.0123+,./:;=>?@89;<       !"#$&' !!!!!!""""#######%%%%%%&&&&((( ( ( ( ())))))****+++++++------....///////z1{1}1~111x2y2{2|2r3t3u3v3w3y3z3[5\5^5_5`5a5Y6Z6\6]6e7g7h7i7j7l7m7S9T9V9W9X9Y9Q:R:T:U:-;/;0;1;2;4;5;&='=)=*=+=,=$>%>'>(>?????? ?@@@@@@AAAABBBBBBBDDDDDDEEEEFFFFFFFHHHHHHIIIIJJJJJJJLLLLLLMMMMhNjNkNlNmNoNpNOOOOOOPPPPQQQQQQQRR R R R RSSS STT T T T TTUUUUUUVVVVWWWWWWWYYYYYYZZZZ[[[[[[[L\M\O\P\Q\R\J]K]M]N]^ ^!^"^#^%^&^ ` ````` a a a aaaaaaaaccccccddddweyeze{e|e~eedgeggghgigjgbhchehfhhhhhhhhhhhhhhiiii/j1j2j3j4j6j7j8j9j;jj6k7k9k:klllll l!lmmmmmmnnnnoooooooIpJpLpMpNpOpGqHqJqKqqqqqqqqqqqqqqrrrr=s?s@sAsBsDsEs0u1u3u4u5u6u.v/v1v2vvvvvvvvNxOxQxRxSxTxLyMyOyPyzzz z!z#z$z | | ||||} } } }}}}}}}}~~~~~~Ԁր׀؀ـۀ܀„ÄĄńDŽȄTUWXYZRSUVtvwxy{|hiklmnfgijmnpqrsklno !     ڕەݕޕߕٖؖۖܖOPRSTUMNPQ:<=>?AB  "$%&')*HIKLMNFGIJPRSTUWXԢբעآ٢ڢңӣգ֣5789:<=>?ABCD<=?@ϥѥҥӥԥ֥ץ78:;<=5689HJKLMOP̱ͱϱбѱұʲ˲Ͳβ¶ĶŶƶǶɶʶrtuvwyzWYZ[\^_9:<=>?78:;    :<=>?ABJKMNOPHIKLrtuvwyz\]_`abZ[]^79:;<>?013456./12CEFGHJK-.0123+,./vwyz{|tuwxNPQRSUV5689:;3467wxz{|}uvxyKMNOPRStvwxy{|;<>?@A9:<=                                !!!!!!!######$$$$r%t%u%v%w%y%z%''''' '(((((((((((******++++Q,S,T,U,V,X,Y,i.j.l.m.n.o.g/h/j/k/W0Y0Z0[0\0^0_0<2=2?2@2A2B2:3;3=3>3G4I4J4K4L4N4O4061636465666.7/717278888888999999::::;;;;;;;======>>>>???????AAAAAABBBBCCCCCCCEEEEEEFFFFGGGGGGGIIIIIIJJJJKKKKKKKMMMNNNNNNN]O_O`OaObOdOeOfOgOiOjOkOlOdPePgPhPuQwQxQyQzQ|Q}QbScSeSfSgShS`TaTcTdTUUUUUUUuWvWxWyWzW{WsXtXvXwX[Y]Y^Y_Y`YbYcYA[B[D[E[F[G[?\@\B\C\\\\\\\\\\\\\\]]]]]^_^`^a^b^d^e^_```b`c`d`e`]a^a`aaa-b/b0b1b2b4b5b]c^c`cacbccc[d\d^d_deeeeeee g g g ggghh h hhhhhhhhJiKiMiNiOiPiHjIjKjLjgkikjkkklknkokllllllmmmmn?n@nAnCnDn p!p#p$p%p&pqq!q"qqqqqqqqssssssttttuuuuuuuwwwwwwxxxx\y^y_y`yaycydyyyyyyyzzzzm{o{p{q{r{t{u{^}_}a}b}c}d}\~]~_~`~eghijlmBCEFGH@ACDڈۈ݈ވ߈؉ىۉ܉uvxyz{stvwprstuwxVWYZ[\TUWXkmnoprsvxyz{}~uvxyz{stvw    ~}~{|~    NPQRSUV;<>?@A9:<=*+-./0()+,@BCDEGHIJLMNOGHJK 9;<=>@A%&()*+#$&' "#mnpqrsklno245679:FGIJKLDEGH                           |~vwyz{|tuwxwyz{|~`!a!c!d!e!f!^"_"a"b"v#x#y#z#{#}#~#f%g%i%j%k%l%d&e&g&h&,'.'/'0'1'3'4'R(S(U(V(W(X(P)Q)S)T):*<*=*>*?*A*B*G,H,J,K,L,M,E-F-H-I-...... .@/A/C/D/E/F/>0?0A0B0000000022222233334444444e6f6h6i6j6k6c7d7f7g7Z8\8]8^8_8a8b8+:,:.:/:0:1:);*;,;-;;;;;;;<======>>>>???????&@'@)@*@+@,@$A%A'A(AAAAAAAAQBRBTBUBVBWBOCPCRCSC:DD?DADBD-F.F0F1F2F3F+G,G.G/G"H$H%H&H'H)H*HIIIIIIJJJJ_KaKbKcKdKfKgKKKKKKKLLLLMMMMMMMOOOO O!OPPPPPPPPPPPRRRRRRSSSSTTTTTTTVVVVVV~WWWWXXXXXXXZZZ Z!Z"Z[[[[[[[[[[[t]u]w]x]y]z]r^s^u^v^M_O_P_Q_R_T_U_______````aaaaaaaccccccdddd^e`eaebeceeefeDgEgGgHgIgJgBhChEhFh i iiiiiiiiiiiijjjjnkpkqkrkskukvk4l5l7l8l9l:l2m3m5m6mmmmmmmmnnnnnnooooppppppprrrrrrsssstttttttvvvvvv}w~wwwwwwwwwwwwwwwwwxxxxZyQ{R{}{~{{{{T|U|^|v|||||}x}}|~~~~"#$1234Acd{΀π؀܁!"9:?WXs%ȇ݇w0EY#$@k?@^bQϒѓyȕ>n()\-WXuyzӠbΣGpb٫[ԭbڰ]´I4ķ+j nC#dR,g\X`$S7p.#$%&'(CPQRS()*+,->PQRSdefghi| #$%&IJlmno"#$'ʑ00ʑ00ʑ00ʑ00ʑ0000ʑ00Wʑ00ʑ00ʑ00ʑ0000ʑ00ʑ00ʑ00ʑ00ʑ0000ʑ0000ʑ0000ʑ00000000000000000000000000000W0X000000000000000k0l00000000000000000000ʑ0!0"`%000000000000000000000000000000ʑ0607'00000000000000000000ʑ0A0B(00000000000000000000ʑ0L0M*00000000000000000000ʑ0`0aD,000000000000000000000000000000ʑ0v0w.0000000000000000ʑ0v0ʑ0v0000000000000000000000000000000000000000000000000000000000000ʑ00000000=00=00=00=00=00=00=0000=00=00=00=0000=0000=00=00=00=0000=000 00 00 00 0000 0000000000000000000000000000000000000000000 0000 00 00 00 0000 0000 00 00 00 000 0 000"0 0"0 0"0 0"0 000$0000&00&00&00&0000(0000*00*00*00*0000,0000.0 0.0 0.0 0.0 00000 00020 020 020 020 00040 00060 060 060 060 00080000:00:00:00:0000<0000>00>00>00>0000@0000B00B00B00B0000D0000F0=0F0=0F0=0F0=000H0=000J0=0J0=0J0=0J0=000L0=000N0=0N0=0N0=0N0=000P0=000R0=0R0=0R0=0R0=000T0=000V0=0V0=0V0=0V0=000X04000Z040Z040Z040Z04000\04000^040^040^040^04000`04000b040b040b040b04000d04000f040f040f040f04000h04000j040j040j040j04000l04000n030n030n030n03000p03000r030r030r030r03000t03000v030v030v030v03000x03000z030z030z030z03000|03000~030~030~030~0300003000030030030030000300003003003003000030000300300300300003000030030030030000300003003003003000030000300300300300003000030030030030000300003003003003000030000300300300300003000030030030030000300003003003003000030000300300300300003000030030030030000300003003003003000030000300300300300003000030030030030000300003003003003000030000300300300300003000030030030030000300003003003003000030000300300300300003000030030030030000}0000}00}00}00}0000}0000}00}00}00}0000}0000}00}00}00}0000}0000}00}00}00}0000}0000}00}00}00}0000}0000}00}00}00}0000}0000}00}00}00}0000}0000}00}00}00}0000}0000}00}00}00}0000}0000}00}00}00}0001}0001}01}01}01}0001}0001}01}01}01}0001}000 1}0 1}0 1}0 1}000 1}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}000 1}000"1}0"1}0"1}0"1}000$1}000&1}0&1}0&1}0&1}000(1}000*1}0*1}0*1}0*1}000,1}000.1}0.1}0.1}0.1}00001}00021}021}021}021}00041}00061}061}061}061}00081}000:1}0:1}0:1}0:1}000<1}000>1}0>1}0>1}0>1}000@1}000B1}0B1}0B1}0B1}000D1}000F1}0F1}0F1}0F1}000H1}000J1}0J1}0J1}0J1}000L1}000N1}0N1}0N1}0N1}000P1}000R1}0R1}0R1}0R1}000T1}000V1}0V1}0V1}0V1}000X1}000Z1}0Z1}0Z1}0Z1}000\1}000^1}0^1}0^1}0^1}000`1}000b1}0b1}0b1}0b1}000d1}000f1}0f1}0f1}0f1}000h1}000j1}0j1}0j1}0j1}000l1}000n1}0n1}0n1}0n1}000p1}000r1}0r1}0r1}0r1}000t1}000v1}0v1}0v1}0v1}000x1}000z1}0z1}0z1}0z1}000|1}000~1}0~1}0~1}0~1}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0001}0001}01}01}01}0002}0002}02}02}02}0002}0002}02}02}02}0002}000 2}0 2}0 2}0 2}000 2}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}000 2}000"2}0"2}0"2}0"2}000$2}000&2}0&2}0&2}0&2}000(2}000*2}0*2}0*2}0*2}000,2}000.2}0.2}0.2}0.2}00002}00022}022}022}022}00042}00062}062}062}062}00082}000:2}0:2}0:2}0:2}000<2}000>2}0>2}0>2}0>2}000@2}000B2}0B2}0B2}0B2}000D2}000F2}0F2}0F2}0F2}000H2}000J2}0J2}0J2}0J2}000L2}000N2}0N2}0N2}0N2}000P2}000R2}0R2}0R2}0R2}000T2}000V2}0V2}0V2}0V2}000X2}000Z2}0Z2}0Z2}0Z2}000\2}000^2}0^2}0^2}0^2}000`2}000b2}0b2}0b2}0b2}000d2}000f2}0f2}0f2}0f2}000h2}000j2}0j2}0j2}0j2}000l2}000n2}0n2}0n2}0n2}000p2}000r2}0r2}0r2}0r2}000t2}000v2}0v2}0v2}0v2}000x2}000z2}0z2}0z2}0z2}000|2}000~2}0~2}0~2}0~2}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0002}0002}02}02}02}0003}0003}03}03}03}0003}0003}03}03}03}0003}000 3}0 3}0 3}0 3}000 3}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}000 3}000"3}0"3}0"3}0"3}000$3}000&3}0&3}0&3}0&3}000(3}000*3}0*3}0*3}0*3}000,3}000.3}0.3}0.3}0.3}00003}00023}023}023}023}00043}00063}063}063}063}00083}000:3}0:3}0:3}0:3}000<3}000>3}0>3}0>3}0>3}000@3}000B3}0B3}0B3}0B3}000D3}000F3}0F3}0F3}0F3}000H3}000J3}0J3}0J3}0J3}000L3}000N3}0N3}0N3}0N3}000P3}000R3}0R3}0R3}0R3}000T3}000V3}0V3}0V3}0V3}000X3}000Z3}0Z3}0Z3}0Z3}000\3}000^3}0^3}0^3}0^3}000`3}000b3}0b3}0b3}0b3}000d3}000f3}0f3}0f3}0f3}000h3}000j3}0j3}0j3}0j3}000l3}000n3}0n3}0n3}0n3}000p3}000r3}0r3}0r3}0r3}000t3}000v3}0v3}0v3}0v3}000x3}000z3}0z3}0z3}0z3}000|3}000~3}0~3}0~3}0~3}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03}03}03}0003}0003}03 03 03 00000000 0000@200 0000PW 0 00 0@00 0000@000@3000000@0  00000@0T0000@0n00@000@0 5 h  0 0K%;% ' $'  0"0KU;U W d  0$0KH;  0&0MX=X Z @Z  0(0Mxb=b c s  0*00*0M4|=x  ܂  0,0M0=t    0.0fȱ0000@ȱ0020@ȱ0040@ȱ0060@ȱ0080@00:00:0@w0<0@wȑ00>0@0@0@ĺ0B0@x0D0@0F0@44l 0H0@00J00J0@00L0@00N0@440P0@"00R0@u0Pp0T0@"00V0@u0F0X0M!=! 8# 3  0Z00Z0MA=4A xB B  0\0M$Z=DZ [ `  0^0Mt~=  ~  0`0M̆= 0 $  0b0M=`  Ķ  0d0M`=    0f0MT=t    0h06Nl 4> 4 44 0j00j06N(4>H-4.4.4 0l06N@i4>`i4j44R4 0n0@0FO0p0@0"0r0@00t0.@00v0@0u0x0@0"0z00z0@00|0F@0"0~0@ 0u\00W&700@c0u 00F0"00@0'00@PF0"0000@000@000@000@000@000@000@000@00000@000@000@000@000@000@000@000@00000@000@000@000@000@000@000@000@00000@000@000@000@000@000@000@000@00000@000@000@000@000@000@000@000@000h00h@000h@000h@000h@000h@000h@000h@000h@000h00h@000h@000h@000h@000h@000h@000h@000h@000h00h@000h@000h@001h@001h@001h@001h@001h@00 1h0 1h@00 1h@001h@001h@001h@001h@001h@001h@001h01h@001h@001h@00 1h@00"1h@00$1h@00&1h@00(1h@00*1h0*1h@00,1h@00.1h@0001h@0021h@0041h@0061h@0081h@00:1h0:1h@00<1h@00>1h@00@1h@00B1h@00D1h@00F1h@00H1h@00J1h0J1h@00L1h@00N1h@00P1h@00R1h@00T1h@00V1h@00X1h@00Z1h0Z1h@00\1h@00^1h@00`1h@00b1h@00d1h@00f1h@00h1h@00j1h0j1h@00l1h@00n1h@00p1h@00r1h@00t1h@00v1h@00x1h@00z1h0z1h@00|1h@00~1h@001h@001h@001h@001h@001h@001h01h@001h@001h@001h@001h@001h@001h@001h@001h01h@001h@001h@001h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h@001h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h@001h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h01h01 01h01 01h01 01h01 01h01 01h01 01h01 01h@001h01 01h01 01h01 01h01 01 01 01 01 01 @0ʑ0&7ʑ0&700)00)00)`@0@ @0D @0@ @0D 00'`00'`@0@ 00'`@0D 0 0&`0 0&`0 0&`0 0&`0 0&`0 0&`0 0&`0 0&`0 0&`@0@ 0 0&`@0@ @0@ @0@ @0@ @0@ 00&F@0@ @0D @0@ 00%F@0@ @0D @0@ @0@ @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@@0@@0@@0@ @0@ 0=070=070=07@0D @0@ 0@07@0@ 0B07@0@ @0@ @0@ @0@ @0@ 0H0i@0@ @0@ 0K0i@0@ @0@ @0D @0@ 0P0i@0@ 0R0i@0@ @0@ 0U0i@0@ @0@ @0D 0Y0i0Y0i@0@ 0[0i@0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@@0@@0@@0@@0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ @0@ 0000@0@ @0D @0@ 0000@0@ @0D @0@ @0@ @0@ @0@ @0@ 0000@0@ @0D @0@ 0000@0@ @0D @0@ @0@ @0@ @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0@ @0D @0@ @0@ @0D @0@ @0@ @0@ @0D 0$0 00@@0D  0 00 &!#(03=F@MzSVejzqvCy0o`mȰf}s63эkeN2DUY:r1h[D rh2qG K1nLc"$^'*-f13 7h:=]A$DKG+JqLOSU)Y\z_Vb0gjmBIMPUY_dhkpsw{~  !&)-149<?DHLPUX_bgkqtz}      ! & * / 3 6 ; > B F K N Q U Y \ a d i p s w |       % ( + / 3 8 ; ? C F L O U Z _ b h l p s x |         # ( + / 3 6 ; > B F I N R U Y ] a e j m p t y }       $ + . 2 7 = A D H M O V [ z 2 &(Ai#xBDvx "ce \^[]xzz|y{qs @B')bd689;Z\ tvTV$&hj*,acce=?HJQSnp= ?   o q       k m  ACjl$&z|!`b :<46  ~!!""""##$$$$%%8&:&&&''((/)1)))**++',),,,--E.G...}//=0?000+1-11122s3u3&4(444556666$7&7778888H9J999C:E:i;k;<<<<==@>B>>>t?v?/@1@@@MAOAAABBCChDjDsEuESFUFWGYGGGHHIIIIoJqJJJKLLLMMNNaOcOXPZPQQQQRR S SSSfThT=U?UUUVV8W:WXXXXYYZZ~[[\\\\]]^^__``aabcbzc|c d ddeee+f-fffgghhhhii0j2jjjkkll|m~m>n@nooooppqqrr.s0sssttuuuuvv(w*wwwxx-y/yyyzz0{2{{{||1}3}}E~I~JzwV>9LQ<9B4/>C! _dKH ţħϯԯ  ',aGB38ob]&% +0 "'RZUZkq,pmQ:5zwaQ L @ E 8 5yv5glTQzfa  "#0$ &''')*+-.//12356|77o9l:;=>??ABBCDDEFFHIJJnLkM NOPQQSTU2W-XXXZ[\z^u_g`l`TbQcd0f+ghhijXk`k[lmmooprsXt]t;v8wwyz|||}~5:fc!Pvq  ڗșÚdi6lg[X?īPmsxb_p[VLQ'$w|^[`]:lgOTJQL16LIw|_d| <`]%YTBG   < 9 ? ~7< !"$z%`&e&C(@) *+,--r/o0t1^3Y4k5p56789:p;u;\=Y>>@ABB0C-DEFGyH~HeJbK LMNOOQRMS7U2VuWzW`Y]ZZ\]^^`abVeQfKgPgphmiujVlQmPnUn=p:qr tuuuwxQy4{/|} }}~mWR‚!&' ƔGL30in&!UZDAQN@2-޿>CIF38>;h^c# L1,). UP$) a'",174khxOJ     c^8=~glS!P"""#%%'()+,|--b/_01345!55678 99:;}<E=,?'@@@:A7BCEFFFHIKM NNNPQRTUWWXYZ\]^^z`warbZdUecfhfShPiZj%m nnopqrtuvv/z,{)|~LIe`chQNKFA}id+0֖˜"'-*v{QND ${hc*/3 "ӹƻݽ̿xjeEJ96mj30,1BA<WT +(wr$diSP    T;)$  "#5$:$@$=% &'())5+2,,;-6.E/J/ 12345q6v6;788/9;<<=A=+?(@UA>C9DDDFGI KLMM0O-PdQLSGT'U,UWXXaZ\[1\6\ ^__abccefgij]kbkGmDnnpq-s2s uvvy z{{}~AZUłƒԄԊы ogb@Eƞ|% #( #ʮϮIJX]IFR83  uzda=d_ZPKsxsp S X > ;   ^cXU+ ~x} !t#o$I%N%&'(* +&,+,-.h/01A3F3/5,6(79: ;;==?@ABCDEGHI8K=KMNNPQRRTUVXYZZ[\]_`uazabcVd@f;gJhOhijkmnUoZo0q-rsstIuNuuvwyz{{}~~$zwONI߉܊zuSXӐБhm74͟%*VS  ޫڬTYٰ:)aλknZwBv{      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~    !"#%&')*+,./12345789;<>?@BCDFGHJKLNOQRSTVWYZ[]^_abdefgijlmnpqrsuvwxy{|~     !#$%&')*,-.01345689:<=?@ACDEFGHJKLNOQRSTVWXZ[\]^`abcefgijlmnoqrtuvxyz|}    "#$%'(*+,./0235678:;=>@ABCEFGIJKMNOQRSTVWYZ[\]^`acdefhijlmnoprsuvwxy{|~                     " # $ % ' ( ) + , - . 0 1 2 4 5 7 8 9 : < = ? @ A C D E G H I J L M O P R S T V W X Z [ ] ^ _ ` b c e f g h j k l m n o q r t u v x y z { } ~                      ! " # $ & ' ) * , - . 0 1 2 4 5 6 7 9 : < = > @ A B D E G H I J K M N P Q R S T V W X Y [ \ ] ^ ` a c d e f g i j k m n o q r t u v w y z { } ~                    ! " $ % & ' ) * , - . 0 1 2 4 5 7 8 9 : < = ? @ A C D E G H J K L M O P Q S T V W X Z [ \ ^ _ ` b c d f g h i k l n o q r s u v w x z { | ~                      ! " # % & ' ( ) * , - / 0 1 3 4 5 6 8 9 : ; < > ? @ B C E F G I J K L N P Q R S T U W X Y Z \ ] ^ _ ` a { | } ~  w(N  # % @ K M h o q  & / y T  2q+-HRTo{}#13(Rl rw$$$~%%%%%%%%%%&&Z&&&&+'q't'''/10901.16181S1Z1\1w11111111111122292C2E2`2j2l222222@3x3334W4Z444w@@@AAAAAAAB$B&BABKBMBhBqBsBBBBBBBBBBCCC,C3C}CCCCNDDDDE RwRRSSSSSSSSSST T"T=TETGTbTnTpTTTTUBU\UUUUbVgV^]^e^_*_;_=_X_a_c_~__________```/`1`L`R`T`o`x`z`````aTaaaabAbEbbbkkklllllllmm!mp2q4q:qqrrrrrAsMsQsssst ttatjtvtjuluruu/v9vvvvvvvDwMwPwwwwx xx y yyfyyyWcfĮǮ"%xݰ?I ]hkƲɲ%1%'-IShն7EQEGMPZ kvy̺Һպ(/;/17%/BKN  g=G \hk '3')/?I ]hk'3')/GQ alo%3?35;u4DGgzz|OY fmp" bko#,/t~/8;OZfZ\bfz}19<CSV iq}qsyeo",0NWcWY_fps'36Xb #v}3<H<>DITWgssu{ \gj'*}#'z:EHS] jqu$+7+-3lux*7:Malp#/2I   K \ _     * -          I   HQTluy2  `il .1*-@MPFOR!tL+5=1 3 9  ! !s!~!!!!!2":"=""""""###$S$$$%%%r%w%z%%%%*&/&3&&&&''''.(8(((((((K)Z)]))))**&*++"+u+,#,v,,,,,,A-I-L----. .. ///h///)01040000000I1V1^1R2T2Z2222R3]3`33334 4$4w444444555=6667 7#7v7~7777718?8B88889999:::::K;W;Z;;;; <<<j<s<<s=u={==C>M>>>>>????@W@@@.A4A7AAAAAABSB`BcBBBBCCCD'D8D,E.E4EEEE/F?FBFFFFFG G\GhGkGGGGHHH&III JJJgJlJoJJJJK&K)K|KKK~LLLL)M3MMMMMMM@NINLNNNNNOOPPPaPPP'Q1Q4QQQQQQQIRURYRRRRSSS TTT0U;U>UUUUVVVV~WWWWW;XFXIXXXXXYYWY^YjY^Z`ZfZZ[[c[o[r[[[['\5\=\1]3]9]]]]M^Y^]^^^^__"_u______```Aavaaaaa5bEbHbbbbb ccacpcxcldndtdde)e|eeeeee;fFfNfBgDgJggggIhQhThhhh iiihisiviiiijjj,kkkkkkDlSlWllll mmmimvmmvnxn~nnnnooo;pppqqqlqrquqqqq(r1r4rrrrssss5t?tttttuuVulupuuuu$v1v9v-w/w5ww(x2xxxxxxx=yByEyyyyyyzzzzQ{||k|q|t||||%}+}.}}}}}}}~~~?)36NX k݄:AD  \dnqĈΈ҈%14K _jmɌ̌'*}E=CFQX[CSVfuuw}Ж hqtǗϗҗ%25Ghy|ϛߛ5@CI̠֠)03@FI`jƤɤ&)|ܥ;EQEGMq{Ҩܨߨ2=@V@GJܮ9IL rְ;Ųϲ"36ZnrŴڴڵܵ5?PDFL hsvɸոظ+59BHK ^gsgio¾PYaUW]kqt'19-/5+25FQT mw+59I!t8EHfp#/2BMYMOUWa$'zC38<GNQy<KN p}fp%.47AGJhr&03GUaUW]$.BLOm(.2<EHX^j^`fWarz}2;G;=C7AMTWiQY\lvz,V]`lssu{)3@FJ [cmp$/2H   \ b f       r z  v x ~  J T     afnbdjajm),EDMPdnznpvYcQVY cjvjlr jsv,8;N    !!X!a!e!!!!"#"&"y"""####/$9$$$$$$$P%W%Z%%%%&&"&'''q'''<(E(I((((())[)e)h))))***!+ ,,f,m,p,,,,%-0-3-------...I/z/////90A0D0000011W1_1g1[2]2c22F3P333344 4^4e4h444455%566!6t666G7O7R77778 88d8l8o8888999(:::$;-;0;;;;;;;<<<A===L>X>[>>>> ???g?n?r????@@@(AAA)B2B5BBBBBBBICSCVCCCCDDDEEEEFFWF`FcFFFFG"G%GxGGGHHHH4I>IIIIIIJSJ\J`JJJJKK%KLL!LtLLL(M1M4MMMMMMMDNNNQNNNNOOOPPPPPPBQMQUQIRKRQRRRRDSPSTSSSS TTTkTtTwTTTTUUU)V3VDV8W:W@WWXXXXXOYVYYYYYY ZZZnZzZZz[|[[[\\\\]V]\]_]]]] ^^^h^m^y^m_o_u__```aa[ahalaaaab%b(b{bbbcccc~ddddd8eCeFeeeeef f\fcfofcgegkgg@hJhhhhhiiWi\i_iiii jj"jkkkqkkk l'l*l}llllll=mHmKmmmmnnnop"pup}ppppp5q;q>qqqqqqrrrsWsssBtJtMttttu uubumuuuivkvqvvrw|wwww4x>xAxxxxyyyyzz.{9{<{{{{{{{P|[|^||||}}}~~~~~~GSVhp|prxˁ&yڂ;FI  g!t|xzӇfpÈˈӈljɉω"Ċ#&yڋ;ILq{Ύَ܎/:=kuȑБӑ&03HUaUW]˔ǕakƖɖ'*}ߗ?JVJLRELP clthjpÞ^hßƟ!)%xס4@CVaeͣäɤ bknȦ˦&)|ߨJTdlpêΪѪ$,8,.4)3AHK   eڰ7=@MT\PRX$.@JM  c˷շ(03E˺'+~ݻ<FI_iǾʾ&."$*}Zdg'+~CDMP bhk",=139pwz+HOR _eqegmv/58CJVJLRlsv'.1B ^il#&y>[cf #v;AEV^j^`f8BSS`c"u;#+.BMP|BTW"ugq%03BMYMOUCLO cmq(Zcf&)||8AES\h\^dEVY%({&y<      e   [ e i      " u ~  z |   CM ^jm'3')/,8@46< sBIL ^T^apx{='zHOR   dR X [     !!!k!t!w!!!!"""9###G$P$S$$$$ %%%i%t%w%%%%&&&0'( (`(h(k(((()$)')z))))))***B+++,&,*,},,,,,,A-R-U----... //////C0N0Q0000 111i1t11t2v2|22p3z3333*42454444444J5U5a5U6W6]66c7m7777!8,8/8888888A9M9Y9M:O:U::+;5;;;;;;;Q<a<e<<<<= =,= >">(>{>> ?\?b?e????@@@p@v@y@@@@AAA/BBBBBBMC[C^CCCCD.D1DDDDEEEEFFEGNGQGGGGH HHdHlHoHHHHIII%JJJ%K6K9KKKKKKKNLYL\LLLLMMMNfNpNNNN$O)O-OOOOOOOPPPBQQQQR RSS S\STTaTjTmTTTT#U.U1UUUUUUUVVVGWWWGX]XaXXXXYY!YtYYYYYYZZZ=[[[[[[A\J\R\F]H]N]]^&^y^^^^^^<_F_I_____``aa a`aaa)b2b6bbbbbbbGcPcSccccddd eueeeee3fj2k4k:kkl!ltlzl~llll,m3m6mmmmmmmnnnGooo@pGpOpCqEqKqqqqrrrs;sEsssst ttbtktntttt!u*u6u*v,v2vvvvw*w-wwwwwwwCxLxTxHyJyPyyz$zwzzzzzz={F{I{{{{{||}} }_}}}(~3~6~~~~Ҁ܀/58FNQȄ.1HRZNPVr|ψ݈4>AVbnbdj~ی<DHYgsgio!t@GJaCPShsvɕԕԖ֖ܖ/FMUIKQ8BMTW  c *}>FNBDJNXiqtǢҢڢΣУ֣)3D8:@ͥץ*5=139>ILhy}Щݩݪߪ8M=IMFP alo±ʱұƲȲβ!LWZ nʶ/2FRUߺ>HKpzͽԽ׽*47U_mw{,3?35;bjm",/I  _ko"+.8Bdsv2DPDFL[gj&)|pz09<MVbVX^5?T^b*6*,2AK  _hk'3')/PX\ lt|prxLVgru'/;/177EI  `lo  ix{2:=GPSfq}qsy6lux,59IShsv+r|2CILZ_b nux-9A57=oz}1+36MW[   : A D       X d g       !   QZ^rx{5T\_q||~!$w8CG%({Rcf& `hl),   C!!!%","/"""""""<#C#F####$$$$p%z%%%%1&=&@&&&&&' '''(X(((/)6)9)))))))E*L*O****+++,O,Y,,,,-*--------.S.c.o.c/e/k//U0_0000111p1x1{1111.262B26383>33E4O4444555f5o5r5555#6*666*7,727778[8b8e88889!9$9w999999:::=;;;;;<V<b<e<<<< =/=2====>>>>??+@9@<@@@@@@@PA[A^AAAABBBCCCCD D\DmDpDDDD*E@EDEEEEFFFGGGHHHhHzH}HHHHiHiPiDjFjLjjekokkkk#l.l1llllmmmm:nDnnnnnnnRoZo]oooopp&pqq"quqqq!r)r-rrrrrrr@sHsKsssstttuuu!v,v/vvvvvvvCwLwOwwwwxxxyZydyyyyzzz{k{u{{{{)|3|6|||||||J}X}d}X~Z~`~~cm%({؀߀5<H<>DVbeƒŃ"&yل?NWZ kvÿԈԉ։܉/Xcf‹ŋ!$wލFQThs{oqwʑnx˒ْ֒,36GP\PRXisƖЖԖ'36iqtǚКӚ&37 gnqĞϞҞ%14VdgâƢ),t~ѥ9JNfo{oqwʨ s}ө۩ީ1;> ZYehȭ˭),HUYozz|ճLVY lwwyҷ ]gj͹й#.1eorŽ۽޽1@CF[^"u9AD [LVivy*5A57=V_b&)|Gq{~1DGi ]im(0$&,QY\nx{4>OCEK \mp"36N'15HTWdnr&-07AZdg#+!'z#v4:=CMQkGPS aksgio0:HQU$/2>DL@BHdor(48?HK  _jm%$04GMP  oy}0 @ C           " % x      3 < @    Zbe!t ^eh!$w6=@TY\z:EH dp|prxu0 : =       O!Z!f!Z"\"b""t#~####2$<$?$$$$$$%S%`%l%`&b&h&&*'4'''''''H(P(X(L)N)T))8*B*****++f+w+z++++0,A,M,A-C-I--. .s.{.~....1/>/F/:0<0B0000R1]1`1111222r2}222223337444H5O5R555566 6]6c6k6_7a7g77X8b8888999m9r9u9999$:):1:%;';-;;;<S<Y<\<<<< ===g=n=r====>>>&???@$@,@ A"A(A{AAAGBOBWBKCMCSCC8DBDDDDDEEWEaEdEEEEF'F3F'G)G/GG H*H}HHHHHH;IEIHIIIIJJJJ]KgKKKKLLLMMMMMNSN]N`NNNNOO!OPPPpPPPKQXQ[QQQQR(R+R~RRRRRRSSSETTTTTTMUYU\UUUUVVVoVzVVzW|WWWXXXXXOY[Y_YYYYZZ"Z[[[q[[[Q\X\[\\\\]]]l]r]z]n^p^v^^K_U____``` aaab b b`bhbkbbbbc)c-ccccdddd\efeeeef f#fvf}fffff1g>gJg>h@hFhh iifioiriiiijjj-klkvkkkk)l2l:l.m0m6mmmm#n-n0nnnnnnnoooLpppq$q'qzqqqqqq5rIrLrrrrssstttttuSu^uauuuuvvvqvyvvyw{wwwwxxxxVyXyzrzzz6{A{{:|Q||}}}d}v}x}}}}_~z~'y  *,T-9?1%XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCCXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCCXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXCXXXXXXCXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXCXXXXXXCXXXXCXXXXXXCXXXXXXCXXXXCXXXXXXCXXXXXXCXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXCXXXCXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXCXXXXXXCXXXXXXCXXXXXXCXXXCXXXXXXCXXXXXXCXCXXXXXCXXXXXXCXXCXXXXCXCXXXXXXCXXXXXCXXXXXXCXXXXXXCXXXXXCXXXXXXCXXXXXXCXXCXXXXXXCXXXXXXCXXXXXXCXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXCXXXXCXXXXXXCXXXXXXCXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXCXXXXXXCXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXCXXXXCXXXXXXCXXXXXXCXXXXXXCXXCXXCXXXXXXCXXXXCXXXXXXCXCXXXXXXCXCXXXXXXCXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXCXXXXXXCXXXXCXXXXXXCXXXCXXXXXXCXXXXXXCXCXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXCXXCXXXXXCXXXXXXCXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXCXXCXXXXXXCXXXXXXCXXXCXXXXXXCXXXXXXCXXXXXXCXCXCXXXXXXCXXCXCXXXXXXCXXXXXCXXXXXXCXXXCXXXXXXCXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXCXXXXXXCXXXXCXXXXXCXCXXCXXXXXXCXXCXXXCXXXXXCXXXXXCXXXXXXCXXXXCXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXCXXXXXXCXXXXXCXXCXXXXXXCXXXXXCXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXCXXXXXXCXXXXXXCXXXXXXCXCXXXXXXCXXXXCXXXXXXCXXCXXXXCXXXXXXCXXXXXXCXXXXXXCXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXCXXXXXXCXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXCXXXXXCXXXXXCXXXXXCXXXXXCXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXXXCXXXXCXXXXXXCXXXXCXXXXXXCXXXXXCXXXXXXCXXXXXXCXXCXXCXXXXXXCXXXXXCXXCXXXXXCXXXXXXCXXXXXXCXXXXXCXXXXXCXXCXXXXXXCXXXXXXCXXXCXXXCXXXXCXXXXXXCXXXXXXCXXCXXXXXXXCXXXXXXCXXXX8@0(  B S  ?l}l~,l,l,lll,x x x x lx x ,x lx |<dl l  씀 , l  앀 , l  얀 , l  엀 , l  였 , l  와 , l  욀 , l  움 , l  ˜윀 Ø, Ęl Ř Ƙ은 ǘ, Șl ɘ ʘ잀 ˘, ̘l ͘ Θ쟀 Ϙ, Иl ј Ҙ저 Ә, Ԙl ՘ ֘졀 ט, ؘl ٘ ژ좀 ۘ, ܘl ݘ ޘ죀 ߘl   , l   , l  ssz   !!RR !!22^SiSySSSaammhh~FF%%;;ii//|,,,,7799>>??DDHH8J8JKK"Q"QuW^|^|||11>>||  '      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijkx   " " %%VV !!22hSqSSSS a ammqqLL++HHkk55##,,,,7799>>??DDHH?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijkBl*urn:schemas-microsoft-com:office:smarttagscountry-region8i*urn:schemas-microsoft-com:office:smarttagsCity9k*urn:schemas-microsoft-com:office:smarttagsplace=$*urn:schemas-microsoft-com:office:smarttags PlaceName=J*urn:schemas-microsoft-com:office:smarttags PlaceType flkkilklklklklklkikillkikikiklkiklkJJiklklklkiklkklkiklklklklklkkklklklkJ$klklklklkiklklkiklklkkikikikikikiki +: QW#:? k o 01<@r{&1NQ  !!)!-!@!E!G!H!!!!!,"0"####(( ))))r0x000001161V1Z1z1122<2C2c2j255556677W8d8o8r8z8~869:9R:]:::M;X;;;:<><<<E=N=>>>>??@@@@AAAAB$BDBKBBBBBBB8EItIzIIIII J#J+J9J:J?JJJKKKK@MFMMMMMNNNNNN O O=ODOOOPPPPPPQQSSSSSS@TETeTnTTTXXXX"Y#Y+_;_Y_a________``/`M`R`p`x```igmgkkmm?mEmempmoor'rrrrrss\u`uuuuuww| } }}%}-}}}}}~~-~6~ORsbjDL:<؇ۇAGŠ+1{!'`f-3mr@E_c#'(+BKĭbj ߰!$%,-5@HsxóγԳݳ޳ 7=.3>Fֵݵ| %&.9AMV˷ҷ qƸѸٸFQù˹:Blo/5ADX^»ƻ  HS >A{ڽ*3hlʾ׾ݾov}ѿֿ?Jw{"*_c*  #BEORqx}:=]d'2:JMv}!"+6>y*2`h+3GO')hpqwDKV^3ABFJNYacgz +36>L[hk 'M\$)*1<D eit|15DLv%0ouv}49JRfklqrv lqrxFKLR]eQVW]hpbfqy #]esyzBJ(Ta|/7DL,4]kQVai .6v49DLYg"+?Ggpglmu(0BJKOZb_c&*5= $&1v}T\ (3^l'-8@ !*5=\c ;CDMX`%OWGO~ $Z]6\em      ] e       : @ K S         C G         1;FN-137 4<Uc)019DLen$/7PWX]hp.0PXckWfrwx~ $%/:B %df6AMU`h15w?DOWou\bmu AIV_doouv}yH M ` h s {      !Y!]!w!!!!!"" """""""""#$#/#7#R#[#_#j#######7$B$$$%%%%%%%% &&&&&&&&&&&&'''d'i'j'v'''''''''b(g(((((h)o)p)v)))))))B*M*x******+++++%+0+8+E+P+V+a+++++++,,,,,, ------*-2-------6.:.a.h...H/L/]/e///////0000X1`1111122 22222'222:222233333G4R444.525555555555566666777Q7U77777778%8T8_888888899q9y99999: :::::::;";C;I;J;Q;\;d;;;;;7<B<m<v<<<<<====>>>>*>2>>>? ? ???'???,@1@K@S@@@@@@@@@HAQAAA BB B&B1B9BBBBBCCCCPDXDDDDD}EEEEEEEE2F8F>FQFUFbFyFFFFFFFFFFFFFF G+GGGGG H(HHHSH^HfHHHHHII7I?I[IfIyIIIIIIJ JAJPJJJJJJJ}KKKK LLELILdLuLzL|LLLLLLL MM2M8M9MCMNMVMMMMNNNNNNNNNNNNN!O(OSBSMSUSSSSSSSnTyTTTTT9UAUPUXUUUUUUVVVMV^VVVVV,W2W@WFWQWYWWWWWWWZZNZRZZZ[[u[|[2\9\O^S^^^8_?___X`^`hbpbbb4c9cccccSd[dee8f=fffffggggkk;l@lnnnnTobooo"p2pqqqqqqqqqqr r6r=rrrrrBsMssst tbtjt,v/vGwMwyyyy.^h'(/ bl&3-0<GLVv~~ׅ̅ˌNRitX[œ˓#ޔmsݖil!ܘߘkq*.ORnq8CcfU[ $ -0pr̸͸˻λHLfvesjuHL$0-<!KV'Y11<<+H=HO&OOO+_`spvppp+s.s:wEwwwzN{}8~io6[n7protBɃA͇Rދ y5>DN;J,8vA0bL  I Gt!"%&w,.78:x<WcYd[6\N^_aqc}eGfJhit2v;e`>*Jr:#ߴlþl24xd gbsok "=()g,-/`1%;;EGIKESTdhfhj!lmvprCtnu~uzώO5ƣ1Em_cTRz,-/y17R9;%=BD&KL[K\*bcecgulms/uwMx0SЈg?˱I[/,4v :&"#%'0)*,h.4/6;=,@ACEwww,x0x~~4>k>R\xQRϒݔȕŖۘ'33333333333333333333333333333tp$$/>022Z44h@@RR]i^` aopotЭMv$İƱ%Tn)Rֵc M˷׹'N),eԽѾ}7zFJy%~ >~Ot+[h;j*Bm?J3$P,U.Xo4^f+lFqQ|^vIq#s#xDAKvo"Tg= BoJ1<i !MJ!;m2 :d-\1\z   H  4 `     z  '[I)YDP}DxrO2Buw6dW-oyW  _!!!,"""#D##$x$$$'%&3&&&''}((h))`**+E+++,,-?---o..E/r//000>1m12G223334455666*7778899::C;q;c<<==>?>?4???,@`@@AAA BFBB CCC:DeDDDEEFFGG;HsH ILIIJJ KKKLL2McMM$NNN!OQOO+PPP0Q]QQRRR8SbSSSTT9UeUU%VVV,WfWWWWWsX{XtYwYZ\]]cafa{bgd`eceYi\iEmHm7q:qouruyyy{||}ۀހɄ͈̄Јތ 58>Aslo;>*-JM47,/,/8;Y_bvyoc\ADx{03  =6 9 #$''+"+//W2Z2245599x={=M>?@@C8D1E4EHHLL PPSSTUVVcZfZ6]9]``qdtdGgJgjjkm{nnooprss2w5w2xzzz|}~~X zJߵPILloaZ]2wRUpZ]jcfaG@Cx{3 { ~ gjsvcor##''**..`2c26!699<<@@DDHHL!LOOPUQNRQRUDV=W@WXZ[[r_u_`bcchgkgkknnssnvqvyy}}ux!}pӈ̉ωuaZ˔ĕǕOmph)"%ƤɤT14UX շi.'*=69jmORcfBRad       M3,/@9<  '""#%&&**..y2|2Z6]6R:U:%>(> ?@AAEEFHIIMMPPQ RS SVVWYZZK]N] a addchhi>j7k:knnoOpHqqrr/v2vMyPy } }}~SVgjlo ٖܖUNQ GJӣD=@ץ=69˲β8;IL[^/2,/|ux47vS|:=     $$((++h/k/;3>3/727::>>BBFFJJNlOePhP}QhSaTdTtXwX@\\]]^aaa\d_dh hhPiIjLjmmq"qqsttxxdyyzz]~`~ADى܉twUXtw| :=),OHK$'loLEH   ux_"b"e&h&4'X(Q)T)(*B*F-I-?0B033d7g7*;-;>>?,@%A(AAWBPCSC,G/GJJgKKLLPPSSWW[[s^v^U__``acddChFhjjvk:l3m6moosswxz~{|}~~#$:X%#$@@^ѓ)q-XdiJo'', ڿf)p4RdJ  ciS"dA2*/lx|9 LHA~vR"ESNVtE<,e)H@i I(J#{M6zNbrp,2UUQU" 0eZV[F]J\_j bn|mhhh^h`OJQJo(hH%h88^8`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHohxx^x`OJQJo(hHhHH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hH^`.^`.pp^p`.@ @ ^@ `.^`.^`.^`.^`.PP^P`.^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`.^`.pp^p`.@ @ ^@ `.^`.^`.^`.^`.PP^P`.^`.^`.pp^p`.@ @ ^@ `.^`.^`.^`.^`.PP^P`.^`.^`.pp^p`.@ @ ^@ `.^`.^`.^`.^`.PP^P`.hh^h`CJOJQJo(88^8`CJOJQJo(o^`CJOJQJo(  ^ `CJOJQJo(  ^ `CJOJQJo(xx^x`CJOJQJo(HH^H`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(hhh^h`OJQJo(hH>h88^8`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHohxx^x`OJQJo(hHhHH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hH^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(hhh^h`OJQJo(hH>h88^8`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHohxx^x`OJQJo(hHhHH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHhh^h`CJOJQJo(88^8`CJOJQJo(o^`CJOJQJo(  ^ `CJOJQJo(  ^ `CJOJQJo(xx^x`CJOJQJo(HH^H`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(_j0eZ]J\, S"V[|mRe)HA2zNVtEp,2U IdJ HAlx|9f)"E{MUQUG:t        0ʄ        U)b>U}KN&<  ma qAlb\R=C6l %OVuVRmoE$\GXV:j\bxu2*a]0|5Nged<"{ged<Dh)P)$R xeztRr% R=Cu2M8k|P$1nU)SM]bWnB JR,i:vlP R 2pajx_h&= t\~R (Yt'53k>gRda}4 SY+O lP 2 0T-p TAV <WD . p <  m I% >z,h h!eD <  6l ca@R G\,6l [zt<4,u,,jx'xt~#pj;NVc&rY;b%+R4 ;j\bVuVR lSh~"'7)sb2gz/5`tWSpYZ;I8OEb]< ro['T_u2M9QNbO'x<<8k!H+1;4CdO 17`(O%eY7)sb^QztRY[PK[p2ged<Y?'xN>K0?A @S!v6mrc  tdX@1L rN'53W 2a)Y2 2a)BL  =7 Yj 'xp!!]MPv " ]l\Z"['Sh~" mrQ;"{&5"<X*:# .}l]#IZrE,i#-6dM^#WV~#:[lw#p!h$u2*h=$;b%+b&%e~sTCP%H+%ged< %8nKCN%Aq0&K_l&'t`]'!Lo!k'E(}'oA+3(L(|K{17`(jyE(ged<G))P)JEg1u) ^0w)Yxq)ged<^n)4){u2*SMfP*yV~;b%+yl+\H+R=C+JE$,~qR,u,2RPLl,X\=>0T-J-hSj5.)S/X\=>qCt/'xVM0Do!l Uy0sV08,#5+w0SMax51sGAf1aL1 T{)2L1I,2p SN2VS\g2}03#/4LoA+3^ ^'534 ;^Q3lda}4ztR46mm5%e8,#5M(kgz/5 ^|4t6w#d_79Q)@7IZr![9CP%k9kI?9u2M 9E:|`Ft3:ged$hp:!cIwUx:p!D(:lw_4 ;+1;mZMQ9;%Oh; B;6mj;?RztohLoD>j\bb>&XaO>$,kI?m_+k?>gu?\,hW?w#ca@ mr;a@!cI0.A s`+A+-uoA/Ts>`Bu2*AyiB$K5C!HHl C$,JEgedhEG^E/voE! E,h CEo$sGgedhsGlGyl+ }GbFiDH.sm Ijxf%ISJ!cID(:S|I$1n;IJE3\Iax51 I>5=wSJHhv^J }GP4K|`PKv=$KR 8nK-~}KB;@1Lyl+#/4LDkoLNohLoA+3 L]< rmZM|4t6N n_q N]mok>NSMiClNM^#\cO'x9OxvTT Ot\P[#;P0T-lP k|PWD ]MPh2RPm_51Qf%I?RAV VuVRu2*~qR_q NztRhW?RJR RyV~R;I/S!=phS% TxvT$\=]TPKe~sT6l T,&VUged$hWV_GXVphsVRWged< }W'xDWR sY6l H2YxeSpYSYSY0AZT_wdZ)P)x~[|cY[SpY[% p*\+t\j$l_\SJVS\9QB\ged<^ ^(D^EO]^CE ^d_@xlw_T_m_ N4Cd2C'b td-6d>ggedphsG/"hR x].i'xgIi!H/iY[bFiK=,iodfjged<xjg1u)-` klGM(k&5" kzt<[6k|cDk(Do!l&VUj$l=]TKHl![9 ]l!K_lWD PlCE7lged<:[lL a^Pn^ ^%DnIZr nR!Lo4= o<<)@oDo!l]mo0&!=p6=Aq9Q qlw_]< r3\I!r$ bc&r]moIZr=7 mroE sX\=>.sgz/5/Tsso$sJEsU)Ht%Dn TtAl>5=wFt3:!w_\@xh=$jy`l z^Q3Vz>zph{ 2 |K{{(8|gIiu|R 0|RF~| RZwI`%z#+%k*Gu/1,1|3XK3w$4h4G5^P5'6O6yu: ;6?;:><M?+AW C#yCFaFZGsI&F-?@ABJy%~ !3456>~OWijklt+>PQRS[ hy;M_`abj  !"*BPbcdemcq"4567?-?@ABJ()*+3$3EFGHP!"#$,Uk}~.;MNOPXo4ASTUV^ fx !"#+lzFTfghiqQ_qrst|^hz{|}vITfghiq#s#x&89:;D#5678AKXjklmv o;MNOPY"6HIJKTgw1234= BQcdefo,>?@AJ%&'(1<K]^_`i !/ABCDM ,>?@AJ!;Oabcdm&'()2 :FXYZ[d->PQRS\%&'(16\nopqz        H T f g h i r        4 B T U V W `               z       '=OPQR[ +=>?@I);MNOPY&89:;DP_qrst}DZlmnoxr1CDEFO&'()2BWijkluw6FXYZ[dWdvwxy!"#$-  oyW j | } ~   _!n!!!!!!!" "!"""#",""""""""#&#8#9#:#;#D#######$x$$$$$$$$ %%%%%'%&&'&(&)&*&3&&&&&&&&'''''''}(((((((h)x))))))`*o******+'+9+:+;+<+E++++++++,,,,,,,-!-3-4-5-6-?--------o.}......E/T/f/g/h/i/r///////00000000>1O1a1b1c1d1m12)2;2<2=2>2G2223333333333334444444555555566666666 777 7!7*7777777788888889999999:::::::C;S;e;f;g;h;q;c<x<<<<<<=======>!>3>4>5>6>?>??(?)?*?+?4????????,@B@T@U@V@W@`@@@@@@@AAAAAAAA B(B:B;Bp6q7q9q:qrrrrrrrptqtstttutvtnuouquru1v3v4v5v6v8v9vxxxxxxyyyyyyyyyyy{{{{{{||||}}}}}}}ڀۀ݀ހʃ˃̓΃σЃȄɄ˄̄·χч҇Ӈԇ͈̈ψЈߋ݌ތ&()*+-.    !"$%EGHIJLM679:;<4578NPQRSUV?@BCDE=>@AmnpqrsklnoZ\]^_ab<=?@AB:;=>ACDEFHI+,./01)*,-KMNOPRSKLNOPQIJLMRTUVWYZ5689:;3467')*+,./?ABCDFG-.0123+,./ACDEFHI-.0123+,./IKLMNPQ9:<=>?78:;wyz{|~~QSTUVXYvxyz{}~`acdef^_abwxz{|}uvxygijklno]^`abc[\^_Z\]^_abBCEFGH@ACDyz|}~wxz{UWXYZ\]124567/023                            78:;<=5 6 8 9 !!!!!! !""#######$$$$$$$$&&&&&&''''0(2(3(4(5(7(8( *!*#*$*%*&*++!+"+,,,, ,",#,......///////////X1Y1[1\1]1^1V2W2Y2Z22222222444444555566666668888889999:::::::y<z<|<}<~<<w=x=z={=E>G>H>I>J>L>M>??????@@@@@@@@@@@BBBBBBCCCC)D+D,D-D.D0D1D2D3D5D6D7D8D0E1E3E4EEEEEEEEGGGGGGHHHHIIIIIIIKKKKKKLLLL+M-M.M/M0M2M3M O OOOOO P P PPPPPPPPPRRRRRRSSSSTTTTTTTUUUUUUVVVVWWWWWWWdYeYgYhYiYjYbZcZeZfZ[ [ [ [ [[[7\8\:\;\<\=\5]6]8]9]]]]]]]]______````xaza{a|a}aaarcscucvcwcxcpdqdsdtd!e#e$e%e&e(e)eHfIfKfLfMfNfFgGgIgJggggggggiiiiiijjjjkkkkkkk|m}mmmmmzn{n}n~nnnnnnnnnnnnnnooooppppppprrrrrrssss7t9t:t;tt?t3v4v6v7v8v9v1w2w4w5w*x,x-x.x/x1x2xyyyzzzzzzz|||||||}}}}}}~~~~PRSTUWX߄            {|~yz|} ΠРѠҠӠՠ֠bdefgijKLNOPQIJLMޮDzɲʲ˲̲βϲ޵ߵACDEFHIJKMNOPHIKL mnpqrsklno[\^_`aYZ\]3467891245oqrstvwhjklmopSTVWXYQRTUY[\]^`a{}~hjklmopjlmnoqr[\^_`aYZ\]&()*+-.deghijbcefY[\]^`aABDEFG?@BC9;<=>@Ayz|}~wxz{+-./023               | }     z { } ~ L N O P Q S T hiklmnfgij    tuwxyzrsuv[]^_`bcpqstuvnoqr       """"""####1$3$4$5$6$8$9$&&& &!&"&'''''''''''))))))**** , ,,,,,,------....|/~//////a1b1d1e1f1g1_2`2b2c2H3J3K3L3M3O3P35 5"5#5$5%566 6!666666668888889999:::::::;;;;;;<<<<=======??????@@@@AAAAAAACCCCCCDDDDEEEEEEEGGGGGGHHHH6I8I9I:I;I=I>IK K"K#K$K%KLL L!LLLLLLLLNNNNNNOOOOPPPPPPPOQPQRQSQTQUQMRNRPRQRRRRRRRRTTTTTTUUUU5V7V8V9V:VV?VAVBVCVDV?AB~iklmnpqSTVWXYQRTU~bcefgh`acd !"#%&                       ~    EGHIJLM-.0123+,./:;=>?@89;<       !"#$&' !!!!!!""""#######%%%%%%&&&&((( ( ( ( ())))))****+++++++------....///////z1{1}1~111x2y2{2|2r3t3u3v3w3y3z3[5\5^5_5`5a5Y6Z6\6]6e7g7h7i7j7l7m7S9T9V9W9X9Y9Q:R:T:U:-;/;0;1;2;4;5;&='=)=*=+=,=$>%>'>(>?????? ?@@@@@@AAAABBBBBBBDDDDDDEEEEFFFFFFFHHHHHHIIIIJJJJJJJLLLLLLMMMMhNjNkNlNmNoNpNOOOOOOPPPPQQQQQQQRR R R R RSSS STT T T T TTUUUUUUVVVVWWWWWWWYYYYYYZZZZ[[[[[[[L\M\O\P\Q\R\J]K]M]N]^ ^!^"^#^%^&^ ` ````` a a a aaaaaaaaccccccddddweyeze{e|e~eedgeggghgigjgbhchehfhhhhhhhhhhhhhhiiii/j1j2j3j4j6j7j8j9j;jj6k7k9k:klllll l!lmmmmmmnnnnoooooooIpJpLpMpNpOpGqHqJqKqqqqqqqqqqqqqqrrrr=s?s@sAsBsDsEs0u1u3u4u5u6u.v/v1v2vvvvvvvvNxOxQxRxSxTxLyMyOyPyzzz z!z#z$z | | ||||} } } }}}}}}}}~~~~~~Ԁր׀؀ـۀ܀„ÄĄńDŽȄTUWXYZRSUVtvwxy{|hiklmnfgijmnpqrsklno !     ڕەݕޕߕٖؖۖܖOPRSTUMNPQ:<=>?AB  "$%&')*HIKLMNFGIJPRSTUWXԢբעآ٢ڢңӣգ֣5789:<=>?ABCD<=?@ϥѥҥӥԥ֥ץ78:;<=5689HJKLMOP̱ͱϱбѱұʲ˲Ͳβ¶ĶŶƶǶɶʶrtuvwyzWYZ[\^_9:<=>?78:;    :<=>?ABJKMNOPHIKLrtuvwyz\]_`abZ[]^79:;<>?013456./12CEFGHJK-.0123+,./vwyz{|tuwxNPQRSUV5689:;3467wxz{|}uvxyKMNOPRStvwxy{|;<>?@A9:<=                                !!!!!!!######$$$$r%t%u%v%w%y%z%''''' '(((((((((((******++++Q,S,T,U,V,X,Y,i.j.l.m.n.o.g/h/j/k/W0Y0Z0[0\0^0_0<2=2?2@2A2B2:3;3=3>3G4I4J4K4L4N4O4061636465666.7/717278888888999999::::;;;;;;;======>>>>???????AAAAAABBBBCCCCCCCEEEEEEFFFFGGGGGGGIIIIIIJJJJKKKKKKKMMMNNNNNNN]O_O`OaObOdOeOfOgOiOjOkOlOdPePgPhPuQwQxQyQzQ|Q}QbScSeSfSgShS`TaTcTdTUUUUUUUuWvWxWyWzW{WsXtXvXwX[Y]Y^Y_Y`YbYcYA[B[D[E[F[G[?\@\B\C\\\\\\\\\\\\\\]]]]]^_^`^a^b^d^e^_```b`c`d`e`]a^a`aaa-b/b0b1b2b4b5b]c^c`cacbccc[d\d^d_deeeeeee g g g ggghh h hhhhhhhhJiKiMiNiOiPiHjIjKjLjgkikjkkklknkokllllllmmmmn?n@nAnCnDn p!p#p$p%p&pqq!q"qqqqqqqqssssssttttuuuuuuuwwwwwwxxxx\y^y_y`yaycydyyyyyyyzzzzm{o{p{q{r{t{u{^}_}a}b}c}d}\~]~_~`~eghijlmBCEFGH@ACDڈۈ݈ވ߈؉ىۉ܉uvxyz{stvwprstuwxVWYZ[\TUWXkmnoprsvxyz{}~uvxyz{stvw    ~}~{|~    NPQRSUV;<>?@A9:<=*+-./0()+,@BCDEGHIJLMNOGHJK 9;<=>@A%&()*+#$&' "#mnpqrsklno245679:FGIJKLDEGH                           |~vwyz{|tuwxwyz{|~`!a!c!d!e!f!^"_"a"b"v#x#y#z#{#}#~#f%g%i%j%k%l%d&e&g&h&,'.'/'0'1'3'4'R(S(U(V(W(X(P)Q)S)T):*<*=*>*?*A*B*G,H,J,K,L,M,E-F-H-I-...... .@/A/C/D/E/F/>0?0A0B0000000022222233334444444e6f6h6i6j6k6c7d7f7g7Z8\8]8^8_8a8b8+:,:.:/:0:1:);*;,;-;;;;;;;<======>>>>???????&@'@)@*@+@,@$A%A'A(AAAAAAAAQBRBTBUBVBWBOCPCRCSC:DD?DADBD-F.F0F1F2F3F+G,G.G/G"H$H%H&H'H)H*HIIIIIIJJJJ_KaKbKcKdKfKgKKKKKKKLLLLMMMMMMMOOOO O!OPPPPPPPPPPPRRRRRRSSSSTTTTTTTVVVVVV~WWWWXXXXXXXZZZ Z!Z"Z[[[[[[[[[[[t]u]w]x]y]z]r^s^u^v^M_O_P_Q_R_T_U_______````aaaaaaaccccccdddd^e`eaebeceeefeDgEgGgHgIgJgBhChEhFh i iiiiiiiiiiiijjjjnkpkqkrkskukvk4l5l7l8l9l:l2m3m5m6mmmmmmmmnnnnnnooooppppppprrrrrrsssstttttttvvvvvv}w~wwwwwwwwwwwwwwwwwxZyQ{R{}{~{T|U|"#234Acd{΀π؀܁:?WXsw-WXuyz#$%&'(CPQRS()*+,->PQRSfghi| #$%&IJlmno"#'@ MZMZl MZMZ&@2 2!2"2,2-:;<>?ABIJSTXYZfghijrprq*s*tvuvvvwvx))))=>tuwx67;<GHbcqrpp%@ @*,\@8t@HJ@N@R@\@h@np@~ @@$@4@P@X@`@d@<@D@d@b@@$L@j@x@ @0 @P @ @1@UnknownGz Times New Roman5Symbol3& z ArialI& ??Arial Unicode MSK5   MS Gothic-3 0000?5 z Courier New;Wingdings"1 hNfƽf+ J| J| #d4 2QHX)?W2/ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER Compaq_Owner Compaq_Owner`                Oh+'0   8D d p |0ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER Compaq_Owner Normal.dotCompaq_Owner43Microsoft Office Word@v#%@+* @8Gh J՜.+,D՜.+,\ hp|   | ' 0ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER Title$E 8@ _PID_HLINKSAD0&o4https://clinicaltrials.gov/ct2/keydates/NCT02993731H/%3https://clinicaltrials.gov/ct2/archive/NCT02993731Hd4,https://clinicaltrials.gov/show/NCT02993731H!IBhttps://clinicaltrials.gov/ct2/show/study/NCT02993731?show_locs=Ylocnq93https://clinicaltrials.gov/ct2/about-studies/learnH -https://clinicaltrials.gov/ct2/info/fdalinksH<.Ghttps://druginfo.nlm.nih.gov/drugportal/name/Gemcitabine+hydrochlorideHF9https://druginfo.nlm.nih.gov/drugportal/name/GemcitabineHz68https://druginfo.nlm.nih.gov/drugportal/name/PaclitaxelH;c(https://druginfo.nlm.nih.gov/drugportalH"+3https://clinicaltrials.gov/ct2/help/how-read-studyHG5https://clinicaltrials.gov/ct2/about-site/disclaimerH!.8https://clinicaltrials.gov/ct2/show/results/NCT02993731H?v7https://clinicaltrials.gov/ct2/show/record/NCT02993731HXQ6https://clinicaltrials.gov/ct2/show/study/NCT02993731 contactsG5https://clinicaltrials.gov/ct2/about-site/disclaimerH[3https://clinicaltrials.gov/ct2/about-studies/learnConsiderations?e0https://clinicaltrials.gov/ct2/show/NCT02993731H] 9http://click.skem1.com/click/bbu3-q26rk-f9wuxe-63syewy9/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wuxd-63syewy8/HS 9http://click.skem1.com/click/bbu3-q26rk-f9wuxc-63syewy7/HR 9http://click.skem1.com/click/bbu3-q26rk-f9wuxb-63syewy6/HQ9http://click.skem1.com/click/bbu3-q26rk-f9wuxa-63syewy5/HQV9http://click.skem1.com/click/bbu3-q26rk-f9wux9-63syewy5/HPW9http://click.skem1.com/click/bbu3-q26rk-f9wux8-63syewy4/HWX9http://click.skem1.com/click/bbu3-q26rk-f9wux7-63syewy3/HVY9http://click.skem1.com/click/bbu3-q26rk-f9wux6-63syewy2/HUZ9http://click.skem1.com/click/bbu3-q26rk-f9wux5-63syewy1/HT[9http://click.skem1.com/click/bbu3-q26rk-f9wux4-63syewy0/H]\9http://click.skem1.com/click/bbu3-q26rk-f9wux3-63syewy9/H\]9http://click.skem1.com/click/bbu3-q26rk-f9wux2-63syewy8/HS^9http://click.skem1.com/click/bbu3-q26rk-f9wux1-63syewy7/HR_}9http://click.skem1.com/click/bbu3-q26rk-f9wux0-63syewy6/HRz9http://click.skem1.com/click/bbu3-q26rk-f9wuwz-63syewy9/HSw9http://click.skem1.com/click/bbu3-q26rk-f9wuwy-63syewy8/H\q9http://click.skem1.com/click/bbu3-q26rk-f9wuwx-63syewy7/H]n9http://click.skem1.com/click/bbu3-q26rk-f9wuww-63syewy6/H^k9http://click.skem1.com/click/bbu3-q26rk-f9wuwv-63syewy5/H_e9http://click.skem1.com/click/bbu3-q26rk-f9wuwu-63syewy4/HXb9http://click.skem1.com/click/bbu3-q26rk-f9wuwt-63syewy3/HY_9http://click.skem1.com/click/bbu3-q26rk-f9wuws-63syewy2/HZY9http://click.skem1.com/click/bbu3-q26rk-f9wuwr-63syewy1/H[V9http://click.skem1.com/click/bbu3-q26rk-f9wuwq-63syewy0/HRS9http://click.skem1.com/click/bbu3-q26rk-f9wuwp-63syewy9/HSP9http://click.skem1.com/click/bbu3-q26rk-f9wuwo-63syewy8/H\M9http://click.skem1.com/click/bbu3-q26rk-f9wuwn-63syewy7/H]J9http://click.skem1.com/click/bbu3-q26rk-f9wuwm-63syewy6/H^D9http://click.skem1.com/click/bbu3-q26rk-f9wuwl-63syewy5/H_A9http://click.skem1.com/click/bbu3-q26rk-f9wuwk-63syewy4/HX>9http://click.skem1.com/click/bbu3-q26rk-f9wuwj-63syewy3/HY;9http://click.skem1.com/click/bbu3-q26rk-f9wuwi-63syewy2/HZ89http://click.skem1.com/click/bbu3-q26rk-f9wuwh-63syewy1/H[59http://click.skem1.com/click/bbu3-q26rk-f9wuwg-63syewy0/HR /9http://click.skem1.com/click/bbu3-q26rk-f9wuwf-63syewy9/HS ,9http://click.skem1.com/click/bbu3-q26rk-f9wuwe-63syewy8/H\ &9http://click.skem1.com/click/bbu3-q26rk-f9wuwd-63syewy7/H] #9http://click.skem1.com/click/bbu3-q26rk-f9wuwc-63syewy6/H^  9http://click.skem1.com/click/bbu3-q26rk-f9wuwb-63syewy5/H_9http://click.skem1.com/click/bbu3-q26rk-f9wuwa-63syewy4/H_V9http://click.skem1.com/click/bbu3-q26rk-f9wuw9-63syewy4/HXW9http://click.skem1.com/click/bbu3-q26rk-f9wuw8-63syewy3/HYX9http://click.skem1.com/click/bbu3-q26rk-f9wuw7-63syewy2/HZY9http://click.skem1.com/click/bbu3-q26rk-f9wuw6-63syewy1/H[Z 9http://click.skem1.com/click/bbu3-q26rk-f9wuw5-63syewy0/HR[9http://click.skem1.com/click/bbu3-q26rk-f9wuw4-63syewy9/HS\9http://click.skem1.com/click/bbu3-q26rk-f9wuw3-63syewy8/H\]9http://click.skem1.com/click/bbu3-q26rk-f9wuw2-63syewy7/H]^9http://click.skem1.com/click/bbu3-q26rk-f9wuw1-63syewy6/H^_9http://click.skem1.com/click/bbu3-q26rk-f9wuw0-63syewy5/HR9http://click.skem1.com/click/bbu3-q26rk-f9wuvz-63syewy8/H]9http://click.skem1.com/click/bbu3-q26rk-f9wuvy-63syewy7/H\9http://click.skem1.com/click/bbu3-q26rk-f9wuvx-63syewy6/H_9http://click.skem1.com/click/bbu3-q26rk-f9wuvw-63syewy5/H^9http://click.skem1.com/click/bbu3-q26rk-f9wuvv-63syewy4/HY9http://click.skem1.com/click/bbu3-q26rk-f9wuvu-63syewy3/HX9http://click.skem1.com/click/bbu3-q26rk-f9wuvt-63syewy2/H[9http://click.skem1.com/click/bbu3-q26rk-f9wuvs-63syewy1/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wuvr-63syewy0/HS9http://click.skem1.com/click/bbu3-q26rk-f9wuvq-63syewy9/HR9http://click.skem1.com/click/bbu3-q26rk-f9wuvp-63syewy8/H]9http://click.skem1.com/click/bbu3-q26rk-f9wuvo-63syewy7/H\9http://click.skem1.com/click/bbu3-q26rk-f9wuvn-63syewy6/H_9http://click.skem1.com/click/bbu3-q26rk-f9wuvm-63syewy5/H^9http://click.skem1.com/click/bbu3-q26rk-f9wuvl-63syewy4/HY9http://click.skem1.com/click/bbu3-q26rk-f9wuvk-63syewy3/HX9http://click.skem1.com/click/bbu3-q26rk-f9wuvj-63syewy2/H[9http://click.skem1.com/click/bbu3-q26rk-f9wuvi-63syewy1/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wuvh-63syewy0/HS9http://click.skem1.com/click/bbu3-q26rk-f9wuvg-63syewy9/HR 9http://click.skem1.com/click/bbu3-q26rk-f9wuvf-63syewy8/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wuve-63syewy7/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wuvd-63syewy6/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wuvc-63syewy5/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wuvb-63syewy4/HY9http://click.skem1.com/click/bbu3-q26rk-f9wuva-63syewy3/HYV9http://click.skem1.com/click/bbu3-q26rk-f9wuv9-63syewy3/HXW9http://click.skem1.com/click/bbu3-q26rk-f9wuv8-63syewy2/H[X9http://click.skem1.com/click/bbu3-q26rk-f9wuv7-63syewy1/HZY9http://click.skem1.com/click/bbu3-q26rk-f9wuv6-63syewy0/HSZ9http://click.skem1.com/click/bbu3-q26rk-f9wuv5-63syewy9/HR[9http://click.skem1.com/click/bbu3-q26rk-f9wuv4-63syewy8/H]\~9http://click.skem1.com/click/bbu3-q26rk-f9wuv3-63syewy7/H\]{9http://click.skem1.com/click/bbu3-q26rk-f9wuv2-63syewy6/H_^x9http://click.skem1.com/click/bbu3-q26rk-f9wuv1-63syewy5/H^_u9http://click.skem1.com/click/bbu3-q26rk-f9wuv0-63syewy4/H^o9http://click.skem1.com/click/bbu3-q26rk-f9wuuz-63syewy7/H_l9http://click.skem1.com/click/bbu3-q26rk-f9wuuy-63syewy6/H\i9http://click.skem1.com/click/bbu3-q26rk-f9wuux-63syewy5/H]f9http://click.skem1.com/click/bbu3-q26rk-f9wuuw-63syewy4/HZc9http://click.skem1.com/click/bbu3-q26rk-f9wuuv-63syewy3/H[`9http://click.skem1.com/click/bbu3-q26rk-f9wuuu-63syewy2/HXZ9http://click.skem1.com/click/bbu3-q26rk-f9wuut-63syewy1/HYW9http://click.skem1.com/click/bbu3-q26rk-f9wuus-63syewy0/HPT9http://click.skem1.com/click/bbu3-q26rk-f9wuur-63syewy9/HQQ9http://click.skem1.com/click/bbu3-q26rk-f9wuuq-63syewy8/H^N9http://click.skem1.com/click/bbu3-q26rk-f9wuup-63syewy7/H_H9http://click.skem1.com/click/bbu3-q26rk-f9wuuo-63syewy6/H\E9http://click.skem1.com/click/bbu3-q26rk-f9wuun-63syewy5/H]B9http://click.skem1.com/click/bbu3-q26rk-f9wuum-63syewy4/HZ?9http://click.skem1.com/click/bbu3-q26rk-f9wuul-63syewy3/H[<9http://click.skem1.com/click/bbu3-q26rk-f9wuuk-63syewy2/HX99http://click.skem1.com/click/bbu3-q26rk-f9wuuj-63syewy1/HY39http://click.skem1.com/click/bbu3-q26rk-f9wuui-63syewy0/HP09http://click.skem1.com/click/bbu3-q26rk-f9wuuh-63syewy9/HQ-9http://click.skem1.com/click/bbu3-q26rk-f9wuug-63syewy8/H^ *9http://click.skem1.com/click/bbu3-q26rk-f9wuuf-63syewy7/H_ $9http://click.skem1.com/click/bbu3-q26rk-f9wuue-63syewy6/H\ !9http://click.skem1.com/click/bbu3-q26rk-f9wuud-63syewy5/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wuuc-63syewy4/HZ 9http://click.skem1.com/click/bbu3-q26rk-f9wuub-63syewy3/H[9http://click.skem1.com/click/bbu3-q26rk-f9wuua-63syewy2/H[V9http://click.skem1.com/click/bbu3-q26rk-f9wuu9-63syewy2/HXW9http://click.skem1.com/click/bbu3-q26rk-f9wuu8-63syewy1/HYX 9http://click.skem1.com/click/bbu3-q26rk-f9wuu7-63syewy0/HPY 9http://click.skem1.com/click/bbu3-q26rk-f9wuu6-63syewy9/HQZ9http://click.skem1.com/click/bbu3-q26rk-f9wuu5-63syewy8/H^[9http://click.skem1.com/click/bbu3-q26rk-f9wuu4-63syewy7/H_\9http://click.skem1.com/click/bbu3-q26rk-f9wuu3-63syewy6/H\]9http://click.skem1.com/click/bbu3-q26rk-f9wuu2-63syewy5/H]^9http://click.skem1.com/click/bbu3-q26rk-f9wuu1-63syewy4/HZ_9http://click.skem1.com/click/bbu3-q26rk-f9wuu0-63syewy3/H^9http://click.skem1.com/click/bbu3-q26rk-f9wutz-63syewy6/H]9http://click.skem1.com/click/bbu3-q26rk-f9wuty-63syewy5/H\9http://click.skem1.com/click/bbu3-q26rk-f9wutx-63syewy4/H[9http://click.skem1.com/click/bbu3-q26rk-f9wutw-63syewy3/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wutv-63syewy2/HY9http://click.skem1.com/click/bbu3-q26rk-f9wutu-63syewy1/HX9http://click.skem1.com/click/bbu3-q26rk-f9wutt-63syewy0/HQ9http://click.skem1.com/click/bbu3-q26rk-f9wuts-63syewy9/HP9http://click.skem1.com/click/bbu3-q26rk-f9wutr-63syewy8/H_9http://click.skem1.com/click/bbu3-q26rk-f9wutq-63syewy7/H^9http://click.skem1.com/click/bbu3-q26rk-f9wutp-63syewy6/H]9http://click.skem1.com/click/bbu3-q26rk-f9wuto-63syewy5/H\9http://click.skem1.com/click/bbu3-q26rk-f9wutn-63syewy4/H[9http://click.skem1.com/click/bbu3-q26rk-f9wutm-63syewy3/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wutl-63syewy2/HY9http://click.skem1.com/click/bbu3-q26rk-f9wutk-63syewy1/HX9http://click.skem1.com/click/bbu3-q26rk-f9wutj-63syewy0/HQ9http://click.skem1.com/click/bbu3-q26rk-f9wuti-63syewy9/HP9http://click.skem1.com/click/bbu3-q26rk-f9wuth-63syewy8/H_9http://click.skem1.com/click/bbu3-q26rk-f9wutg-63syewy7/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wutf-63syewy6/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wute-63syewy5/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wutd-63syewy4/H[ 9http://click.skem1.com/click/bbu3-q26rk-f9wutc-63syewy3/HZ 9http://click.skem1.com/click/bbu3-q26rk-f9wutb-63syewy2/HY9http://click.skem1.com/click/bbu3-q26rk-f9wuta-63syewy1/HYV9http://click.skem1.com/click/bbu3-q26rk-f9wut9-63syewy1/HXW9http://click.skem1.com/click/bbu3-q26rk-f9wut8-63syewy0/HQX9http://click.skem1.com/click/bbu3-q26rk-f9wut7-63syewy9/HPY9http://click.skem1.com/click/bbu3-q26rk-f9wut6-63syewy8/H_Z9http://click.skem1.com/click/bbu3-q26rk-f9wut5-63syewy7/H^[9http://click.skem1.com/click/bbu3-q26rk-f9wut4-63syewy6/H]\9http://click.skem1.com/click/bbu3-q26rk-f9wut3-63syewy5/H\]|9http://click.skem1.com/click/bbu3-q26rk-f9wut2-63syewy4/H[^y9http://click.skem1.com/click/bbu3-q26rk-f9wut1-63syewy3/HZ_v9http://click.skem1.com/click/bbu3-q26rk-f9wut0-63syewy2/HZs9http://click.skem1.com/click/bbu3-q26rk-f9wusz-63syewy5/H[m9http://click.skem1.com/click/bbu3-q26rk-f9wusy-63syewy4/H\j9http://click.skem1.com/click/bbu3-q26rk-f9wusx-63syewy3/H]g9http://click.skem1.com/click/bbu3-q26rk-f9wusw-63syewy2/H^d9http://click.skem1.com/click/bbu3-q26rk-f9wusv-63syewy1/H_a9http://click.skem1.com/click/bbu3-q26rk-f9wusu-63syewy0/HV^9http://click.skem1.com/click/bbu3-q26rk-f9wust-63syewy9/HWX9http://click.skem1.com/click/bbu3-q26rk-f9wuss-63syewy8/HXU9http://click.skem1.com/click/bbu3-q26rk-f9wusr-63syewy7/HYR9http://click.skem1.com/click/bbu3-q26rk-f9wusq-63syewy6/HZO9http://click.skem1.com/click/bbu3-q26rk-f9wusp-63syewy5/H[L9http://click.skem1.com/click/bbu3-q26rk-f9wuso-63syewy4/H\I9http://click.skem1.com/click/bbu3-q26rk-f9wusn-63syewy3/H]C9http://click.skem1.com/click/bbu3-q26rk-f9wusm-63syewy2/H^@9http://click.skem1.com/click/bbu3-q26rk-f9wusl-63syewy1/H_=9http://click.skem1.com/click/bbu3-q26rk-f9wusk-63syewy0/HV:9http://click.skem1.com/click/bbu3-q26rk-f9wusj-63syewy9/HW79http://click.skem1.com/click/bbu3-q26rk-f9wusi-63syewy8/HX49http://click.skem1.com/click/bbu3-q26rk-f9wush-63syewy7/HY.9http://click.skem1.com/click/bbu3-q26rk-f9wusg-63syewy6/HZ +9http://click.skem1.com/click/bbu3-q26rk-f9wusf-63syewy5/H[ (9http://click.skem1.com/click/bbu3-q26rk-f9wuse-63syewy4/H\ %9http://click.skem1.com/click/bbu3-q26rk-f9wusd-63syewy3/H] "9http://click.skem1.com/click/bbu3-q26rk-f9wusc-63syewy2/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wusb-63syewy1/H_9http://click.skem1.com/click/bbu3-q26rk-f9wusa-63syewy0/H_V9http://click.skem1.com/click/bbu3-q26rk-f9wus9-63syewy0/HVW9http://click.skem1.com/click/bbu3-q26rk-f9wus8-63syewy9/HWX9http://click.skem1.com/click/bbu3-q26rk-f9wus7-63syewy8/HXY 9http://click.skem1.com/click/bbu3-q26rk-f9wus6-63syewy7/HYZ9http://click.skem1.com/click/bbu3-q26rk-f9wus5-63syewy6/HZ[9http://click.skem1.com/click/bbu3-q26rk-f9wus4-63syewy5/H[\9http://click.skem1.com/click/bbu3-q26rk-f9wus3-63syewy4/H\]9http://click.skem1.com/click/bbu3-q26rk-f9wus2-63syewy3/H]^9http://click.skem1.com/click/bbu3-q26rk-f9wus1-63syewy2/H^_9http://click.skem1.com/click/bbu3-q26rk-f9wus0-63syewy1/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wurz-63syewy4/H]9http://click.skem1.com/click/bbu3-q26rk-f9wury-63syewy3/H\9http://click.skem1.com/click/bbu3-q26rk-f9wurx-63syewy2/H_9http://click.skem1.com/click/bbu3-q26rk-f9wurw-63syewy1/H^9http://click.skem1.com/click/bbu3-q26rk-f9wurv-63syewy0/HW9http://click.skem1.com/click/bbu3-q26rk-f9wuru-63syewy9/HV9http://click.skem1.com/click/bbu3-q26rk-f9wurt-63syewy8/HY9http://click.skem1.com/click/bbu3-q26rk-f9wurs-63syewy7/HX9http://click.skem1.com/click/bbu3-q26rk-f9wurr-63syewy6/H[9http://click.skem1.com/click/bbu3-q26rk-f9wurq-63syewy5/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wurp-63syewy4/H]9http://click.skem1.com/click/bbu3-q26rk-f9wuro-63syewy3/H\9http://click.skem1.com/click/bbu3-q26rk-f9wurn-63syewy2/H_9http://click.skem1.com/click/bbu3-q26rk-f9wurm-63syewy1/H^9http://click.skem1.com/click/bbu3-q26rk-f9wurl-63syewy0/HW9http://click.skem1.com/click/bbu3-q26rk-f9wurk-63syewy9/HV9http://click.skem1.com/click/bbu3-q26rk-f9wurj-63syewy8/HY9http://click.skem1.com/click/bbu3-q26rk-f9wuri-63syewy7/HX9http://click.skem1.com/click/bbu3-q26rk-f9wurh-63syewy6/H[9http://click.skem1.com/click/bbu3-q26rk-f9wurg-63syewy5/HZ 9http://click.skem1.com/click/bbu3-q26rk-f9wurf-63syewy4/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wure-63syewy3/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wurd-63syewy2/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wurc-63syewy1/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wurb-63syewy0/HW9http://click.skem1.com/click/bbu3-q26rk-f9wura-63syewy9/HWV9http://click.skem1.com/click/bbu3-q26rk-f9wur9-63syewy9/HVW9http://click.skem1.com/click/bbu3-q26rk-f9wur8-63syewy8/HYX9http://click.skem1.com/click/bbu3-q26rk-f9wur7-63syewy7/HXY9http://click.skem1.com/click/bbu3-q26rk-f9wur6-63syewy6/H[Z9http://click.skem1.com/click/bbu3-q26rk-f9wur5-63syewy5/HZ[9http://click.skem1.com/click/bbu3-q26rk-f9wur4-63syewy4/H]\9http://click.skem1.com/click/bbu3-q26rk-f9wur3-63syewy3/H\]}9http://click.skem1.com/click/bbu3-q26rk-f9wur2-63syewy2/H_^z9http://click.skem1.com/click/bbu3-q26rk-f9wur1-63syewy1/H^_w9http://click.skem1.com/click/bbu3-q26rk-f9wur0-63syewy0/H^t9http://click.skem1.com/click/bbu3-q26rk-f9wuqz-63syewy3/H_n9http://click.skem1.com/click/bbu3-q26rk-f9wuqy-63syewy2/H\h9http://click.skem1.com/click/bbu3-q26rk-f9wuqx-63syewy1/H]e9http://click.skem1.com/click/bbu3-q26rk-f9wuqw-63syewy0/HTb9http://click.skem1.com/click/bbu3-q26rk-f9wuqv-63syewy9/HU_9http://click.skem1.com/click/bbu3-q26rk-f9wuqu-63syewy8/HZ\9http://click.skem1.com/click/bbu3-q26rk-f9wuqt-63syewy7/H[Y9http://click.skem1.com/click/bbu3-q26rk-f9wuqs-63syewy6/HXS9http://click.skem1.com/click/bbu3-q26rk-f9wuqr-63syewy5/HYP9http://click.skem1.com/click/bbu3-q26rk-f9wuqq-63syewy4/H^M9http://click.skem1.com/click/bbu3-q26rk-f9wuqp-63syewy3/H_J9http://click.skem1.com/click/bbu3-q26rk-f9wuqo-63syewy2/H\G9http://click.skem1.com/click/bbu3-q26rk-f9wuqn-63syewy1/H]A9http://click.skem1.com/click/bbu3-q26rk-f9wuqm-63syewy0/HT>9http://click.skem1.com/click/bbu3-q26rk-f9wuql-63syewy9/HU;9http://click.skem1.com/click/bbu3-q26rk-f9wuqk-63syewy8/HZ89http://click.skem1.com/click/bbu3-q26rk-f9wuqj-63syewy7/H[59http://click.skem1.com/click/bbu3-q26rk-f9wuqi-63syewy6/HX29http://click.skem1.com/click/bbu3-q26rk-f9wuqh-63syewy5/HY,9http://click.skem1.com/click/bbu3-q26rk-f9wuqg-63syewy4/H^ )9http://click.skem1.com/click/bbu3-q26rk-f9wuqf-63syewy3/H_ &9http://click.skem1.com/click/bbu3-q26rk-f9wuqe-63syewy2/H\ #9http://click.skem1.com/click/bbu3-q26rk-f9wuqd-63syewy1/H]  9http://click.skem1.com/click/bbu3-q26rk-f9wuqc-63syewy0/HT 9http://click.skem1.com/click/bbu3-q26rk-f9wuqb-63syewy9/HU9http://click.skem1.com/click/bbu3-q26rk-f9wuqa-63syewy8/HUV9http://click.skem1.com/click/bbu3-q26rk-f9wuq9-63syewy8/HZW9http://click.skem1.com/click/bbu3-q26rk-f9wuq8-63syewy7/H[X9http://click.skem1.com/click/bbu3-q26rk-f9wuq7-63syewy6/HXY 9http://click.skem1.com/click/bbu3-q26rk-f9wuq6-63syewy5/HYZ9http://click.skem1.com/click/bbu3-q26rk-f9wuq5-63syewy4/H^[9http://click.skem1.com/click/bbu3-q26rk-f9wuq4-63syewy3/H_\9http://click.skem1.com/click/bbu3-q26rk-f9wuq3-63syewy2/H\]9http://click.skem1.com/click/bbu3-q26rk-f9wuq2-63syewy1/H]^9http://click.skem1.com/click/bbu3-q26rk-f9wuq1-63syewy0/HT_9http://click.skem1.com/click/bbu3-q26rk-f9wuq0-63syewy9/H^9http://click.skem1.com/click/bbu3-q26rk-f9wupz-63syewy2/H]9http://click.skem1.com/click/bbu3-q26rk-f9wupy-63syewy1/H\9http://click.skem1.com/click/bbu3-q26rk-f9wupx-63syewy0/HU9http://click.skem1.com/click/bbu3-q26rk-f9wupw-63syewy9/HT9http://click.skem1.com/click/bbu3-q26rk-f9wupv-63syewy8/H[9http://click.skem1.com/click/bbu3-q26rk-f9wupu-63syewy7/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wupt-63syewy6/HY9http://click.skem1.com/click/bbu3-q26rk-f9wups-63syewy5/HX9http://click.skem1.com/click/bbu3-q26rk-f9wupr-63syewy4/H_9http://click.skem1.com/click/bbu3-q26rk-f9wupq-63syewy3/H^9http://click.skem1.com/click/bbu3-q26rk-f9wupp-63syewy2/H]9http://click.skem1.com/click/bbu3-q26rk-f9wupo-63syewy1/H\9http://click.skem1.com/click/bbu3-q26rk-f9wupn-63syewy0/HU9http://click.skem1.com/click/bbu3-q26rk-f9wupm-63syewy9/HT9http://click.skem1.com/click/bbu3-q26rk-f9wupl-63syewy8/H[9http://click.skem1.com/click/bbu3-q26rk-f9wupk-63syewy7/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wupj-63syewy6/HY9http://click.skem1.com/click/bbu3-q26rk-f9wupi-63syewy5/HX9http://click.skem1.com/click/bbu3-q26rk-f9wuph-63syewy4/H_9http://click.skem1.com/click/bbu3-q26rk-f9wupg-63syewy3/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wupf-63syewy2/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wupe-63syewy1/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wupd-63syewy0/HU 9http://click.skem1.com/click/bbu3-q26rk-f9wupc-63syewy9/HT 9http://click.skem1.com/click/bbu3-q26rk-f9wupb-63syewy8/H[9http://click.skem1.com/click/bbu3-q26rk-f9wupa-63syewy7/H[V9http://click.skem1.com/click/bbu3-q26rk-f9wup9-63syewy7/HZW9http://click.skem1.com/click/bbu3-q26rk-f9wup8-63syewy6/HYX9http://click.skem1.com/click/bbu3-q26rk-f9wup7-63syewy5/HXY9http://click.skem1.com/click/bbu3-q26rk-f9wup6-63syewy4/H_Z9http://click.skem1.com/click/bbu3-q26rk-f9wup5-63syewy3/H^[9http://click.skem1.com/click/bbu3-q26rk-f9wup4-63syewy2/H]\9http://click.skem1.com/click/bbu3-q26rk-f9wup3-63syewy1/H\]~9http://click.skem1.com/click/bbu3-q26rk-f9wup2-63syewy0/HU^{9http://click.skem1.com/click/bbu3-q26rk-f9wup1-63syewy9/HT_u9http://click.skem1.com/click/bbu3-q26rk-f9wup0-63syewy8/HBr9http://click.skem1.com/click/bbu3-q26rk-f9wuoz-63syewy1/HCo9http://click.skem1.com/click/bbu3-q26rk-f9wuoy-63syewy0/HJl9http://click.skem1.com/click/bbu3-q26rk-f9wuox-63syewy9/HKi9http://click.skem1.com/click/bbu3-q26rk-f9wuow-63syewy8/HDf9http://click.skem1.com/click/bbu3-q26rk-f9wuov-63syewy7/HE`9http://click.skem1.com/click/bbu3-q26rk-f9wuou-63syewy6/HF]9http://click.skem1.com/click/bbu3-q26rk-f9wuot-63syewy5/HGZ9http://click.skem1.com/click/bbu3-q26rk-f9wuos-63syewy4/H@W9http://click.skem1.com/click/bbu3-q26rk-f9wuor-63syewy3/HAT9http://click.skem1.com/click/bbu3-q26rk-f9wuoq-63syewy2/HBQ9http://click.skem1.com/click/bbu3-q26rk-f9wuop-63syewy1/HCK9http://click.skem1.com/click/bbu3-q26rk-f9wuoo-63syewy0/HJH9http://click.skem1.com/click/bbu3-q26rk-f9wuon-63syewy9/HKE9http://click.skem1.com/click/bbu3-q26rk-f9wuom-63syewy8/HDB9http://click.skem1.com/click/bbu3-q26rk-f9wuol-63syewy7/HE?9http://click.skem1.com/click/bbu3-q26rk-f9wuok-63syewy6/HF<9http://click.skem1.com/click/bbu3-q26rk-f9wuoj-63syewy5/HG69http://click.skem1.com/click/bbu3-q26rk-f9wuoi-63syewy4/H@39http://click.skem1.com/click/bbu3-q26rk-f9wuoh-63syewy3/HA09http://click.skem1.com/click/bbu3-q26rk-f9wuog-63syewy2/HB -9http://click.skem1.com/click/bbu3-q26rk-f9wuof-63syewy1/HC *9http://click.skem1.com/click/bbu3-q26rk-f9wuoe-63syewy0/HJ '9http://click.skem1.com/click/bbu3-q26rk-f9wuod-63syewy9/HK !9http://click.skem1.com/click/bbu3-q26rk-f9wuoc-63syewy8/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wuob-63syewy7/HE9http://click.skem1.com/click/bbu3-q26rk-f9wuoa-63syewy6/HEV9http://click.skem1.com/click/bbu3-q26rk-f9wuo9-63syewy6/HFW9http://click.skem1.com/click/bbu3-q26rk-f9wuo8-63syewy5/HGX9http://click.skem1.com/click/bbu3-q26rk-f9wuo7-63syewy4/H@Y 9http://click.skem1.com/click/bbu3-q26rk-f9wuo6-63syewy3/HAZ 9http://click.skem1.com/click/bbu3-q26rk-f9wuo5-63syewy2/HB[9http://click.skem1.com/click/bbu3-q26rk-f9wuo4-63syewy1/HC\9http://click.skem1.com/click/bbu3-q26rk-f9wuo3-63syewy0/HJ]9http://click.skem1.com/click/bbu3-q26rk-f9wuo2-63syewy9/HK^9http://click.skem1.com/click/bbu3-q26rk-f9wuo1-63syewy8/HD_9http://click.skem1.com/click/bbu3-q26rk-f9wuo0-63syewy7/HB9http://click.skem1.com/click/bbu3-q26rk-f9wunz-63syewy0/HK9http://click.skem1.com/click/bbu3-q26rk-f9wuny-63syewy9/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wunx-63syewy8/HE9http://click.skem1.com/click/bbu3-q26rk-f9wunw-63syewy7/HD9http://click.skem1.com/click/bbu3-q26rk-f9wunv-63syewy6/HG9http://click.skem1.com/click/bbu3-q26rk-f9wunu-63syewy5/HF9http://click.skem1.com/click/bbu3-q26rk-f9wunt-63syewy4/HA9http://click.skem1.com/click/bbu3-q26rk-f9wuns-63syewy3/H@9http://click.skem1.com/click/bbu3-q26rk-f9wunr-63syewy2/HC9http://click.skem1.com/click/bbu3-q26rk-f9wunq-63syewy1/HB9http://click.skem1.com/click/bbu3-q26rk-f9wunp-63syewy0/HK9http://click.skem1.com/click/bbu3-q26rk-f9wuno-63syewy9/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wunn-63syewy8/HE9http://click.skem1.com/click/bbu3-q26rk-f9wunm-63syewy7/HD9http://click.skem1.com/click/bbu3-q26rk-f9wunl-63syewy6/HG9http://click.skem1.com/click/bbu3-q26rk-f9wunk-63syewy5/HF9http://click.skem1.com/click/bbu3-q26rk-f9wunj-63syewy4/HA9http://click.skem1.com/click/bbu3-q26rk-f9wuni-63syewy3/H@9http://click.skem1.com/click/bbu3-q26rk-f9wunh-63syewy2/HC9http://click.skem1.com/click/bbu3-q26rk-f9wung-63syewy1/HB 9http://click.skem1.com/click/bbu3-q26rk-f9wunf-63syewy0/HK 9http://click.skem1.com/click/bbu3-q26rk-f9wune-63syewy9/HJ 9http://click.skem1.com/click/bbu3-q26rk-f9wund-63syewy8/HE 9http://click.skem1.com/click/bbu3-q26rk-f9wunc-63syewy7/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wunb-63syewy6/HG9http://click.skem1.com/click/bbu3-q26rk-f9wuna-63syewy5/HGV9http://click.skem1.com/click/bbu3-q26rk-f9wun9-63syewy5/HFW9http://click.skem1.com/click/bbu3-q26rk-f9wun8-63syewy4/HAX9http://click.skem1.com/click/bbu3-q26rk-f9wun7-63syewy3/H@Y9http://click.skem1.com/click/bbu3-q26rk-f9wun6-63syewy2/HCZ9http://click.skem1.com/click/bbu3-q26rk-f9wun5-63syewy1/HB[9http://click.skem1.com/click/bbu3-q26rk-f9wun4-63syewy0/HK\9http://click.skem1.com/click/bbu3-q26rk-f9wun3-63syewy9/HJ]9http://click.skem1.com/click/bbu3-q26rk-f9wun2-63syewy8/HE^|9http://click.skem1.com/click/bbu3-q26rk-f9wun1-63syewy7/HD_y9http://click.skem1.com/click/bbu3-q26rk-f9wun0-63syewy6/HHv9http://click.skem1.com/click/bbu3-q26rk-f9wumz-63syewy9/HIs9http://click.skem1.com/click/bbu3-q26rk-f9wumy-63syewy8/HFp9http://click.skem1.com/click/bbu3-q26rk-f9wumx-63syewy7/HGj9http://click.skem1.com/click/bbu3-q26rk-f9wumw-63syewy6/HDg9http://click.skem1.com/click/bbu3-q26rk-f9wumv-63syewy5/HEa9http://click.skem1.com/click/bbu3-q26rk-f9wumu-63syewy4/HB^9http://click.skem1.com/click/bbu3-q26rk-f9wumt-63syewy3/HC[9http://click.skem1.com/click/bbu3-q26rk-f9wums-63syewy2/H@X9http://click.skem1.com/click/bbu3-q26rk-f9wumr-63syewy1/HAU9http://click.skem1.com/click/bbu3-q26rk-f9wumq-63syewy0/HHR9http://click.skem1.com/click/bbu3-q26rk-f9wump-63syewy9/HIL9http://click.skem1.com/click/bbu3-q26rk-f9wumo-63syewy8/HFI9http://click.skem1.com/click/bbu3-q26rk-f9wumn-63syewy7/HGF9http://click.skem1.com/click/bbu3-q26rk-f9wumm-63syewy6/HDC9http://click.skem1.com/click/bbu3-q26rk-f9wuml-63syewy5/HE@9http://click.skem1.com/click/bbu3-q26rk-f9wumk-63syewy4/HB=9http://click.skem1.com/click/bbu3-q26rk-f9wumj-63syewy3/HC79http://click.skem1.com/click/bbu3-q26rk-f9wumi-63syewy2/H@49http://click.skem1.com/click/bbu3-q26rk-f9wumh-63syewy1/HA19http://click.skem1.com/click/bbu3-q26rk-f9wumg-63syewy0/HH .9http://click.skem1.com/click/bbu3-q26rk-f9wumf-63syewy9/HI +9http://click.skem1.com/click/bbu3-q26rk-f9wume-63syewy8/HF (9http://click.skem1.com/click/bbu3-q26rk-f9wumd-63syewy7/HG "9http://click.skem1.com/click/bbu3-q26rk-f9wumc-63syewy6/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wumb-63syewy5/HE9http://click.skem1.com/click/bbu3-q26rk-f9wuma-63syewy4/HEV9http://click.skem1.com/click/bbu3-q26rk-f9wum9-63syewy4/HBW9http://click.skem1.com/click/bbu3-q26rk-f9wum8-63syewy3/HCX9http://click.skem1.com/click/bbu3-q26rk-f9wum7-63syewy2/H@Y 9http://click.skem1.com/click/bbu3-q26rk-f9wum6-63syewy1/HAZ9http://click.skem1.com/click/bbu3-q26rk-f9wum5-63syewy0/HH[9http://click.skem1.com/click/bbu3-q26rk-f9wum4-63syewy9/HI\9http://click.skem1.com/click/bbu3-q26rk-f9wum3-63syewy8/HF]9http://click.skem1.com/click/bbu3-q26rk-f9wum2-63syewy7/HG^9http://click.skem1.com/click/bbu3-q26rk-f9wum1-63syewy6/HD_9http://click.skem1.com/click/bbu3-q26rk-f9wum0-63syewy5/HH9http://click.skem1.com/click/bbu3-q26rk-f9wulz-63syewy8/HG9http://click.skem1.com/click/bbu3-q26rk-f9wuly-63syewy7/HF9http://click.skem1.com/click/bbu3-q26rk-f9wulx-63syewy6/HE9http://click.skem1.com/click/bbu3-q26rk-f9wulw-63syewy5/HD9http://click.skem1.com/click/bbu3-q26rk-f9wulv-63syewy4/HC9http://click.skem1.com/click/bbu3-q26rk-f9wulu-63syewy3/HB9http://click.skem1.com/click/bbu3-q26rk-f9wult-63syewy2/HA9http://click.skem1.com/click/bbu3-q26rk-f9wuls-63syewy1/H@9http://click.skem1.com/click/bbu3-q26rk-f9wulr-63syewy0/HI9http://click.skem1.com/click/bbu3-q26rk-f9wulq-63syewy9/HH9http://click.skem1.com/click/bbu3-q26rk-f9wulp-63syewy8/HG9http://click.skem1.com/click/bbu3-q26rk-f9wulo-63syewy7/HF9http://click.skem1.com/click/bbu3-q26rk-f9wuln-63syewy6/HE9http://click.skem1.com/click/bbu3-q26rk-f9wulm-63syewy5/HD9http://click.skem1.com/click/bbu3-q26rk-f9wull-63syewy4/HC9http://click.skem1.com/click/bbu3-q26rk-f9wulk-63syewy3/HB9http://click.skem1.com/click/bbu3-q26rk-f9wulj-63syewy2/HA9http://click.skem1.com/click/bbu3-q26rk-f9wuli-63syewy1/H@9http://click.skem1.com/click/bbu3-q26rk-f9wulh-63syewy0/HI9http://click.skem1.com/click/bbu3-q26rk-f9wulg-63syewy9/HH 9http://click.skem1.com/click/bbu3-q26rk-f9wulf-63syewy8/HG 9http://click.skem1.com/click/bbu3-q26rk-f9wule-63syewy7/HF 9http://click.skem1.com/click/bbu3-q26rk-f9wuld-63syewy6/HE 9http://click.skem1.com/click/bbu3-q26rk-f9wulc-63syewy5/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wulb-63syewy4/HC9http://click.skem1.com/click/bbu3-q26rk-f9wula-63syewy3/HCV9http://click.skem1.com/click/bbu3-q26rk-f9wul9-63syewy3/HBW9http://click.skem1.com/click/bbu3-q26rk-f9wul8-63syewy2/HAX9http://click.skem1.com/click/bbu3-q26rk-f9wul7-63syewy1/H@Y9http://click.skem1.com/click/bbu3-q26rk-f9wul6-63syewy0/HIZ9http://click.skem1.com/click/bbu3-q26rk-f9wul5-63syewy9/HH[9http://click.skem1.com/click/bbu3-q26rk-f9wul4-63syewy8/HG\}9http://click.skem1.com/click/bbu3-q26rk-f9wul3-63syewy7/HF]z9http://click.skem1.com/click/bbu3-q26rk-f9wul2-63syewy6/HE^w9http://click.skem1.com/click/bbu3-q26rk-f9wul1-63syewy5/HD_q9http://click.skem1.com/click/bbu3-q26rk-f9wul0-63syewy4/H@n9http://click.skem1.com/click/bbu3-q26rk-f9wukz-63syewy7/HAk9http://click.skem1.com/click/bbu3-q26rk-f9wuky-63syewy6/HBh9http://click.skem1.com/click/bbu3-q26rk-f9wukx-63syewy5/HCe9http://click.skem1.com/click/bbu3-q26rk-f9wukw-63syewy4/HDb9http://click.skem1.com/click/bbu3-q26rk-f9wukv-63syewy3/HE\9http://click.skem1.com/click/bbu3-q26rk-f9wuku-63syewy2/HFY9http://click.skem1.com/click/bbu3-q26rk-f9wukt-63syewy1/HGV9http://click.skem1.com/click/bbu3-q26rk-f9wuks-63syewy0/HNS9http://click.skem1.com/click/bbu3-q26rk-f9wukr-63syewy9/HOP9http://click.skem1.com/click/bbu3-q26rk-f9wukq-63syewy8/H@M9http://click.skem1.com/click/bbu3-q26rk-f9wukp-63syewy7/HAG9http://click.skem1.com/click/bbu3-q26rk-f9wuko-63syewy6/HBD9http://click.skem1.com/click/bbu3-q26rk-f9wukn-63syewy5/HCA9http://click.skem1.com/click/bbu3-q26rk-f9wukm-63syewy4/HD>9http://click.skem1.com/click/bbu3-q26rk-f9wukl-63syewy3/HE;9http://click.skem1.com/click/bbu3-q26rk-f9wukk-63syewy2/HF89http://click.skem1.com/click/bbu3-q26rk-f9wukj-63syewy1/HG29http://click.skem1.com/click/bbu3-q26rk-f9wuki-63syewy0/HN/9http://click.skem1.com/click/bbu3-q26rk-f9wukh-63syewy9/HO,9http://click.skem1.com/click/bbu3-q26rk-f9wukg-63syewy8/H@ )9http://click.skem1.com/click/bbu3-q26rk-f9wukf-63syewy7/HA &9http://click.skem1.com/click/bbu3-q26rk-f9wuke-63syewy6/HB #9http://click.skem1.com/click/bbu3-q26rk-f9wukd-63syewy5/HC 9http://click.skem1.com/click/bbu3-q26rk-f9wukc-63syewy4/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wukb-63syewy3/HE9http://click.skem1.com/click/bbu3-q26rk-f9wuka-63syewy2/HEV9http://click.skem1.com/click/bbu3-q26rk-f9wuk9-63syewy2/HFW9http://click.skem1.com/click/bbu3-q26rk-f9wuk8-63syewy1/HGX9http://click.skem1.com/click/bbu3-q26rk-f9wuk7-63syewy0/HNY9http://click.skem1.com/click/bbu3-q26rk-f9wuk6-63syewy9/HOZ9http://click.skem1.com/click/bbu3-q26rk-f9wuk5-63syewy8/H@[9http://click.skem1.com/click/bbu3-q26rk-f9wuk4-63syewy7/HA\9http://click.skem1.com/click/bbu3-q26rk-f9wuk3-63syewy6/HB]9http://click.skem1.com/click/bbu3-q26rk-f9wuk2-63syewy5/HC^9http://click.skem1.com/click/bbu3-q26rk-f9wuk1-63syewy4/HD_9http://click.skem1.com/click/bbu3-q26rk-f9wuk0-63syewy3/H@9http://click.skem1.com/click/bbu3-q26rk-f9wujz-63syewy6/HC9http://click.skem1.com/click/bbu3-q26rk-f9wujy-63syewy5/HB9http://click.skem1.com/click/bbu3-q26rk-f9wujx-63syewy4/HE9http://click.skem1.com/click/bbu3-q26rk-f9wujw-63syewy3/HD9http://click.skem1.com/click/bbu3-q26rk-f9wujv-63syewy2/HG9http://click.skem1.com/click/bbu3-q26rk-f9wuju-63syewy1/HF9http://click.skem1.com/click/bbu3-q26rk-f9wujt-63syewy0/HO9http://click.skem1.com/click/bbu3-q26rk-f9wujs-63syewy9/HN9http://click.skem1.com/click/bbu3-q26rk-f9wujr-63syewy8/HA9http://click.skem1.com/click/bbu3-q26rk-f9wujq-63syewy7/H@9http://click.skem1.com/click/bbu3-q26rk-f9wujp-63syewy6/HC9http://click.skem1.com/click/bbu3-q26rk-f9wujo-63syewy5/HB9http://click.skem1.com/click/bbu3-q26rk-f9wujn-63syewy4/HE9http://click.skem1.com/click/bbu3-q26rk-f9wujm-63syewy3/HD9http://click.skem1.com/click/bbu3-q26rk-f9wujl-63syewy2/HG9http://click.skem1.com/click/bbu3-q26rk-f9wujk-63syewy1/HF9http://click.skem1.com/click/bbu3-q26rk-f9wujj-63syewy0/HO9http://click.skem1.com/click/bbu3-q26rk-f9wuji-63syewy9/HN9http://click.skem1.com/click/bbu3-q26rk-f9wujh-63syewy8/HA9http://click.skem1.com/click/bbu3-q26rk-f9wujg-63syewy7/H@ 9http://click.skem1.com/click/bbu3-q26rk-f9wujf-63syewy6/HC 9http://click.skem1.com/click/bbu3-q26rk-f9wuje-63syewy5/HB 9http://click.skem1.com/click/bbu3-q26rk-f9wujd-63syewy4/HE 9http://click.skem1.com/click/bbu3-q26rk-f9wujc-63syewy3/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wujb-63syewy2/HG9http://click.skem1.com/click/bbu3-q26rk-f9wuja-63syewy1/HGV9http://click.skem1.com/click/bbu3-q26rk-f9wuj9-63syewy1/HFW9http://click.skem1.com/click/bbu3-q26rk-f9wuj8-63syewy0/HOX9http://click.skem1.com/click/bbu3-q26rk-f9wuj7-63syewy9/HNY9http://click.skem1.com/click/bbu3-q26rk-f9wuj6-63syewy8/HAZ9http://click.skem1.com/click/bbu3-q26rk-f9wuj5-63syewy7/H@[9http://click.skem1.com/click/bbu3-q26rk-f9wuj4-63syewy6/HC\9http://click.skem1.com/click/bbu3-q26rk-f9wuj3-63syewy5/HB]~9http://click.skem1.com/click/bbu3-q26rk-f9wuj2-63syewy4/HE^x9http://click.skem1.com/click/bbu3-q26rk-f9wuj1-63syewy3/HD_u9http://click.skem1.com/click/bbu3-q26rk-f9wuj0-63syewy2/H@r9http://click.skem1.com/click/bbu3-q26rk-f9wuiz-63syewy5/HAo9http://click.skem1.com/click/bbu3-q26rk-f9wuiy-63syewy4/HFl9http://click.skem1.com/click/bbu3-q26rk-f9wuix-63syewy3/HGi9http://click.skem1.com/click/bbu3-q26rk-f9wuiw-63syewy2/HDc9http://click.skem1.com/click/bbu3-q26rk-f9wuiv-63syewy1/HE`9http://click.skem1.com/click/bbu3-q26rk-f9wuiu-63syewy0/HL]9http://click.skem1.com/click/bbu3-q26rk-f9wuit-63syewy9/HMZ9http://click.skem1.com/click/bbu3-q26rk-f9wuis-63syewy8/HBW9http://click.skem1.com/click/bbu3-q26rk-f9wuir-63syewy7/HCT9http://click.skem1.com/click/bbu3-q26rk-f9wuiq-63syewy6/H@N9http://click.skem1.com/click/bbu3-q26rk-f9wuip-63syewy5/HAK9http://click.skem1.com/click/bbu3-q26rk-f9wuio-63syewy4/HFH9http://click.skem1.com/click/bbu3-q26rk-f9wuin-63syewy3/HGE9http://click.skem1.com/click/bbu3-q26rk-f9wuim-63syewy2/HDB9http://click.skem1.com/click/bbu3-q26rk-f9wuil-63syewy1/HE?9http://click.skem1.com/click/bbu3-q26rk-f9wuik-63syewy0/HL99http://click.skem1.com/click/bbu3-q26rk-f9wuij-63syewy9/HM69http://click.skem1.com/click/bbu3-q26rk-f9wuii-63syewy8/HB39http://click.skem1.com/click/bbu3-q26rk-f9wuih-63syewy7/HC09http://click.skem1.com/click/bbu3-q26rk-f9wuig-63syewy6/H@ -9http://click.skem1.com/click/bbu3-q26rk-f9wuif-63syewy5/HA *9http://click.skem1.com/click/bbu3-q26rk-f9wuie-63syewy4/HF $9http://click.skem1.com/click/bbu3-q26rk-f9wuid-63syewy3/HG !9http://click.skem1.com/click/bbu3-q26rk-f9wuic-63syewy2/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wuib-63syewy1/HE9http://click.skem1.com/click/bbu3-q26rk-f9wuia-63syewy0/HEV9http://click.skem1.com/click/bbu3-q26rk-f9wui9-63syewy0/HLW9http://click.skem1.com/click/bbu3-q26rk-f9wui8-63syewy9/HMX9http://click.skem1.com/click/bbu3-q26rk-f9wui7-63syewy8/HBY 9http://click.skem1.com/click/bbu3-q26rk-f9wui6-63syewy7/HCZ 9http://click.skem1.com/click/bbu3-q26rk-f9wui5-63syewy6/H@[9http://click.skem1.com/click/bbu3-q26rk-f9wui4-63syewy5/HA\9http://click.skem1.com/click/bbu3-q26rk-f9wui3-63syewy4/HF]9http://click.skem1.com/click/bbu3-q26rk-f9wui2-63syewy3/HG^9http://click.skem1.com/click/bbu3-q26rk-f9wui1-63syewy2/HD_9http://click.skem1.com/click/bbu3-q26rk-f9wui0-63syewy1/H@9http://click.skem1.com/click/bbu3-q26rk-f9wuhz-63syewy4/HG9http://click.skem1.com/click/bbu3-q26rk-f9wuhy-63syewy3/HF9http://click.skem1.com/click/bbu3-q26rk-f9wuhx-63syewy2/HE9http://click.skem1.com/click/bbu3-q26rk-f9wuhw-63syewy1/HD9http://click.skem1.com/click/bbu3-q26rk-f9wuhv-63syewy0/HM9http://click.skem1.com/click/bbu3-q26rk-f9wuhu-63syewy9/HL9http://click.skem1.com/click/bbu3-q26rk-f9wuht-63syewy8/HC9http://click.skem1.com/click/bbu3-q26rk-f9wuhs-63syewy7/HB9http://click.skem1.com/click/bbu3-q26rk-f9wuhr-63syewy6/HA9http://click.skem1.com/click/bbu3-q26rk-f9wuhq-63syewy5/H@9http://click.skem1.com/click/bbu3-q26rk-f9wuhp-63syewy4/HG9http://click.skem1.com/click/bbu3-q26rk-f9wuho-63syewy3/HF9http://click.skem1.com/click/bbu3-q26rk-f9wuhn-63syewy2/HE9http://click.skem1.com/click/bbu3-q26rk-f9wuhm-63syewy1/HD9http://click.skem1.com/click/bbu3-q26rk-f9wuhl-63syewy0/HM9http://click.skem1.com/click/bbu3-q26rk-f9wuhk-63syewy9/HL9http://click.skem1.com/click/bbu3-q26rk-f9wuhj-63syewy8/HC9http://click.skem1.com/click/bbu3-q26rk-f9wuhi-63syewy7/HB9http://click.skem1.com/click/bbu3-q26rk-f9wuhh-63syewy6/HA9http://click.skem1.com/click/bbu3-q26rk-f9wuhg-63syewy5/H@ 9http://click.skem1.com/click/bbu3-q26rk-f9wuhf-63syewy4/HG 9http://click.skem1.com/click/bbu3-q26rk-f9wuhe-63syewy3/HF 9http://click.skem1.com/click/bbu3-q26rk-f9wuhd-63syewy2/HE 9http://click.skem1.com/click/bbu3-q26rk-f9wuhc-63syewy1/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wuhb-63syewy0/HM9http://click.skem1.com/click/bbu3-q26rk-f9wuha-63syewy9/HMV9http://click.skem1.com/click/bbu3-q26rk-f9wuh9-63syewy9/HLW9http://click.skem1.com/click/bbu3-q26rk-f9wuh8-63syewy8/HCX9http://click.skem1.com/click/bbu3-q26rk-f9wuh7-63syewy7/HBY9http://click.skem1.com/click/bbu3-q26rk-f9wuh6-63syewy6/HAZ9http://click.skem1.com/click/bbu3-q26rk-f9wuh5-63syewy5/H@[9http://click.skem1.com/click/bbu3-q26rk-f9wuh4-63syewy4/HG\|9http://click.skem1.com/click/bbu3-q26rk-f9wuh3-63syewy3/HF]y9http://click.skem1.com/click/bbu3-q26rk-f9wuh2-63syewy2/HE^v9http://click.skem1.com/click/bbu3-q26rk-f9wuh1-63syewy1/HD_s9http://click.skem1.com/click/bbu3-q26rk-f9wuh0-63syewy0/HHp9http://click.skem1.com/click/bbu3-q26rk-f9wugz-63syewy3/HIm9http://click.skem1.com/click/bbu3-q26rk-f9wugy-63syewy2/HJg9http://click.skem1.com/click/bbu3-q26rk-f9wugx-63syewy1/HKd9http://click.skem1.com/click/bbu3-q26rk-f9wugw-63syewy0/HBa9http://click.skem1.com/click/bbu3-q26rk-f9wugv-63syewy9/HC^9http://click.skem1.com/click/bbu3-q26rk-f9wugu-63syewy8/HL[9http://click.skem1.com/click/bbu3-q26rk-f9wugt-63syewy7/HMX9http://click.skem1.com/click/bbu3-q26rk-f9wugs-63syewy6/HNR9http://click.skem1.com/click/bbu3-q26rk-f9wugr-63syewy5/HOO9http://click.skem1.com/click/bbu3-q26rk-f9wugq-63syewy4/HHL9http://click.skem1.com/click/bbu3-q26rk-f9wugp-63syewy3/HII9http://click.skem1.com/click/bbu3-q26rk-f9wugo-63syewy2/HJF9http://click.skem1.com/click/bbu3-q26rk-f9wugn-63syewy1/HKC9http://click.skem1.com/click/bbu3-q26rk-f9wugm-63syewy0/HB=9http://click.skem1.com/click/bbu3-q26rk-f9wugl-63syewy9/HC:9http://click.skem1.com/click/bbu3-q26rk-f9wugk-63syewy8/HL79http://click.skem1.com/click/bbu3-q26rk-f9wugj-63syewy7/HM49http://click.skem1.com/click/bbu3-q26rk-f9wugi-63syewy6/HN19http://click.skem1.com/click/bbu3-q26rk-f9wugh-63syewy5/HO+9http://click.skem1.com/click/bbu3-q26rk-f9wugg-63syewy4/HH (9http://click.skem1.com/click/bbu3-q26rk-f9wugf-63syewy3/HI %9http://click.skem1.com/click/bbu3-q26rk-f9wuge-63syewy2/HJ "9http://click.skem1.com/click/bbu3-q26rk-f9wugd-63syewy1/HK 9http://click.skem1.com/click/bbu3-q26rk-f9wugc-63syewy0/HB 9http://click.skem1.com/click/bbu3-q26rk-f9wugb-63syewy9/HC9http://click.skem1.com/click/bbu3-q26rk-f9wuga-63syewy8/HCV9http://click.skem1.com/click/bbu3-q26rk-f9wug9-63syewy8/HLW9http://click.skem1.com/click/bbu3-q26rk-f9wug8-63syewy7/HMX 9http://click.skem1.com/click/bbu3-q26rk-f9wug7-63syewy6/HNY 9http://click.skem1.com/click/bbu3-q26rk-f9wug6-63syewy5/HOZ9http://click.skem1.com/click/bbu3-q26rk-f9wug5-63syewy4/HH[9http://click.skem1.com/click/bbu3-q26rk-f9wug4-63syewy3/HI\9http://click.skem1.com/click/bbu3-q26rk-f9wug3-63syewy2/HJ]9http://click.skem1.com/click/bbu3-q26rk-f9wug2-63syewy1/HK^9http://click.skem1.com/click/bbu3-q26rk-f9wug1-63syewy0/HB_9http://click.skem1.com/click/bbu3-q26rk-f9wug0-63syewy9/HH9http://click.skem1.com/click/bbu3-q26rk-f9wufz-63syewy2/HK9http://click.skem1.com/click/bbu3-q26rk-f9wufy-63syewy1/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wufx-63syewy0/HC9http://click.skem1.com/click/bbu3-q26rk-f9wufw-63syewy9/HB9http://click.skem1.com/click/bbu3-q26rk-f9wufv-63syewy8/HM9http://click.skem1.com/click/bbu3-q26rk-f9wufu-63syewy7/HL9http://click.skem1.com/click/bbu3-q26rk-f9wuft-63syewy6/HO9http://click.skem1.com/click/bbu3-q26rk-f9wufs-63syewy5/HN9http://click.skem1.com/click/bbu3-q26rk-f9wufr-63syewy4/HI9http://click.skem1.com/click/bbu3-q26rk-f9wufq-63syewy3/HH9http://click.skem1.com/click/bbu3-q26rk-f9wufp-63syewy2/HK9http://click.skem1.com/click/bbu3-q26rk-f9wufo-63syewy1/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wufn-63syewy0/HC9http://click.skem1.com/click/bbu3-q26rk-f9wufm-63syewy9/HB9http://click.skem1.com/click/bbu3-q26rk-f9wufl-63syewy8/HM9http://click.skem1.com/click/bbu3-q26rk-f9wufk-63syewy7/HL9http://click.skem1.com/click/bbu3-q26rk-f9wufj-63syewy6/HO9http://click.skem1.com/click/bbu3-q26rk-f9wufi-63syewy5/HN9http://click.skem1.com/click/bbu3-q26rk-f9wufh-63syewy4/HI9http://click.skem1.com/click/bbu3-q26rk-f9wufg-63syewy3/HH 9http://click.skem1.com/click/bbu3-q26rk-f9wuff-63syewy2/HK 9http://click.skem1.com/click/bbu3-q26rk-f9wufe-63syewy1/HJ 9http://click.skem1.com/click/bbu3-q26rk-f9wufd-63syewy0/HC 9http://click.skem1.com/click/bbu3-q26rk-f9wufc-63syewy9/HB 9http://click.skem1.com/click/bbu3-q26rk-f9wufb-63syewy8/HM9http://click.skem1.com/click/bbu3-q26rk-f9wufa-63syewy7/HMV9http://click.skem1.com/click/bbu3-q26rk-f9wuf9-63syewy7/HLW9http://click.skem1.com/click/bbu3-q26rk-f9wuf8-63syewy6/HOX9http://click.skem1.com/click/bbu3-q26rk-f9wuf7-63syewy5/HNY9http://click.skem1.com/click/bbu3-q26rk-f9wuf6-63syewy4/HIZ9http://click.skem1.com/click/bbu3-q26rk-f9wuf5-63syewy3/HH[9http://click.skem1.com/click/bbu3-q26rk-f9wuf4-63syewy2/HK\9http://click.skem1.com/click/bbu3-q26rk-f9wuf3-63syewy1/HJ]}9http://click.skem1.com/click/bbu3-q26rk-f9wuf2-63syewy0/HC^z9http://click.skem1.com/click/bbu3-q26rk-f9wuf1-63syewy9/HB_t9http://click.skem1.com/click/bbu3-q26rk-f9wuf0-63syewy8/HHq9http://click.skem1.com/click/bbu3-q26rk-f9wuez-63syewy1/HIn9http://click.skem1.com/click/bbu3-q26rk-f9wuey-63syewy0/H@k9http://click.skem1.com/click/bbu3-q26rk-f9wuex-63syewy9/HAe9http://click.skem1.com/click/bbu3-q26rk-f9wuew-63syewy8/HNb9http://click.skem1.com/click/bbu3-q26rk-f9wuev-63syewy7/HO_9http://click.skem1.com/click/bbu3-q26rk-f9wueu-63syewy6/HL\9http://click.skem1.com/click/bbu3-q26rk-f9wuet-63syewy5/HMY9http://click.skem1.com/click/bbu3-q26rk-f9wues-63syewy4/HJV9http://click.skem1.com/click/bbu3-q26rk-f9wuer-63syewy3/HKP9http://click.skem1.com/click/bbu3-q26rk-f9wueq-63syewy2/HHM9http://click.skem1.com/click/bbu3-q26rk-f9wuep-63syewy1/HIJ9http://click.skem1.com/click/bbu3-q26rk-f9wueo-63syewy0/H@G9http://click.skem1.com/click/bbu3-q26rk-f9wuen-63syewy9/HAD9http://click.skem1.com/click/bbu3-q26rk-f9wuem-63syewy8/HN>9http://click.skem1.com/click/bbu3-q26rk-f9wuel-63syewy7/HO;9http://click.skem1.com/click/bbu3-q26rk-f9wuek-63syewy6/HL89http://click.skem1.com/click/bbu3-q26rk-f9wuej-63syewy5/HM59http://click.skem1.com/click/bbu3-q26rk-f9wuei-63syewy4/HJ29http://click.skem1.com/click/bbu3-q26rk-f9wueh-63syewy3/HK,9http://click.skem1.com/click/bbu3-q26rk-f9wueg-63syewy2/HH )9http://click.skem1.com/click/bbu3-q26rk-f9wuef-63syewy1/HI &9http://click.skem1.com/click/bbu3-q26rk-f9wuee-63syewy0/H@  9http://click.skem1.com/click/bbu3-q26rk-f9wued-63syewy9/HA 9http://click.skem1.com/click/bbu3-q26rk-f9wuec-63syewy8/HN 9http://click.skem1.com/click/bbu3-q26rk-f9wueb-63syewy7/HO9http://click.skem1.com/click/bbu3-q26rk-f9wuea-63syewy6/HOV9http://click.skem1.com/click/bbu3-q26rk-f9wue9-63syewy6/HLW9http://click.skem1.com/click/bbu3-q26rk-f9wue8-63syewy5/HMX 9http://click.skem1.com/click/bbu3-q26rk-f9wue7-63syewy4/HJY9http://click.skem1.com/click/bbu3-q26rk-f9wue6-63syewy3/HKZ9http://click.skem1.com/click/bbu3-q26rk-f9wue5-63syewy2/HH[9http://click.skem1.com/click/bbu3-q26rk-f9wue4-63syewy1/HI\9http://click.skem1.com/click/bbu3-q26rk-f9wue3-63syewy0/H@]9http://click.skem1.com/click/bbu3-q26rk-f9wue2-63syewy9/HA^9http://click.skem1.com/click/bbu3-q26rk-f9wue1-63syewy8/HN_9http://click.skem1.com/click/bbu3-q26rk-f9wue0-63syewy7/HH9http://click.skem1.com/click/bbu3-q26rk-f9wudz-63syewy0/HA9http://click.skem1.com/click/bbu3-q26rk-f9wudy-63syewy9/H@9http://click.skem1.com/click/bbu3-q26rk-f9wudx-63syewy8/HO9http://click.skem1.com/click/bbu3-q26rk-f9wudw-63syewy7/HN9http://click.skem1.com/click/bbu3-q26rk-f9wudv-63syewy6/HM9http://click.skem1.com/click/bbu3-q26rk-f9wudu-63syewy5/HL9http://click.skem1.com/click/bbu3-q26rk-f9wudt-63syewy4/HK9http://click.skem1.com/click/bbu3-q26rk-f9wuds-63syewy3/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wudr-63syewy2/HI9http://click.skem1.com/click/bbu3-q26rk-f9wudq-63syewy1/HH9http://click.skem1.com/click/bbu3-q26rk-f9wudp-63syewy0/HA9http://click.skem1.com/click/bbu3-q26rk-f9wudo-63syewy9/H@9http://click.skem1.com/click/bbu3-q26rk-f9wudn-63syewy8/HO9http://click.skem1.com/click/bbu3-q26rk-f9wudm-63syewy7/HN9http://click.skem1.com/click/bbu3-q26rk-f9wudl-63syewy6/HM9http://click.skem1.com/click/bbu3-q26rk-f9wudk-63syewy5/HL9http://click.skem1.com/click/bbu3-q26rk-f9wudj-63syewy4/HK9http://click.skem1.com/click/bbu3-q26rk-f9wudi-63syewy3/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wudh-63syewy2/HI9http://click.skem1.com/click/bbu3-q26rk-f9wudg-63syewy1/HH 9http://click.skem1.com/click/bbu3-q26rk-f9wudf-63syewy0/HA 9http://click.skem1.com/click/bbu3-q26rk-f9wude-63syewy9/H@ 9http://click.skem1.com/click/bbu3-q26rk-f9wudd-63syewy8/HO 9http://click.skem1.com/click/bbu3-q26rk-f9wudc-63syewy7/HN 9http://click.skem1.com/click/bbu3-q26rk-f9wudb-63syewy6/HM9http://click.skem1.com/click/bbu3-q26rk-f9wuda-63syewy5/HMV9http://click.skem1.com/click/bbu3-q26rk-f9wud9-63syewy5/HLW9http://click.skem1.com/click/bbu3-q26rk-f9wud8-63syewy4/HKX9http://click.skem1.com/click/bbu3-q26rk-f9wud7-63syewy3/HJY9http://click.skem1.com/click/bbu3-q26rk-f9wud6-63syewy2/HIZ~9http://click.skem1.com/click/bbu3-q26rk-f9wud5-63syewy1/HH[{9http://click.skem1.com/click/bbu3-q26rk-f9wud4-63syewy0/HA\x9http://click.skem1.com/click/bbu3-q26rk-f9wud3-63syewy9/H@]r9http://click.skem1.com/click/bbu3-q26rk-f9wud2-63syewy8/HO^o9http://click.skem1.com/click/bbu3-q26rk-f9wud1-63syewy7/HN_l9http://click.skem1.com/click/bbu3-q26rk-f9wud0-63syewy6/HFi9http://click.skem1.com/click/bbu3-q26rk-f9wucz-63syewy9/HGf9http://click.skem1.com/click/bbu3-q26rk-f9wucy-63syewy8/HHc9http://click.skem1.com/click/bbu3-q26rk-f9wucx-63syewy7/HI]9http://click.skem1.com/click/bbu3-q26rk-f9wucw-63syewy6/HJZ9http://click.skem1.com/click/bbu3-q26rk-f9wucv-63syewy5/HKW9http://click.skem1.com/click/bbu3-q26rk-f9wucu-63syewy4/HLT9http://click.skem1.com/click/bbu3-q26rk-f9wuct-63syewy3/HMQ9http://click.skem1.com/click/bbu3-q26rk-f9wucs-63syewy2/HNK9http://click.skem1.com/click/bbu3-q26rk-f9wucr-63syewy1/HOH9http://click.skem1.com/click/bbu3-q26rk-f9wucq-63syewy0/HFE9http://click.skem1.com/click/bbu3-q26rk-f9wucp-63syewy9/HGB9http://click.skem1.com/click/bbu3-q26rk-f9wuco-63syewy8/HH?9http://click.skem1.com/click/bbu3-q26rk-f9wucn-63syewy7/HI<9http://click.skem1.com/click/bbu3-q26rk-f9wucm-63syewy6/HJ69http://click.skem1.com/click/bbu3-q26rk-f9wucl-63syewy5/HK39http://click.skem1.com/click/bbu3-q26rk-f9wuck-63syewy4/HL09http://click.skem1.com/click/bbu3-q26rk-f9wucj-63syewy3/HM*9http://click.skem1.com/click/bbu3-q26rk-f9wuci-63syewy2/HN'9http://click.skem1.com/click/bbu3-q26rk-f9wuch-63syewy1/HO$9http://click.skem1.com/click/bbu3-q26rk-f9wucg-63syewy0/HF !9http://click.skem1.com/click/bbu3-q26rk-f9wucf-63syewy9/HG 9http://click.skem1.com/click/bbu3-q26rk-f9wuce-63syewy8/HH 9http://click.skem1.com/click/bbu3-q26rk-f9wucd-63syewy7/HI 9http://click.skem1.com/click/bbu3-q26rk-f9wucc-63syewy6/HJ 9http://click.skem1.com/click/bbu3-q26rk-f9wucb-63syewy5/HK9http://click.skem1.com/click/bbu3-q26rk-f9wuca-63syewy4/HKV 9http://click.skem1.com/click/bbu3-q26rk-f9wuc9-63syewy4/HLW 9http://click.skem1.com/click/bbu3-q26rk-f9wuc8-63syewy3/HMX9http://click.skem1.com/click/bbu3-q26rk-f9wuc7-63syewy2/HNY9http://click.skem1.com/click/bbu3-q26rk-f9wuc6-63syewy1/HOZ9http://click.skem1.com/click/bbu3-q26rk-f9wuc5-63syewy0/HF[9http://click.skem1.com/click/bbu3-q26rk-f9wuc4-63syewy9/HG\9http://click.skem1.com/click/bbu3-q26rk-f9wuc3-63syewy8/HH]9http://click.skem1.com/click/bbu3-q26rk-f9wuc2-63syewy7/HI^9http://click.skem1.com/click/bbu3-q26rk-f9wuc1-63syewy6/HJ_9http://click.skem1.com/click/bbu3-q26rk-f9wuc0-63syewy5/HF9http://click.skem1.com/click/bbu3-q26rk-f9wubz-63syewy8/HI9http://click.skem1.com/click/bbu3-q26rk-f9wuby-63syewy7/HH9http://click.skem1.com/click/bbu3-q26rk-f9wubx-63syewy6/HK9http://click.skem1.com/click/bbu3-q26rk-f9wubw-63syewy5/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wubv-63syewy4/HM9http://click.skem1.com/click/bbu3-q26rk-f9wubu-63syewy3/HL9http://click.skem1.com/click/bbu3-q26rk-f9wubt-63syewy2/HO9http://click.skem1.com/click/bbu3-q26rk-f9wubs-63syewy1/HN9http://click.skem1.com/click/bbu3-q26rk-f9wubr-63syewy0/HG9http://click.skem1.com/click/bbu3-q26rk-f9wubq-63syewy9/HF9http://click.skem1.com/click/bbu3-q26rk-f9wubp-63syewy8/HI9http://click.skem1.com/click/bbu3-q26rk-f9wubo-63syewy7/HH9http://click.skem1.com/click/bbu3-q26rk-f9wubn-63syewy6/HK9http://click.skem1.com/click/bbu3-q26rk-f9wubm-63syewy5/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wubl-63syewy4/HM9http://click.skem1.com/click/bbu3-q26rk-f9wubk-63syewy3/HL9http://click.skem1.com/click/bbu3-q26rk-f9wubj-63syewy2/HO9http://click.skem1.com/click/bbu3-q26rk-f9wubi-63syewy1/HN9http://click.skem1.com/click/bbu3-q26rk-f9wubh-63syewy0/HG9http://click.skem1.com/click/bbu3-q26rk-f9wubg-63syewy9/HF 9http://click.skem1.com/click/bbu3-q26rk-f9wubf-63syewy8/HI 9http://click.skem1.com/click/bbu3-q26rk-f9wube-63syewy7/HH 9http://click.skem1.com/click/bbu3-q26rk-f9wubd-63syewy6/HK 9http://click.skem1.com/click/bbu3-q26rk-f9wubc-63syewy5/HJ 9http://click.skem1.com/click/bbu3-q26rk-f9wubb-63syewy4/HM9http://click.skem1.com/click/bbu3-q26rk-f9wuba-63syewy3/HMV9http://click.skem1.com/click/bbu3-q26rk-f9wub9-63syewy3/HLW9http://click.skem1.com/click/bbu3-q26rk-f9wub8-63syewy2/HOX|9http://click.skem1.com/click/bbu3-q26rk-f9wub7-63syewy1/HNYy9http://click.skem1.com/click/bbu3-q26rk-f9wub6-63syewy0/HGZs9http://click.skem1.com/click/bbu3-q26rk-f9wub5-63syewy9/HF[p9http://click.skem1.com/click/bbu3-q26rk-f9wub4-63syewy8/HI\m9http://click.skem1.com/click/bbu3-q26rk-f9wub3-63syewy7/HH]j9http://click.skem1.com/click/bbu3-q26rk-f9wub2-63syewy6/HK^g9http://click.skem1.com/click/bbu3-q26rk-f9wub1-63syewy5/HJ_d9http://click.skem1.com/click/bbu3-q26rk-f9wub0-63syewy4/HJ^9http://click.skem1.com/click/bbu3-q26rk-f9wuaz-63syewy7/HK[9http://click.skem1.com/click/bbu3-q26rk-f9wuay-63syewy6/HHX9http://click.skem1.com/click/bbu3-q26rk-f9wuax-63syewy5/HIU9http://click.skem1.com/click/bbu3-q26rk-f9wuaw-63syewy4/HNR9http://click.skem1.com/click/bbu3-q26rk-f9wuav-63syewy3/HOO9http://click.skem1.com/click/bbu3-q26rk-f9wuau-63syewy2/HLI9http://click.skem1.com/click/bbu3-q26rk-f9wuat-63syewy1/HMF9http://click.skem1.com/click/bbu3-q26rk-f9wuas-63syewy0/HD@9http://click.skem1.com/click/bbu3-q26rk-f9wuar-63syewy9/HE=9http://click.skem1.com/click/bbu3-q26rk-f9wuaq-63syewy8/HJ:9http://click.skem1.com/click/bbu3-q26rk-f9wuap-63syewy7/HK79http://click.skem1.com/click/bbu3-q26rk-f9wuao-63syewy6/HH49http://click.skem1.com/click/bbu3-q26rk-f9wuan-63syewy5/HI.9http://click.skem1.com/click/bbu3-q26rk-f9wuam-63syewy4/HN+9http://click.skem1.com/click/bbu3-q26rk-f9wual-63syewy3/HO(9http://click.skem1.com/click/bbu3-q26rk-f9wuak-63syewy2/HL%9http://click.skem1.com/click/bbu3-q26rk-f9wuaj-63syewy1/HM"9http://click.skem1.com/click/bbu3-q26rk-f9wuai-63syewy0/HD9http://click.skem1.com/click/bbu3-q26rk-f9wuah-63syewy9/HE9http://click.skem1.com/click/bbu3-q26rk-f9wuag-63syewy8/HJ 9http://click.skem1.com/click/bbu3-q26rk-f9wuaf-63syewy7/HK 9http://click.skem1.com/click/bbu3-q26rk-f9wuae-63syewy6/HH 9http://click.skem1.com/click/bbu3-q26rk-f9wuad-63syewy5/HI  9http://click.skem1.com/click/bbu3-q26rk-f9wuac-63syewy4/HN  9http://click.skem1.com/click/bbu3-q26rk-f9wuab-63syewy3/HO9http://click.skem1.com/click/bbu3-q26rk-f9wuaa-63syewy2/HOV9http://click.skem1.com/click/bbu3-q26rk-f9wua9-63syewy2/HLW9http://click.skem1.com/click/bbu3-q26rk-f9wua8-63syewy1/HMX9http://click.skem1.com/click/bbu3-q26rk-f9wua7-63syewy0/HDY9http://click.skem1.com/click/bbu3-q26rk-f9wua6-63syewy9/HEZ9http://click.skem1.com/click/bbu3-q26rk-f9wua5-63syewy8/HJ[9http://click.skem1.com/click/bbu3-q26rk-f9wua4-63syewy7/HK\9http://click.skem1.com/click/bbu3-q26rk-f9wua3-63syewy6/HH]9http://click.skem1.com/click/bbu3-q26rk-f9wua2-63syewy5/HI^9http://click.skem1.com/click/bbu3-q26rk-f9wua1-63syewy4/HN_9http://click.skem1.com/click/bbu3-q26rk-f9wua0-63syewy3/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9z-63syewy7/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9y-63syewy6/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9x-63syewy5/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9w-63syewy4/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9v-63syewy3/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9u-63syewy2/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9t-63syewy1/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9s-63syewy0/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9r-63syewy9/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9q-63syewy8/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9p-63syewy7/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9o-63syewy6/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9n-63syewy5/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9m-63syewy4/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9l-63syewy3/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9k-63syewy2/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9j-63syewy1/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9i-63syewy0/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9h-63syewy9/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9g-63syewy8/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu9f-63syewy7/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu9e-63syewy6/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu9d-63syewy5/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu9c-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu9b-63syewy3/H9http://click.skem1.com/click/bbu3-q26rk-f9wu9a-63syewy2/HV9http://click.skem1.com/click/bbu3-q26rk-f9wu99-63syewy2/HW9http://click.skem1.com/click/bbu3-q26rk-f9wu98-63syewy1/HX}9http://click.skem1.com/click/bbu3-q26rk-f9wu97-63syewy0/HYz9http://click.skem1.com/click/bbu3-q26rk-f9wu96-63syewy9/HZw9http://click.skem1.com/click/bbu3-q26rk-f9wu95-63syewy8/H[q9http://click.skem1.com/click/bbu3-q26rk-f9wu94-63syewy7/H\n9http://click.skem1.com/click/bbu3-q26rk-f9wu93-63syewy6/H]k9http://click.skem1.com/click/bbu3-q26rk-f9wu92-63syewy5/H^h9http://click.skem1.com/click/bbu3-q26rk-f9wu91-63syewy4/H_e9http://click.skem1.com/click/bbu3-q26rk-f9wu90-63syewy3/Hb9http://click.skem1.com/click/bbu3-q26rk-f9wu8z-63syewy6/H\9http://click.skem1.com/click/bbu3-q26rk-f9wu8y-63syewy5/HY9http://click.skem1.com/click/bbu3-q26rk-f9wu8x-63syewy4/HV9http://click.skem1.com/click/bbu3-q26rk-f9wu8w-63syewy3/HS9http://click.skem1.com/click/bbu3-q26rk-f9wu8v-63syewy2/HP9http://click.skem1.com/click/bbu3-q26rk-f9wu8u-63syewy1/HM9http://click.skem1.com/click/bbu3-q26rk-f9wu8t-63syewy0/HG9http://click.skem1.com/click/bbu3-q26rk-f9wu8s-63syewy9/HD9http://click.skem1.com/click/bbu3-q26rk-f9wu8r-63syewy8/HA9http://click.skem1.com/click/bbu3-q26rk-f9wu8q-63syewy7/H>9http://click.skem1.com/click/bbu3-q26rk-f9wu8p-63syewy6/H;9http://click.skem1.com/click/bbu3-q26rk-f9wu8o-63syewy5/H89http://click.skem1.com/click/bbu3-q26rk-f9wu8n-63syewy4/H29http://click.skem1.com/click/bbu3-q26rk-f9wu8m-63syewy3/H/9http://click.skem1.com/click/bbu3-q26rk-f9wu8l-63syewy2/H,9http://click.skem1.com/click/bbu3-q26rk-f9wu8k-63syewy1/H)9http://click.skem1.com/click/bbu3-q26rk-f9wu8j-63syewy0/H&9http://click.skem1.com/click/bbu3-q26rk-f9wu8i-63syewy9/H#9http://click.skem1.com/click/bbu3-q26rk-f9wu8h-63syewy8/H9http://click.skem1.com/click/bbu3-q26rk-f9wu8g-63syewy7/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu8f-63syewy6/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu8e-63syewy5/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu8d-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu8c-63syewy3/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu8b-63syewy2/H9http://click.skem1.com/click/bbu3-q26rk-f9wu8a-63syewy1/HV9http://click.skem1.com/click/bbu3-q26rk-f9wu89-63syewy1/HW9http://click.skem1.com/click/bbu3-q26rk-f9wu88-63syewy0/HX9http://click.skem1.com/click/bbu3-q26rk-f9wu87-63syewy9/HY9http://click.skem1.com/click/bbu3-q26rk-f9wu86-63syewy8/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wu85-63syewy7/H[9http://click.skem1.com/click/bbu3-q26rk-f9wu84-63syewy6/H\9http://click.skem1.com/click/bbu3-q26rk-f9wu83-63syewy5/H]9http://click.skem1.com/click/bbu3-q26rk-f9wu82-63syewy4/H^9http://click.skem1.com/click/bbu3-q26rk-f9wu81-63syewy3/H_9http://click.skem1.com/click/bbu3-q26rk-f9wu80-63syewy2/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7z-63syewy5/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7y-63syewy4/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7x-63syewy3/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7w-63syewy2/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7v-63syewy1/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7u-63syewy0/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7t-63syewy9/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7s-63syewy8/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7r-63syewy7/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7q-63syewy6/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7p-63syewy5/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7o-63syewy4/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7n-63syewy3/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7m-63syewy2/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7l-63syewy1/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7k-63syewy0/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7j-63syewy9/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7i-63syewy8/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7h-63syewy7/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7g-63syewy6/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu7f-63syewy5/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu7e-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu7d-63syewy3/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu7c-63syewy2/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu7b-63syewy1/H9http://click.skem1.com/click/bbu3-q26rk-f9wu7a-63syewy0/HV9http://click.skem1.com/click/bbu3-q26rk-f9wu79-63syewy0/HW~9http://click.skem1.com/click/bbu3-q26rk-f9wu78-63syewy9/HX{9http://click.skem1.com/click/bbu3-q26rk-f9wu77-63syewy8/HYx9http://click.skem1.com/click/bbu3-q26rk-f9wu76-63syewy7/HZu9http://click.skem1.com/click/bbu3-q26rk-f9wu75-63syewy6/H[o9http://click.skem1.com/click/bbu3-q26rk-f9wu74-63syewy5/H\l9http://click.skem1.com/click/bbu3-q26rk-f9wu73-63syewy4/H]i9http://click.skem1.com/click/bbu3-q26rk-f9wu72-63syewy3/H^f9http://click.skem1.com/click/bbu3-q26rk-f9wu71-63syewy2/H_c9http://click.skem1.com/click/bbu3-q26rk-f9wu70-63syewy1/H`9http://click.skem1.com/click/bbu3-q26rk-f9wu6z-63syewy4/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wu6y-63syewy3/HT9http://click.skem1.com/click/bbu3-q26rk-f9wu6x-63syewy2/HQ9http://click.skem1.com/click/bbu3-q26rk-f9wu6w-63syewy1/HN9http://click.skem1.com/click/bbu3-q26rk-f9wu6v-63syewy0/HK9http://click.skem1.com/click/bbu3-q26rk-f9wu6u-63syewy9/HH9http://click.skem1.com/click/bbu3-q26rk-f9wu6t-63syewy8/HE9http://click.skem1.com/click/bbu3-q26rk-f9wu6s-63syewy7/H?9http://click.skem1.com/click/bbu3-q26rk-f9wu6r-63syewy6/H<9http://click.skem1.com/click/bbu3-q26rk-f9wu6q-63syewy5/H99http://click.skem1.com/click/bbu3-q26rk-f9wu6p-63syewy4/H69http://click.skem1.com/click/bbu3-q26rk-f9wu6o-63syewy3/H39http://click.skem1.com/click/bbu3-q26rk-f9wu6n-63syewy2/H09http://click.skem1.com/click/bbu3-q26rk-f9wu6m-63syewy1/H*9http://click.skem1.com/click/bbu3-q26rk-f9wu6l-63syewy0/H'9http://click.skem1.com/click/bbu3-q26rk-f9wu6k-63syewy9/H$9http://click.skem1.com/click/bbu3-q26rk-f9wu6j-63syewy8/H!9http://click.skem1.com/click/bbu3-q26rk-f9wu6i-63syewy7/H9http://click.skem1.com/click/bbu3-q26rk-f9wu6h-63syewy6/H9http://click.skem1.com/click/bbu3-q26rk-f9wu6g-63syewy5/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu6f-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu6e-63syewy3/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu6d-63syewy2/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu6c-63syewy1/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu6b-63syewy0/H9http://click.skem1.com/click/bbu3-q26rk-f9wu6a-63syewy9/HV9http://click.skem1.com/click/bbu3-q26rk-f9wu69-63syewy9/HW9http://click.skem1.com/click/bbu3-q26rk-f9wu68-63syewy8/HX9http://click.skem1.com/click/bbu3-q26rk-f9wu67-63syewy7/HY9http://click.skem1.com/click/bbu3-q26rk-f9wu66-63syewy6/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wu65-63syewy5/H[9http://click.skem1.com/click/bbu3-q26rk-f9wu64-63syewy4/H\9http://click.skem1.com/click/bbu3-q26rk-f9wu63-63syewy3/H]9http://click.skem1.com/click/bbu3-q26rk-f9wu62-63syewy2/H^9http://click.skem1.com/click/bbu3-q26rk-f9wu61-63syewy1/H_9http://click.skem1.com/click/bbu3-q26rk-f9wu60-63syewy0/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5z-63syewy3/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5y-63syewy2/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5x-63syewy1/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5w-63syewy0/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5v-63syewy9/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5u-63syewy8/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5t-63syewy7/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5s-63syewy6/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5r-63syewy5/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5q-63syewy4/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5p-63syewy3/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5o-63syewy2/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5n-63syewy1/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5m-63syewy0/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5l-63syewy9/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5k-63syewy8/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5j-63syewy7/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5i-63syewy6/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5h-63syewy5/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5g-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu5f-63syewy3/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu5e-63syewy2/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu5d-63syewy1/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu5c-63syewy0/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu5b-63syewy9/H9http://click.skem1.com/click/bbu3-q26rk-f9wu5a-63syewy8/HV9http://click.skem1.com/click/bbu3-q26rk-f9wu59-63syewy8/HW9http://click.skem1.com/click/bbu3-q26rk-f9wu58-63syewy7/HX|9http://click.skem1.com/click/bbu3-q26rk-f9wu57-63syewy6/HYv9http://click.skem1.com/click/bbu3-q26rk-f9wu56-63syewy5/HZs9http://click.skem1.com/click/bbu3-q26rk-f9wu55-63syewy4/H[p9http://click.skem1.com/click/bbu3-q26rk-f9wu54-63syewy3/H\j9http://click.skem1.com/click/bbu3-q26rk-f9wu53-63syewy2/H]d9http://click.skem1.com/click/bbu3-q26rk-f9wu52-63syewy1/H^a9http://click.skem1.com/click/bbu3-q26rk-f9wu51-63syewy0/H_^9http://click.skem1.com/click/bbu3-q26rk-f9wu50-63syewy9/H[9http://click.skem1.com/click/bbu3-q26rk-f9wu4z-63syewy2/HX9http://click.skem1.com/click/bbu3-q26rk-f9wu4y-63syewy1/HU9http://click.skem1.com/click/bbu3-q26rk-f9wu4x-63syewy0/HO9http://click.skem1.com/click/bbu3-q26rk-f9wu4w-63syewy9/HL9http://click.skem1.com/click/bbu3-q26rk-f9wu4v-63syewy8/HI9http://click.skem1.com/click/bbu3-q26rk-f9wu4u-63syewy7/HF9http://click.skem1.com/click/bbu3-q26rk-f9wu4t-63syewy6/HC9http://click.skem1.com/click/bbu3-q26rk-f9wu4s-63syewy5/H@9http://click.skem1.com/click/bbu3-q26rk-f9wu4r-63syewy4/H:9http://click.skem1.com/click/bbu3-q26rk-f9wu4q-63syewy3/H79http://click.skem1.com/click/bbu3-q26rk-f9wu4p-63syewy2/H49http://click.skem1.com/click/bbu3-q26rk-f9wu4o-63syewy1/H.9http://click.skem1.com/click/bbu3-q26rk-f9wu4n-63syewy0/H+9http://click.skem1.com/click/bbu3-q26rk-f9wu4m-63syewy9/H(9http://click.skem1.com/click/bbu3-q26rk-f9wu4l-63syewy8/H%9http://click.skem1.com/click/bbu3-q26rk-f9wu4k-63syewy7/H"9http://click.skem1.com/click/bbu3-q26rk-f9wu4j-63syewy6/H9http://click.skem1.com/click/bbu3-q26rk-f9wu4i-63syewy5/H9http://click.skem1.com/click/bbu3-q26rk-f9wu4h-63syewy4/H9http://click.skem1.com/click/bbu3-q26rk-f9wu4g-63syewy3/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu4f-63syewy2/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu4e-63syewy1/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu4d-63syewy0/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu4c-63syewy9/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu4b-63syewy8/H9http://click.skem1.com/click/bbu3-q26rk-f9wu4a-63syewy7/HV 9http://click.skem1.com/click/bbu3-q26rk-f9wu49-63syewy7/HW 9http://click.skem1.com/click/bbu3-q26rk-f9wu48-63syewy6/HX 9http://click.skem1.com/click/bbu3-q26rk-f9wu47-63syewy5/HY 9http://click.skem1.com/click/bbu3-q26rk-f9wu46-63syewy4/HZ 9http://click.skem1.com/click/bbu3-q26rk-f9wu45-63syewy3/H[ 9http://click.skem1.com/click/bbu3-q26rk-f9wu44-63syewy2/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wu43-63syewy1/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wu42-63syewy0/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wu41-63syewy9/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wu40-63syewy8/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3z-63syewy1/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3y-63syewy0/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3x-63syewy9/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3w-63syewy8/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3v-63syewy7/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3u-63syewy6/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3t-63syewy5/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3s-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3r-63syewy3/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3q-63syewy2/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3p-63syewy1/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3o-63syewy0/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3n-63syewy9/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3m-63syewy8/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3l-63syewy7/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3k-63syewy6/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3j-63syewy5/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3i-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3h-63syewy3/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3g-63syewy2/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu3f-63syewy1/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu3e-63syewy0/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu3d-63syewy9/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu3c-63syewy8/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu3b-63syewy7/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu3a-63syewy6/HV} 9http://click.skem1.com/click/bbu3-q26rk-f9wu39-63syewy6/HWz 9http://click.skem1.com/click/bbu3-q26rk-f9wu38-63syewy5/HXw 9http://click.skem1.com/click/bbu3-q26rk-f9wu37-63syewy4/HYt 9http://click.skem1.com/click/bbu3-q26rk-f9wu36-63syewy3/HZn 9http://click.skem1.com/click/bbu3-q26rk-f9wu35-63syewy2/H[h 9http://click.skem1.com/click/bbu3-q26rk-f9wu34-63syewy1/H\e 9http://click.skem1.com/click/bbu3-q26rk-f9wu33-63syewy0/H]b 9http://click.skem1.com/click/bbu3-q26rk-f9wu32-63syewy9/H^_ 9http://click.skem1.com/click/bbu3-q26rk-f9wu31-63syewy8/H_\ 9http://click.skem1.com/click/bbu3-q26rk-f9wu30-63syewy7/HY 9http://click.skem1.com/click/bbu3-q26rk-f9wu2z-63syewy0/HS 9http://click.skem1.com/click/bbu3-q26rk-f9wu2y-63syewy9/HM 9http://click.skem1.com/click/bbu3-q26rk-f9wu2x-63syewy8/HJ 9http://click.skem1.com/click/bbu3-q26rk-f9wu2w-63syewy7/HG 9http://click.skem1.com/click/bbu3-q26rk-f9wu2v-63syewy6/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wu2u-63syewy5/HA 9http://click.skem1.com/click/bbu3-q26rk-f9wu2t-63syewy4/H> 9http://click.skem1.com/click/bbu3-q26rk-f9wu2s-63syewy3/H8 9http://click.skem1.com/click/bbu3-q26rk-f9wu2r-63syewy2/H5 9http://click.skem1.com/click/bbu3-q26rk-f9wu2q-63syewy1/H2 9http://click.skem1.com/click/bbu3-q26rk-f9wu2p-63syewy0/H/ 9http://click.skem1.com/click/bbu3-q26rk-f9wu2o-63syewy9/H) 9http://click.skem1.com/click/bbu3-q26rk-f9wu2n-63syewy8/H& 9http://click.skem1.com/click/bbu3-q26rk-f9wu2m-63syewy7/H# 9http://click.skem1.com/click/bbu3-q26rk-f9wu2l-63syewy6/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu2k-63syewy5/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu2j-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu2i-63syewy3/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu2h-63syewy2/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu2g-63syewy1/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu2f-63syewy0/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu2e-63syewy9/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu2d-63syewy8/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu2c-63syewy7/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu2b-63syewy6/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu2a-63syewy5/HV 9http://click.skem1.com/click/bbu3-q26rk-f9wu29-63syewy5/HW 9http://click.skem1.com/click/bbu3-q26rk-f9wu28-63syewy4/HX 9http://click.skem1.com/click/bbu3-q26rk-f9wu27-63syewy3/HY 9http://click.skem1.com/click/bbu3-q26rk-f9wu26-63syewy2/HZ 9http://click.skem1.com/click/bbu3-q26rk-f9wu25-63syewy1/H[ 9http://click.skem1.com/click/bbu3-q26rk-f9wu24-63syewy0/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wu23-63syewy9/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wu22-63syewy8/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wu21-63syewy7/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wu20-63syewy6/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1z-63syewy9/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1y-63syewy8/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1x-63syewy7/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1w-63syewy6/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1v-63syewy5/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1u-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1t-63syewy3/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1s-63syewy2/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1r-63syewy1/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1q-63syewy0/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1p-63syewy9/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1o-63syewy8/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1n-63syewy7/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1m-63syewy6/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1l-63syewy5/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1k-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1j-63syewy3/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1i-63syewy2/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1h-63syewy1/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu1g-63syewy0/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu1f-63syewy9/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu1e-63syewy8/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu1d-63syewy7/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu1c-63syewy6/H ~ 9http://click.skem1.com/click/bbu3-q26rk-f9wu1b-63syewy5/Hx 9http://click.skem1.com/click/bbu3-q26rk-f9wu1a-63syewy4/HVu 9http://click.skem1.com/click/bbu3-q26rk-f9wu19-63syewy4/HWr 9http://click.skem1.com/click/bbu3-q26rk-f9wu18-63syewy3/HXo 9http://click.skem1.com/click/bbu3-q26rk-f9wu17-63syewy2/HYl 9http://click.skem1.com/click/bbu3-q26rk-f9wu16-63syewy1/HZi 9http://click.skem1.com/click/bbu3-q26rk-f9wu15-63syewy0/H[c 9http://click.skem1.com/click/bbu3-q26rk-f9wu14-63syewy9/H\` 9http://click.skem1.com/click/bbu3-q26rk-f9wu13-63syewy8/H]] 9http://click.skem1.com/click/bbu3-q26rk-f9wu12-63syewy7/H^Z 9http://click.skem1.com/click/bbu3-q26rk-f9wu11-63syewy6/H_W 9http://click.skem1.com/click/bbu3-q26rk-f9wu10-63syewy5/HT 9http://click.skem1.com/click/bbu3-q26rk-f9wu0z-63syewy8/HN 9http://click.skem1.com/click/bbu3-q26rk-f9wu0y-63syewy7/HK 9http://click.skem1.com/click/bbu3-q26rk-f9wu0x-63syewy6/HH 9http://click.skem1.com/click/bbu3-q26rk-f9wu0w-63syewy5/HE 9http://click.skem1.com/click/bbu3-q26rk-f9wu0v-63syewy4/HB 9http://click.skem1.com/click/bbu3-q26rk-f9wu0u-63syewy3/H? 9http://click.skem1.com/click/bbu3-q26rk-f9wu0t-63syewy2/H9 9http://click.skem1.com/click/bbu3-q26rk-f9wu0s-63syewy1/H6 9http://click.skem1.com/click/bbu3-q26rk-f9wu0r-63syewy0/H3 9http://click.skem1.com/click/bbu3-q26rk-f9wu0q-63syewy9/H0 9http://click.skem1.com/click/bbu3-q26rk-f9wu0p-63syewy8/H- 9http://click.skem1.com/click/bbu3-q26rk-f9wu0o-63syewy7/H* 9http://click.skem1.com/click/bbu3-q26rk-f9wu0n-63syewy6/H$ 9http://click.skem1.com/click/bbu3-q26rk-f9wu0m-63syewy5/H! 9http://click.skem1.com/click/bbu3-q26rk-f9wu0l-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu0k-63syewy3/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu0j-63syewy2/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu0i-63syewy1/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu0h-63syewy0/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu0g-63syewy9/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu0f-63syewy8/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu0e-63syewy7/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu0d-63syewy6/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu0c-63syewy5/H  9http://click.skem1.com/click/bbu3-q26rk-f9wu0b-63syewy4/H 9http://click.skem1.com/click/bbu3-q26rk-f9wu0a-63syewy3/HV 9http://click.skem1.com/click/bbu3-q26rk-f9wu09-63syewy3/HW 9http://click.skem1.com/click/bbu3-q26rk-f9wu08-63syewy2/HX 9http://click.skem1.com/click/bbu3-q26rk-f9wu07-63syewy1/HY 9http://click.skem1.com/click/bbu3-q26rk-f9wu06-63syewy0/HZ 9http://click.skem1.com/click/bbu3-q26rk-f9wu05-63syewy9/H[ 9http://click.skem1.com/click/bbu3-q26rk-f9wu04-63syewy8/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wu03-63syewy7/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wu02-63syewy6/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wu01-63syewy5/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wu00-63syewy4/HW 9http://click.skem1.com/click/bbu3-q26rk-f9wtzz-63syewy1/HV 9http://click.skem1.com/click/bbu3-q26rk-f9wtzy-63syewy0/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wtzx-63syewy9/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wtzw-63syewy8/HQ 9http://click.skem1.com/click/bbu3-q26rk-f9wtzv-63syewy7/HP 9http://click.skem1.com/click/bbu3-q26rk-f9wtzu-63syewy6/HS 9http://click.skem1.com/click/bbu3-q26rk-f9wtzt-63syewy5/HR 9http://click.skem1.com/click/bbu3-q26rk-f9wtzs-63syewy4/HU 9http://click.skem1.com/click/bbu3-q26rk-f9wtzr-63syewy3/HT 9http://click.skem1.com/click/bbu3-q26rk-f9wtzq-63syewy2/HW 9http://click.skem1.com/click/bbu3-q26rk-f9wtzp-63syewy1/HV 9http://click.skem1.com/click/bbu3-q26rk-f9wtzo-63syewy0/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wtzn-63syewy9/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wtzm-63syewy8/HQ 9http://click.skem1.com/click/bbu3-q26rk-f9wtzl-63syewy7/HP 9http://click.skem1.com/click/bbu3-q26rk-f9wtzk-63syewy6/HS 9http://click.skem1.com/click/bbu3-q26rk-f9wtzj-63syewy5/HR 9http://click.skem1.com/click/bbu3-q26rk-f9wtzi-63syewy4/HU 9http://click.skem1.com/click/bbu3-q26rk-f9wtzh-63syewy3/HT  9http://click.skem1.com/click/bbu3-q26rk-f9wtzg-63syewy2/HW 9http://click.skem1.com/click/bbu3-q26rk-f9wtzf-63syewy1/HV  9http://click.skem1.com/click/bbu3-q26rk-f9wtze-63syewy0/H_  9http://click.skem1.com/click/bbu3-q26rk-f9wtzd-63syewy9/H^  9http://click.skem1.com/click/bbu3-q26rk-f9wtzc-63syewy8/HQ | 9http://click.skem1.com/click/bbu3-q26rk-f9wtzb-63syewy7/HPy 9http://click.skem1.com/click/bbu3-q26rk-f9wtza-63syewy6/HPWv 9http://click.skem1.com/click/bbu3-q26rk-f9wtz9-63syewy6/HSVp 9http://click.skem1.com/click/bbu3-q26rk-f9wtz8-63syewy5/HRYm 9http://click.skem1.com/click/bbu3-q26rk-f9wtz7-63syewy4/HUXj 9http://click.skem1.com/click/bbu3-q26rk-f9wtz6-63syewy3/HT[g 9http://click.skem1.com/click/bbu3-q26rk-f9wtz5-63syewy2/HWZd 9http://click.skem1.com/click/bbu3-q26rk-f9wtz4-63syewy1/HV]a 9http://click.skem1.com/click/bbu3-q26rk-f9wtz3-63syewy0/H_\[ 9http://click.skem1.com/click/bbu3-q26rk-f9wtz2-63syewy9/H^_X 9http://click.skem1.com/click/bbu3-q26rk-f9wtz1-63syewy8/HQ^U 9http://click.skem1.com/click/bbu3-q26rk-f9wtz0-63syewy7/HUR 9http://click.skem1.com/click/bbu3-q26rk-f9wtyz-63syewy0/H\O 9http://click.skem1.com/click/bbu3-q26rk-f9wtyy-63syewy9/H]L 9http://click.skem1.com/click/bbu3-q26rk-f9wtyx-63syewy8/HRF 9http://click.skem1.com/click/bbu3-q26rk-f9wtyw-63syewy7/HSC 9http://click.skem1.com/click/bbu3-q26rk-f9wtyv-63syewy6/HP@ 9http://click.skem1.com/click/bbu3-q26rk-f9wtyu-63syewy5/HQ= 9http://click.skem1.com/click/bbu3-q26rk-f9wtyt-63syewy4/HV: 9http://click.skem1.com/click/bbu3-q26rk-f9wtys-63syewy3/HW7 9http://click.skem1.com/click/bbu3-q26rk-f9wtyr-63syewy2/HT1 9http://click.skem1.com/click/bbu3-q26rk-f9wtyq-63syewy1/HU. 9http://click.skem1.com/click/bbu3-q26rk-f9wtyp-63syewy0/H\+ 9http://click.skem1.com/click/bbu3-q26rk-f9wtyo-63syewy9/H]( 9http://click.skem1.com/click/bbu3-q26rk-f9wtyn-63syewy8/HR% 9http://click.skem1.com/click/bbu3-q26rk-f9wtym-63syewy7/HS" 9http://click.skem1.com/click/bbu3-q26rk-f9wtyl-63syewy6/HP 9http://click.skem1.com/click/bbu3-q26rk-f9wtyk-63syewy5/HQ 9http://click.skem1.com/click/bbu3-q26rk-f9wtyj-63syewy4/HV 9http://click.skem1.com/click/bbu3-q26rk-f9wtyi-63syewy3/HW 9http://click.skem1.com/click/bbu3-q26rk-f9wtyh-63syewy2/HT  9http://click.skem1.com/click/bbu3-q26rk-f9wtyg-63syewy1/HU 9http://click.skem1.com/click/bbu3-q26rk-f9wtyf-63syewy0/H\  9http://click.skem1.com/click/bbu3-q26rk-f9wtye-63syewy9/H]  9http://click.skem1.com/click/bbu3-q26rk-f9wtyd-63syewy8/HR  9http://click.skem1.com/click/bbu3-q26rk-f9wtyc-63syewy7/HS  9http://click.skem1.com/click/bbu3-q26rk-f9wtyb-63syewy6/HP 9http://click.skem1.com/click/bbu3-q26rk-f9wtya-63syewy5/HPW 9http://click.skem1.com/click/bbu3-q26rk-f9wty9-63syewy5/HQV 9http://click.skem1.com/click/bbu3-q26rk-f9wty8-63syewy4/HVY 9http://click.skem1.com/click/bbu3-q26rk-f9wty7-63syewy3/HWX 9http://click.skem1.com/click/bbu3-q26rk-f9wty6-63syewy2/HT[ 9http://click.skem1.com/click/bbu3-q26rk-f9wty5-63syewy1/HUZ 9http://click.skem1.com/click/bbu3-q26rk-f9wty4-63syewy0/H\] 9http://click.skem1.com/click/bbu3-q26rk-f9wty3-63syewy9/H]\ 9http://click.skem1.com/click/bbu3-q26rk-f9wty2-63syewy8/HR_ 9http://click.skem1.com/click/bbu3-q26rk-f9wty1-63syewy7/HS^ 9http://click.skem1.com/click/bbu3-q26rk-f9wty0-63syewy6/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wtxz-63syewy9/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wtxy-63syewy8/HS 9http://click.skem1.com/click/bbu3-q26rk-f9wtxx-63syewy7/HR 9http://click.skem1.com/click/bbu3-q26rk-f9wtxw-63syewy6/HQ 9http://click.skem1.com/click/bbu3-q26rk-f9wtxv-63syewy5/HP 9http://click.skem1.com/click/bbu3-q26rk-f9wtxu-63syewy4/HW 9http://click.skem1.com/click/bbu3-q26rk-f9wtxt-63syewy3/HV 9http://click.skem1.com/click/bbu3-q26rk-f9wtxs-63syewy2/HU 9http://click.skem1.com/click/bbu3-q26rk-f9wtxr-63syewy1/HT 9http://click.skem1.com/click/bbu3-q26rk-f9wtxq-63syewy0/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wtxp-63syewy9/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wtxo-63syewy8/HS 9http://click.skem1.com/click/bbu3-q26rk-f9wtxn-63syewy7/HR 9http://click.skem1.com/click/bbu3-q26rk-f9wtxm-63syewy6/HQ 9http://click.skem1.com/click/bbu3-q26rk-f9wtxl-63syewy5/HP 9http://click.skem1.com/click/bbu3-q26rk-f9wtxk-63syewy4/HW 9http://click.skem1.com/click/bbu3-q26rk-f9wtxj-63syewy3/HV 9http://click.skem1.com/click/bbu3-q26rk-f9wtxi-63syewy2/HU 9http://click.skem1.com/click/bbu3-q26rk-f9wtxh-63syewy1/HT  9http://click.skem1.com/click/bbu3-q26rk-f9wtxg-63syewy0/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wtxf-63syewy9/H\  9http://click.skem1.com/click/bbu3-q26rk-f9wtxe-63syewy8/HS  9http://click.skem1.com/click/bbu3-q26rk-f9wtxd-63syewy7/HR  9http://click.skem1.com/click/bbu3-q26rk-f9wtxc-63syewy6/HQ } 9http://click.skem1.com/click/bbu3-q26rk-f9wtxb-63syewy5/HPz 9http://click.skem1.com/click/bbu3-q26rk-f9wtxa-63syewy4/HPWw 9http://click.skem1.com/click/bbu3-q26rk-f9wtx9-63syewy4/HWVq 9http://click.skem1.com/click/bbu3-q26rk-f9wtx8-63syewy3/HVYn 9http://click.skem1.com/click/bbu3-q26rk-f9wtx7-63syewy2/HUXk 9http://click.skem1.com/click/bbu3-q26rk-f9wtx6-63syewy1/HT[h 9http://click.skem1.com/click/bbu3-q26rk-f9wtx5-63syewy0/H]Ze 9http://click.skem1.com/click/bbu3-q26rk-f9wtx4-63syewy9/H\]_ 9http://click.skem1.com/click/bbu3-q26rk-f9wtx3-63syewy8/HS\\ 9http://click.skem1.com/click/bbu3-q26rk-f9wtx2-63syewy7/HR_Y 9http://click.skem1.com/click/bbu3-q26rk-f9wtx1-63syewy6/HQ^V 9http://click.skem1.com/click/bbu3-q26rk-f9wtx0-63syewy5/HSS 9http://click.skem1.com/click/bbu3-q26rk-f9wtwz-63syewy8/H\P 9http://click.skem1.com/click/bbu3-q26rk-f9wtwy-63syewy7/H]J 9http://click.skem1.com/click/bbu3-q26rk-f9wtwx-63syewy6/H^G 9http://click.skem1.com/click/bbu3-q26rk-f9wtww-63syewy5/H_D 9http://click.skem1.com/click/bbu3-q26rk-f9wtwv-63syewy4/HXA 9http://click.skem1.com/click/bbu3-q26rk-f9wtwu-63syewy3/HY> 9http://click.skem1.com/click/bbu3-q26rk-f9wtwt-63syewy2/HZ; 9http://click.skem1.com/click/bbu3-q26rk-f9wtws-63syewy1/H[5 9http://click.skem1.com/click/bbu3-q26rk-f9wtwr-63syewy0/HR2 9http://click.skem1.com/click/bbu3-q26rk-f9wtwq-63syewy9/HS/ 9http://click.skem1.com/click/bbu3-q26rk-f9wtwp-63syewy8/H\, 9http://click.skem1.com/click/bbu3-q26rk-f9wtwo-63syewy7/H]) 9http://click.skem1.com/click/bbu3-q26rk-f9wtwn-63syewy6/H^& 9http://click.skem1.com/click/bbu3-q26rk-f9wtwm-63syewy5/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wtwl-63syewy4/HX 9http://click.skem1.com/click/bbu3-q26rk-f9wtwk-63syewy3/HY 9http://click.skem1.com/click/bbu3-q26rk-f9wtwj-63syewy2/HZ 9http://click.skem1.com/click/bbu3-q26rk-f9wtwi-63syewy1/H[ 9http://click.skem1.com/click/bbu3-q26rk-f9wtwh-63syewy0/HR  9http://click.skem1.com/click/bbu3-q26rk-f9wtwg-63syewy9/HS 9http://click.skem1.com/click/bbu3-q26rk-f9wtwf-63syewy8/H\  9http://click.skem1.com/click/bbu3-q26rk-f9wtwe-63syewy7/H]  9http://click.skem1.com/click/bbu3-q26rk-f9wtwd-63syewy6/H^  9http://click.skem1.com/click/bbu3-q26rk-f9wtwc-63syewy5/H_  9http://click.skem1.com/click/bbu3-q26rk-f9wtwb-63syewy4/HX 9http://click.skem1.com/click/bbu3-q26rk-f9wtwa-63syewy3/HXW 9http://click.skem1.com/click/bbu3-q26rk-f9wtw9-63syewy3/HYV 9http://click.skem1.com/click/bbu3-q26rk-f9wtw8-63syewy2/HZY 9http://click.skem1.com/click/bbu3-q26rk-f9wtw7-63syewy1/H[X 9http://click.skem1.com/click/bbu3-q26rk-f9wtw6-63syewy0/HR[ 9http://click.skem1.com/click/bbu3-q26rk-f9wtw5-63syewy9/HSZ 9http://click.skem1.com/click/bbu3-q26rk-f9wtw4-63syewy8/H\] 9http://click.skem1.com/click/bbu3-q26rk-f9wtw3-63syewy7/H]\ 9http://click.skem1.com/click/bbu3-q26rk-f9wtw2-63syewy6/H^_ 9http://click.skem1.com/click/bbu3-q26rk-f9wtw1-63syewy5/H_^ 9http://click.skem1.com/click/bbu3-q26rk-f9wtw0-63syewy4/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wtvz-63syewy7/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wtvy-63syewy6/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wtvx-63syewy5/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wtvw-63syewy4/HY 9http://click.skem1.com/click/bbu3-q26rk-f9wtvv-63syewy3/HX 9http://click.skem1.com/click/bbu3-q26rk-f9wtvu-63syewy2/H[ 9http://click.skem1.com/click/bbu3-q26rk-f9wtvt-63syewy1/HZ 9http://click.skem1.com/click/bbu3-q26rk-f9wtvs-63syewy0/HS 9http://click.skem1.com/click/bbu3-q26rk-f9wtvr-63syewy9/HR 9http://click.skem1.com/click/bbu3-q26rk-f9wtvq-63syewy8/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wtvp-63syewy7/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wtvo-63syewy6/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wtvn-63syewy5/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wtvm-63syewy4/HY 9http://click.skem1.com/click/bbu3-q26rk-f9wtvl-63syewy3/HX 9http://click.skem1.com/click/bbu3-q26rk-f9wtvk-63syewy2/H[ 9http://click.skem1.com/click/bbu3-q26rk-f9wtvj-63syewy1/HZ 9http://click.skem1.com/click/bbu3-q26rk-f9wtvi-63syewy0/HS 9http://click.skem1.com/click/bbu3-q26rk-f9wtvh-63syewy9/HR  9http://click.skem1.com/click/bbu3-q26rk-f9wtvg-63syewy8/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wtvf-63syewy7/H\  9http://click.skem1.com/click/bbu3-q26rk-f9wtve-63syewy6/H_  9http://click.skem1.com/click/bbu3-q26rk-f9wtvd-63syewy5/H^  9http://click.skem1.com/click/bbu3-q26rk-f9wtvc-63syewy4/HY ~ 9http://click.skem1.com/click/bbu3-q26rk-f9wtvb-63syewy3/HXx 9http://click.skem1.com/click/bbu3-q26rk-f9wtva-63syewy2/HXWu 9http://click.skem1.com/click/bbu3-q26rk-f9wtv9-63syewy2/H[Vr 9http://click.skem1.com/click/bbu3-q26rk-f9wtv8-63syewy1/HZYo 9http://click.skem1.com/click/bbu3-q26rk-f9wtv7-63syewy0/HSXl 9http://click.skem1.com/click/bbu3-q26rk-f9wtv6-63syewy9/HR[i 9http://click.skem1.com/click/bbu3-q26rk-f9wtv5-63syewy8/H]Zc 9http://click.skem1.com/click/bbu3-q26rk-f9wtv4-63syewy7/H\]` 9http://click.skem1.com/click/bbu3-q26rk-f9wtv3-63syewy6/H_\] 9http://click.skem1.com/click/bbu3-q26rk-f9wtv2-63syewy5/H^_Z 9http://click.skem1.com/click/bbu3-q26rk-f9wtv1-63syewy4/HY^W 9http://click.skem1.com/click/bbu3-q26rk-f9wtv0-63syewy3/H_T 9http://click.skem1.com/click/bbu3-q26rk-f9wtuz-63syewy6/H\N 9http://click.skem1.com/click/bbu3-q26rk-f9wtuy-63syewy5/H]K 9http://click.skem1.com/click/bbu3-q26rk-f9wtux-63syewy4/HZH 9http://click.skem1.com/click/bbu3-q26rk-f9wtuw-63syewy3/H[E 9http://click.skem1.com/click/bbu3-q26rk-f9wtuv-63syewy2/HXB 9http://click.skem1.com/click/bbu3-q26rk-f9wtuu-63syewy1/HY< 9http://click.skem1.com/click/bbu3-q26rk-f9wtut-63syewy0/HP9 9http://click.skem1.com/click/bbu3-q26rk-f9wtus-63syewy9/HQ6 9http://click.skem1.com/click/bbu3-q26rk-f9wtur-63syewy8/H^3 9http://click.skem1.com/click/bbu3-q26rk-f9wtuq-63syewy7/H_0 9http://click.skem1.com/click/bbu3-q26rk-f9wtup-63syewy6/H\- 9http://click.skem1.com/click/bbu3-q26rk-f9wtuo-63syewy5/H]' 9http://click.skem1.com/click/bbu3-q26rk-f9wtun-63syewy4/HZ$ 9http://click.skem1.com/click/bbu3-q26rk-f9wtum-63syewy3/H[! 9http://click.skem1.com/click/bbu3-q26rk-f9wtul-63syewy2/HX 9http://click.skem1.com/click/bbu3-q26rk-f9wtuk-63syewy1/HY 9http://click.skem1.com/click/bbu3-q26rk-f9wtuj-63syewy0/HP 9http://click.skem1.com/click/bbu3-q26rk-f9wtui-63syewy9/HQ 9http://click.skem1.com/click/bbu3-q26rk-f9wtuh-63syewy8/H^  9http://click.skem1.com/click/bbu3-q26rk-f9wtug-63syewy7/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wtuf-63syewy6/H\  9http://click.skem1.com/click/bbu3-q26rk-f9wtue-63syewy5/H]  9http://click.skem1.com/click/bbu3-q26rk-f9wtud-63syewy4/HZ  9http://click.skem1.com/click/bbu3-q26rk-f9wtuc-63syewy3/H[ 9http://click.skem1.com/click/bbu3-q26rk-f9wtub-63syewy2/HX9http://click.skem1.com/click/bbu3-q26rk-f9wtua-63syewy1/HXW9http://click.skem1.com/click/bbu3-q26rk-f9wtu9-63syewy1/HYV9http://click.skem1.com/click/bbu3-q26rk-f9wtu8-63syewy0/HPY9http://click.skem1.com/click/bbu3-q26rk-f9wtu7-63syewy9/HQX9http://click.skem1.com/click/bbu3-q26rk-f9wtu6-63syewy8/H^[9http://click.skem1.com/click/bbu3-q26rk-f9wtu5-63syewy7/H_Z9http://click.skem1.com/click/bbu3-q26rk-f9wtu4-63syewy6/H\]9http://click.skem1.com/click/bbu3-q26rk-f9wtu3-63syewy5/H]\9http://click.skem1.com/click/bbu3-q26rk-f9wtu2-63syewy4/HZ_9http://click.skem1.com/click/bbu3-q26rk-f9wtu1-63syewy3/H[^9http://click.skem1.com/click/bbu3-q26rk-f9wtu0-63syewy2/H]9http://click.skem1.com/click/bbu3-q26rk-f9wttz-63syewy5/H\9http://click.skem1.com/click/bbu3-q26rk-f9wtty-63syewy4/H[9http://click.skem1.com/click/bbu3-q26rk-f9wttx-63syewy3/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wttw-63syewy2/HY9http://click.skem1.com/click/bbu3-q26rk-f9wttv-63syewy1/HX9http://click.skem1.com/click/bbu3-q26rk-f9wttu-63syewy0/HQ9http://click.skem1.com/click/bbu3-q26rk-f9wttt-63syewy9/HP9http://click.skem1.com/click/bbu3-q26rk-f9wtts-63syewy8/H_9http://click.skem1.com/click/bbu3-q26rk-f9wttr-63syewy7/H^9http://click.skem1.com/click/bbu3-q26rk-f9wttq-63syewy6/H]9http://click.skem1.com/click/bbu3-q26rk-f9wttp-63syewy5/H\9http://click.skem1.com/click/bbu3-q26rk-f9wtto-63syewy4/H[9http://click.skem1.com/click/bbu3-q26rk-f9wttn-63syewy3/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wttm-63syewy2/HY9http://click.skem1.com/click/bbu3-q26rk-f9wttl-63syewy1/HX9http://click.skem1.com/click/bbu3-q26rk-f9wttk-63syewy0/HQ9http://click.skem1.com/click/bbu3-q26rk-f9wttj-63syewy9/HP9http://click.skem1.com/click/bbu3-q26rk-f9wtti-63syewy8/H_9http://click.skem1.com/click/bbu3-q26rk-f9wtth-63syewy7/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wttg-63syewy6/H]9http://click.skem1.com/click/bbu3-q26rk-f9wttf-63syewy5/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wtte-63syewy4/H[ 9http://click.skem1.com/click/bbu3-q26rk-f9wttd-63syewy3/HZ |9http://click.skem1.com/click/bbu3-q26rk-f9wttc-63syewy2/HY v9http://click.skem1.com/click/bbu3-q26rk-f9wttb-63syewy1/HXs9http://click.skem1.com/click/bbu3-q26rk-f9wtta-63syewy0/HXWp9http://click.skem1.com/click/bbu3-q26rk-f9wtt9-63syewy0/HQVj9http://click.skem1.com/click/bbu3-q26rk-f9wtt8-63syewy9/HPYg9http://click.skem1.com/click/bbu3-q26rk-f9wtt7-63syewy8/H_Xd9http://click.skem1.com/click/bbu3-q26rk-f9wtt6-63syewy7/H^[a9http://click.skem1.com/click/bbu3-q26rk-f9wtt5-63syewy6/H]Z^9http://click.skem1.com/click/bbu3-q26rk-f9wtt4-63syewy5/H\][9http://click.skem1.com/click/bbu3-q26rk-f9wtt3-63syewy4/H[\U9http://click.skem1.com/click/bbu3-q26rk-f9wtt2-63syewy3/HZ_R9http://click.skem1.com/click/bbu3-q26rk-f9wtt1-63syewy2/HY^O9http://click.skem1.com/click/bbu3-q26rk-f9wtt0-63syewy1/H[L9http://click.skem1.com/click/bbu3-q26rk-f9wtsz-63syewy4/H\I9http://click.skem1.com/click/bbu3-q26rk-f9wtsy-63syewy3/H]F9http://click.skem1.com/click/bbu3-q26rk-f9wtsx-63syewy2/H^@9http://click.skem1.com/click/bbu3-q26rk-f9wtsw-63syewy1/H_=9http://click.skem1.com/click/bbu3-q26rk-f9wtsv-63syewy0/HV:9http://click.skem1.com/click/bbu3-q26rk-f9wtsu-63syewy9/HW79http://click.skem1.com/click/bbu3-q26rk-f9wtst-63syewy8/HX49http://click.skem1.com/click/bbu3-q26rk-f9wtss-63syewy7/HY19http://click.skem1.com/click/bbu3-q26rk-f9wtsr-63syewy6/HZ+9http://click.skem1.com/click/bbu3-q26rk-f9wtsq-63syewy5/H[(9http://click.skem1.com/click/bbu3-q26rk-f9wtsp-63syewy4/H\"9http://click.skem1.com/click/bbu3-q26rk-f9wtso-63syewy3/H]9http://click.skem1.com/click/bbu3-q26rk-f9wtsn-63syewy2/H^9http://click.skem1.com/click/bbu3-q26rk-f9wtsm-63syewy1/H_9http://click.skem1.com/click/bbu3-q26rk-f9wtsl-63syewy0/HV9http://click.skem1.com/click/bbu3-q26rk-f9wtsk-63syewy9/HW9http://click.skem1.com/click/bbu3-q26rk-f9wtsj-63syewy8/HX 9http://click.skem1.com/click/bbu3-q26rk-f9wtsi-63syewy7/HY 9http://click.skem1.com/click/bbu3-q26rk-f9wtsh-63syewy6/HZ 9http://click.skem1.com/click/bbu3-q26rk-f9wtsg-63syewy5/H[9http://click.skem1.com/click/bbu3-q26rk-f9wtsf-63syewy4/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wtse-63syewy3/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wtsd-63syewy2/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wtsc-63syewy1/H_ 9http://click.skem1.com/click/bbu3-q26rk-f9wtsb-63syewy0/HV9http://click.skem1.com/click/bbu3-q26rk-f9wtsa-63syewy9/HVW9http://click.skem1.com/click/bbu3-q26rk-f9wts9-63syewy9/HWV9http://click.skem1.com/click/bbu3-q26rk-f9wts8-63syewy8/HXY9http://click.skem1.com/click/bbu3-q26rk-f9wts7-63syewy7/HYX9http://click.skem1.com/click/bbu3-q26rk-f9wts6-63syewy6/HZ[9http://click.skem1.com/click/bbu3-q26rk-f9wts5-63syewy5/H[Z9http://click.skem1.com/click/bbu3-q26rk-f9wts4-63syewy4/H\]9http://click.skem1.com/click/bbu3-q26rk-f9wts3-63syewy3/H]\9http://click.skem1.com/click/bbu3-q26rk-f9wts2-63syewy2/H^_9http://click.skem1.com/click/bbu3-q26rk-f9wts1-63syewy1/H_^9http://click.skem1.com/click/bbu3-q26rk-f9wts0-63syewy0/H]9http://click.skem1.com/click/bbu3-q26rk-f9wtrz-63syewy3/H\9http://click.skem1.com/click/bbu3-q26rk-f9wtry-63syewy2/H_9http://click.skem1.com/click/bbu3-q26rk-f9wtrx-63syewy1/H^9http://click.skem1.com/click/bbu3-q26rk-f9wtrw-63syewy0/HW9http://click.skem1.com/click/bbu3-q26rk-f9wtrv-63syewy9/HV9http://click.skem1.com/click/bbu3-q26rk-f9wtru-63syewy8/HY9http://click.skem1.com/click/bbu3-q26rk-f9wtrt-63syewy7/HX9http://click.skem1.com/click/bbu3-q26rk-f9wtrs-63syewy6/H[9http://click.skem1.com/click/bbu3-q26rk-f9wtrr-63syewy5/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wtrq-63syewy4/H]9http://click.skem1.com/click/bbu3-q26rk-f9wtrp-63syewy3/H\9http://click.skem1.com/click/bbu3-q26rk-f9wtro-63syewy2/H_9http://click.skem1.com/click/bbu3-q26rk-f9wtrn-63syewy1/H^9http://click.skem1.com/click/bbu3-q26rk-f9wtrm-63syewy0/HW9http://click.skem1.com/click/bbu3-q26rk-f9wtrl-63syewy9/HV9http://click.skem1.com/click/bbu3-q26rk-f9wtrk-63syewy8/HY9http://click.skem1.com/click/bbu3-q26rk-f9wtrj-63syewy7/HX9http://click.skem1.com/click/bbu3-q26rk-f9wtri-63syewy6/H[9http://click.skem1.com/click/bbu3-q26rk-f9wtrh-63syewy5/HZ 9http://click.skem1.com/click/bbu3-q26rk-f9wtrg-63syewy4/H]9http://click.skem1.com/click/bbu3-q26rk-f9wtrf-63syewy3/H\ }9http://click.skem1.com/click/bbu3-q26rk-f9wtre-63syewy2/H_ z9http://click.skem1.com/click/bbu3-q26rk-f9wtrd-63syewy1/H^ w9http://click.skem1.com/click/bbu3-q26rk-f9wtrc-63syewy0/HW t9http://click.skem1.com/click/bbu3-q26rk-f9wtrb-63syewy9/HVq9http://click.skem1.com/click/bbu3-q26rk-f9wtra-63syewy8/HVWn9http://click.skem1.com/click/bbu3-q26rk-f9wtr9-63syewy8/HYVh9http://click.skem1.com/click/bbu3-q26rk-f9wtr8-63syewy7/HXYe9http://click.skem1.com/click/bbu3-q26rk-f9wtr7-63syewy6/H[Xb9http://click.skem1.com/click/bbu3-q26rk-f9wtr6-63syewy5/HZ[_9http://click.skem1.com/click/bbu3-q26rk-f9wtr5-63syewy4/H]Z\9http://click.skem1.com/click/bbu3-q26rk-f9wtr4-63syewy3/H\]Y9http://click.skem1.com/click/bbu3-q26rk-f9wtr3-63syewy2/H_\S9http://click.skem1.com/click/bbu3-q26rk-f9wtr2-63syewy1/H^_P9http://click.skem1.com/click/bbu3-q26rk-f9wtr1-63syewy0/HW^M9http://click.skem1.com/click/bbu3-q26rk-f9wtr0-63syewy9/H_J9http://click.skem1.com/click/bbu3-q26rk-f9wtqz-63syewy2/H\G9http://click.skem1.com/click/bbu3-q26rk-f9wtqy-63syewy1/H]D9http://click.skem1.com/click/bbu3-q26rk-f9wtqx-63syewy0/HT>9http://click.skem1.com/click/bbu3-q26rk-f9wtqw-63syewy9/HU;9http://click.skem1.com/click/bbu3-q26rk-f9wtqv-63syewy8/HZ89http://click.skem1.com/click/bbu3-q26rk-f9wtqu-63syewy7/H[59http://click.skem1.com/click/bbu3-q26rk-f9wtqt-63syewy6/HX29http://click.skem1.com/click/bbu3-q26rk-f9wtqs-63syewy5/HY/9http://click.skem1.com/click/bbu3-q26rk-f9wtqr-63syewy4/H^)9http://click.skem1.com/click/bbu3-q26rk-f9wtqq-63syewy3/H_#9http://click.skem1.com/click/bbu3-q26rk-f9wtqp-63syewy2/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wtqo-63syewy1/H]9http://click.skem1.com/click/bbu3-q26rk-f9wtqn-63syewy0/HT9http://click.skem1.com/click/bbu3-q26rk-f9wtqm-63syewy9/HU9http://click.skem1.com/click/bbu3-q26rk-f9wtql-63syewy8/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wtqk-63syewy7/H[9http://click.skem1.com/click/bbu3-q26rk-f9wtqj-63syewy6/HX 9http://click.skem1.com/click/bbu3-q26rk-f9wtqi-63syewy5/HY9http://click.skem1.com/click/bbu3-q26rk-f9wtqh-63syewy4/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wtqg-63syewy3/H_9http://click.skem1.com/click/bbu3-q26rk-f9wtqf-63syewy2/H\ 9http://click.skem1.com/click/bbu3-q26rk-f9wtqe-63syewy1/H] 9http://click.skem1.com/click/bbu3-q26rk-f9wtqd-63syewy0/HT 9http://click.skem1.com/click/bbu3-q26rk-f9wtqc-63syewy9/HU 9http://click.skem1.com/click/bbu3-q26rk-f9wtqb-63syewy8/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wtqa-63syewy7/HZW9http://click.skem1.com/click/bbu3-q26rk-f9wtq9-63syewy7/H[V9http://click.skem1.com/click/bbu3-q26rk-f9wtq8-63syewy6/HXY9http://click.skem1.com/click/bbu3-q26rk-f9wtq7-63syewy5/HYX9http://click.skem1.com/click/bbu3-q26rk-f9wtq6-63syewy4/H^[9http://click.skem1.com/click/bbu3-q26rk-f9wtq5-63syewy3/H_Z9http://click.skem1.com/click/bbu3-q26rk-f9wtq4-63syewy2/H\]9http://click.skem1.com/click/bbu3-q26rk-f9wtq3-63syewy1/H]\9http://click.skem1.com/click/bbu3-q26rk-f9wtq2-63syewy0/HT_9http://click.skem1.com/click/bbu3-q26rk-f9wtq1-63syewy9/HU^9http://click.skem1.com/click/bbu3-q26rk-f9wtq0-63syewy8/H]9http://click.skem1.com/click/bbu3-q26rk-f9wtpz-63syewy1/H\9http://click.skem1.com/click/bbu3-q26rk-f9wtpy-63syewy0/HU9http://click.skem1.com/click/bbu3-q26rk-f9wtpx-63syewy9/HT9http://click.skem1.com/click/bbu3-q26rk-f9wtpw-63syewy8/H[9http://click.skem1.com/click/bbu3-q26rk-f9wtpv-63syewy7/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wtpu-63syewy6/HY9http://click.skem1.com/click/bbu3-q26rk-f9wtpt-63syewy5/HX9http://click.skem1.com/click/bbu3-q26rk-f9wtps-63syewy4/H_9http://click.skem1.com/click/bbu3-q26rk-f9wtpr-63syewy3/H^9http://click.skem1.com/click/bbu3-q26rk-f9wtpq-63syewy2/H]9http://click.skem1.com/click/bbu3-q26rk-f9wtpp-63syewy1/H\9http://click.skem1.com/click/bbu3-q26rk-f9wtpo-63syewy0/HU9http://click.skem1.com/click/bbu3-q26rk-f9wtpn-63syewy9/HT9http://click.skem1.com/click/bbu3-q26rk-f9wtpm-63syewy8/H[9http://click.skem1.com/click/bbu3-q26rk-f9wtpl-63syewy7/HZ9http://click.skem1.com/click/bbu3-q26rk-f9wtpk-63syewy6/HY9http://click.skem1.com/click/bbu3-q26rk-f9wtpj-63syewy5/HX9http://click.skem1.com/click/bbu3-q26rk-f9wtpi-63syewy4/H_9http://click.skem1.com/click/bbu3-q26rk-f9wtph-63syewy3/H^ 9http://click.skem1.com/click/bbu3-q26rk-f9wtpg-63syewy2/H]9http://click.skem1.com/click/bbu3-q26rk-f9wtpf-63syewy1/H\ {9http://click.skem1.com/click/bbu3-q26rk-f9wtpe-63syewy0/HU x9http://click.skem1.com/click/bbu3-q26rk-f9wtpd-63syewy9/HT u9http://click.skem1.com/click/bbu3-q26rk-f9wtpc-63syewy8/H[ r9http://click.skem1.com/click/bbu3-q26rk-f9wtpb-63syewy7/HZo9http://click.skem1.com/click/bbu3-q26rk-f9wtpa-63syewy6/HZWl9http://click.skem1.com/click/bbu3-q26rk-f9wtp9-63syewy6/HYVf9http://click.skem1.com/click/bbu3-q26rk-f9wtp8-63syewy5/HXYc9http://click.skem1.com/click/bbu3-q26rk-f9wtp7-63syewy4/H_X`9http://click.skem1.com/click/bbu3-q26rk-f9wtp6-63syewy3/H^[]9http://click.skem1.com/click/bbu3-q26rk-f9wtp5-63syewy2/H]ZZ9http://click.skem1.com/click/bbu3-q26rk-f9wtp4-63syewy1/H\]W9http://click.skem1.com/click/bbu3-q26rk-f9wtp3-63syewy0/HU\Q9http://click.skem1.com/click/bbu3-q26rk-f9wtp2-63syewy9/HT_N9http://click.skem1.com/click/bbu3-q26rk-f9wtp1-63syewy8/H[^K9http://click.skem1.com/click/bbu3-q26rk-f9wtp0-63syewy7/HCH9http://click.skem1.com/click/bbu3-q26rk-f9wtoz-63syewy0/HJE9http://click.skem1.com/click/bbu3-q26rk-f9wtoy-63syewy9/HKB9http://click.skem1.com/click/bbu3-q26rk-f9wtox-63syewy8/HD<9http://click.skem1.com/click/bbu3-q26rk-f9wtow-63syewy7/HE69http://click.skem1.com/click/bbu3-q26rk-f9wtov-63syewy6/HF39http://click.skem1.com/click/bbu3-q26rk-f9wtou-63syewy5/HG09http://click.skem1.com/click/bbu3-q26rk-f9wtot-63syewy4/H@-9http://click.skem1.com/click/bbu3-q26rk-f9wtos-63syewy3/HA*9http://click.skem1.com/click/bbu3-q26rk-f9wtor-63syewy2/HB'9http://click.skem1.com/click/bbu3-q26rk-f9wtoq-63syewy1/HC!9http://click.skem1.com/click/bbu3-q26rk-f9wtop-63syewy0/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wtoo-63syewy9/HK9http://click.skem1.com/click/bbu3-q26rk-f9wton-63syewy8/HD9http://click.skem1.com/click/bbu3-q26rk-f9wtom-63syewy7/HE9http://click.skem1.com/click/bbu3-q26rk-f9wtol-63syewy6/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtok-63syewy5/HG 9http://click.skem1.com/click/bbu3-q26rk-f9wtoj-63syewy4/H@ 9http://click.skem1.com/click/bbu3-q26rk-f9wtoi-63syewy3/HA9http://click.skem1.com/click/bbu3-q26rk-f9wtoh-63syewy2/HB 9http://click.skem1.com/click/bbu3-q26rk-f9wtog-63syewy1/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtof-63syewy0/HJ 9http://click.skem1.com/click/bbu3-q26rk-f9wtoe-63syewy9/HK 9http://click.skem1.com/click/bbu3-q26rk-f9wtod-63syewy8/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wtoc-63syewy7/HE 9http://click.skem1.com/click/bbu3-q26rk-f9wtob-63syewy6/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtoa-63syewy5/HFW9http://click.skem1.com/click/bbu3-q26rk-f9wto9-63syewy5/HGV9http://click.skem1.com/click/bbu3-q26rk-f9wto8-63syewy4/H@Y9http://click.skem1.com/click/bbu3-q26rk-f9wto7-63syewy3/HAX9http://click.skem1.com/click/bbu3-q26rk-f9wto6-63syewy2/HB[9http://click.skem1.com/click/bbu3-q26rk-f9wto5-63syewy1/HCZ9http://click.skem1.com/click/bbu3-q26rk-f9wto4-63syewy0/HJ]9http://click.skem1.com/click/bbu3-q26rk-f9wto3-63syewy9/HK\9http://click.skem1.com/click/bbu3-q26rk-f9wto2-63syewy8/HD_9http://click.skem1.com/click/bbu3-q26rk-f9wto1-63syewy7/HE^9http://click.skem1.com/click/bbu3-q26rk-f9wto0-63syewy6/HK9http://click.skem1.com/click/bbu3-q26rk-f9wtnz-63syewy9/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wtny-63syewy8/HE9http://click.skem1.com/click/bbu3-q26rk-f9wtnx-63syewy7/HD9http://click.skem1.com/click/bbu3-q26rk-f9wtnw-63syewy6/HG9http://click.skem1.com/click/bbu3-q26rk-f9wtnv-63syewy5/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtnu-63syewy4/HA9http://click.skem1.com/click/bbu3-q26rk-f9wtnt-63syewy3/H@9http://click.skem1.com/click/bbu3-q26rk-f9wtns-63syewy2/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtnr-63syewy1/HB9http://click.skem1.com/click/bbu3-q26rk-f9wtnq-63syewy0/HK9http://click.skem1.com/click/bbu3-q26rk-f9wtnp-63syewy9/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wtno-63syewy8/HE9http://click.skem1.com/click/bbu3-q26rk-f9wtnn-63syewy7/HD9http://click.skem1.com/click/bbu3-q26rk-f9wtnm-63syewy6/HG9http://click.skem1.com/click/bbu3-q26rk-f9wtnl-63syewy5/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtnk-63syewy4/HA9http://click.skem1.com/click/bbu3-q26rk-f9wtnj-63syewy3/H@9http://click.skem1.com/click/bbu3-q26rk-f9wtni-63syewy2/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtnh-63syewy1/HB 9http://click.skem1.com/click/bbu3-q26rk-f9wtng-63syewy0/HK9http://click.skem1.com/click/bbu3-q26rk-f9wtnf-63syewy9/HJ |9http://click.skem1.com/click/bbu3-q26rk-f9wtne-63syewy8/HE y9http://click.skem1.com/click/bbu3-q26rk-f9wtnd-63syewy7/HD v9http://click.skem1.com/click/bbu3-q26rk-f9wtnc-63syewy6/HG p9http://click.skem1.com/click/bbu3-q26rk-f9wtnb-63syewy5/HFm9http://click.skem1.com/click/bbu3-q26rk-f9wtna-63syewy4/HFWd9http://click.skem1.com/click/bbu3-q26rk-f9wtn9-63syewy4/HAVa9http://click.skem1.com/click/bbu3-q26rk-f9wtn8-63syewy3/H@Y^9http://click.skem1.com/click/bbu3-q26rk-f9wtn7-63syewy2/HCX[9http://click.skem1.com/click/bbu3-q26rk-f9wtn6-63syewy1/HB[X9http://click.skem1.com/click/bbu3-q26rk-f9wtn5-63syewy0/HKZU9http://click.skem1.com/click/bbu3-q26rk-f9wtn4-63syewy9/HJ]O9http://click.skem1.com/click/bbu3-q26rk-f9wtn3-63syewy8/HE\L9http://click.skem1.com/click/bbu3-q26rk-f9wtn2-63syewy7/HD_I9http://click.skem1.com/click/bbu3-q26rk-f9wtn1-63syewy6/HG^F9http://click.skem1.com/click/bbu3-q26rk-f9wtn0-63syewy5/HIC9http://click.skem1.com/click/bbu3-q26rk-f9wtmz-63syewy8/HF@9http://click.skem1.com/click/bbu3-q26rk-f9wtmy-63syewy7/HG:9http://click.skem1.com/click/bbu3-q26rk-f9wtmx-63syewy6/HD79http://click.skem1.com/click/bbu3-q26rk-f9wtmw-63syewy5/HE49http://click.skem1.com/click/bbu3-q26rk-f9wtmv-63syewy4/HB19http://click.skem1.com/click/bbu3-q26rk-f9wtmu-63syewy3/HC.9http://click.skem1.com/click/bbu3-q26rk-f9wtmt-63syewy2/H@+9http://click.skem1.com/click/bbu3-q26rk-f9wtms-63syewy1/HA%9http://click.skem1.com/click/bbu3-q26rk-f9wtmr-63syewy0/HH"9http://click.skem1.com/click/bbu3-q26rk-f9wtmq-63syewy9/HI9http://click.skem1.com/click/bbu3-q26rk-f9wtmp-63syewy8/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtmo-63syewy7/HG9http://click.skem1.com/click/bbu3-q26rk-f9wtmn-63syewy6/HD9http://click.skem1.com/click/bbu3-q26rk-f9wtmm-63syewy5/HE9http://click.skem1.com/click/bbu3-q26rk-f9wtml-63syewy4/HB 9http://click.skem1.com/click/bbu3-q26rk-f9wtmk-63syewy3/HC 9http://click.skem1.com/click/bbu3-q26rk-f9wtmj-63syewy2/H@9http://click.skem1.com/click/bbu3-q26rk-f9wtmi-63syewy1/HA9http://click.skem1.com/click/bbu3-q26rk-f9wtmh-63syewy0/HH 9http://click.skem1.com/click/bbu3-q26rk-f9wtmg-63syewy9/HI9http://click.skem1.com/click/bbu3-q26rk-f9wtmf-63syewy8/HF 9http://click.skem1.com/click/bbu3-q26rk-f9wtme-63syewy7/HG 9http://click.skem1.com/click/bbu3-q26rk-f9wtmd-63syewy6/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wtmc-63syewy5/HE 9http://click.skem1.com/click/bbu3-q26rk-f9wtmb-63syewy4/HB9http://click.skem1.com/click/bbu3-q26rk-f9wtma-63syewy3/HBW9http://click.skem1.com/click/bbu3-q26rk-f9wtm9-63syewy3/HCV9http://click.skem1.com/click/bbu3-q26rk-f9wtm8-63syewy2/H@Y9http://click.skem1.com/click/bbu3-q26rk-f9wtm7-63syewy1/HAX9http://click.skem1.com/click/bbu3-q26rk-f9wtm6-63syewy0/HH[9http://click.skem1.com/click/bbu3-q26rk-f9wtm5-63syewy9/HIZ9http://click.skem1.com/click/bbu3-q26rk-f9wtm4-63syewy8/HF]9http://click.skem1.com/click/bbu3-q26rk-f9wtm3-63syewy7/HG\9http://click.skem1.com/click/bbu3-q26rk-f9wtm2-63syewy6/HD_9http://click.skem1.com/click/bbu3-q26rk-f9wtm1-63syewy5/HE^9http://click.skem1.com/click/bbu3-q26rk-f9wtm0-63syewy4/HG9http://click.skem1.com/click/bbu3-q26rk-f9wtlz-63syewy7/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtly-63syewy6/HE9http://click.skem1.com/click/bbu3-q26rk-f9wtlx-63syewy5/HD9http://click.skem1.com/click/bbu3-q26rk-f9wtlw-63syewy4/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtlv-63syewy3/HB9http://click.skem1.com/click/bbu3-q26rk-f9wtlu-63syewy2/HA9http://click.skem1.com/click/bbu3-q26rk-f9wtlt-63syewy1/H@9http://click.skem1.com/click/bbu3-q26rk-f9wtls-63syewy0/HI9http://click.skem1.com/click/bbu3-q26rk-f9wtlr-63syewy9/HH9http://click.skem1.com/click/bbu3-q26rk-f9wtlq-63syewy8/HG9http://click.skem1.com/click/bbu3-q26rk-f9wtlp-63syewy7/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtlo-63syewy6/HE9http://click.skem1.com/click/bbu3-q26rk-f9wtln-63syewy5/HD9http://click.skem1.com/click/bbu3-q26rk-f9wtlm-63syewy4/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtll-63syewy3/HB9http://click.skem1.com/click/bbu3-q26rk-f9wtlk-63syewy2/HA9http://click.skem1.com/click/bbu3-q26rk-f9wtlj-63syewy1/H@9http://click.skem1.com/click/bbu3-q26rk-f9wtli-63syewy0/HI9http://click.skem1.com/click/bbu3-q26rk-f9wtlh-63syewy9/HH 9http://click.skem1.com/click/bbu3-q26rk-f9wtlg-63syewy8/HG}9http://click.skem1.com/click/bbu3-q26rk-f9wtlf-63syewy7/HF z9http://click.skem1.com/click/bbu3-q26rk-f9wtle-63syewy6/HE w9http://click.skem1.com/click/bbu3-q26rk-f9wtld-63syewy5/HD t9http://click.skem1.com/click/bbu3-q26rk-f9wtlc-63syewy4/HC q9http://click.skem1.com/click/bbu3-q26rk-f9wtlb-63syewy3/HBn9http://click.skem1.com/click/bbu3-q26rk-f9wtla-63syewy2/HBWh9http://click.skem1.com/click/bbu3-q26rk-f9wtl9-63syewy2/HAVe9http://click.skem1.com/click/bbu3-q26rk-f9wtl8-63syewy1/H@Yb9http://click.skem1.com/click/bbu3-q26rk-f9wtl7-63syewy0/HIX_9http://click.skem1.com/click/bbu3-q26rk-f9wtl6-63syewy9/HH[\9http://click.skem1.com/click/bbu3-q26rk-f9wtl5-63syewy8/HGZY9http://click.skem1.com/click/bbu3-q26rk-f9wtl4-63syewy7/HF]S9http://click.skem1.com/click/bbu3-q26rk-f9wtl3-63syewy6/HE\M9http://click.skem1.com/click/bbu3-q26rk-f9wtl2-63syewy5/HD_J9http://click.skem1.com/click/bbu3-q26rk-f9wtl1-63syewy4/HC^G9http://click.skem1.com/click/bbu3-q26rk-f9wtl0-63syewy3/HAD9http://click.skem1.com/click/bbu3-q26rk-f9wtkz-63syewy6/HBA9http://click.skem1.com/click/bbu3-q26rk-f9wtky-63syewy5/HC>9http://click.skem1.com/click/bbu3-q26rk-f9wtkx-63syewy4/HD89http://click.skem1.com/click/bbu3-q26rk-f9wtkw-63syewy3/HE59http://click.skem1.com/click/bbu3-q26rk-f9wtkv-63syewy2/HF29http://click.skem1.com/click/bbu3-q26rk-f9wtku-63syewy1/HG/9http://click.skem1.com/click/bbu3-q26rk-f9wtkt-63syewy0/HN,9http://click.skem1.com/click/bbu3-q26rk-f9wtks-63syewy9/HO)9http://click.skem1.com/click/bbu3-q26rk-f9wtkr-63syewy8/H@#9http://click.skem1.com/click/bbu3-q26rk-f9wtkq-63syewy7/HA 9http://click.skem1.com/click/bbu3-q26rk-f9wtkp-63syewy6/HB9http://click.skem1.com/click/bbu3-q26rk-f9wtko-63syewy5/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtkn-63syewy4/HD9http://click.skem1.com/click/bbu3-q26rk-f9wtkm-63syewy3/HE9http://click.skem1.com/click/bbu3-q26rk-f9wtkl-63syewy2/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtkk-63syewy1/HG 9http://click.skem1.com/click/bbu3-q26rk-f9wtkj-63syewy0/HN9http://click.skem1.com/click/bbu3-q26rk-f9wtki-63syewy9/HO9http://click.skem1.com/click/bbu3-q26rk-f9wtkh-63syewy8/H@ 9http://click.skem1.com/click/bbu3-q26rk-f9wtkg-63syewy7/HA9http://click.skem1.com/click/bbu3-q26rk-f9wtkf-63syewy6/HB 9http://click.skem1.com/click/bbu3-q26rk-f9wtke-63syewy5/HC 9http://click.skem1.com/click/bbu3-q26rk-f9wtkd-63syewy4/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wtkc-63syewy3/HE 9http://click.skem1.com/click/bbu3-q26rk-f9wtkb-63syewy2/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtka-63syewy1/HFW9http://click.skem1.com/click/bbu3-q26rk-f9wtk9-63syewy1/HGV9http://click.skem1.com/click/bbu3-q26rk-f9wtk8-63syewy0/HNY9http://click.skem1.com/click/bbu3-q26rk-f9wtk7-63syewy9/HOX9http://click.skem1.com/click/bbu3-q26rk-f9wtk6-63syewy8/H@[9http://click.skem1.com/click/bbu3-q26rk-f9wtk5-63syewy7/HAZ9http://click.skem1.com/click/bbu3-q26rk-f9wtk4-63syewy6/HB]9http://click.skem1.com/click/bbu3-q26rk-f9wtk3-63syewy5/HC\9http://click.skem1.com/click/bbu3-q26rk-f9wtk2-63syewy4/HD_9http://click.skem1.com/click/bbu3-q26rk-f9wtk1-63syewy3/HE^9http://click.skem1.com/click/bbu3-q26rk-f9wtk0-63syewy2/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtjz-63syewy5/HB9http://click.skem1.com/click/bbu3-q26rk-f9wtjy-63syewy4/HE9http://click.skem1.com/click/bbu3-q26rk-f9wtjx-63syewy3/HD9http://click.skem1.com/click/bbu3-q26rk-f9wtjw-63syewy2/HG9http://click.skem1.com/click/bbu3-q26rk-f9wtjv-63syewy1/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtju-63syewy0/HO9http://click.skem1.com/click/bbu3-q26rk-f9wtjt-63syewy9/HN9http://click.skem1.com/click/bbu3-q26rk-f9wtjs-63syewy8/HA9http://click.skem1.com/click/bbu3-q26rk-f9wtjr-63syewy7/H@9http://click.skem1.com/click/bbu3-q26rk-f9wtjq-63syewy6/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtjp-63syewy5/HB9http://click.skem1.com/click/bbu3-q26rk-f9wtjo-63syewy4/HE9http://click.skem1.com/click/bbu3-q26rk-f9wtjn-63syewy3/HD9http://click.skem1.com/click/bbu3-q26rk-f9wtjm-63syewy2/HG9http://click.skem1.com/click/bbu3-q26rk-f9wtjl-63syewy1/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtjk-63syewy0/HO9http://click.skem1.com/click/bbu3-q26rk-f9wtjj-63syewy9/HN9http://click.skem1.com/click/bbu3-q26rk-f9wtji-63syewy8/HA9http://click.skem1.com/click/bbu3-q26rk-f9wtjh-63syewy7/H@ 9http://click.skem1.com/click/bbu3-q26rk-f9wtjg-63syewy6/HC{9http://click.skem1.com/click/bbu3-q26rk-f9wtjf-63syewy5/HB x9http://click.skem1.com/click/bbu3-q26rk-f9wtje-63syewy4/HE u9http://click.skem1.com/click/bbu3-q26rk-f9wtjd-63syewy3/HD r9http://click.skem1.com/click/bbu3-q26rk-f9wtjc-63syewy2/HG o9http://click.skem1.com/click/bbu3-q26rk-f9wtjb-63syewy1/HFl9http://click.skem1.com/click/bbu3-q26rk-f9wtja-63syewy0/HFWf9http://click.skem1.com/click/bbu3-q26rk-f9wtj9-63syewy0/HOVc9http://click.skem1.com/click/bbu3-q26rk-f9wtj8-63syewy9/HNY`9http://click.skem1.com/click/bbu3-q26rk-f9wtj7-63syewy8/HAX]9http://click.skem1.com/click/bbu3-q26rk-f9wtj6-63syewy7/H@[Z9http://click.skem1.com/click/bbu3-q26rk-f9wtj5-63syewy6/HCZW9http://click.skem1.com/click/bbu3-q26rk-f9wtj4-63syewy5/HB]Q9http://click.skem1.com/click/bbu3-q26rk-f9wtj3-63syewy4/HE\N9http://click.skem1.com/click/bbu3-q26rk-f9wtj2-63syewy3/HD_K9http://click.skem1.com/click/bbu3-q26rk-f9wtj1-63syewy2/HG^H9http://click.skem1.com/click/bbu3-q26rk-f9wtj0-63syewy1/HAE9http://click.skem1.com/click/bbu3-q26rk-f9wtiz-63syewy4/HFB9http://click.skem1.com/click/bbu3-q26rk-f9wtiy-63syewy3/HG<9http://click.skem1.com/click/bbu3-q26rk-f9wtix-63syewy2/HD99http://click.skem1.com/click/bbu3-q26rk-f9wtiw-63syewy1/HE69http://click.skem1.com/click/bbu3-q26rk-f9wtiv-63syewy0/HL39http://click.skem1.com/click/bbu3-q26rk-f9wtiu-63syewy9/HM09http://click.skem1.com/click/bbu3-q26rk-f9wtit-63syewy8/HB-9http://click.skem1.com/click/bbu3-q26rk-f9wtis-63syewy7/HC'9http://click.skem1.com/click/bbu3-q26rk-f9wtir-63syewy6/H@$9http://click.skem1.com/click/bbu3-q26rk-f9wtiq-63syewy5/HA!9http://click.skem1.com/click/bbu3-q26rk-f9wtip-63syewy4/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtio-63syewy3/HG9http://click.skem1.com/click/bbu3-q26rk-f9wtin-63syewy2/HD9http://click.skem1.com/click/bbu3-q26rk-f9wtim-63syewy1/HE9http://click.skem1.com/click/bbu3-q26rk-f9wtil-63syewy0/HL9http://click.skem1.com/click/bbu3-q26rk-f9wtik-63syewy9/HM 9http://click.skem1.com/click/bbu3-q26rk-f9wtij-63syewy8/HB 9http://click.skem1.com/click/bbu3-q26rk-f9wtii-63syewy7/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtih-63syewy6/H@ 9http://click.skem1.com/click/bbu3-q26rk-f9wtig-63syewy5/HA9http://click.skem1.com/click/bbu3-q26rk-f9wtif-63syewy4/HF 9http://click.skem1.com/click/bbu3-q26rk-f9wtie-63syewy3/HG 9http://click.skem1.com/click/bbu3-q26rk-f9wtid-63syewy2/HD 9http://click.skem1.com/click/bbu3-q26rk-f9wtic-63syewy1/HE 9http://click.skem1.com/click/bbu3-q26rk-f9wtib-63syewy0/HL9http://click.skem1.com/click/bbu3-q26rk-f9wtia-63syewy9/HLW9http://click.skem1.com/click/bbu3-q26rk-f9wti9-63syewy9/HMV9http://click.skem1.com/click/bbu3-q26rk-f9wti8-63syewy8/HBY9http://click.skem1.com/click/bbu3-q26rk-f9wti7-63syewy7/HCX9http://click.skem1.com/click/bbu3-q26rk-f9wti6-63syewy6/H@[9http://click.skem1.com/click/bbu3-q26rk-f9wti5-63syewy5/HAZ9http://click.skem1.com/click/bbu3-q26rk-f9wti4-63syewy4/HF]9http://click.skem1.com/click/bbu3-q26rk-f9wti3-63syewy3/HG\9http://click.skem1.com/click/bbu3-q26rk-f9wti2-63syewy2/HD_9http://click.skem1.com/click/bbu3-q26rk-f9wti1-63syewy1/HE^9http://click.skem1.com/click/bbu3-q26rk-f9wti0-63syewy0/HG9http://click.skem1.com/click/bbu3-q26rk-f9wthz-63syewy3/HF9http://click.skem1.com/click/bbu3-q26rk-f9wthy-63syewy2/HE9http://click.skem1.com/click/bbu3-q26rk-f9wthx-63syewy1/HD9http://click.skem1.com/click/bbu3-q26rk-f9wthw-63syewy0/HM9http://click.skem1.com/click/bbu3-q26rk-f9wthv-63syewy9/HL9http://click.skem1.com/click/bbu3-q26rk-f9wthu-63syewy8/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtht-63syewy7/HB9http://click.skem1.com/click/bbu3-q26rk-f9wths-63syewy6/HA9http://click.skem1.com/click/bbu3-q26rk-f9wthr-63syewy5/H@9http://click.skem1.com/click/bbu3-q26rk-f9wthq-63syewy4/HG9http://click.skem1.com/click/bbu3-q26rk-f9wthp-63syewy3/HF9http://click.skem1.com/click/bbu3-q26rk-f9wtho-63syewy2/HE9http://click.skem1.com/click/bbu3-q26rk-f9wthn-63syewy1/HD9http://click.skem1.com/click/bbu3-q26rk-f9wthm-63syewy0/HM9http://click.skem1.com/click/bbu3-q26rk-f9wthl-63syewy9/HL9http://click.skem1.com/click/bbu3-q26rk-f9wthk-63syewy8/HC9http://click.skem1.com/click/bbu3-q26rk-f9wthj-63syewy7/HB9http://click.skem1.com/click/bbu3-q26rk-f9wthi-63syewy6/HA9http://click.skem1.com/click/bbu3-q26rk-f9wthh-63syewy5/H@ 9http://click.skem1.com/click/bbu3-q26rk-f9wthg-63syewy4/HG9http://click.skem1.com/click/bbu3-q26rk-f9wthf-63syewy3/HF |9http://click.skem1.com/click/bbu3-q26rk-f9wthe-63syewy2/HE y9http://click.skem1.com/click/bbu3-q26rk-f9wthd-63syewy1/HD v9http://click.skem1.com/click/bbu3-q26rk-f9wthc-63syewy0/HM s9http://click.skem1.com/click/bbu3-q26rk-f9wthb-63syewy9/HLp9http://click.skem1.com/click/bbu3-q26rk-f9wtha-63syewy8/HLWj9http://click.skem1.com/click/bbu3-q26rk-f9wth9-63syewy8/HCVg9http://click.skem1.com/click/bbu3-q26rk-f9wth8-63syewy7/HBYd9http://click.skem1.com/click/bbu3-q26rk-f9wth7-63syewy6/HAXa9http://click.skem1.com/click/bbu3-q26rk-f9wth6-63syewy5/H@[^9http://click.skem1.com/click/bbu3-q26rk-f9wth5-63syewy4/HGZ[9http://click.skem1.com/click/bbu3-q26rk-f9wth4-63syewy3/HF]U9http://click.skem1.com/click/bbu3-q26rk-f9wth3-63syewy2/HE\R9http://click.skem1.com/click/bbu3-q26rk-f9wth2-63syewy1/HD_O9http://click.skem1.com/click/bbu3-q26rk-f9wth1-63syewy0/HM^L9http://click.skem1.com/click/bbu3-q26rk-f9wth0-63syewy9/HII9http://click.skem1.com/click/bbu3-q26rk-f9wtgz-63syewy2/HJF9http://click.skem1.com/click/bbu3-q26rk-f9wtgy-63syewy1/HK@9http://click.skem1.com/click/bbu3-q26rk-f9wtgx-63syewy0/HB=9http://click.skem1.com/click/bbu3-q26rk-f9wtgw-63syewy9/HC:9http://click.skem1.com/click/bbu3-q26rk-f9wtgv-63syewy8/HL79http://click.skem1.com/click/bbu3-q26rk-f9wtgu-63syewy7/HM49http://click.skem1.com/click/bbu3-q26rk-f9wtgt-63syewy6/HN19http://click.skem1.com/click/bbu3-q26rk-f9wtgs-63syewy5/HO+9http://click.skem1.com/click/bbu3-q26rk-f9wtgr-63syewy4/HH(9http://click.skem1.com/click/bbu3-q26rk-f9wtgq-63syewy3/HI%9http://click.skem1.com/click/bbu3-q26rk-f9wtgp-63syewy2/HJ"9http://click.skem1.com/click/bbu3-q26rk-f9wtgo-63syewy1/HK9http://click.skem1.com/click/bbu3-q26rk-f9wtgn-63syewy0/HB9http://click.skem1.com/click/bbu3-q26rk-f9wtgm-63syewy9/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtgl-63syewy8/HL9http://click.skem1.com/click/bbu3-q26rk-f9wtgk-63syewy7/HM9http://click.skem1.com/click/bbu3-q26rk-f9wtgj-63syewy6/HN 9http://click.skem1.com/click/bbu3-q26rk-f9wtgi-63syewy5/HO 9http://click.skem1.com/click/bbu3-q26rk-f9wtgh-63syewy4/HH 9http://click.skem1.com/click/bbu3-q26rk-f9wtgg-63syewy3/HI9http://click.skem1.com/click/bbu3-q26rk-f9wtgf-63syewy2/HJ 9http://click.skem1.com/click/bbu3-q26rk-f9wtge-63syewy1/HK 9http://click.skem1.com/click/bbu3-q26rk-f9wtgd-63syewy0/HB 9http://click.skem1.com/click/bbu3-q26rk-f9wtgc-63syewy9/HC 9http://click.skem1.com/click/bbu3-q26rk-f9wtgb-63syewy8/HL9http://click.skem1.com/click/bbu3-q26rk-f9wtga-63syewy7/HLW9http://click.skem1.com/click/bbu3-q26rk-f9wtg9-63syewy7/HMV9http://click.skem1.com/click/bbu3-q26rk-f9wtg8-63syewy6/HNY9http://click.skem1.com/click/bbu3-q26rk-f9wtg7-63syewy5/HOX9http://click.skem1.com/click/bbu3-q26rk-f9wtg6-63syewy4/HH[9http://click.skem1.com/click/bbu3-q26rk-f9wtg5-63syewy3/HIZ9http://click.skem1.com/click/bbu3-q26rk-f9wtg4-63syewy2/HJ]9http://click.skem1.com/click/bbu3-q26rk-f9wtg3-63syewy1/HK\9http://click.skem1.com/click/bbu3-q26rk-f9wtg2-63syewy0/HB_9http://click.skem1.com/click/bbu3-q26rk-f9wtg1-63syewy9/HC^9http://click.skem1.com/click/bbu3-q26rk-f9wtg0-63syewy8/HK9http://click.skem1.com/click/bbu3-q26rk-f9wtfz-63syewy1/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wtfy-63syewy0/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtfx-63syewy9/HB9http://click.skem1.com/click/bbu3-q26rk-f9wtfw-63syewy8/HM9http://click.skem1.com/click/bbu3-q26rk-f9wtfv-63syewy7/HL9http://click.skem1.com/click/bbu3-q26rk-f9wtfu-63syewy6/HO9http://click.skem1.com/click/bbu3-q26rk-f9wtft-63syewy5/HN9http://click.skem1.com/click/bbu3-q26rk-f9wtfs-63syewy4/HI9http://click.skem1.com/click/bbu3-q26rk-f9wtfr-63syewy3/HH9http://click.skem1.com/click/bbu3-q26rk-f9wtfq-63syewy2/HK9http://click.skem1.com/click/bbu3-q26rk-f9wtfp-63syewy1/HJ9http://click.skem1.com/click/bbu3-q26rk-f9wtfo-63syewy0/HC9http://click.skem1.com/click/bbu3-q26rk-f9wtfn-63syewy9/HB9http://click.skem1.com/click/bbu3-q26rk-f9wtfm-63syewy8/HM9http://click.skem1.com/click/bbu3-q26rk-f9wtfl-63syewy7/HL9http://click.skem1.com/click/bbu3-q26rk-f9wtfk-63syewy6/HO9http://click.skem1.com/click/bbu3-q26rk-f9wtfj-63syewy5/HN9http://click.skem1.com/click/bbu3-q26rk-f9wtfi-63syewy4/HI9http://click.skem1.com/click/bbu3-q26rk-f9wtfh-63syewy3/HH 9http://click.skem1.com/click/bbu3-q26rk-f9wtfg-63syewy2/HK9http://click.skem1.com/click/bbu3-q26rk-f9wtff-63syewy1/HJ 9http://click.skem1.com/click/bbu3-q26rk-f9wtfe-63syewy0/HC }9http://click.skem1.com/click/bbu3-q26rk-f9wtfd-63syewy9/HB z9http://click.skem1.com/click/bbu3-q26rk-f9wtfc-63syewy8/HM w9http://click.skem1.com/click/bbu3-q26rk-f9wtfb-63syewy7/HLt9http://click.skem1.com/click/bbu3-q26rk-f9wtfa-63syewy6/HLWn9http://click.skem1.com/click/bbu3-q26rk-f9wtf9-63syewy6/HOVk9http://click.skem1.com/click/bbu3-q26rk-f9wtf8-63syewy5/HNYh9http://click.skem1.com/click/bbu3-q26rk-f9wtf7-63syewy4/HIXe9http://click.skem1.com/click/bbu3-q26rk-f9wtf6-63syewy3/HH[b9http://click.skem1.com/click/bbu3-q26rk-f9wtf5-63syewy2/HKZ_9http://click.skem1.com/click/bbu3-q26rk-f9wtf4-63syewy1/H# Y1https://academic.oup.com/annonc/issue/29/suppl_5H@VAhttps://www.postersessiononline.eu/pr/congreso.asp?cod=519481837HASfhttps://www.oncolink.org/cancer-treatment/chemotherapy/overview/intraperitoneal-chemotherapy-ip-chemoHzHPIhttps://academic.oup.com/annonc/search-results?f_TocHeadingTitle=PostersH3XMFhttps://academic.oup.com/annonc/article/29/suppl_5/mdy151.182/5039256HBOJ*https://doi.org/10.1093/annonc/mdy151.182HWEG javascript:;HWED javascript:;HWEA javascript:;HWE> javascript:;HzH;Ihttps://academic.oup.com/annonc/search-results?f_TocHeadingTitle=PostersH)]5Zhttps://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.184/25056944/mdy151.184.pdfH5T2Fhttps://academic.oup.com/annonc/article/29/suppl_5/mdy151.184/5039292HBO/*https://doi.org/10.1093/annonc/mdy151.184HWE, javascript:;HWE) javascript:;HWE& javascript:;HWE# javascript:;HWE  javascript:;HWE javascript:;HzHIhttps://academic.oup.com/annonc/search-results?f_TocHeadingTitle=PostersH,WZhttps://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.163/25057304/mdy151.163.pdfH# 1https://academic.oup.com/annonc/issue/29/suppl_5HBA*https://doi.org/10.1093/annonc/mdy151.163H4VFhttps://academic.oup.com/annonc/article/29/suppl_5/mdy151.163/5039455HWE  javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HzHIhttps://academic.oup.com/annonc/search-results?f_TocHeadingTitle=PostersH%RZhttps://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.162/25057290/mdy151.162.pdfH5WFhttps://academic.oup.com/annonc/article/29/suppl_5/mdy151.162/5039448HBA*https://doi.org/10.1093/annonc/mdy151.162HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HzHIhttps://academic.oup.com/annonc/search-results?f_TocHeadingTitle=PostersH+WZhttps://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.140/25056760/mdy151.140.pdfH1PFhttps://academic.oup.com/annonc/article/29/suppl_5/mdy151.140/5039210HBC*https://doi.org/10.1093/annonc/mdy151.140HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HzHIhttps://academic.oup.com/annonc/search-results?f_TocHeadingTitle=PostersH$WZhttps://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.154/25057087/mdy151.154.pdfH4UFhttps://academic.oup.com/annonc/article/29/suppl_5/mdy151.154/5039355HBB*https://doi.org/10.1093/annonc/mdy151.154H4UFhttps://academic.oup.com/annonc/article/29/suppl_5/mdy151.154/5039355HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE~ javascript:;HWE{ javascript:;HWEx javascript:;HzHuIhttps://academic.oup.com/annonc/search-results?f_TocHeadingTitle=PostersH-]rZhttps://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.146/25056904/mdy151.146.pdfH7VoFhttps://academic.oup.com/annonc/article/29/suppl_5/mdy151.146/5039276HBCl*https://doi.org/10.1093/annonc/mdy151.146HWEi javascript:;HWEf javascript:;HWEc javascript:;HWE` javascript:;HzH]Ihttps://academic.oup.com/annonc/search-results?f_TocHeadingTitle=PostersH%_ZZhttps://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.183/25056887/mdy151.183.pdfH2ZWFhttps://academic.oup.com/annonc/article/29/suppl_5/mdy151.183/5039270HBOT*https://doi.org/10.1093/annonc/mdy151.183H2ZQFhttps://academic.oup.com/annonc/article/29/suppl_5/mdy151.183/5039270HWEN javascript:;HWEK javascript:;HWEH javascript:;HWEE javascript:;HWEB javascript:;HWE? javascript:;HWE< javascript:;HWE9 javascript:;HWE6 javascript:;HWE3 javascript:;HzH0Ihttps://academic.oup.com/annonc/search-results?f_TocHeadingTitle=PostersHzF-?https://academic.oup.com/journals/pages/about_us/legal/noticesH$S*Zhttps://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.136/25056695/mdy151.136.pdfH4Q'Fhttps://academic.oup.com/annonc/article/29/suppl_5/mdy151.136/5039178HBD$*https://doi.org/10.1093/annonc/mdy151.136HWE! javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE javascript:;HWE  javascript:;HWE  javascript:;HWE javascript:;H# 1https://academic.oup.com/annonc/issue/29/suppl_5HzHIhttps://academic.oup.com/annonc/search-results?f_TocHeadingTitle=PostersH  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~        !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVRoot Entry Ffh Data  1Table\* WordDocument4SummaryInformation(DocumentSummaryInformation8FCompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q